Heterocyclic compounds as NRAS inhibitors

Abstract

Disclosed herein are compounds, and salts thereof, which inhibit targeted NRAS mutants, pharmaceutical formulations, and methods of treatment of NRAS-mediated diseases, such as certain cancers.

Description

HETEROCYCLIC COMPOUNDS AS NRAS INHIBITORS

[0001] This application claims the benefit of priority of United States provisional application no.63 / 495,563, filed April 12, 2023, the contents of which are incorporated by reference as if written herein in their entirety.

[0002] RAS proteins serve a critical role in cell proliferation as they regulate signal transduction received from extracellular stimuli to downstream pathways such as MAPK, PI3K-AKT and Ral-GDS. These pathways are involved in cellular events such as cell cycle, cell differentiation and cell survival. Dysregulation in RAS signaling is most often associated with activating mutations in the RAS protein typically found at codons 12,13 and 61. Such activating mutations break down the cycling between active (GTP-bound) and inactive (GDP-bound) RAS leading to cancer.

[0003] Approximately 20% of all human cancers present with mutations in RAS proteins. KRAS mutations are responsible for 75% of these cases and are predominantly found in PDAC, colorectal cancer and adenocarcinoma, followed by NRAS (17%) in hematopoietic cancers and malignant melanoma and HRAS (7%) in head and neck squamous cell carcinomas and bladder tumors. NRAS mutant-driven acute myeloid leukemia (AML) accounts for 11–30% of all AML patients.44% of occurring mutation in AML is observed at codon 12 (NRAS G12D represents 30%) followed by codon 13 and 61. In contrast, in melanoma, NRAS mutations are predominantly observed at codon 61 and to a lesser extent at codons 12 and 13.

[0004] Targeting RAS mutant cancers has been historically challenging. After the initial failed attempts to prevent KRAS attachment and activation in the membrane by using farnesyl transferase inhibitors, focus has shifted to upstream and downstream targets in the RAS signaling pathway. Inhibition of RTKs (receptor tyrosine kinases), SHP2 and SOS, all found upstream of RAS, has shown limited impact on RAS driven cancers, while regulation of downstream proteins such as MEK, RAF and PI3K are often plagued by toxicity issues. However, it has been discovered that directly targeting the mutant RAS proteins offers new possibilities for inhibiting the main oncogene. The direct targeting of KRAS G12C mutant tumors has been demonstrated in the clinic to be an effective mode of treatment of NSCLC (non-small cell lung cancer), resulting in the FDA approval of sotorasib. Others have shown that KRAS G12D mutant cancers can also be targeted with non-covalent inhibitors, with the non-conserved KRAS residue H95 theorized to play a significant role in binding selectivity.

[0005] Despite the significant attention focused on targeting RAS mutants, there exists a need for compounds and methods for the treatment of RAS G12D-mediated diseases, specifically NRAS G12D-mediated diseases. The present disclosure fulfills these and other needs, as evident in reference to the following disclosure. SUMMARY

[0006] Provided is a compound of Formula I, I), or a salt or tautomer thereof, w chosen from N and CR1J is1; X is chosen from CR4and NR4; Y is chosen from CR7, N, and NR7; Z is chosen from CR5, N, and NR5; R1is chosen from OH and NH2; R2is chosen from H and halo; R3is chosen from H, alkyl, alkoxy, and halo; R4is chosen from H, alkyl, amino, cycloalkyl, heterocycloalkyl, aryl, and heteroaryl, wherein alkyl, amino, cycloalkyl, heterocycloalkyl, aryl, and heteroaryl may be optionally substituted by one or more R8; R5is chosen from H, alkyl, alkynyl, amino, alkoxy, cycloalkyl, heterocycloalkyl, haloalkyl, aryl, heteroaryl, halo, cyano, alkyl sulfonyl, or hydroxyl, wherein alkyl, alkynyl, amino, alkoxy, cycloalkyl, heterocycloalkyl, haloalkyl, aryl, heteroaryl, and alkyl sulfonyl may be optionally substituted by one or more R9; R6is chosen from H, alkyl, alkoxy, and halo; R7is chosen from H, alkyl, alkynyl, cycloalkyl, heterocycloalkyl, haloalkyl, aryl, - CH2OH, cyano, and heteroaryl, wherein alkyl, alkynyl, cycloalkyl, heterocycloalkyl, haloalkyl, aryl, and heteroaryl may be optionally substituted by one or more R12; each R8is independently chosen from alkyl, cycloalkyl, heterocycloalkyl, alkoxy, cyano, halo, and hydroxy, wherein alkyl, cycloalkyl, and alkoxy may be optionally substituted by one or more R10;each R9is independently chosen from alkyl, cycloalkyl, heterocycloalkyl, alkoxy, cyano, halo, and hydroxy; each R10is independently chosen from amino, halo, cyano, and hydroxy; R11is chosen from H, alkyl, halo, haloalkyl, cycloalkyl, and cyano; and each R12is independently chosen from alkyl, cycloalkyl, heterocycloalkyl, alkoxy, amino, cyano, halo, and hydroxy.

[0007] Also provided is a compound of Formula IC, C), or a salt or tautomer thereof, wJ is chosen from N and CR11; X is chosen from CR4and NR4; Y is chosen from CR7, N, and NR7; Z is chosen from CR5, N, and NR5; R1is chosen from OH and NH2; R2is chosen from H and halo; R3is chosen from H, alkyl, alkenyl, alkoxy, cycloalkoxy, cycloalkyl, heterocycloalkyl, amino, alkylamino, dialkylamino, hydroxyalkyl, -C(O)CH3, haloalkyl, cyanoalkyl, benzyl, haloalkoxy, heterocycloalkoxy, halocycloalkoxy, cycloalkylamino, arylamino, and halo; R4is chosen from H, alkyl, amino, alkylamino, cycloalkyl, heterocycloalkyl, aryl, and heteroaryl, wherein alkyl, amino, alkylamino, cycloalkyl, heterocycloalkyl, aryl, and heteroaryl may be optionally substituted by one or more R8; R5is chosen from H, alkyl, alkynyl, amino, alkoxy, cycloalkyl, heterocycloalkyl, haloalkyl, aryl, heteroaryl, halo, cyano, alkyl sulfonyl, or hydroxyl, wherein alkyl, alkynyl, amino, alkoxy, cycloalkyl, heterocycloalkyl, haloalkyl, aryl, heteroaryl, and alkyl sulfonyl may be optionally substituted by one or more R9; and R6is chosen from H, alkyl, alkoxy, and halo; OR R5and R6combine to form a heterocycloalkyl;R7is chosen from H, alkyl, alkynyl, cycloalkyl, heterocycloalkyl, haloalkyl, aryl, - CH2OH, cyano, oxo, and heteroaryl, wherein alkyl, alkynyl, cycloalkyl, heterocycloalkyl, haloalkyl, aryl, and heteroaryl may be optionally substituted by one or more R12; each R8is independently chosen from alkyl, cycloalkyl, heterocycloalkyl, alkoxy, amino, alkylamino, dialkylamino, cyano, halo, hydroxy, oxo, and -C(0)0CH3, wherein alkyl, cycloalkyl, and alkoxy may be optionally substituted by one or more R10; each R9is independently chosen from alkyl, cycloalkyl, heterocycloalkyl, alkoxy, cyano, halo, amino, alkylamino, dialkylamino, and hydroxy; each R10is independently chosen from amino, halo, cyano, and hydroxy;R11is chosen from H, alkyl, halo, haloalkyl, cycloalkyl, and cyano; and each R12is independently chosen from alkyl, cycloalkyl, heterocycloalkyl, alkoxy, amino, cyano, halo, and hydroxy.

[0008] Also provided is a compound as disclosed herein, or a pharmaceutically acceptable salt thereof.

[0009] Also provided is a pharmaceutical formulation comprising a compound as disclosed herein, or a pharmaceutically acceptable salt thereof, together with a pharmaceutically acceptable carrier.

[0010] Also provided is a method for treating a disease or condition that benefits from or is treatable by inhibition of NRAS G12D, comprising the administration of a therapeutically effective amount of a compound described herein, or a pharmaceutically acceptable salt thereof, to a subject in need thereof.[Oi l] Also provided are methods of inhibiting at least one NRAS G12D function comprising the step of contacting NRAS G12D with a compound as described herein, or a pharmaceutically acceptable salt thereof. The cell phenotype, cell proliferation, activity of NRAS G12D, change in biochemical output produced by active NRAS G12D, expression of NRAS G12D, or binding of NRAS G12D with a natural binding partner may be monitored. Such methods may be modes of treatment of disease, biological assays, cellular assays, biochemical assays, or the like.

[0012] Also provided are methods of treatment of an NRAS G12D-mediated disease comprising the administration of a therapeutically effective amount of a compound as disclosed herein, or a pharmaceutically acceptable salt thereof, to a patient in need thereof.

[0013] Also provided is a method of inhibition of NRAS G12D comprising contacting NRAS G12D with a compound as disclosed herein, or a pharmaceutically acceptable salt thereof.

[0014] Also provided is a method of modulation of an NRAS G12D-mediated function in a subject comprising the administration of a therapeutically effective amount of a compound as disclosed herein, or a pharmaceutically acceptable salt thereof.

[0015] These and other aspects of the invention will be apparent upon reference to the following detailed description.DETAILED DESCRIPTION

[0016] As used in the present specification, the following words and phrases are generally intended to have the meanings as set forth below, except to the extent that the context in which they are used indicates otherwise.

[0017] In the following description, certain specific details are set forth in order to provide a thorough understanding of various embodiments. However, one skilled in the art will understand that the invention may be practiced without these details. In other instances, well-known structures have not been shown or described in detail to avoid unnecessarily obscuring descriptions of the embodiments. Unless the context requires otherwise, throughout the specification and claims which follow, the word “comprise” and variations thereof, such as, “comprises” and “comprising” are to be construed in an open, inclusive sense, that is, as “including, but not limited to.” Further, headings provided herein are for convenience only and do not interpret the scope or meaning of the claimed invention.

[0018] Reference throughout this specification to “one embodiment” or “an embodiment” or “some embodiments” or “a certain embodiment” means that a particular feature, structure or characteristic described in connection with the embodiment is included in at least one embodiment. Thus, the appearances of the phrases “in one embodiment” or “in an embodiment” or “in some embodiments” or “in a certain embodiment” in various places throughout this specification are not necessarily all referring to the same embodiment. Furthermore, the particular features, structures, or characteristics may be combined in any suitable manner in one or more embodiments.

[0019] Also, as used in this specification and the appended claims, the singular forms “a,” “an,” and “the” include plural referents unless the content clearly dictates otherwise.

[0020] When ranges of values are disclosed, and the notation “from m ... to n2” or “between m . . . and m” is used, where m and n2 are the numbers, then unless otherwise specified, this notation is intended to include the numbers themselves and the range between them. This range may be integral or continuous between and including the end values. By way of example, the range “from 2 to 6 carbons” is intended to include two, three, four, five,and six carbons, since carbons come in integer units. Compare, by way of example, the range “from 1 to 3 µM (micromolar),” which is intended to include 1 µM, 3 µM, and everything in between to any number of significant figures (e.g., 1.255 µM, 2.1 µM, 2.9999 µM, etc.).

[0021] As used herein, “about” means ± 20% of the stated value, and includes more specifically values of ± 10%, ± 5%, ± 2% and ± 1% of the stated value.

[0022] The term “alkoxy”, and, interchangeably, “(alkyl)oxy”, as used herein, refers to an alkyl radical attached to a molecule by oxygen.

[0023] The term “alkyl,” as used herein, refers to a straight-chain or branched-chain saturated, hydrocarbon radical containing from 1 to 20 carbon atoms. In some embodiments, alkyl will comprise from 1 to 10 carbon atoms. In some embodiments, alkyl will comprise from 1 to 8 carbon atoms.

[0024] The term “alkyl sulfonyl", as used herein, refers to a -S(O)2R group, wherein R is alkyl.

[0025] The term “alkynyl,” as used herein, refers to a straight-chain or branched chain hydrocarbon radical having one or more triple bonds and containing from 2 to 20 carbon atoms. In certain embodiments, said alkynyl comprises from 2 to 6 carbon atoms. In further embodiments, said alkynyl comprises from 2 to 4 carbon atoms

[0026] The term “amino,” as used herein, refers to -NRR’, wherein R and R’are independently chosen from hydrogen, alkyl, acyl, heteroalkyl, aryl, cycloalkyl, heteroaryl, and heterocycloalkyl. Additionally, R and R’ may combine with the amino nitrogen atom to form heterocycloalkyl.

[0027] The term "aryl," as used herein, means a carbocyclic aromatic system containing one, two or three rings wherein such polycyclic ring systems are fused together.

[0028] The term “cyano,” as used herein, refers to -CN.

[0029] The term “cycloalkyl,” or, alternatively, “carbocycle,” as used herein, refers to a saturated monocyclic, bicyclic or tricyclic alkyl group wherein each cyclic moiety contains from 3 to 12 carbon atom ring members. In some embodiments, cycloalkyl will comprise from 5 to 7 carbon atoms. In some embodiments, cycloalkyl will comprise a spirocyclic ring system. “Bicyclic” and “tricyclic” as used herein are intended to include both fused ring systems, as well as the multicyclic (multicentered) saturated type.

[0030] The term “halo,” or “halogen,” as used herein, refers to fluorine, chlorine, bromine, or iodine.

[0031] The term “haloalkyl,” as used herein, refers to an alkyl radical having the meaning as defined above wherein one or more hydrogens are replaced with a halogen. Specificallyembraced are monohaloalkyl, dihaloalkyl and polyhaloalkyl radicals. Dihalo and polyhaloalkyl radicals may have two or more of the same halo atoms or a combination of different halo radicals.

[0032] The term "heteroaryl," as used herein, refers to a 3 to 15 membered unsaturated heteromonocyclic ring, or a fused monocyclic, bicyclic, or tricyclic ring system in which at least one of the fused rings is aromatic, which contains at least one atom chosen from N, O, and S. In some embodiments, heteroaryl will comprise from 1 to 4 heteroatoms as ring members. In some embodiments, heteroaryl will comprise from 1 to 2 heteroatoms as ring members. In some embodiments, heteroaryl will comprise from 5 to 7 atoms. The term also embraces fused polycyclic groups wherein heterocyclic rings are fused with aryl rings wherein heteroaryl rings are fused with other heteroaryl rings wherein heteroaryl rings are fused with heterocycloalkyl rings, or wherein heteroaryl rings are fused with cycloalkyl rings.

[0033] The terms “heterocycloalkyl” and, interchangeably, “heterocycle,” as used herein, refers to a saturated, partially unsaturated, or fully unsaturated (but nonaromatic) monocyclic; saturated, partially unsaturated, or fully unsaturated (but not fully aromatic) bridged; saturated, partially unsaturated, or fully unsaturated (but not fully aromatic) bicyclic; or saturated, partially unsaturated, or fully unsaturated (but not fully aromatic) tricyclic heterocyclic group containing at least one heteroatom as a ring member wherein each heteroatom may be independently chosen from nitrogen, oxygen, and sulfur.

[0034] In some embodiments, heterocycloalkyl will comprise a spirocyclic ring system. In some embodiments, heterocycloalkyl will comprise from 1 to 4 heteroatoms as ring members. In some embodiments, heterocycloalkyl will comprise from 1 to 2 heteroatoms as ring members. In some embodiments, heterocycloalkyl will comprise from 3 to 8 ring members in each ring. In some embodiments, heterocycloalkyl will comprise from 3 to 7 ring members in each ring. In some embodiments, heterocycloalkyl will comprise from 5 to 6 ring members in each ring. “Heterocycloalkyl” and “heterocycle” are intended to include sulfones, sulfoxides, N-oxides of tertiary nitrogen ring members, and carbocyclic fused and benzo fused ring systems; additionally, both terms also include systems where a heterocycle ring is fused to an aryl or heteroaryl group, as defined herein, or an additional heterocycle group.

[0035] The terms “hydroxy” and, interchangeably, “hydroxyl,” as used herein, refers to - OH.

[0036] The term “oxo,” as used herein, refers to =O.

[0037] The term “spirocyclic ring system” refers to a polycyclic ring system comprising two rings such that a single atom is common to both rings.

[0038] Asymmetric centers exist in the compounds and pharmaceutically acceptable salts thereof, disclosed herein. These centers are designated by the symbols “R” or “S,” depending on the configuration of substituents around the chiral carbon atom. It should be understood that the disclosure encompasses all stereochemical isomeric forms, including diastereomeric, enantiomeric, and epimeric forms, as well as d-isomers and 1 -isomers, and mixtures thereof. Individual stereoisomers of compounds, and pharmaceutically acceptable salts thereof, can be prepared synthetically from commercially available starting materials which contain chiral centers or by preparation of mixtures of enantiomeric products followed by separation such as conversion to a mixture of diastereomers followed by separation or recrystallization, chromatographic techniques, direct separation of enantiomers on chiral chromatographic columns, or any other appropriate method known in the art. Starting compounds, and pharmaceutically acceptable salts thereof, of particular stereochemistry are either commercially available or can be made and resolved by techniques known in the art. Additionally, the compounds, and pharmaceutically acceptable salts thereof, disclosed herein may exist as geometric isomers. The present disclosure includes all cis, trans, syn, anti, entgegen (E), and zusammen (Z) isomers as well as the appropriate mixtures thereof.

[0039] Additionally, the compounds disclosed herein can exist in unsolvated as well as solvated forms with pharmaceutically acceptable solvents such as water, ethanol, and the like. In general, the solvated forms are considered equivalent to the unsolvated forms.

[0040] The term “bond” refers to a covalent linkage between two atoms, or two moieties when the atoms joined by the bond are considered to be part of larger substructure. A bond may be single, double, or triple unless otherwise specified. A dashed line between two atoms in a drawing of a molecule indicates that an additional bond may be present or absent at that position.

[0041] The term “halogenating agent,” as used herein, refers to a compound or salt that adds a halogen atom or atoms to an organic compound in a chemical reaction.

[0042] The term “oxidizing agent”, as used herein, refers to a compound that effects the oxidation of an organic compound in a chemical reaction (also known as an “oxidation reaction” or an “oxidation”).

[0043] As used herein, "administering to a patient" refers to the process of introducing a composition or dosage form into the patient via an art-recognized means of introduction.

[0044] The term “disease” as used herein is intended to be generally synonymous, and is used interchangeably with, the terms “disorder,” “syndrome,” and “condition” (as in medical condition), in that all reflect an abnormal condition of the human or animal body or of one ofits parts that impairs normal functioning, is typically manifested by distinguishing signs and symptoms, and causes the human or animal to have a reduced duration or quality of life.

[0045] The term "combination therapy" means the administration of two or more therapeutic agents to treat a therapeutic condition or disorder described in the present disclosure. Such administration encompasses co-administration of these therapeutic agents in a substantially simultaneous manner, such as in a single capsule having a fixed ratio of active ingredients or in multiple, separate capsules for each active ingredient. In addition, such administration also encompasses use of each type of therapeutic agent in a sequential manner. In either case, the treatment regimen will provide beneficial effects of the drug combination in treating the conditions or disorders described herein.

[0046] The phrase "therapeutically effective" is intended to qualify the amount of active ingredients used in the treatment of a disease or disorder or on the effecting of a clinical endpoint. The precise therapeutically effective amount for a subject may depend upon, e.g., the subject’s size and health, the nature and extent of the condition, the therapeutics or combination of therapeutics selected for administration, and other variables known to those of skill in the art. The effective amount for a given situation is determined by routine experimentation and is within the judgment of the clinician.

[0047] As used herein, the term “treat,” “treating”, or “treatment” means the administration of therapy to an individual who already manifests at least one symptom of a disease or condition or who has previously manifested at least one symptom of a disease or condition. For example, “treating” can include alleviating, abating or ameliorating a disease or condition symptoms, preventing additional symptoms, ameliorating the underlying metabolic causes of symptoms, inhibiting the disease or condition, e.g., arresting the development of the disease or condition, relieving the disease or condition, causing regression of the disease or condition, relieving a condition caused by the disease or condition, or stopping the symptoms of the disease or condition. For example, the term “treating” in reference to a disorder means a reduction in severity of one or more symptoms associated with that particular disorder. Therefore, treating a disorder does not necessarily mean a reduction in severity of all symptoms associated with a disorder and does not necessarily mean a complete reduction in the severity of one or more symptoms associated with a disorder.

[0048] The term “patient” is generally synonymous with the term “subject” and includes all mammals including humans. Examples of patients include humans, livestock such ascows, goats, sheep, pigs, and rabbits, and companion animals such as dogs, cats, rabbits, and horses. Preferably, the patient is a human.

[0049] Those skilled in the art will appreciate that the invention(s) described herein is susceptible to variations and modifications other than those specifically described. It is to be understood that the invention(s) includes all such variations and modifications. The invention(s) also includes all the steps, features, compositions and compounds referred to or indicated in this specification, individually or collectively, and any and all combinations or any two or more of steps or features unless specifically stated otherwise.

[0050] The present invention(s) is not to be limited in scope by the specific embodiments described herein, which are intended for the purpose of exemplification only. Functionally equivalent products, compositions, and methods are clearly within the scope of the invention(s), as described herein.

[0051] It is appreciated that certain features of the invention(s), which are, for clarity, described in the context of separate embodiments, can also be provided in combination in a single embodiment. Conversely, various features of the invention(s), which are, for brevity, described in the context of a single embodiment, can also be provided separately or in any suitable subcombination.

[0052] Provided is a compound of Formula I,or a salt or tautomer thereof, whereinJ is chosen from N and CR11;X is chosen from CR4and NR4;Y is chosen from CR7, N, and NR7;Z is chosen from CR5, N, and NR5;R1is chosen from OH and NH2;R2is chosen from H and halo;R3is chosen from H, alkyl, alkoxy, and halo;R4is chosen from H, alkyl, amino, cycloalkyl, heterocycloalkyl, aryl, and heteroaryl, wherein alkyl, amino, cycloalkyl, heterocycloalkyl, aryl, and heteroaryl may be optionally substituted by one or more R8;R5is chosen from H, alkyl, alkynyl, amino, alkoxy, cycloalkyl, heterocycloalkyl, haloalkyl, aryl, heteroaryl, halo, cyano, alkyl sulfonyl, or hydroxyl, wherein alkyl, alkynyl, amino, alkoxy, cycloalkyl, heterocycloalkyl, haloalkyl, aryl, heteroaryl, and alkyl sulfonyl may be optionally substituted by one or more R9;R6is chosen from H, alkyl, alkoxy, and halo;R7is chosen from H, alkyl, alkynyl, cycloalkyl, heterocycloalkyl, haloalkyl, aryl, - CH2OH, cyano, and heteroaryl, wherein alkyl, alkynyl, cycloalkyl, heterocycloalkyl, haloalkyl, aryl, and heteroaryl may be optionally substituted by one or more R12; each R8is independently chosen from alkyl, cycloalkyl, heterocycloalkyl, alkoxy, cyano, halo, and hydroxy, wherein alkyl, cycloalkyl, and alkoxy may be optionally substituted by one or more R10; each R9is independently chosen from alkyl, cycloalkyl, heterocycloalkyl, alkoxy, cyano, halo, and hydroxy; each R10is independently chosen from amino, halo, cyano, and hydroxy;R11is chosen from H, alkyl, halo, haloalkyl, cycloalkyl, and cyano; and each R12is independently chosen from alkyl, cycloalkyl, heterocycloalkyl, alkoxy, amino, cyano, halo, and hydroxy.

[0053] In some embodiments,J is chosen from N and CR11;X is CR4;Y is chosen from CR7, N, and NR7;Z is chosen from N, and NR5;R1is OH;R2is H;R3is H;R4is chosen from amino and heterocycloalkyl, either of which may be optionally substituted by one or more R8;R5is chosen from H, alkyl, alkynyl, and cycloalkyl, wherein alkyl, alkynyl, and cycloalkyl may be optionally substituted by one or more R9;R6is chosen from H and halo;R7is chosen from H, alkyl, alkynyl, -CH2OH, and cyano, wherein alkyl and alkynyl may be optionally substituted by one or more R12; each R8is independently chosen from cycloalkyl and heterocycloalkyl, either of which may be optionally substituted by one or more R10;each R9is independently heterocycloalkyl; each R10is independently amino;R11is chosen from H, halo, haloalkyl, cycloalkyl, and cyano; and each R12is independently chosen from alkyl, cycloalkyl, heterocycloalkyl, alkoxy, amino, cyano, halo, and hydroxy.

[0054] Also provided is a compound of Formula IC,or a salt or tautomer thereof, whereinJ is chosen from N and CR11;X is chosen from CR4and NR4;Y is chosen from CR7, N, and NR7;Z is chosen from CR5, N, and NR5;R1is chosen from OH and NH2;R2is chosen from H and halo;R3is chosen from H, alkyl, alkenyl, alkoxy, cycloalkoxy, cycloalkyl, heterocycloalkyl, amino, alkylamino, dialkylamino, hydroxyalkyl, -C(O)CHs, haloalkyl, cyanoalkyl, benzyl, haloalkoxy, heterocycloalkoxy, halocycloalkoxy, cycloalkylamino, arylamino, and halo;R4is chosen from H, alkyl, amino, alkylamino, cycloalkyl, heterocycloalkyl, aryl, and heteroaryl, wherein alkyl, amino, alkylamino, cycloalkyl, heterocycloalkyl, aryl, and heteroaryl may be optionally substituted by one or more R8;R5is chosen from H, alkyl, alkynyl, amino, alkoxy, cycloalkyl, heterocycloalkyl, haloalkyl, aryl, heteroaryl, halo, cyano, alkyl sulfonyl, or hydroxyl, wherein alkyl, alkynyl, amino, alkoxy, cycloalkyl, heterocycloalkyl, haloalkyl, aryl, heteroaryl, and alkyl sulfonyl may be optionally substituted by one or more R9; andR6is chosen from H, alkyl, alkoxy, and halo; ORR5and R6combine to form a heterocycloalkyl;R7is chosen from H, alkyl, alkynyl, cycloalkyl, heterocycloalkyl, haloalkyl, aryl, - CH2OH, cyano, oxo, and heteroaryl, wherein alkyl, alkynyl, cycloalkyl, heterocycloalkyl, haloalkyl, aryl, and heteroaryl may be optionally substituted by one or more R12;each R8is independently chosen from alkyl, cycloalkyl, heterocycloalkyl, alkoxy, amino, alkylamino, dialkylamino, cyano, halo, hydroxy, oxo, and -C(O)OCHs, wherein alkyl, cycloalkyl, and alkoxy may be optionally substituted by one or more R10; each R9is independently chosen from alkyl, cycloalkyl, heterocycloalkyl, alkoxy, cyano, halo, amino, alkylamino, dialkylamino, and hydroxy; each R10is independently chosen from amino, halo, cyano, and hydroxy;R11is chosen from H, alkyl, halo, haloalkyl, cycloalkyl, and cyano; and each R12is independently chosen from alkyl, cycloalky], heterocycloalkyl, alkoxy, amino, cyano, halo, and hydroxy.

[0055] In some embodiments, R3is chosen from H, alkyl, alkenyl, cycloalkyl, alkylamino dialkylamino, alkoxy, cycloalkoxy, hydroxyalkyl, -C(O)CH3, cyanoalkyl, haloalkyl, benzyl, haloalkoxy, heterocycloalkoxy, cycloalkylamino, heterocycloalkyl, halocycloalkoxy, and arylamino.

[0056] In some embodiments, R3is chosen from H, cyclobutyl, isopropenyl, methyl, ethyl, dimethylamino, isopropoxy, cyclobutoxy, isobutoxy, cyclopentoxy, methoxy, 2- hydroxypropanyl, -C(O)CHs, 1 -hydroxyethyl, methylamino, propylnitrile, trifluoromethyl, benzyl, difluoromethoxy, azetidinyloxy, cyclopropylamino, isopropyl(methyl)amino, isopropylamino, azetidinyl, isobutyl, 3,3-difluorocyclobutoxy, ethy l(me thy 1) amino, diethylamino, cyclopropoxy, phenylamino, oxetanyloxy, and trifluoroethoxy.

[0057] In some embodiments, X is chosen from CR4and NR4.

[0058] In some embodiments, X is CR4.

[0059] In some embodiments, R4is chosen from amino and heterocycloalkyl, wherein either may be optionally substituted by one or two R8.

[0060] In some embodiments, R4is heterocycloalkyl.

[0061] In some embodiments, R4is chosen from 3,8-diazabicyclo[3.2.1]octanyl, 8- azabicyclo[3.2.1]oct-2-enyl, piperazinyl, 2,5-diazabicyclo[2.2.2]octanyl, 2,5- diazabicyclo[2.2.1]heptanyl, 3,8-diazabicyclo[3.2.1]octanyl, and 3-azabicyclo[3.1.0]hexanyl.

[0062] In some embodiments, R4is chosen from

[0065] In some embodiments, R8is heterocycloalkyl.

[0066] In some embodiments .

[0067] In some embodiments nally su10bstituted with one or two R .

[0068] In some embodiments, R8is cyclobutyl substituted by one R10.

[0069] In some embodiments, R10is dimethylamino.

[0070] In some embodiments .

[0071] In some embodiments

[0072] In some embodiments, R6is fluoro.

[0073] In some embodiments, R6is H.

[0074] In some embodiments, the compound has a structural formula of Formula II:or a salt or tautomer thereof, wherein R1, R2, J, X, Y, and Z are as described herein.

[0075] In some embodiments, the compound has a structural formula of Formula III:or a salt or tautomer thereof, wherein R1, R2, J, X, Y, and Z are as described herein.

[0076] In some embodiments, the compound has a structural formula of Formula IV:or a salt or tautomer thereof, wherein n is chosen from 0, 1 , 2, or 3 ; and wherein R1, R2, R3, R8, X, Y, and Z are as described herein.

[0077] In some embodiments, n is 0.

[0078] In some embodiments, n is 1.

[0079] In some embodiments, n is 2.

[0080] In some embodiments, n is 3.

[0081] In some embodiments, J is CH.

[0082] In some embodiments, J is CR11.

[0083] In some embodiments, R11is chosen from H and fluoro.

[0084] In some embodiments, J is N.

[0085] In some embodiments, Y is CR7.

[0086] In some embodiments, R7is H.

[0087] In some embodiments, R7is alkyl.

[0088] In some embodiments, R7is methyl.

[0089] In some embodiments, R7is -CH2OH.

[0090] In some embodiments, R7is oxo.

[0091] In some embodiments, Y is N.

[0092] In some embodiments, Z is NR5.

[0093] In some embodiments, R5is chosen from H, alkyl and cycloalkyl, wherein alkyl and cycloalkyl may be optionally substituted by one or two R9.

[0094] In some embodiments, R5is chosen from H, methyl, ethyl, zi-propyl, isopropyl, cyclopropyl, and cyclobutyl.|095 ] In some embodiments, R5is alkyl substituted by one R9.

[0096] In some embodiments, R9is heterocycloalkyl.

[0097] In some embodiments, R9is tetrahydrofuranyl.

[0098] In some embodiments, R9is dimethylamino.

[0099] In some embodiments, R9is cyano.

[0100] In some embodiments, R5is cyclopropyl substituted by one or two R9.

[0101] In some embodiments, R9is fluoro.

[0102] In some embodiments, R9is methyl.

[0103] In some embodiments, R1is NH2.

[0104] In some embodiments, R1is OH.

[0105] In some embodiments, R2is chosen from H, chloro, and fluoro.

[0106] In some embodiments, R2is H.

[0107] In some embodiments, the compound of Formula I is chosen from a compound of structural formula:salt or tautomer thereof.

[0108] The compounds disclosed herein can exist as pharmaceutically acceptable salts. The present disclosure includes compounds listed herein in the form of salts, including acid addition salts. Suitable salts include those formed with both organic and inorganic acids.Such acid addition salts will normally be pharmaceutically acceptable. However, salts of non- pharmaceutically acceptable salts may be of utility in the preparation and purification of the compound in question. Basic addition salts may also be formed and be pharmaceutically acceptable. For a more complete discussion of the preparation and selection of salts, refer to Pharmaceutical Salts: Properties, Selection, and Use (Stahl, P. Heinrich. Wiley-VCHA, Zurich, Switzerland, 2002).

[0109] The term “pharmaceutically acceptable salt,” as used herein, represents salts or zwitterionic forms of the compounds disclosed herein. The salts can be prepared during the final isolation and purification of the compounds or separately by reacting the appropriatecompound in the form of the free base with a suitable acid. Representative acid addition salts include acetate, adipate, alginate, L-ascorbate, aspartate, benzoate, benzenesulfonate (besylate), bisulfate, butyrate, camphorate, camphorsulfonate, citrate, digluconate, formate, fumarate, gentisate, glutarate, glycerophosphate, glycolate, hemisulfate, heptanoate, hexanoate, hippurate, hydrochloride, hydrobromide, hydroiodide, 2-hydroxyethansulfonate (isethionate), lactate, maleate, malonate, DL-mandelate, mesitylenesulfonate, methanesulfonate, naphthylenesulfonate, nicotinate, 2-naphthalenesulfonate, oxalate, pamoate, pectinate, persulfate, 3-phenylproprionate, phosphonate, picrate, pivalate, propionate, pyroglutamate, succinate, sulfonate, tartrate, L-tartrate, trichloroacetate, trifluoroacetate, phosphate, glutamate, bicarbonate, para-toluenesulfonate (p-tosylate), and undecanoate. Also, basic groups in the compounds disclosed herein can be quatemized with methyl, ethyl, propyl, and butyl chlorides, bromides, and iodides; dimethyl, diethyl, dibutyl, and diamyl sulfates; decyl, lauryl, myristyl, and steryl chlorides, bromides, and iodides; and benzyl and phenethyl bromides. Examples of acids which can be employed to form pharmaceutically acceptable addition salts include inorganic acids such as hydrochloric, hydrobromic, sulfuric, and phosphoric, and organic acids such as oxalic, maleic, succinic, and citric. Salts can also be formed by coordination of the compounds with an alkali metal or alkaline earth ion. Hence, the present disclosure contemplates sodium, potassium, magnesium, and calcium salts of the compounds disclosed herein, and the like.

[0110] Basic addition salts can be prepared during the final isolation and purification of the compounds by reacting a carboxy group with a suitable base such as the hydroxide, carbonate, or bicarbonate of a metal cation or with ammonia or an organic primary, secondary, or tertiary amine. The cations of pharmaceutically acceptable salts include lithium, sodium, potassium, calcium, magnesium, and aluminum, as well as nontoxic quaternary amine cations such as ammonium, tetramethylammonium, tetraethylammonium, methylamine, dimethylamine, trimethylamine, triethylamine, diethylamine, ethylamine, tributylamine, pyridine, / V, A-dimethylaniline, A-methylpiperidine, jV-methylmorpholine, dicyclohexylamine, procaine, dibenzylamine, N, A-dibenzylphenethylamine, 1 -ephenamine, and A,A"-dibenzylethylenediamine. Other representative organic amines useful for the formation of base addition salts include ethylenediamine, ethanolamine, diethanolamine, piperidine, and piperazine.

[0111] While it may be possible for the compounds, and pharmaceutically acceptable salts thereof, of the subject disclosure to be administered as the raw chemical, it is also possible to present them as a pharmaceutical formulation.

[0112] Also provided is a pharmaceutical formulation comprising a compound as disclosed herein, or a pharmaceutically acceptable salt thereof, together with a pharmaceutically acceptable carrier. The formulations may conveniently be presented in unit dosage form and may be prepared by any of the methods well known in the art of pharmacy. Typically, these methods include the step of bringing into association a compound, or pharmaceutically acceptable salts thereof, of the subject disclosure or a pharmaceutically acceptable salt thereof ("active ingredient") with the carrier which constitutes one or more accessory ingredients. In general, the formulations are prepared by uniformly and intimately bringing into association the active ingredient with liquid carriers or finely divided solid carriers or both and then, if necessary, shaping the product into the desired formulation.

[0113] Preferred unit dosage formulations are those containing an effective dose, or an appropriate fraction thereof, of the active ingredient.

[0114] Compounds, or pharmaceutically acceptable salts thereof, may be administered at a dose of from 0.1 to 500 mg / kg per day. The dose range for adult humans is generally from 5 mg to 2 g / day. The amount of active ingredient that may be combined with the carrier materials to produce a single dosage form will vary depending upon the host treated and the particular mode of administration.

[0115] The compounds, or pharmaceutically acceptable salts thereof, can be administered in various modes. In some embodiments, the pharmaceutical formulation is formulated for oral administration.

[0116] In certain instances, it may be appropriate to administer at least one of the compounds described herein (or a pharmaceutically acceptable salt thereof) in combination with another therapeutic agent. By way of example only, if one of the side effects experienced by a patient upon receiving one of the compounds herein, or pharmaceutically acceptable salt thereof, is hypertension, then it may be appropriate to administer an antihypertensive agent in combination with the initial therapeutic agent. Or, by way of example only, the therapeutic effectiveness of one of the compounds described herein, or pharmaceutically acceptable salts thereof, may be enhanced by administration of an adjuvant (i.e., by itself the adjuvant may only have minimal therapeutic benefit, but in combination with another therapeutic agent, the overall therapeutic benefit to the patient is enhanced). Or, by way of example only, the benefit of experienced by a patient may be increased by administering one of the compounds described herein, or pharmaceutically acceptable salts thereof, with another therapeutic agent (which also includes a therapeutic regimen) that also has therapeutic benefit. In any case, regardless of the disease, disorder or condition beingtreated, the overall benefit experienced by the patient may simply be additive of the two therapeutic agents or the patient may experience a synergistic benefit.

[0117] In any case, the multiple therapeutic agents (at least one of which is a compound disclosed herein, or a pharmaceutically acceptable salt thereof) may be administered in any order or even simultaneously. If simultaneously, the multiple therapeutic agents may be provided in a single, unified form, or in multiple forms (by way of example only, either as a single pill or as two separate pills). One of the therapeutic agents may be given in multiple doses, or both may be given as multiple doses. If not simultaneous, the timing between the multiple doses may be any duration of time ranging from a few minutes to four weeks.

[0118] Also provided is a method for treating a disease or condition that benefits from or is treatable by inhibition of NRAS G12D, comprising the administration of a therapeutically effective amount of a compound described herein, or a pharmaceutically acceptable salt thereof, to a subject in need thereof.

[0119] Also provided are methods of inhibiting at least one NRAS G12D function comprising the step of contacting NRAS G12D with a compound as described herein, or a pharmaceutically acceptable salt thereof. The cell phenotype, cell proliferation, activity of NRAS G12D, change in biochemical output produced by active NRAS G12D, expression of NRAS G12D, or binding of NRAS G12D with a natural binding partner may be monitored. Such methods may be modes of treatment of disease, biological assays, cellular assays, biochemical assays, or the like.

[0120] Also provided are methods of treatment of an NRAS G12D-mediated disease comprising the administration of a therapeutically effective amount of a compound as disclosed herein, or a pharmaceutically acceptable salt thereof, to a patient in need thereof.

[0121] Also provided is a method of inhibition of NRAS G12D comprising contacting NRAS G12D with a compound as disclosed herein, or a pharmaceutically acceptable salt thereof.

[0122] Also provided is a method of modulation of an NRAS G12D-mediated function in a subject comprising the administration of a therapeutically effective amount of a compound as disclosed herein, or a pharmaceutically acceptable salt thereof.

[0123] In some embodiments, the NRAS G12D-mediated disease is cancer.

[0124] In some embodiments, the cancer is chosen from Melanoma, Malignant SolidTumors, Colorectal Carcinoma, Non-Small Cell Lung Carcinoma, Acute Myeloid Leukemia, Myelodysplastic Syndromes, Chronic Myelomonocytic Leukemia, Colorectal Adenocarcinoma, Multiple Myeloma, Non-Hodgkin Lymphoma, Pancreatic Carcinoma,Cutaneous Melanoma, Ovarian Carcinoma, Pancreatic Ductal Adenocarcinoma, Acute Lymphoblastic Leukemia, Thyroid Gland Carcinoma, Glioma, Neurofibromatosis, Poorly Differentiated Thyroid Gland Carcinoma, Myelodysplastic Syndrome With Excess Blasts, Juvenile Myelomonocytic Leukemia, Histiocytic And Dendritic Cell Neoplasm, Head And Neck Squamous Cell Carcinoma, Small Cell Lung Carcinoma, Low Grade Glioma, Squamous Cell Lung Carcinoma, Breast Carcinoma, Chronic Myelomonocytic Leukemia, Thyroid Gland Undifferentiated (Anaplastic) Carcinoma, Embryonal Rhabdomyosarcoma, Thyroid Gland Follicular Carcinoma, T-Cell Acute Lymphoblastic Leukemia, Mucosal Melanoma, Low Grade Ovarian Serous Adenocarcinoma, Thyroid Gland Papillary Carcinoma, Refractory Anemia With Excess Blasts, Myeloid Neoplasm, Myelodysplastic / Myeloproliferative Neoplasm, Rectal Carcinoma, Colon Carcinoma, Malignant Peripheral Nerve Sheath Tumor, Cholangiocarcinoma, Endometrial Carcinoma, Mantle Cell Lymphoma, Secondary Myelodysplastic Syndrome, Therapy-Related Myelodysplastic Syndrome, Lymphoma, Neuronal And Mixed Neuronal-Glial Tumors, Ganglioglioma, Soft Tissue Sarcoma, Bladder Carcinoma, Esophageal Carcinoma, Sarcoma, Thymic Carcinoma, Lung Adenocarcinoma, Lung Carcinoma, Uveal Melanoma, Head And Neck Carcinoma, Diffuse Glioma, Squamous Cell Carcinoma, Chronic Myeloid Leukemia, Adenocarcinoma of the Gastroesophageal Junction, Glioblastoma, Neuroblastoma, Astrocytic Tumor, Hepatocellular Carcinoma, Pancreatic Adenocarcinoma, Diffuse Large B-Cell Lymphoma, Anaplastic Astrocytoma, Gastric Adenocarcinoma, Gastric Carcinoma, Prostate Carcinoma, Renal Cell Carcinoma, B-Cell Acute Lymphoblastic Leukemia, Double-Hit Lymphoma, Dysembryoplastic Neuroepithelial Tumor, Gangliocytoma, Low-Grade Neuroepithelial Tumor, Peripheral T-Cell Lymphoma, Pilocytic Astrocytoma, Pilomyxoid Astrocytoma, Rhabdoid Tumor, and Schwannoma.

[0125] Further embodiments include the embodiments disclosed in the following Schemes, which are not to be construed as limiting in any way.SCHEMESScheme I

[0126] Referring to Scheme I, Step 1, to a solution of the compound of Formula 101 (X = bromine or iodine) in a polar aprotic solvent, such as dimethylformamide, is added a palladium catalyst, such as tetrakis(triphenylphosphine)palladium(0), and a co-catalyst, such as copper iodide, in an inert atmosphere. To the mixture is added ethynyltrimethylsilane and a base, such as triethylamine. The mixture is stirred, optionally at ambient temperature. In some embodiments, the mixture is stirred for 1-2 h. The product, a compound of Formula102, is isolated and purified using methods known in the art.

[0127] Referring to Scheme I, Step 2, to a solution of the compound of Formula 102 in an organic solvent, such as N-methyl-2-pyrrolidinone (NMP), is added a strong base, such as potassium tert-butoxide. The mixture is stirred, optionally at elevated temperatures. In some embodiments, the mixture is stirred between 3-5 h. The product, a compound of Formula103, is isolated and purified using methods known in the art.

[0128] Referring to Scheme I, Step 3, to a solution of the compound of Formula 103 in a polar aprotic solvent, such as dimethylformamide, is added a halogenating agent, such as N- iodosuccinimide or N-bromosuccinimide. The resulting mixture is stirred, optionally atambient temperature. In some embodiments, the mixture is stirred for 1-2 h. The product, a compound of Formula 104, is isolated and purified using methods known in the art.

[0129] Referring to Scheme I, Step 4, to a solution of the compound of Formula 104 (X = bromine or iodine) in a polar aprotic solvent, such as dimethylformamide, is added a strong non-nucleophilic base, such as sodium hydride. The mixture is stirred, optionally at reduced temperature. In some embodiments, the mixture is stirred for 10-30 min. A compound of R5- X (X = halogen) is added to the mixture and stirred. The product, a compound of Formula 105, is isolated and purified using methods known in the art.

[0130] Referring to Scheme I, Step 5, to a suspension of a compound of Formula 105 in a polar solvent, such as dioxane in water, is added a base, such as cesium carbonate, a palladium catalyst, such as cataCXium Pd G3, and a compound of Formula 106. The mixture is stirred, optionally at elevated temperatures. In some embodiments, the mixture is stirred for 4-8 h. The product, a compound of Formula 107, is isolated and purified using methods known in the art.

[0131] Referring to Scheme I, Step 6, to a solution of a compound of Formula 107 in a polar solvent, such as a mixture of dioxane and water, is added a base, such as potassium phosphate, a compound of Formula 108 (PG = protecting group, such as triisopropylsilyl; and R = alkyl, such as methyl, or hydrogen, or in combination with a second R group forms a heterocycloalkyl, such as pinacol borane), and a metal catalyst, such as cataCXium Pd G3. The mixture is stirred, optionally at elevated temperatures. In some embodiments, the mixture is stirred for 1-2 h. The product, a compound of Formula 109, is isolated and purified using methods known in the art.

[0132] Referring to Scheme I, Step 7, a solution of a compound of Formula 109 in an organic solvent, such as dichloromethane, is subjected to any set of deprotection conditions known in the art. The product, a compound of Formula la, is isolated and purified using methods known in the art. Individual enantiomers can be separated by using methods known in the art, such as chiral chromatography.Scheme II208 Formula lb

[0133] Referring to Scheme II, Step 1, to a solution of the compound of Formula 201 (X = bromine or iodine) in a polar aprotic solvent, such as tetrahydrofuran, is added an organometallic compound, such as an isopropylmagnesium chloride and lithium bromide complex. The mixture is stirred, optionally at reduced temperature. In some embodiments, the mixture is stirred for 1-2 h. A solution of a compound of Formula 202 is added and the reaction is stirred for an additional period. In some embodiments, the additional period is 15- 30 minutes. The product, a compound of Formula 203, is isolated and purified using methods known in the art.

[0134] Referring to Scheme II, Step 2, to a solution of the compound of Formula 203 in an organic solvent, such as dichloromethane, is added an oxidizing agent, such as Dess- Martin periodinane. The mixture is stirred, optionally at reduced temperatures. In some embodiments, the mixture is stirred between 3-5 h. The product, a compound of Formula 204, is isolated and purified using methods known in the art.

[0135] Referring to Scheme II, Step 3, to a solution of the compound of Formula 204 in a polar organic solvent, such as methanol, is added hydrazine hydrate. The resulting mixture isstirred, optionally at elevated temperature. In some embodiments, the mixture is stirred for 4- 8 h. The product, a compound of Formula 205, is isolated and purified using methods known in the art.

[0136] Referring to Scheme II, Step 4, to a suspension of a compound of Formula 205 in an organic solvent, such as dichloroethane, is added a base, such as 2,2-bipyridine, a metal catalyst, such as copper (II) acetate, and a compound of Formula 206. The mixture is stirred, optionally at elevated temperatures. In some embodiments, the mixture is stirred for 24-72 h. The product, a compound of Formula 207, is isolated and purified using methods known in the art.

[0137] Referring to Scheme II, Step 5, to a solution of a compound of Formula 207 in a polar solvent, such as a mixture of dioxane and water, is added a base, such as potassium phosphate, a compound of Formula 108 (PG = protecting group, such as triisopropylsilyl; and R = alkyl, such as methyl, or hydrogen, or in combination with a second R group forms a heterocycloalkyl, such as pinacol borane), and a metal catalyst, such as cataCXium Pd G3. The mixture is stirred, optionally at elevated temperatures. In some embodiments, the mixture is stirred for 1-2 h. The product, a compound of Formula 208, is isolated and purified using methods known in the art.

[0138] Referring to Scheme II, Step 6, a solution of a compound of Formula 208 in an organic solvent, such as dichloromethane, is subjected to any set of deprotection conditions known in the art. The product, a compound of Formula lb, is isolated and purified using methods known in the art. Individual enantiomers can be separated by using methods known in the art, such as chiral chromatography.

[0139] Examples of embodiments of the present disclosure are provided in the following examples. The following examples are presented only by way of illustration and to assist one of ordinary skill in using the disclosure. The examples are not intended in any way to otherwise limit the scope of the disclosure.EXAMPLE 14-(3-(3,8-diazabicycIo[3.2.1]octan-3-yl)-7-fluoro-l-methyl-lH-pyrazoIo[4,3-c]pyridin-6- yl)-5-ethynyl-6-fluoronaphthalen-2-ol

[0140] 3-Bromo-6-chloro-7-fluoro-lH-pyrazolo[4,3-c]pyridine To a solution of 6- chloro-7-fluoro-lH-pyrazolo[4,3-c]pyridine (150 mg, 0.874 mmol) in DMF (2 mL) was added NBS (187 mg, 1 .049 mmol) and the resulting mixture was stirred at 20°C for 16 hrs. The reaction mixture was diluted with EtOAc and washed with sat NaCl. The layers were separated and the organic layer was washed with sat NaCl, dried over NazSO4, filtered, and concentrated under reduced pressure to give 3-bromo-6-chloro-7-fluoro-lH-pyrazolo[4,3- c]pyridine (150 mg, 0.6 mmol, 68 % yield) as a yellow solid.MS (ES+) G>lLBrClFN3 requires: 250.5, found: 252.0 [M+H]+.

[0141] 3-Bromo-6-chloro-7-fluoro-l-methyl-lH-pyrazolo[4,3-c]pyridine To a suspension of NaH (31.1 mg, 0.779 mmol) in DMF (1 mL) at 0°C, was added a solution of 3- bromo-6-chloro-7-fluoro-lH-pyrazolo[4,3-c]pyridine (150 mg, 0.599 mmol) in DMF (1 mL) and the resulting mixture was stirred at 0°C for 15min. To this mixture, Mel (0.1 12 mL, 1.797 mmol) was added and the resulting mixture was stirred at 0°C for Ihr. Ice water was added. The reaction mixture was diluted with EtOAc and washed with sat NH4CI. The layers were separated and the organic layer was washed with sat NaCl, dried over Na2SO4, filtered, and concentrated under reduced pressure. The residue was purified via silica gel chromatography (0 - 75 % EtOAc in hexanes) to give 3-bromo-6-chloro-7-fluoro-l-methyl- lH-pyrazolo[4,3-c]pyridine (132 mg, 0.499 mmol, 83 % yield) as an off-white solid. MS (ES+) C7H4B1CIFN3 requires: 264.5, found: 266.1 [M+H]+.

[0142] Tert-butyl 8-(6-chloro 1H-pyrazolo[4,3-c]pyridin-3-yl)-3,8-diazabicyclo[3.2.1]octane-3-carboxylate A suspension of 3-bromo-6-chloro-7-fluoro-1- methyl-1H-pyrazolo[4,3-c]pyridine (60 mg, 0.227 mmol), tert-butyl 3,8- diazabicyclo[3.2.1]octane-3-carboxylate (144 mg, 0.681 mmol), and Cs2CO3 (222 mg, 0.681 mmol) in THF (2 mL) was degassed for 5 mins. BINAP (21.19 mg, 0.034 mmol) and Pd2(dba)3 (10.39 mg, 0.011 mmol) were added and the mixture was degassed for an additional 3 mins. The reaction mixture was then heated to 80°C and stirred for 16 hrs. The reaction mixture was allowed to cool to room temperature. Sat. NH4Cl was added and the layers were separated. The aqueous phase was extracted with EtOAc (3x), the combined organic layers were dried over Na2SO4, filtered, and concentrated under reduced pressure. The residue was purified via silica gel chromatography (0 - 70 % EtOAc in hexanes) to give tert-butyl 8-(6-chloro-7-fluoro-1-methyl-1H-pyrazolo[4,3-c]pyridin-3-yl)-3,8- diazabicyclo[3.2.1]octane-3-carboxylate (78 mg, 0.197 mmol, 87 % yield) as a brown oil. MS (ES+) C18H23ClFN5O2requires: 395.2, found: 396.3.

[0143] Tert-butyl 8-(7-fluymethoxy)-8- ((triisopropylsilyl)ethynyl)naphthalen-1-yl)-1-methyl-1H-pyrazolo[4,3-c]pyridin-3-yl)- 3,8-diazabicyclo[3.2.1]octane-3-carboxylate A solution of ((2-fluoro-6-(methoxymethoxy)-8-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)naphthalen-1- yl)ethynyl)triisopropylsilane (101 mg, 0.197 mmol), tert-butyl 8-(6-chloro-7-fluoro-1- methyl-1H-pyrazolo[4,3-c]pyridin-3-yl)-3,8-diazabicyclo[3.2.1]octane-3-carboxylate (78 mg, 0.197 mmol), and potassium phosphate (41.8 mg, 0.197 mmol) in 1,4-dioxane (2.0 mL) was degassed 5mins. CataCXium Pd G3 (14.35 mg, 0.020 mmol) was added and the mixture was degassed for additional 3 mins. The reaction mixture was then heated to 95°C and stirred for 4 hrs. The reaction mixture was allowed to cool to room temperature. Sat NH4Cl was added and the layers were separated. The aqueous phase was extracted with EtOAc (3x), the combined organic layers were dried over Na2SO4, filtered, and concentrated under reduced pressure. The residue was purified via silica gel chromatography (10 - 55 % EtOAc in hexanes) to give tert-butyl 8-(7-fluoro-6-(7-fluoro-3-(methoxymethoxy)-8- ((triisopropylsilyl)ethynyl)naphthalen-1-yl)-1-methyl-1H-pyrazolo[4,3-c]pyridin-3-yl)-3,8- diazabicyclo[3.2.1]octane-3-carboxylate as a brown oil.

[0144] 3 A solution of tert-uoro-3-(methoxymethoxy)-8- ((triisopropylsilyl)ethynyl)naphthalen-1-yl)-1-methyl-1H-pyrazolo[4,3-c]pyridin-3-yl)-3,8- diazabicyclo[3.2.1]octane-3-carboxylate in DCM (1.0 mL) was treated with HCl (4M, 1.5 mL, 49.4 mmol) was added and stirred for 1 h. The volatiles were removed under reduced pressure. The reaction mixture was diluted with EtOAc and washed with sat NaHCO3. The layers were separated and the organic layer was washed with sat NaCl, filtered, and concentrated under reduced pressure. The residue was diluted with DMSO (1.5 mL) and CsF (120 mg, 0.788 mmol) was added and stirred for 20 min at 80°C .The residue was filtered then purified by mass-triggered preparative HPLC (Mobile phase: A = 0.1% TFA / H2O, B = 0.1% TFA / MeCN; Gradient: B = 10 - 50%; 20 min; Column: XBridge C18, 5 μm, 19 mm x 150 mm) to give 4-(3-(3,8-diazabicyclo[3.2.1]octan-8-yl)-7-fluoro-1-methyl-1H- pyrazolo[4,3-c]pyridin-6-yl)-5-ethynyl-6-fluoronaphthalen-2-ol (22 mg, 0.049 mmol, 25.06 % yield) as a pale yellow powder.MS (ES+) C25H21F2N5O requires: 445.2, found: 446.4 [M+H]+.1H NMR (600 MHz, METHANOL-d4) δ ppm 2.10 - 2.21 (m, 2 H), 2.28 - 2.49 (m,2 H), 2.65 (s, 4 H), 4.16 (s, 3 H), 4.25 - 4.33 (m, 1 H), 4.66 - 4.80 (m, 2 H), 7.31 - 7.47 (m, 3 H), 7.88 - 8.01 (m, 1 H), 9.16 - 9.31 (m, 1 H). EXAMPLE 2 4-(3-((1R,5S,6S)-3-azabicycl luoro-1-methyl-1H-pyrrolo[3,2-c]pyridin-6-yl)-5-ethynyl-6-fluoronaphthalen-2-ol 2,2,2-trifluoroacetate

[0145] 2-Chloro-3-fluoro-5-iodne To a solution of 2-chloro-3- fluoropyridin-4-amine (500 mg, 3.41 mmol) in acetonitrile (10 mL) was added NIS (921 mg, 4.09 mmol) and p-TsOH (32.4 mg, 0.171 mmol) and the resulting mixture was stirred at 70 °C for 1 h. The reaction mixture was allowed to cool to room temperature. The reaction mixture was diluted with EtOAc (50.0 mL) and washed with 10% Na2SO3 (15.0 mL). The layers were separated and the organic layer was washed with sat NaHCO3(15.0 mL), filtered through a short silica gel column, and concentrated under reduced pressure to get 2-chloro-3- fluoro-5-iodopyridin-4-amine (900 mg, 3.30 mmol, 97 % yield) as a brown foam-solid. MS (ES+) C5H3ClFIN2 requires: 272, found: 273 [M+H]+.

[0146] 2-Chloro-3-fluoro-5-((yl)pyridin-4-amine A solution of 2-chloro-3-fluoro-5-iodopyridin-4-amine (4.6 g, 16.88 mmol), Pd(PPh3)4 (0.976 g, 0.844 mmol), and copper(I) iodide (0.482 g, 2.53 mmol) in DMF (84 mL) was degassed with N2for 5 minutes. ethynyltrimethylsilane (2.64 mL, 18.57 mmol) and Et3N (5.88 mL, 42.2mmol) were added and the mixture was degassed with N2for an additional 5 minutes. The reaction mixture was heated to rt and stirred for 1 h. The reaction mixture was diluted with EtOAc (100 mL) and washed with sat NH4Cl (150 mL). The layers were separated and the organic layer was washed with sat NaCl (100 mL), dried over MgSO4, filtered, and concentrated under reduced pressure. The residue was purified via silica gel chromatography (0 - 20 % EtOAc in hexanes) to give 2-chloro-3-fluoro-5-((trimethylsilyl)ethynyl)pyridin-4- amine (3.85 g, 15.86 mmol, 94 % yield) as a white solid. MS (ES+) C10H12ClFN2Si requires: 242, found: 243 [M+H]+.

[0147] 6-Chloro-7-fluoro-1H-pyr ridine To a solution of 2-chloro-3-fluoro-5-((trimethylsilyl)ethynyl)pyridin-4-amine (10 mg, 0.041 mmol) in N-methyl-2- pyrrolidinone (206 µL) was added KOtBu (12 mg, 0.107 mmol) and the resulting mixture was stirred at 50 °C for 4 h. The reaction mixture was diluted with EtOAc (5.00 mL), saturated NH4Cl (5.00 mL) was added, and the layers were separated. The aqueous phase was extracted with EtOAc (1 x 5.00 mL), the combined organic layers were washed with sat NaCl, dried over MgSO4, filtered, and concentrated under reduced pressure to give 6-chloro- 7-fluoro-1H-pyrrolo[3,2-c]pyridine (6.7 mg, 0.039 mmol, 95 % yield) MS (ES+) C7H4ClFN2 requires: 170, found: 171 [M+H]+.

[0148] 6-Chloro-7-fluoro-3-iodo-3,2-c]pyridine To a solution of 6- chloro-7-fluoro-1H-pyrrolo[3,2-c]pyridine (261 mg, 1.53 mmol) in DMF (7650 µL) was added N-iodosuccinimide (516 mg, 2.295 mmol) and the resulting mixture was stirred at rt for 1 h. The reaction mixture was diluted with EtOAc (100 mL) and washed with sat NH4Cl (100 mL). The layers were separated and the organic layer was washed with sat NaCl (100 mL), dried over MgSO4, filtered, and concentrated under reduced pressure to give 6-chloro-7- fluoro-3-iodo-1H-pyrrolo[3,2-c]pyridine (265.7 mg, 0.896 mmol, 58.6 % yield) as a tan solid. MS (ES+) C7H3ClFIN2 requires: 296, found: 297 [M+H]+.

[0149] 6-Chloro-7-fluoro-3-iodo- -pyrrolo[3,2-c]pyridine To a solution of 6-chloro-7-fluoro-3-iodo-1H-pyrrolo[3,2-c]pyridine (265 mg, 0.894 mmol) in DMF (4469 µL) was added NaH (35.8 mg, 0.894 mmol) and the resulting mixture was stirred at 0 °C for 15 min. Neat MeI (55.9 µL, 0.894 mmol) was added to the cooled solution, which was then allowed to warm to rt. The reaction mixture was diluted with EtOAc (100 mL), sat. NH4Cl (200 mL) was added, and the layers were separated. The aqueous phase was extracted with EtOAc (2 x 100 mL), the combined organic layers were washed with sat NaCl, dried over MgSO4, filtered, and concentrated under reduced pressure. The residue was purified via silica gel chromatography (0 - 30 % EtOAc in hexanes) to give 6-chloro-7-fluoro-3-iodo-1- methyl-1H-pyrrolo[3,2-c]pyridine (230 mg, 0.741 mmol, 83 % yield) as a white solid. MS (ES+) C8H5ClFIN2 requires: 310, found: 311 [M+H]+.

[0150] Tert-butyl (1R,5S,6S)-6ro-1-methyl-1H-pyrrolo[3,2- c]pyridin-3-yl)-3-azabicyclo[3.1.0]hexane-3-carboxylate A suspension of tert-butyl (1R,5S,6S)-6-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)-3-azabicyclo[3.1.0]hexane-3- carboxylate (171 mg, 0.553 mmol), 6-chloro-7-fluoro-3-iodo-1-methyl-1H-pyrrolo[3,2- c]pyridine (156 mg, 0.502 mmol), and cesium carbonate (491 mg, 1.507 mmol) in 1,4- dioxane (1884 µL) and water (628 µL) was degassed with N2 for 2 minutes. CataCXium Pd G3 (36.6 mg, 0.050 mmol) was added and the mixture was degassed with N2 for an additional 2 minutes. The reaction mixture was heated to 90 °C and stirred for 5 h. The reaction mixture was allowed to cool to room temperature. The reaction mixture was diluted with EtOAc (25.0 mL) and washed with sat NaCl (10.0 mL). The layers were separated and the organic layer was washed with sat NaCl (10.0 mL), dried over Na2SO4, filtered, and concentrated under reduced pressure. The residue was purified via silica gel chromatography (0 -80 % EtOAc in hexanes) to give tert-butyl (1R,5S,6S)-6-(6-chloro-7-fluoro-1-methyl-1H-pyrrolo[3,2-c]pyridin-3-yl)-3-azabicyclo[3.1.0]hexane-3-carboxylate (63 mg, 0.172 mmol, 34.3 % yield) as a pale yellow oil.MS (ES+) C18H21ClFN3O2 requires: 365, found: 366 [M+H]+.

[0151] Tert-butyl (1R,5S,6S) oro-3-(methoxymethoxy)-8-((triisopropylsilyl)ethynyl)naphthalen-1-yl)-1-methyl-1H-pyrrolo[3,2-c]pyridin-3-yl)-3- azabicyclo[3.1.0]hexane-3-carboxylate A suspension of ((2-fluoro-6- (methoxymethoxy)-8-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)naphthalen-1- yl)ethynyl)triisopropylsilane (92 mg, 0.180 mmol), tert-butyl (1R,5S,6s)-6-(6-chloro-7- fluoro-1-methyl-1H-pyrrolo[3,2-c]pyridin-3-yl)-3-azabicyclo[3.1.0]hexane-3-carboxylate (60 mg, 0.164 mmol), and potassium phosphate (104 mg, 0.492 mmol) in 1,4-dioxane (1230 µL) and water (410 µL) was degassed under vacuum for 5 minutes. CataCXium Pd G3 (11.9 mg, 0.0164 mmol) was added and the mixture was degassed with N2for an additional 5 minutes. The reaction mixture was heated to 90 °C and stirred for 1 h. Sat. NH4Cl (5.00 mL) was added and the layers were separated. The aqueous phase was extracted with EtOAc (3 x 5.00 mL), the combined organic layers were dried over Na2SO4, filtered, and concentrated under reduced pressure. The residue was purified via silica gel chromatography (0 - 50 % EtOAc in hexanes) to give tert-butyl (1R,5S,6S)-6-(7-fluoro-6-(7-fluoro-3-(methoxymethoxy)-8- ((triisopropylsilyl)ethynyl)naphthalen-1-yl)-1-methyl-1H-pyrrolo[3,2-c]pyridin-3-yl)-3- azabicyclo[3.1.0]hexane-3-carboxylate (5.9 mg, 8.24 μmol, 5.02 % yield) as a yellow solid. MS (ES+) C41H51F2N3O4Si requires: 715, found: 717 [M+2H]+.

[0152] 4-(3-((1R,5S,6S)-3-azy . . -yl)-7-fluoro-1-methyl-1H- pyrrolo[3,2-c]pyridin-6-yl)-5-ethynyl-6-fluoronaphthalen-2-ol 2,2,2-trifluoroacetateTo a solution of tert-butyl (1R,5S,6S)-6-(7-fluoro-6-(7-fluoro-3- (methoxymethoxy)-8-((triisopropylsilyl)ethynyl)naphthalen-1-yl)-1-methyl-1H-pyrrolo[3,2- c]pyridin-3-yl)-3-azabicyclo[3.1.0]hexane-3-carboxylate (5.9 mg, 8.24 μmol) in dichloromethane (0.4 mL) was added HCl in dioxane (0.021 mL, 0.082 mmol) and the resulting mixture was stirred at rt for 2 h. The volatiles were removed under reduced pressure. The residue was taken up in DMF (0.4 mL) and treated with CsF (25.04 mg, 0.165 mmol). The reaction mixture was heated to 60 °C for 1h then diluted with 0.6 mL of DMSO, filtered, and purified by HPLC. The residue was purified by mass-triggered preparative HPLC (Mobile phase: A = 0.1% TFA / H2O, B = 0.1% TFA / MeCN; Gradient: B = 10 - 40%; 20 min; Column: XBridge C18, 5 μm, 19 mm x 150 mm) to give 4-(3-((1R,5S,6S)-3- azabicyclo[3.1.0]hexan-6-yl)-7-fluoro-1-methyl-1H-pyrrolo[3,2-c]pyridin-6-yl)-5-ethynyl-6- fluoronaphthalen-2-ol 2,2,2-trifluoroacetate (1.3 mg, 2.455 μmol, 29.8 % yield) as a white solid. MS (ES+) C25H19F2N3O requires: 415, found: 416 [M+H]+.1H NMR (600 MHz, methanol-dz) δ 9.28 (s, 1H), 8.12 (dd, J = 9.2, 5.6 Hz, 1H), 7.80 (s, 1H), 7.67 (d, J = 2.6 Hz, 1H), 7.63 – 7.50 (m, 2H), 4.29 (s, 3H), 3.91 (dd, J = 11.8, 3.4 Hz, 2H), 3.79 (dd, J = 11.6, 3.8 Hz, 2H), 3.56 (s, 1H), 2.50 (dt, J = 8.1, 3.8 Hz, 2H), 2.46 (d, J = 3.8 Hz, 1H). EXAMPLE 3 NH 4-(3-((1R,5S,6r)-3-azabicyro-1-methyl-1H-pyrazolo[4,3- c]pyridin-6-yl)-5-ethynyl-6-fluoronaphthalen-2-ol

[0153] 6-Chloro-7-fluoro-3-iodo[4,3-c]pyridine To a solution of 6- chloro-7-fluoro-1H-pyrazolo[4,3-c]pyridine (200 mg, 1.166 mmol) in DMF (5 mL) was added NIS (315 mg, 1.399 mmol) and the resulting mixture was stirred at 80 °C for 3 h. Thereaction mixture was allowed to cool to room temperature. Ice-water was added and stirred for 15 min. The solid was collected via vacuum filtration using a Buchner funnel. The filter cake was washed with hexanes and dried under reduced pressure to a constant weight to provide 6-chloro-7-fluoro-3-iodo-1H-pyrazolo[4,3-c]pyridine (320 mg, 1.076 mmol, 92 % yield) as an off-white solid.MS (ES+) C6H2ClFIN3 requires: 297, found: 298 [M+H]+.

[0154] 6-Chloro-7-fluoro-3-iodo -pyrazolo[4,3-c]pyridine To asolution of 6-chloro-7-fluoro-3-iodo-1H-pyrazolo[4,3-c]pyridine (1) (180 mg, 0.605 mmol) in DMF (2 mL) was added NaH (31.5 mg, 0.787 mmol) and the resulting mixture was stirred at 0 °C for 10 min. To this mixture, MeI (0.189 mL, 3.03 mmol) in DMF (2 mL) was added and the resulting mixture was stirred at 0 °C rt for 1 h. The reaction mixture was allowed to cool to room temperature. Ice-water was added and stirred for 15 min. The solid was collected via vacuum filtration using a Buchner funnel. The filter cake was washed with hexanes and dried under reduced pressure to a constant weight to provide 6-chloro-7-fluoro- 3-iodo-1-methyl-1H-pyrazolo[4,3-c]pyridine (210 mg, 0.674 mmol) as an off-white solid. It was then used for next step without further purification. MS (ES+) C7H4ClFIN3 requires: 311, found: 312 [M+H]+.

[0155] Tert-butyl (1R,5S,6r1-methyl-1H-pyrazolo[4,3- c]pyridin-3-yl)-3-azabicyclo[3.1.0]hexane-3-carboxylate A suspension of 6-chloro-7- fluoro-3-iodo-1-methyl-1H-pyrazolo[4,3-c]pyridine (90 mg, 0.289 mmol), tert-butyl (1R,5S,6r)-6-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)-3-azabicyclo[3.1.0]hexane-3- carboxylate (89 mg, 0.289 mmol), and cesium carbonate (282 mg, 0.867 mmol) in 1,4- dioxane (2167 µL) was degassed with N2 for 1 minute. CataCXium Pd G3 (21.04 mg, 0.029 mmol) was added and the mixture was degassed with N2for an additional 2 minutes. Thereaction mixture was heated to 80 °C and stirred for 2 h. The reaction mixture was allowed to cool to room temperature. The reaction mixture was diluted with EtOAc (20.0 mL) and washed with sat NaCl (5.00 mL). The layers were separated and the organic layer was washed with sat NaCl (5.00 mL), dried over Na2SO4, filtered, and concentrated under reduced pressure. The residue was purified via silica gel chromatography (0 - 65 % EtOAc in hexanes) to give tert-butyl (1R,5S,6r)-6-(6-chloro-7-fluoro-1-methyl-1H-pyrazolo[4,3- c]pyridin-3-yl)-3-azabicyclo[3.1.0]hexane-3-carboxylate (61 mg, 0.166 mmol, 57.6 % yield) as a pale yellow solid.MS (ES+) C17H20ClFN4O2 requires: 366, found: 367 [M+H]+. H NBoc H

[0156] Tert-butyl (1R methoxymethoxy)-8-((triisopropylsilyl)ethynyl)naphthalen-1-yl)-1-methyl-1H-pyrazolo[4,3-c]pyridin-3-yl)-3- azabicyclo[3.1.0]hexane-3-carboxylate A suspension of ((2-fluoro-6- (methoxymethoxy)-8-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)naphthalen-1- yl)ethynyl)triisopropylsilane (85 mg, 0.166 mmol), tert-butyl (1R,5S,6r)-6-(6-chloro-7- fluoro-1-methyl-1H-pyrazolo[4,3-c]pyridin-3-yl)-3-azabicyclo[3.1.0]hexane-3-carboxylate (61 mg, 0.166 mmol), and potassium phosphate (35.3 mg, 0.166 mmol) in 1,4-dioxane (887 µL) and water (222 µL) was degassed under vacuum for 5 minutes. CataCXium Pd G3 (12.11 mg, 0.017 mmol) was added and the mixture was degassed with N2 for an additional 5 minutes. The reaction mixture was heated to 100 °C and stirred for 2 h. The reaction mixture was allowed to cool to room temperature. The reaction mixture was diluted with EtOAc, filtered through celite, and the filtrate was concentrated under reduced pressure. The residue was purified via silica gel chromatography (0 - 65 % EtOAc in hexanes) to give tert-butyl (1R,5S,6r)-6-(7-fluoro-6-(7-fluoro-3-(methoxymethoxy)-8- ((triisopropylsilyl)ethynyl)naphthalen-1-yl)-1-methyl-1H-pyrazolo[4,3-c]pyridin-3-yl)-3- azabicyclo[3.1.0]hexane-3-carboxylate (90 mg, 0.126 mmol, 75 % yield) as a brown oil. MS (ES+) C40H50F2N4O4Si requires: 716, found: 718 [M+2H]+.

[0157] 4- ethyl-1H- pyrazolo[4,3-c]pyridin-6-yl)-5-ethynyl-6-fluoronaphthalen-2-ol To a solution of tert-butyl (1R,5S,6r)-6-(7-fluoro-6-(7-fluoro-3-(methoxymethoxy)-8- ((triisopropylsilyl)ethynyl)naphthalen-1-yl)-1-methyl-1H-pyrazolo[4,3-c]pyridin-3-yl)-3- azabicyclo[3.1.0]hexane-3-carboxylate (90 mg, 0.126 mmol) in 1,4-dioxane (0.5 mL) was added HCl (4 M in dioxane) (2.0 mL, 8.00 mmol) and the resulting mixture was stirred at rt for 1 h. The volatiles were removed under reduced pressure. The reaction mixture was diluted with EtOAc (15.0 mL) and washed with sat NaHCO3(5.00 mL). The layers were separated and the organic layer was washed with sat NaCl (5.00 mL), dried over Na2SO4, filtered, and concentrated under reduced pressure an orange solid. The residue was taken up in DMSO (1.5 mL) and treated with cesium fluoride (108 mg, 0.712 mmol). The resulting mixture was stirred at rt for 1 h. The reaction mixture was filtered and the filtrate was purified by mass- triggered preparative HPLC (Mobile phase: A = 0.1% TFA / H2O, B = 0.1% TFA / MeCN; Gradient: B = 10 - 50%; 12 min; Column: XBridge C18, 5 μm, 19 mm x 150 mm) to give 4- (3-((1R,5S,6r)-3-azabicyclo[3.1.0]hexan-6-yl)-7-fluoro-1-methyl-1H-pyrazolo[4,3-c]pyridin- 6-yl)-5-ethynyl-6-fluoronaphthalen-2-ol 2,2,2-trifluoroacetate (26 mg, 0.049 mmol, 41.3 % yield) as an off-white solid. MS (ES+) C24H18F2N4O requires: 416, found: 417 [M+H]+. 1H NMR (600 MHz, methanol-d4) δ 2.54 - 2.62 (m, 3 H) 3.25 - 3.28 (m, 1 H) 3.61 - 3.69 (m, 2 H) 3.69 - 3.75 (m, 2 H) 4.20 (s, 3 H) 7.27 -7.30 (m, 1 H) 7.33 - 7.38 (m, 1 H) 7.39 - 7.41 (m, 1 H) 7.83 - 7.98 (m, 1 H) 8.99 - 9.13 (m, 1 H). EXAMPLE 44-(3-((1R,5S,6r)-3-azabicyclo[3 opropyl-7-fluoro-1H-pyrazolo[4,3-c]pyridin-6-yl)-5-ethynyl-6-fluoronaphthalen-2-ol 2,2,2-trifluoroacetate O O

[0158] Tert-butyl (1R,5S,6roropyridin-3-yl)(hydroxy)methyl)- 3 azabicyclo[3.1.0]hexane-3-carboxylate To a solution of 5-bromo-2,4-dichloro-3- fluoropyridine (1.0 g, 4.08 mmol) in THF (10 mL) was added isopropylmagnesium chloride / lithium bromide complex (3.77 mL, 4.90 mmol) and the resulting mixture was stirred at -78 °C for 1 h. A solution of tert-butyl (1R,5S,6r)-6-formyl-3-azabicyclo[3.1.0]hexane-3- carboxylate (1.0 g, 4.73 mmol) in THF (2.0 mL) was added dropwise at -78 °C. After 15 min, the cooling bath was removed and the reaction was allowed to warm to rt over 30 min. The reaction mixture was diluted with EtOAc (100 mL) and washed with sat NH4Cl (100 mL). The layers were separated and the organic layer was dried over MgSO4, filtered, and concentrated under reduced pressure. The residue was purified via silica gel chromatography (0 - 100 % EtOAc in hexanes) to give tert-butyl (1R,5S,6r)-6-((4,6-dichloro-5-fluoropyridin- 3-yl)(hydroxy)methyl)-3 azabicyclo[3.1.0]hexane-3-carboxylate (851 mg, 2.256 mmol, 55.2 % yield) as a white solid. MS (ES+) C16H19Cl2FN2O3 requires: 376, found: 321 [M-tBu]+.O O

[0159] Tert-butyl (1R,5S,6r ronicotinoyl)-3-azabicyclo[3.1.0]hexane-3-carboxylate To a solution of tert-butyl (1R,5S,6r)-6-((4,6- dichloro-5-fluoropyridin-3-yl)(hydroxy)methyl)-3-azabicyclo[3.1.0]hexane-3-carboxylate (851 mg, 2.256 mmol) in DCM (10 mL) was added Dess-Martin periodinane (1148 mg, 2.71 mmol) and the resulting mixture was stirred at 0 °C for 3 h. The reaction mixture was diluted with CH2Cl2(75.0 mL), sat Na2S2O3(25.0 mL) and sat NaHCO3(25 mL) were added and the biphasic mixture was stirred rapidly for 30 min. The layers were separated. The aqueous phase was extracted with CH2Cl2(1 x 50.0 mL), the combined organic layers dried over MgSO4, filtered, and concentrated under reduced pressure. The residue was purified via silica gel chromatography (0 - 60 % EtOAc in hexanes) to give tert-butyl (1R,5S,6r)-6-(4,6- dichloro-5-fluoronicotinoyl)-3-azabicyclo[3.1.0]hexane-3-carboxylate (727 mg, 1.938 mmol, 86 % yield) as a white solid. MS (ES+) C16H17Cl2FN2O3 requires: 374, found: 319 [M- tBu]+. O

[0160] Tert-butyl (1R,5S,6H-pyrazolo[4,3-c]pyridin-3-yl)-3- azabicyclo[3.1.0]hexane-3-carboxylate To a solution of tert-butyl (1R,5S,6r)-6-(4,6- dichloro-5-fluoronicotinoyl)-3-azabicyclo[3.1.0]hexane-3-carboxylate (527 mg, 1.405 mmol) in MeOH (3 mL) was added hydrazine hydrate (105 mg, 2.107 mmol) and the resulting mixture was stirred at 50 °C for 6 h. The volatiles were removed under reduced pressure. The residue was purified via silica gel chromatography (0 - 80 % EtOAc in hexanes) to give tert-butyl (1R,5S,6r)-6-(6-chloro-7-fluoro-1H-pyrazolo[4,3-c]pyridin-3-yl)-3-azabicyclo[3.1.0]hexane-3-carboxylate (303 mg, 0.859 mmol, 61.2 % yield) as a white solid. MS (ES+) C16H18ClFN4O2 requires: 352, found: 353 [M+H]+.

[0161] Tert-butyl (1R,5S,6 opyl-7-fluoro-1H-pyrazolo[4,3-c]pyridin-3-yl)-3-azabicyclo[3.1.0]hexane-3-carboxylate To a solution of tert-butyl (1R,5S,6r)-6-(6-chloro-7-fluoro-1H-pyrazolo[4,3-c]pyridin-3-yl)-3-azabicyclo[3.1.0]hexane- 3-carboxylate (55 mg, 0.156 mmol) in dichloroethane (779 µL) was added copper (II) acetate (28.3 mg, 0.156 mmol) and 2,2'-bipyridine (24.35 mg, 0.156 mmol) and cyclopropylboronic acid (33.5 mg, 0.390 mmol) and the resulting mixture was stirred at 50 °C for 48 h. The reaction was filtered through celite and the filtrate was concentrated. The residue was purified via silica gel chromatography (0 - 100 % EtOAc in hexanes) to give tert-butyl (1R,5S,6r)-6-(6-chloro-1-cyclopropyl-7-fluoro-1H-pyrazolo[4,3-c]pyridin-3-yl)-3- azabicyclo[3.1.0]hexane-3-carboxylate (51 mg, 0.130 mmol, 83 % yield) as a colorless oil. MS (ES+) C19H22ClFN4O2 requires: 392, found: 393 [M+H]+.

[0162] Tert-butyl (1R,6-(7-fluoro-3- (methoxymethoxy)-8-((triisopropylsilyl)ethynyl)naphthalen-1-yl)-1H-pyrazolo[4,3- c]pyridin-3-yl)-3-azabicyclo[3.1.0]hexane-3-carboxylate A suspension of ((2-fluoro-6- (methoxymethoxy)-8-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)naphthalen-1- yl)ethynyl)triisopropylsilane (53.5 mg, 0.104 mmol), tert-butyl (1R,5S,6r)-6-(6-chloro-1- cyclopropyl-7-fluoro-1H-pyrazolo[4,3-c]pyridin-3-yl)-3-azabicyclo[3.1.0]hexane-3- carboxylate (41mg, 0.104 mmol), and potassium phosphate (66.5 mg, 0.313 mmol) in 1,4-dioxane (557 µL) and water (139 µL) was degassed under vacuum for 5 minutes. CataCXium Pd G3 (7.60 mg, 10.44 μmol) was added and the mixture was degassed with N2for an additional 5 minutes. The reaction mixture was heated to 100 °C and stirred for 2h. The reaction mixture was allowed to cool to room temperature. The reaction mixture was diluted with EtOAc, filtered through celite, and the filtrate was concentrated under reduced pressure. The residue was purified via silica gel chromatography (0 - 65 % EtOAc in hexanes) to give tert-butyl (1R,5S,6r)-6-(1-cyclopropyl-7-fluoro-6-(7-fluoro-3-(methoxymethoxy)-8- ((triisopropylsilyl)ethynyl)naphthalen-1-yl)-1H-pyrazolo[4,3-c]pyridin-3-yl)-3- azabicyclo[3.1.0]hexane-3-carboxylate (37.2 mg, 0.050 mmol, 48.0 % yield) as a brown oil. MS (ES+) C42H52F2N4O4Si requires: 742, found: 743 [M+H]+.

[0163] 4-(3-((1R,5S,6r)-3-a-yl)-1-cyclopropyl-7-fluoro-1H- pyrazolo[4,3-c]pyridin-6-yl)-5-ethynyl-6-fluoronaphthalen-2-ol 2,2,2-trifluoroacetate To a solution of tert-butyl (1R,5S,6r)-6-(1-cyclopropyl-7-fluoro-6-(7-fluoro-3- (methoxymethoxy)-8-((triisopropylsilyl)ethynyl)naphthalen-1-yl)-1H-pyrazolo[4,3-c]pyridin- 3-yl)-3-azabicyclo[3.1.0]hexane-3-carboxylate (37.2 mg, 0.050 mmol) in DCM (0.5 mL) was added HCl (0.125 mL, 0.501 mmol) and the resulting mixture was stirred at rt for 1 h. The volatiles were removed under reduced pressure. The residue was taken up in DMF (0.4 mL) and treated with CsF (152 mg, 1.001 mmol). The reaction was heated to 60 C for 1h then diluted with 0.6 mL of DMSO. The residue was purified by mass-triggered preparative HPLC (Mobile phase: A = 0.1% TFA / H2O, B = 0.1% TFA / MeCN; Gradient: B = 20 - 60%; 20 min; Column: XBridge C18, 5 μm, 19 mm x 150 mm) to give 4-(3-((1R,5S,6r)-3- azabicyclo[3.1.0]hexan-6-yl)-1-cyclopropyl-7-fluoro-1H-pyrazolo[4,3-c]pyridin-6-yl)-5- ethynyl-6-fluoronaphthalen-2-ol 2,2,2-trifluoroacetate (7.5 mg, 0.013 mmol, 26.9 % yield) as an off-white solid. MS (ES+) C26H20F2N4O requires: 442.2, found: 443.3 [M+H]+.1H NMR (600 MHz, methanol-d4) δ 8.91 (s, 1H), 7.88 (dd, J = 9.1, 5.7 Hz, 1H), 7.38 (s, 1H), 7.34 (t, J = 8.9 Hz, 1H), 7.25 (s, 1H), 3.91 – 3.83 (m, 1H), 3.75 – 3.68 (m, 2H), 3.67 – 3.62(m, 2H), 3.21 (s, 1H), 2.64 – 2.53 (m, 2H), 2.49 (s, 1H), 1.28 (d, J = 12.0 Hz, 1H), 1.23 (dd, J = 10.0, 4.4 Hz, 1H), 1.16 (dd, J = 7.1, 4.7 Hz, 2H). EXAMPLE 5 4-(3-((1R,5S,6s)-3-azabicyclo[3 lopropyl-7-fluoro-1H-pyrrolo[3,2-c]pyridin-6-yl)-5-ethynyl-6-fluoronaphthalen-2-ol

[0164] 6-Chloro-7-fluoro-3-iodo-yrrolo[3,2-c]pyridine To a solution of 6-chloro-7-fluoro-1H-pyrrolo[3,2-c]pyridine (219 mg, 1.284 mmol) in DMF (6 mL) was added NIS (289 mg, 1.284 mmol) and the resulting mixture was stirred at rt for 1 h. LCMS showed full conversion to the iodide. To the reaction mixture was added triethylamine (0.358 mL, 2.57 mmol), tosyl-Cl (367 mg, 1.926 mmol), and DMAP (15.69 mg, 0.128 mmol). After 1h, Full conversion to the desired product was observed by LCMS. The reaction mixture was diluted with EtOAc (100 mL) and washed with sat NaHCO3(50.0 mL). The layers were separated and the organic layer was washed with sat Na2S2O3 (50.0 mL), dried over MgSO4, filtered, and concentrated under reduced pressure. The residue was purified via silica gel chromatography (0 - 80 % EtOAc in hexanes) to give 6-chloro-7- fluoro-3-iodo-1-tosyl-1H-pyrrolo[3,2-c]pyridine (509 mg, 1.129 mmol, 88 % yield) as a white solid. MS (ES+) C14H9ClFIN2O2S requires: 449.9, found: 450.9 [M+H]+.

[0165] Tert-butyl (1R,5S,6s)-6-(6-chloro-7-fluoro-1-tosyl-1H-pyrrolo[3,2-c]pyridin- 3-yl)-3-azabicyclo[3.1.0]hexane-3-carboxylate A suspension of 6-chloro-7- fluoro-3-iodo-1-tosyl-1H-pyrrolo[3,2-c]pyridine (542 mg, 1.203 mmol), cesium carbonate (1176 mg, 3.61 mmol), and tert-butyl (1R,5S,6s)-6-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan- 2-yl)-3-azabicyclo[3.1.0]hexane-3-carboxylate (409 mg, 1.323 mmol) in 1,4-dioxane (4510 µL)-water (1503 µL) was degassed with N2for 2 minutes. The reaction mixture was heated to 80 °C and stirred for 2 h. The reaction mixture was allowed to cool to room temperature. The reaction mixture was diluted with EtOAc (25.0 mL) and washed with sat NaCl (10.0 mL). The layers were separated and the organic layer was washed with sat NaCl (10.0 mL), dried over Na2SO4, filtered, and concentrated under reduced pressure. The residue was purified via silica gel chromatography (5 - 75 % EtOAc in hexanes) to give tert-butyl (1R,5S,6s)-6-(6- chloro-7-fluoro-1-tosyl-1H-pyrrolo[3,2-c]pyridin-3-yl)-3-azabicyclo[3.1.0]hexane-3- carboxylate (344.7 mg, 0.681 mmol, 56.6 % yield) as a pale yellow oil.MS (ES+) C24H25ClFN3O4S requires: 505.1 , found: 506.2 [M+H]+.

[0166] Tert-butyl (1R,5S,6s)-6o-1H-pyrrolo[3,2-c]pyridin-3-yl)-3- azabicyclo[3.1.0]hexane-3-carboxylate To a solution of tert-butyl (1R,5S,6s)-6-(6- chloro-7-fluoro-1-tosyl-1H-pyrrolo[3,2-c]pyridin-3-yl)-3-azabicyclo[3.1.0]hexane-3- carboxylate (275 mg, 0.543 mmol) in tetrahydrofuran (4026 µL) and water (2013 µL) was added sodium hydroxide (217 mg, 5.43 mmol) and the resulting mixture was stirred at 80 °C for 3 h. Sat NaHCO3 (25.0 mL) was added and the layers were separated. The aqueous phase was extracted with EtOAc (1 x 20.0 mL), the combined organic layers were washed with sat NaCl, dried over MgSO4, filtered, and concentrated under reduced pressure. The residue was purified via silica gel chromatography (0 - 100 % EtOAc in hexanes) to give tert-butyl (1R,5S,6s)-6-(6-chloro-7-fluoro-1H-pyrrolo[3,2-c]pyridin-3-yl)-3-azabicyclo[3.1.0]hexane-3- carboxylate (162 mg, 0.460 mmol, 85 % yield) as a white solid. MS (ES+) C17H19ClFN3O2 requires: 351.1, found: 352.2 [M+H]+.

[0167] Tert-butyl (1R,5S,6s)-6 propyl-7-fluoro-1H-pyrrolo[3,2-c]pyridin-3-yl)-3-azabicyclo[3.1.0]hexane-3-carboxylate To a solution of tert-butyl (1R,5S,6s)-6-(6-chloro-7-fluoro-1H-pyrrolo[3,2-c]pyridin-3-yl)-3-azabicyclo[3.1.0]hexane-3- carboxylate ( 82 mg, 0.233 mmol) in dichloroethane (1.5 mL) was added copper (II) acetate (42.3 mg, 0.233 mmol) and 2,2'-bipyridine (36.4 mg, 0.233 mmol) and cyclopropylboronic acid (50.1 mg, 0.583 mmol) and the resulting mixture was stirred at 50 °C for 48 h. The reaction was directly loaded onto a 10g silica column. The residue was purified via silica gel chromatography (0 - 100 % EtOAc in hexanes) to give tert-butyl (1R,5S,6s)-6-(6-chloro-1- cyclopropyl-7-fluoro-1H-pyrrolo[3,2-c]pyridin-3-yl)-3-azabicyclo[3.1.0]hexane-3- carboxylate (40 mg, 0.102 mmol, 43.8 % yield) as a colorless oil. MS (ES+) C20H23ClFN3O2 requires: 391.1, found: 392.3 [M+H]+.

[0168] tert-butyl (1R,5S,6s)oro-6-(7-fluoro-3- (methoxymethoxy)-8-((triisopropylsilyl)ethynyl)naphthalen-1-yl)-1H-pyrrolo[3,2- c]pyridin-3-yl)-3-azabicyclo[3.1.0]hexane-3-carboxylate A suspension of ((2-fluoro-6- (methoxymethoxy)-8-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)naphthalen-1- yl)ethynyl)triisopropylsilane (105 mg, 0.204 mmol), tert-butyl (1R,5S,6s)-6-(6-chloro-1- cyclopropyl-7-fluoro-1H-pyrrolo[3,2-c]pyridin-3-yl)-3-azabicyclo[3.1.0]hexane-3- carboxylate (80 mg, 0.204 mmol), and Cs2CO3(66.5 mg, 0.204 mmol) in 1,4-dioxane (1089 µL)-water (272 µL) was degassed under vacuum for 5 minutes. CataCXium Pd G3 (14.87 mg, 0.020 mmol) was added and the mixture was degassed with N2for an additional 5 minutes. The reaction mixture was heated to 100 °C and stirred for 2 h. The reaction mixturewas allowed to cool to room temperature. The reaction mixture was diluted with EtOAc, filtered through celite, and the filtrate was concentrated under reduced pressure. The residue was purified via silica gel chromatography (0 - 65 % EtOAc in hexanes) to give tert-butyl (1R,5S,6s)-6-(1-cyclopropyl-7-fluoro-6-(7-fluoro-3-(methoxymethoxy)-8- ((triisopropylsilyl)ethynyl)naphthalen-1-yl)-1H-pyrrolo[3,2-c]pyridin-3-yl)-3- azabicyclo[3.1.0]hexane-3-carboxylate (14.1 mg, 0.019 mmol, 9.31 % yield) as a brown oil. MS (ES+) C43H53F2N3O4Si requires: 741.4, found: 742.4 [M+H]+.

[0169] 4-(3-((1R,5S,6s)-3-az -yl)-1-cyclopropyl-7-fluoro-1H-pyrrolo[3,2-c]pyridin-6-yl)-5-ethynyl-6-fluoronaphthalen-2-ol To a solution of tert-butyl (1R,5S,6s)-6-(1-cyclopropyl-7-fluoro-6-(7-fluoro-3-(methoxymethoxy)-8- ((triisopropylsilyl)ethynyl)naphthalen-1-yl)-1H-pyrrolo[3,2-c]pyridin-3-yl)-3- azabicyclo[3.1.0]hexane-3-carboxylate (14.1 mg, 0.019 mmol) in DCM (0.5 mL) was added HCl (0.048 mL, 0.190 mmol) and the resulting mixture was stirred at rt for 1 h. The volatiles were removed under reduced pressure. The residue was taken up in DMF (0.4 mL) and treated with CsF (57.7 mg, 0.380 mmol) at 60 °C for 1h. The residue was purified by mass- triggered preparative HPLC (Mobile phase: A = 0.1% TFA / H2O, B = 0.1% TFA / MeCN; Gradient: B = 0 - 90%; 12 min; Column: XBridge C18, 5 μm, 19 mm x 150 mm) to give 4- (3-((1R,5S,6s)-3-azabicyclo[3.1.0]hexan-6-yl)-1-cyclopropyl-7-fluoro-1H-pyrrolo[3,2- c]pyridin-6-yl)-5-ethynyl-6-fluoronaphthalen-2-ol 2,2,2-trifluoroacetate (5 mg, 9.00 μmol, 47.4 % yield) as a white solid.1H NMR (600 MHz, MeOD) δ 9.08 (s, 1H), 7.96 (dd, J = 9.2, 5.7 Hz, 1H), 7.73 (s, 1H), 7.50 (d, J = 2.5 Hz, 1H), 7.45 – 7.39 (m, 2H), 3.82 (tt, J = 7.2, 3.4 Hz, 1H), 3.72 (dd, J = 11.8, 3.7 Hz, 2H), 3.61 (dd, J = 11.8, 4.0 Hz, 2H), 3.39 (s, 1H), 2.65 (s, 3H), 2.34 (qt, J = 7.4, 3.9 Hz, 2H), 2.22 (t, J = 3.8 Hz, 1H), 1.33 – 1.07 (m, 4H). MS (ES+) C27H20F2N3O requires: 441.2, found: 442.2 [M+H]+.

[0170] The following Examples were synthesized with procedures that were similar to the examples disclosed herein and can generally be made by methods disclosed herein from the appropriate starting materials.Table 1. Example Compounds. Example Structure IUPAC Name 6 4-(3-(3,8-diazabicyclo[3.2.1]octan-3-yl)-1- )- l-Example Structure IUPAC Name 11 4-(3-(((1R,5S,6s)-3-azabicyclo[3.1.0]hexan-6- 2- )-Example Structure IUPAC Name 16 4-(3-(3,8-diazabicyclo[3.2.1]octan-3-yl)-1- n- 17 18 19 20 n-Example Structure IUPAC Name 21 4-(3-((1R,5S,6s)-3-azabicyclo[3.1.0]hexan-6- 2- - 2-Example Structure IUPAC Name 25 4-(3-((1R,5S,6r)-3-azabicyclo[3.1.0]hexan-6- 2-Example Structure IUPAC Name 30 4-(3-((1S,4S)-2,5-diazabicyclo[2.2.2]octan-2- 2-. Example MS (ES+)1H NMR (600 MHz, MeOD-d4, unless indicated otherwise) δ m ), ), 2 ) , , ),Example MS (ES+)1H NMR (600 MHz, MeOD-d4, unless indicated otherwise) δ ppm 1 , 1 J , 4 , - , , 7Example MS (ES+)1H NMR (600 MHz, MeOD-d4, unless indicated otherwise) δ ppm , 1 J 1 . , ), , 8 = 6Example MS (ES+)1H NMR (600 MHz, MeOD-d4, unless indicated otherwise) δ ppm t, , , J z,Example MS (ES+)1H NMR (600 MHz, MeOD-d4, unless indicated otherwise) δ ppm z, J ),4-[3-(3,9-diazabicyclo[3.3.1]nonethyl-pyrazolo[4,3-c]pyridin-6-yl]- 5-ethynyl-6-fluoro-naphthalen-2-ol Step 1 Tert-butyl 3-(6-chloro-7-fluoro-1-methyl-pyrazolo[4,3-c]pyridin-3-yl)-3,9- diazabicyclo[3.3.1]nonane-9-carboxylate

[0171] To a solution of 6-chloro-1-methyl-pyrazolo[4,3-c]pyridine (80 mg, 256.84 μmol, 1 eq) and tert-butyl 3, 9-diazabicyclo[3.3.1]nonane-9-carboxylate (58.13 mg, 256.84 μmol, 1.0 eq) in dioxane (0.32 mL) were added Cs2CO3 (251.20 mg, 770.98μmol, 3 eq) and XantPhos Pd G4(24.72 mg, 25.68 μmol, 0.10 eq), the mixture was stirred at 90 °C for 2 h under N2. LCMS showed the starting material was consumed completely and a peak (65%) with the desired mass. The mixture was cooled to 25 °C and filtered, the filtrate was concentrated under vacuum. The residue was purified by prep-TLC (SiO2, Petroleum ether / Ethyl acetate= 3: 2) to afford tert-butyl 3-(6-chloro-7-fluoro-1-methyl-pyrazolo[4,3- c]pyridin-3-yl)-3,9-diazabicyclo[3.3.1]nonane-9-carboxylate (23 mg, 56.11 μmol, 21.85% yield) as a yellow solid. MS (ES+) C19H25ClFN5O2requires: 409, found 410 [M+H]+, Step 2 Tert-butyl 3-[7-fluoro-6-[7-fluoro-3-(methoxymethoxy)-8-(2-triisopropylsilylethynyl)-1- naphthyl]-1-methyl-pyrazolo[4,3-c]pyridin-3-yl]-3,9-diazabicyclo[3.3.1]nonane-9- carboxylate

[0172] To a solution of tert-buro-1-methyl-pyrazolo[4,3-c]pyridin- 3-yl)-3,9-diazabicyclo[3.3.1]nonane-9-carboxylate (22 mg, 53.67 μmol, 1 eq), 2-[2-fluoro-6- (methoxymethoxy)-8-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)-1-naphthyl]ethynyl- triisopropyl-silane (46.7 mg, 91.12 μmol, 1.7 eq) and K3PO4(1.5 M, 110 μL, 3.07 eq) in dioxane (1.1 mL) was added Ad2nBuP Pd G3 (cataCXium® A Pd G3) (5.1 mg, 7.00 μmol, 0.13 eq), the mixture was stirred at 60 °C for 12 h under N2. The mixture was cooled to 25 °C, 2-[2-fluoro-6-(methoxymethoxy)-8-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)-1- naphthyl]ethynyl-triisopropyl-silane (33.01 mg, 64.41 μmol, 1.2 eq) and Ad2nBuP Pd G3 (cataCXium® A Pd G3) (1.95 mg, 2.68 μmol, 0.05 eq) were added, the mixture was stirred at 60 °C for another 5 h under N2. LCMS showed the starting material was consumed completely and a peak (65%) with the desired mass. The mixture was cooled to 25 °C and poured into a mixture of NaCl (2 mL) and water (1 mL). The aqueous phase was extracted with ethyl acetate (5 mL × 2). The combined organic phase was washed with brine (2 mL × 2), dried over anhydrous Na2SO4, filtered and concentrated under vacuum. The residue waspurified by prep-TLC (SiO2, Petroleum ether / Ethyl acetate= 3: 1) to afford tert-butyl 3-[7- fluoro-6-[7-fluoro-3-(methoxymethoxy)-8-(2-triisopropylsilylethynyl)-1-naphthyl]-1-methyl- pyrazolo[4,3-c]pyridin-3-yl]-3,9-diazabicyclo[3.3.1]nonane-9-carboxylate (15 mg, 19.74 μmol, 36.77% yield) as a yellow solid. MS (ES+) C42H55F2N5O4Si requires: 759, found 760 [M+H]+, Step 3 Tert-butyl 3-[6-[8-ethynyl-7-fluoro-3-(methoxymethoxy)-1-naphthyl]-7-fluoro-1-methyl- pyrazolo[4,3-c]pyridin-3-yl]-3,9-diazabicyclo[3.3.1]nonane-9-carboxylate Boc N N N

[0173] To a solution of tert-buuoro-3-(methoxymethoxy)-8-(2- triisopropylsilylethynyl)-1-naphthyl]-1-methyl-pyrazolo[4,3-c]pyridin-3-yl]-3,9- diazabicyclo[3.3.1]nonane-9-carboxylate (15 mg, 19.74 μmol, 1 eq) in DMF (0.5 mL) was added CsF (10 mg, 65.83 μmol, 2.43 μL, 3.34 eq), the mixture was stirred at 25 °C for 1 h. LCMS showed the starting material was consumed completely and a peak (65%) with the desired mass. The mixture was poured into a mixture of saturated NH4Cl (10 mL) and water (10 mL). The aqueous phase was extracted with ethyl acetate (30 mL × 2). The combined organic phase was washed with brine (10 mL × 2), dried over anhydrous Na2SO4, filtered and concentrated under vacuum to afford tert-butyl 3-[6-[8-ethynyl-7-fluoro-3- (methoxymethoxy)-1-naphthyl]-7-fluoro-1-methyl-pyrazolo[4,3-c]pyridin-3-yl]-3,9- diazabicyclo[3.3.1]nonane-9-carboxylate (11.5 mg, 19.05 μmol, 96.52% yield) as a yellow solid was used into the next step without further purification. MS (ES+) C33H35F2N5O4 requires: 603, found 604 [M+H]+, Step 4 4-[3-(3,9-diazabicyclo[3.3.1]nonan-3-yl)-7-fluoro-1-methyl-pyrazolo[4,3-c]pyridin-6-yl]- 5-ethynyl-6-fluoro-naphthalen-2-ol

[0174] To a mixture of tert-bu luoro-3-(methoxymethoxy)-1-naphthyl]-7-fluoro-1-methyl-pyrazolo[4,3-c]pyridin-3-yl]-3,9-diazabicyclo[3.3.1]nonane-9- carboxylate (11.5 mg, 19.05 μmol, 1 eq) in DCM (0.45 mL) was added TFA (230.25 mg, 2.02 mmol, 150 μL, 106.00 eq). The mixture was stirred at 20 °C for 0.5 h. LCMS showed the starting material was consumed completely and a peak (65%) with the desired mass. The mixture was concentrated under vacuum (<28 °C). The residue was purified by Prep-HPLC (column: Phenomenex Luna C18150*25mm*10um; mobile phase: [water (FA)-ACN]; gradient:10%-40% B over 10 min) and freeze-dried to afford 4-[3-(3,9- diazabicyclo[3.3.1]nonan-3-yl)-7-fluoro-1-methyl-pyrazolo[4,3-c]pyridin-6-yl]-5-ethynyl-6- fluoro-naphthalen-2-ol (1.2 mg, 2.61 μmol, 13.71% yield) as a yellow solid.

[0175] MS (ES+) C26H23F2N5O requires: 459, found: 460 [M+H]+

[0176] 1H NMR (400 MHz, CD3OD) δ ppm 8.88 (d, J = 1.1 Hz, 1H), 8.54 (s, 1H), 7.86 (dd, J = 5.9, 9.3 Hz, 1H), 7.36 - 7.29 (m, 2H), 7.21 (d, J = 2.6 Hz, 1H), 4.21 (d, J = 13.1 Hz, 2H), 4.07 (s, 3H), 3.70 - 3.65 (m, 2H), 3.63 - 3.54 (m, 2H), 3.25 (s, 1H), 2.68 - 2.54 (m, 1H), 2.24 - 2.09 (m, 4H), 1.79 - 1.66 (m, 1H) EXAMPLE 32 4-[3-[(3R,5S)-3,5-dimethylpiethyl-pyrazolo[4,3-c]pyridin-6- yl]-5-ethynyl-6-fluoro-naphthalen-2-ol

[0177] Prepared similarly to Example 31 using tert-butyl (2R,6S)-2,6- dimethylpiperazine-1-carboxylate (68.80 mg, 321.05 μmol, 1 eq) in dioxane (1 mL) were added Cs2CO3(313.81 mg, 963.14 μmol, 3 eq) and CPHOS PD G3 (25.89 mg, 32.10 μmol, 0.1 eq) under N2 at 90 °C for 16 hrs on step 1. MS (ES+) C25H23N5F2O requires: 447, found: 448 [M+H]+.1H NMR (400 MHz, CD3OD) δ ppm 8.87 (d, J = 1.2 Hz, 1H), 8.49 (s, 0.3H), 7.89 - 7.83 (m, 1H), 7.36 - 7.29 (m, 2H), 7.20 (d, J = 2.6 Hz, 1H), 4.16 (d, J = 13.4 Hz, 2H), 4.07 (s, 3H), 3.64 - 3.52 (m, 2H), 3.22 (s, 1H), 3.03 - 2.91 (m, 2H), 1.40 (d, J = 6.5 Hz, 6H). EXAMPLE 33 4-[3-[3-(dimethylamino)azetidin-1-yl]-7-fluoro-1-methyl-pyrazolo[4,3-c]pyridin-6-yl]-5- ethynyl-6-fluoro-naphthalen-2-ol

[0178] Prepared similarly toimethylazetidin-3-amine (52.63 mg, 385.26 μmol, 1.2 eq, HCl), Cs2CO3(313.81 mg, 963.14 μmol, 3 eq) in dioxane (3 mL), and added Xantphos Pd G4 (30.90 mg, 32.10 μmol, 0.1 eq) under N2 at 70 °C for 16 h under N2. on step 1. MS (ES+) C24H21F2N5O requires: 433, found: 434 [M+H]+.1H NMR (400 MHz, CD3OD) δ = 8.61 (d, J = 1.3 Hz, 1H), 8.18 (s, 0.1H), 7.85 (dd, J = 5.8, 9.1 Hz, 1H), 7.36 - 7.28 (m, 2H), 7.20 (d, J = 2.4 Hz, 1H), 4.51 - 4.43 (m, 2H), 4.27 - 4.19 (m, 2H), 4.03 (s, 3H), 3.91 - 3.82 (m, 1H), 3.24 (s, 1H), 2.62 (s, 6H). EXAMPLE 344-[3-(3,6-diazabicyclo[3.1.1]he ethyl-pyrazolo[4,3-c]pyridin-6-yl]-5-ethynyl-6-fluoro-naphthalen-2-ol

[0179] Prepared similarly to Example 31 using tert-butyl 3,6-diazabicyclo[3.1.1]heptane- 6-carboxylate (92 mg, 464.03 μmol, 1.2 eq) in dioxane (7 mL), BINAP (24 mg, 38.54 μmol, 0.1 eq), Cs2CO3(376.80 mg, 1.16 mmol, 3 eq) and Pd2(dba)3(36 mg, 39.30 μmol, 0.102 eq) at 70 °C for 12 h under N2 on step 1. MS (ES+) C24H19F2N5O requires: 431, found: 432 [M+H]+.1H NMR (400 MHz, CD3OD) δ ppm 8.88 (d, J = 1.5 Hz, 1H), 8.50 (s, 1H), 7.86 (dd, J = 5.8, 9.1 Hz, 1H), 7.37 - 7.28 (m, 2H), 7.21 (d, J = 2.6 Hz, 1H), 4.49 (d, J = 6.2 Hz, 2H), 4.31 - 4.14 (m, 4H), 4.07 (s, 3H), 3.21 (d, J = 0.9 Hz, 1H), 3.12 - 3.04 (m, 1H), 2.11 (d, J = 10.4 Hz, 1H). EXAMPLE 35 4-[3-(3,6-diazabicyclo[3.1.1]hepethyl-pyrazolo[4,3-c]pyridin-6-yl]- 5-ethynyl-6-fluoro-naphthalen-2-ol

[0180] Prepared similarly to Example 31 using tert-butyl 3,6-diazabicyclo[3.1.1]heptane- 3-carboxylate (12.73 mg, 64.21 μmol, 1.0 eq) in dioxane (0.32 mL), Cs2CO3 (62.80 mg,192.75 μmol, 3 eq) and Sphos-Pd-G3(5.01 mg, 6.42 μmol, 0.1 eq), at 90 °C for 4 h under N2on step 1. MS (ES+) C24H19F2N5O requires: 431, found: 432 [M+H]+1H NMR (400 MHz, CD3OD) δ ppm 8.61 (d, J = 1.5 Hz, 1H), 8.49 (s, 1H), 7.86 (dd, J = 5.7, 9.1 Hz, 1H), 7.37 - 7.29 (m, 2H), 7.20 (d, J = 2.6 Hz, 1H), 4.91 - 4.89 (m, 2H), 4.63 (d, J = 6.2 Hz, 2H), 4.09 (s, 3H), 3.87 (d, J = 13.4 Hz, 2H), 3.27 (s, 1H), 3.16 - 3.11 (m, 1H), 2.06 (d, J = 9.4 Hz, 1H). EXAMPLE 36 4-[3-(6,8-diazabicyclo[3.2.2]nothyl-pyrazolo[4,3-c]pyridin-6-yl]- 5-ethynyl-6-fluoro-naphthalen-2-ol

[0181] Prepared similarly to Example 31 using tert-butyl 6,8-diazabicyclo[3.2.2]nonane- 6-carboxylate (71.93 mg, 317.84 μmol, 1.1 eq) in dioxane (5 mL), Cs2CO3(282.60 mg, 867.35 μmol, 3 eq) and Xantphos Pd G4 (27.90 mg, 28.99 μmol, 0.1 eq) at 90 °C for 16 h under N2 on step 1. MS (ES+) C26H23F2N5O requires: 459, found: 460 [M+H]+1H NMR (400 MHz, DMSO-d6) δ ppm 8.76 (d, J = 3.7 Hz, 1H), 8.54 (s, 0.6H), 7.85 (dd, J = 5.6, 9.0 Hz, 1H), 7.36 - 7.29 (m, 2H), 7.20 (dd, J = 2.3, 5.7 Hz, 1H), 4.09 - 3.99 (m, 4H), 3.91 (d, J = 11.2 Hz, 1H), 3.87 - 3.80 (m, 1H), 3.61 - 3.54 (m, 1H), 3.42 - 3.37 (m, 1H), 3.28 - 3.26 (m, 1H), 3.25 (s, 1H), 2.47 - 2.31 (m, 1H), 2.17 - 2.07 (m, 2H), 2.04 - 1.94 (m, 1H), 1.87 - 1.76 (m, 1H), 1.75 - 1.62 (m, 1H). EXAMPLE 374-[1-cyclopropyl-3-[(1S,5R)-3, y . . ptan-6-yl]-7-fluoro-pyrazolo[4,3- c]pyridin-6-yl]-5-ethynyl-6-fluoro-naphthalen-2-ol

[0182] Prepared similarly to Example 31 using tert-butyl (1R,5R)-3,6- diazabicyclo[3.2.0]heptane-3-carboxylate (69.54 mg, 296.28 μmol, 1 eq, HCl) in dioxane (3 mL), Xantphos Pd G4 (28.51 mg, 29.63 μmol, 0.1 eq), and Cs2CO3 (386.13 mg, 1.19 mmol, 4 eq) at 80 °C for 16 h under N2. MS (ES+) C26H21F2N5O requires:457, found:458 [M+H]+.1H NMR (400 MHz, CD3OD) δ = 8.56 (s, 1H), 8.51 (s, 1H), 7.86 (dd, J = 5.7, 9.1 Hz, 1H), 7.38 - 7.28 (m, 2H), 7.20 (t, J = 2.4 Hz, 1H), 5.25 - 5.16 (m, 1H), 4.49 - 4.37 (m, 1H), 4.12 - 4.01 (m, 1H), 3.84 - 3.65 (m, 3H), 3.58 - 3.45 (m, 1H), 3.38 - 3.32 (m, 1H), 3.28 - 3.16 (m, 2H), 1.26 - 1.16 (m, 2H), 1.15 - 1.06 (m, 2H). EXAMPLE 38 4-[1-(2-azabicyclo[2.2.2]oct-5-hyl-pyrrolo[2,3-c]pyridin-5-yl]-5- ethynyl-6-fluoro-naphthalen-2-ol Step 1 tert-butyl N-(6-chloro-5-fluoro-3-pyridyl)carbamate

[0183] To a solution of 5-bromo -pyridine (4.7 g, 22.34 mmol, 1 eq) and tert-butyl carbamate (2.88 g, 24.57 mmol, 1.1 eq) in dioxane (60 mL) were added Pd2(dba)3(613.58 mg, 670.05 μmol, 0.03 eq), Xantphos (516.94 mg, 893.40 μmol, 0.04 eq) and Cs2CO3 (14.55 g, 44.67 mmol, 2 eq). The mixture was stirred at 85 °C for 16 h under nitrogen. LCMS showed the reaction was completed, several peaks were showed on LCMS and 43% of desired mass. The mixture was concentrated to remove dioxane, diluted with water (200 mL) and extracted with ethyl acetate (200 mL × 2), the combined organic layers were washed with brine (200 mL), dried over anhydrous sodium sulfate and filtered. The filtrate was concentrated to afford a residue. The residue was purified by flash silica gel chromatography (40 g SepaFlash® Silica Flash Column, Eluent of 0~25% Ethyl acetate / Petroleum ether gradient @ 80 mL / min) to afford tert-butyl N-(6-chloro-5-fluoro-3- pyridyl)carbamate (5.1 g, 11.79 mmol, 52.77% yield, 57% purity) as a yellow solid.

[0184] MS (ES+) C10H12ClFN2O2 requires:246 and 248, found:247 and 249 [M+H]+.1H NMR (400 MHz, CDCl3) δ = 8.05 (d, J = 9.3 Hz, 1H), 8.00 (d, J = 2.3 Hz, 1H), 6.77 (s, 1H), 1.53 (s, 9 H). Step 2 tert-butyl N-(6-chloro-5-fluoro-4-iodo-3-pyridyl)carbamate

[0185] To a solution of tert-butyuoro-3-pyridyl)carbamate (4.6 g, 18.65 mmol, 1 eq) and TMEDA (6.50 g, 55.95 mmol, 8.44 mL, 3 eq) in THF (80 mL) were added n-BuLi (2.5 M in heptane, 22.38 mL, 3 eq) at -70 °C under N2atmosphere. The mixture was raised to -20 °C and stirred at -20 °C for 0.5 h. Then the mixture was cooled to -70 °C, to the mixture was added a solution of I2(14.20 g, 55.95 mmol, 11.27 mL, 3 eq) in THF (20 mL) at -70 °C under N2 atmosphere. The mixture was warmed to 20 °C and stirred at 20 °C for 6 h under N2atmosphere. LCMS showed 85% of desired mass. The mixture was quenched with water (200 mL) dropwise at 0 °C, then extracted with ethyl acetate (200 mL × 2). The combined organic layers were washed with saturated Na2SO3 aqueous solution (200 mL), dried over anhydrous sodium sulfate and filtered. The filtrate was concentrated to afford aresidue. The residue was purified by flash silica gel chromatography (80 g SepaFlash® Silica Flash Column, Eluent of 0~20% Ethyl acetate / Petroleum ether gradient @ 80 mL / min) to afford tert-butyl N-(6-chloro-5-fluoro-4-iodo-3-pyridyl)carbamate (5 g, 12.75 mmol, 68.37% yield, 95% purity) as a yellow solid.1H NMR (400 MHz, CDCl3) δ = 8.83 (s, 1H), 6.73 (s, 1H), 1.56 (s, 9H). Step 3 tert-butyl N-[6-chloro-5-fluoro-4-(2-trimethylsilylethynyl)-3-pyridyl]carbamate

[0186] To a solution of tert-buty N-(6-c oro-5- uoro-4-iodo-3-pyridyl)carbamate (5 g, 13.42 mmol, 1 eq), Pd(PPh3)2Cl2(470.99 mg, 671.03 μmol, 0.05 eq) and CuI (766.79 mg, 4.03 mmol, 0.3 eq) in THF (60 mL) were added ethynyl(trimethyl)silane (13.18 g, 134.21 mmol, 18.59 mL, 10 eq) and Et3N (4.07 g, 40.26 mmol, 5.60 mL, 3 eq) under N2. The mixture was stirred at 30 °C for 16 h under nitrogen. LCMS showed the reaction was completed, several peaks were showed on LCMS and 54% of desired mass. The mixture was diluted with water (200 mL), extracted with ethyl acetate (200 mL × 2). The combined organic layers were washed with brine (200 mL), dried over anhydrous sodium sulfate and filtered. The filtrate was concentrated to afford a residue. The residue was purified by flash silica gel chromatography (80 g SepaFlash® Silica Flash Column, Eluent of 0~25% Ethyl acetate / Petroleum ether gradient @ 80 mL / min) to afford tert-butyl N-[6-chloro-5-fluoro-4- (2-trimethylsilylethynyl)-3-pyridyl]carbamate (4.9 g, 12.58 mmol, 93.71% yield, 88% purity) as a yellow solid. MS (ES+) C15H20ClFN2O2Si requires:342 and 344, found:343 and 345 [M+H]+.1H NMR (400 MHz, CDCl3) δ = 9.02 (s, 1H), 7.04 (s, 1H), 1.54 (s, 9H), 0.33 (s, 9H). Step 4 5-chloro-4-fluoro-1H-pyrrolo[2,3-c]pyridine

[0187] To a solution of tert-butylfluoro-4-(2-trimethylsilylethynyl)-3- pyridyl]carbamate (4.9 g, 14.29 mmol, 1 eq) in t-BuOH (50 mL) was added t-BuOK (4.81 g, 42.87 mmol, 3 eq). The mixture was stirred at 80 °C for 16 h. LCMS showed the reaction was completed, several peaks were showed on LCMS and 73% of desired mass. The mixture was concentrated to remove t-BuOH, then diluted with water (100 mL), and extracted with ethyl acetate (100 mL × 2). The combined organic layers were washed with brine (100 mL), dried over anhydrous sodium sulfate and filtered. The filtrate was concentrated to afford a residue. The residue was purified by flash silica gel chromatography (80 g SepaFlash® Silica Flash Column, Eluent of 0~40% Ethyl acetate / Petroleum ether gradient @ 80 mL / min) to afford 5-chloro-4-fluoro-1H-pyrrolo[2,3-c]pyridine (1 g, 3.93 mmol, 27.49% yield, 67% purity) as a yellow solid. MS (ES+) C7H4ClFN2 requires:170 and 172, found:171 and 173 [M+H]+.1H NMR (400 MHz, DMSO-d6) δ = 12.11 (s, 1H), 8.46 (s, 1H), 7.76 (t, J = 2.7 Hz, 1H), 6.66 (s, 1H). Step 5 3-bromo-5-chloro-4-fluoro-1H-pyrrolo[2,3-c]pyridine

[0188] To a solution of 5-chloro-4-fluoro-1H-pyrrolo[2,3-c]pyridine (450 mg, 2.64 mmol, 1 eq) in DMF (10 mL) was added NBS (469.56 mg, 2.64 mmol, 1 eq) at 0 °C. The mixture was stirred at 20 °C for 2 h. LCMS showed the reaction was completed and 60% of desired mass. The mixture was quenched with saturated Na2SO3 aqueous solution (20 mL) and extracted with ethyl acetate (20 mL × 2). The combined organic layers were washed with brine (20 mL), dried over anhydrous sodium sulfate and filtered. The filtrate was concentrated to afford 3-bromo-5-chloro-4-fluoro-1H-pyrrolo[2,3-c]pyridine (658 mg, crude) as yellow oil.MS (ES+) C7H3BrClFN2requires:248 and 250, found:249 and 251 [M+H]+. Step 6 tert-butyl 3-bromo-5-chloro-4-fluoro-pyrrolo[2,3-c]pyridine-1-carboxylate

[0189] To a solution of 3-bromo--c o o- - uoro-1H-pyrrolo[2,3-c]pyridine (658 mg, 2.64 mmol, 1 eq) in dichloromethane (10 mL) were added Et3N (800.70 mg, 7.91 mmol, 1.10 mL, 3 eq) and Boc2O (1.04 g, 4.75 mmol, 1.09 mL, 1.8 eq). The mixture was stirred at 20 °C for 2 h. LCMS showed the reaction was completed, several peaks were showed on LCMS and 74% of desired mass. The mixture was diluted with water (20 mL) and extracted with dichloromethane (20 mL × 2), the combined organic layers were washed with brine (20 mL), dried over anhydrous sodium sulfate and filtered. The filtrate was concentrated to afford a residue. The residue was purified by flash silica gel chromatography (40 g SepaFlash® Silica Flash Column, Eluent of 0~80% Ethyl acetate / Petroleum ether gradient @ 80 mL / min) to afford tert-butyl 3-bromo-5-chloro-4-fluoro-pyrrolo[2,3-c]pyridine-1-carboxylate (1.9 g, crude) as a yellow solid. MS (ES+) C12H11BrClFN2O2 requires:348 and 350, found:349 and 351 [M+H]+. Step 7 tert-butyl 5-chloro-4-fluoro-3-methyl-pyrrolo[2,3-c]pyridine-1-carboxylate

[0190] To a solution of tert-butyl 3-bromo-5-chloro-4-fluoro-pyrrolo[2,3-c]pyridine-1- carboxylate (1.9 g, 5.44 mmol, 1 eq) and 2,4,6-trimethyl-1,3,5,2,4,6-trioxatriborinane (3.5 M, 2.33 mL, 1.5 eq) in dioxane (30 mL) were added Pd(dppf)Cl2(397.69 mg, 543.50 μmol, 0.1 eq) and K3PO4 (3.46 g, 16.31 mmol, 3 eq). The mixture was stirred at 80 °C for 16 h under N2. LCMS showed the reaction was completed and 55% of desired mass. The mixture wasconcentrated to remove dioxane, then diluted with water (30 mL) and extracted with ethyl acetate (30 mL × 2). The combined organic layers were washed with brine (30 mL), dried over anhydrous sodium sulfate and filtered. The filtrate was concentrated to afford a residue. The residue was purified by flash silica gel chromatography (40 g SepaFlash® Silica Flash Column, Eluent of 0~20% Ethyl acetate / Petroleum ether gradient @ 80 mL / min) to afford tert-butyl 5-chloro-4-fluoro-3-methyl-pyrrolo[2,3-c]pyridine-1-carboxylate (200 mg, 632.21 μmol, 11.63% yield, 90% purity) as a white solid.

[0191] MS (ES+) C13H14ClFN2O2requires:284 and 286, found:285 and 287 [M+H]+. Step 8 5-chloro-4-fluoro-3-methyl-1H-pyrrolo[2,3-c]pyridine

[0192] To a solution of tert-butyl 5-chloro-4-fluoro-3-methyl-pyrrolo[2,3-c]pyridine-1- carboxylate (800 mg, 2.81 mmol, 1 eq) in dichloromethane (6 mL) was added TFA (3.07 g, 26.93 mmol, 2 mL, 9.58 eq). The mixture was stirred at 20 °C for 1 h. LCMS showed the reaction was completed and 61% of desired mass. The mixture was concentrated to afford a residue. The residue was purified by prep-HPLC (column: Phenomenex luna C18 150*40mm* 15um;mobile phase: [water(FA)-ACN];gradient:33%-63% B over min). The eluent was concentrated and freeze-dried to afford 5-chloro-4-fluoro-3-methyl-1H- pyrrolo[2,3-c]pyridine (310 mg, 1.66 mmol, 59.17% yield, 99% purity) as a white solid.

[0193] MS (ES+) C8H6ClFN2requires:184 and 186, found:185 and 187 [M+H]+.1H NMR (400 MHz, CDCl3) δ = 8.56 (s, 1H), 8.35 (d, J = 0.8 Hz, 1H), 7.15 (s, 1H), 2.46 (s, 3H). Step 9 tert-butyl 5-(trifluoromethylsulfonyloxy)-2-azabicyclo[2.2.2]oct-5-ene-2-carboxylate

[0194] To a solution of tert-butyl 5-oxo-2-azabicyclo[2.2.2]octane-2-carboxylate (1 g, 4.44 mmol, 1 eq) and 1,1,1-trifluoro-N-phenyl-N- (trifluoromethylsulfonyl)methanesulfonamide (2.38 g, 6.66 mmol, 1.5 eq) in THF (10 mL) was added LiHMDS (1 M in THF, 8.88 mL, 2 eq) at -70 °C under N2atmosphere. The mixture was stirred at -70 °C for 2 h under N2 atmosphere. TLC(Petroleum ether: Ethyl acetate= 5： 1, I2) showed tert-butyl 5-oxo-2-azabicyclo[2.2.2]octane-2-carboxylate remained and a new spot with lower polarity. The mixture was quenched with water (50 mL) at 0°C, then extracted with ethyl acetate (50 mL× 2). The combined organic layers were washed with brine (50 mL), dried over anhydrous sodium sulfate and filtered. The filtrate was concentrated to afford a residue. The residue was purified by flash silica gel chromatography (40 g SepaFlash® Silica Flash Column, Eluent of 0~25% Ethyl acetate / Petroleum ether gradient @ 80 mL / min) to afford tert-butyl 5-(trifluoromethylsulfonyloxy)-2- azabicyclo[2.2.2]oct-5-ene-2-carboxylate (660 mg, 923.48 μmol, 20.80% yield, 50% purity) as colorless oil. Step 10 tert-butyl 5-(5-chloro-4-fluoro-3-methyl-pyrrolo[2,3-c]pyridin-1-yl)-2- azabicyclo[2.2.2]oct-5-ene-2-carboxylate

[0195] To a solution of 5-chloro-4-fluoro-3-methyl-1H-pyrrolo[2,3-c]pyridine (90 mg, 487.55 μmol, 1 eq) and tert-butyl 5-(trifluoromethylsulfonyloxy)-2-azabicyclo[2.2.2]oct-5- ene-2-carboxylate (660 mg, 1.85 mmol, 3.79 eq) in dioxane (5 mL) were added K3PO4 (310.47 mg, 1.46 mmol, 3 eq), XPhos (46.48 mg, 97.51 μmol, 0.2 eq) and Pd2(dba)3(44.65 mg, 48.75 μmol, 0.1 eq). The mixture was stirred at 100 °C for 16 h under N2. LCMS showed 28% of 5-chloro-4-fluoro-3-methyl-1H-pyrrolo[2,3-c]pyridine remained, several peaks were showed on LCMS and 18% of desired mass. The mixture was diluted with water (10 mL) and extracted with ethyl acetate (10 mL × 2). The combined organic layers were washed with brine (10 mL), dried over anhydrous sodium sulfate and filtered. The filtrate wasconcentrated to afford a residue. The residue was purified by prep-TLC (Petroleum ether : Ethyl acetate=3:1) to afford tert-butyl 5-(5-chloro-4-fluoro-3-methyl-pyrrolo[2,3-c]pyridin-1- yl)-2-azabicyclo[2.2.2]oct-5-ene-2-carboxylate (97 mg, 123.77 μmol, 25.39% yield, 50% purity) as yellow oil.

[0196] MS (ES+) C20H23ClFN3O2 requires:391 and 393, found:392 and 394 [M+H]+. Step 11 tert-butyl 5-[4-fluoro-5-[7-fluoro-3-(methoxymethoxy)-8-(2-triisopropylsilylethynyl)-1- naphthyl]-3-methyl-pyrrolo[2,3-c]pyridin-1-yl]-2-azabicyclo[2.2.2]oct-5-ene-2- carboxylate

[0197] To a solution of tert-butyl 5-(5-chloro-4-fluoro-3-methyl-pyrrolo[2,3-c]pyridin-1- yl)-2-azabicyclo[2.2.2]oct-5-ene-2-carboxylate (59 mg, 150.56 μmol, 1 eq) and 2-[2-fluoro- 6-(methoxymethoxy)-8-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)-1-naphthyl]ethynyl- triisopropyl-silane (100.32 mg, 195.73 μmol, 1.3 eq) in dioxane (3 mL) were added CATACXIUM(R) A PD G3 (10.96 mg, 15.06 μmol, 0.1 eq) and K3PO4 (1.5 M in water, 301.12 μL, 3 eq). The mixture was stirred at 100 °C for 16 h under N2. LCMS showed the reaction was completed, several peaks were showed on LCMS and 16% of desired mass. The mixture was diluted with water (10 mL) and extracted with ethyl acetate (10 mL × 2). The combined organic layers were washed with brine (10 mL), dried over anhydrous sodium sulfate and filtered. The filtrate was concentrated to afford a residue. The residue was purified by prep-TLC (Petroleum ether: Ethyl acetate= 3: 1) to afford tert-butyl 5-[4-fluoro-5-[7- fluoro-3-(methoxymethoxy)-8-(2-triisopropylsilylethynyl)-1-naphthyl]-3-methyl-pyrrolo[2,3- c]pyridin-1-yl]-2-azabicyclo[2.2.2]oct-5-ene-2-carboxylate (17 mg, 21.31 μmol, 14.15% yield, 93% purity) as yellow oil.

[0198] MS (ES+) C43H53F2N3O4Si requires:741, found:742 [M+H]+.Step 12 tert-butyl 5-[5-[8-ethynyl-7-fluoro-3-(methoxymethoxy)-1-naphthyl]-4-fluoro-3-methyl- pyrrolo[2,3-c]pyridin-1-yl]-2-azabicyclo[2.2.2]oct-5-ene-2-carboxylate

[0199] To a solution of tert-bu y -[ - uoro- -[ - uoro-3-(methoxymethoxy)-8-(2- triisopropylsilylethynyl)-1-naphthyl]-3-methyl-pyrrolo[2,3-c]pyridin-1-yl]-2- azabicyclo[2.2.2]oct-5-ene-2-carboxylate (17 mg, 22.91 μmol, 1 eq) in DMF (1 mL) was added CsF (10.44 mg, 68.74 μmol, 2.54 μL, 3 eq). The mixture was stirred at 20 °C for 30 min. LCMS showed the reaction was completed and 93% of desired mass. The mixture was diluted with water (5 mL) and extracted with ethyl acetate (5 mL). The organic layer was washed with brine (5 mL), dried over anhydrous sodium sulfate and filtered. The filtrate was concentrated to afford tert-butyl 5-[5-[8-ethynyl-7-fluoro-3-(methoxymethoxy)-1-naphthyl]- 4-fluoro-3-methyl-pyrrolo[2,3-c]pyridin-1-yl]-2-azabicyclo[2.2.2]oct-5-ene-2-carboxylate (14 mg, crude) as yellow oil.

[0200] MS (ES+) C34H33F2N3O4 requires:585, found:586 [M+H]+. Step 13 4-[1-(2-azabicyclo[2.2.2]oct-5-en-5-yl)-4-fluoro-3-methyl-pyrrolo[2,3-c]pyridin-5-yl]-5- ethynyl-6-fluoro-naphthalen-2-ol

[0201] To a solution of tert-butyl 5-[5-[8-ethynyl-7-fluoro-3-(methoxymethoxy)-1- naphthyl]-4-fluoro-3-methyl-pyrrolo[2,3-c]pyridin-1-yl]-2-azabicyclo[2.2.2]oct-5-ene-2- carboxylate (14 mg, 23.91 μmol, 1 eq) in dichloromethane (0.6 mL) was added TFA (460.50 mg, 4.04 mmol, 0.3 mL). The mixture was stirred at 20 °C for 20 min. LCMS showed 81% of desired mass was detected. The mixture was quenched with saturated NaHCO3 aqueous solution (5 mL), then extracted with dichloromethane (3 mL × 2). The combined organic layers were concentrated to afford a residue. The residue was purified by prep-HPLC (column: Phenomenex luna C18150*25mm* 10um;mobile phase: [water(FA)- ACN];gradient:13%-33% B over 10 min). The eluent was freeze-dried to afford 4-[1-(2- azabicyclo[2.2.2]oct-5-en-5-yl)-4-fluoro-3-methyl-pyrrolo[2,3-c]pyridin-5-yl]-5-ethynyl-6- fluoro-naphthalen-2-ol (2.9 mg, 5.83 μmol, 24.39% yield, 98% purity, FA) as a white solid.

[0202] MS (ES+) C27H21F2N3O requires:441, found:442 [M+H]+.

[0203] 1H NMR (400 MHz, CD3OD) δ = 8.76 - 8.67 (m, 1H), 8.52 (s, 1H), 7.85 (dd, J = 5.8, 9.1 Hz, 1H), 7.61 (s, 1H), 7.37 - 7.26 (m, 2H), 7.17 (t, J = 2.3 Hz, 1H), 6.58 - 6.48 (m, 1H), 4.56 - 4.54 (m, 1H), 3.67 - 3.58 (m, 1H), 3.41 - 3.37 (m, 1H), 3.20 - 3.09 (m, 2H), 2.47 (s, 3H), 2.30 - 2.17 (m, 1H), 2.12 - 2.00 (m, 1H), 1.95 - 1.76 (m, 2H). EXAMPLE 39 4-[1-(2-azabicyclo[2.2.2]octayl-pyrrolo[2,3-c]pyridin-5-yl]-5- ethynyl-6-fluoro-naphthalen-2-ol Step 1 tert-butyl 5-hydroxy-2-azabicyclo[2.2.2]octane-2-carboxylate

[0204] To a solution of tert-butyl 5-oxo-2-azabicyclo[2.2.2]octane-2-carboxylate (500 mg, 2.22 mmol, 1 eq) in THF (10 mL) was added LiAlH4(2.5 M, 1.33 mL, 1.5 eq) at -20 °C under N2 atmosphere. The mixture was stirred at 0 °C for 2 h under N2 atmosphere. TLC (Petroleum ether : Ethyl acetate=1:1, I2) showed the reaction was completed and a new major spot with higher polarity. The mixture was quenched with saturated NH4Cl aqueous solution (10 mL), then diluted with water (10 mL) and extracted with ethyl acetate (20 mL × 2). The combined organic layers were concentrated to afford a residue. The residue was purified by flash silica gel chromatography (20 g SepaFlash® Silica Flash Column, Eluent of 0-60% Ethyl acetate / Petroleum ether gradient @ 80 mL / min) to afford tert-butyl 5-hydroxy-2- azabicyclo[2.2.2]octane-2-carboxylate (530 mg, 1.73 mmol, 77.74% yield, 74% purity) as colorless oil.

[0205] MS (ES+) C12H21NO3 requires:227, found:172 [M+H-t-Bu]+. Step 2 tert-butyl 5-(5-chloro-4-fluoro-3-methyl-pyrrolo[2,3-c]pyridin-1-yl)-2- azabicyclo[2.2.2]octane-2-carboxylate

[0206] To a solution of 5-chloryl-1H-pyrrolo[2,3-c]pyridine (90 mg, 487.55 μmol, 1 eq) and tert-butyl 5-hydroxy-2-azabicyclo[2.2.2]octane-2-carboxylate (166.23 mg, 731.32 μmol, 1.5 eq) in toluene (5 mL) was added 2-(tributyl- phosphanylidene)acetonitrile (176.50 mg, 731.32 μmol, 1.5 eq). The mixture was stirred at 100 °C for 16 h. LCMS showed 26% of 5-chloro-4-fluoro-3-methyl-1H-pyrrolo[2,3- c]pyridine remained, several peaks were showed on LCMS and 19% of desired mass. The mixture was diluted with water (10 mL) and extracted with ethyl acetate (10 mL × 2). The combined organic layers were washed with brine (10 mL), dried over anhydrous sodium sulfate and filtrated. The filtrate was concentrated to afford a residue. The residue was purified by prep-TLC (Petroleum ether: Ethyl acetate= 3: 1) to afford tert-butyl 5-(5-chloro- 4-fluoro-3-methyl-pyrrolo[2,3-c]pyridin-1-yl)-2-azabicyclo[2.2.2]octane-2-carboxylate (38 mg, 75.25 μmol, 15.43% yield, 78% purity) as yellow oil.MS (ES+) C20H25ClFN3O2requires:393 and 395, found:394 and 396 [M+H]+. Step 3 tert-butyl 5-[4-fluoro-5-[7-fluoro-3-(methoxymethoxy)-8-(2-triisopropylsilylethynyl)-1- naphthyl]-3-methyl-pyrrolo[2,3-c]pyridin-1-yl]-2-azabicyclo[2.2.2]octane-2-carboxylate

[0207] To l-pyrrolo[2,3-c]pyridin-1- yl)-2-azabicyclo[2.2.2]octane-2-carboxylate (38 mg, 96.48 μmol, 1 eq) and 2-[2-fluoro-6- (methoxymethoxy)-8-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)-1-naphthyl]ethynyl- triisopropyl-silane (64.28 mg, 125.42 μmol, 1.3 eq) in dioxane (2 mL) were added CATACXIUM(R) A PD G3 (7.03 mg, 9.65 μmol, 0.1 eq) and K3PO4(1.5 M in water, 192.95 μL, 3 eq). The mixture was stirred at 100 °C for 16 h under N2. LCMS showed 15% of tert- butyl 5-(5-chloro-4-fluoro-3-methyl-pyrrolo[2,3-c]pyridin-1-yl)-2-azabicyclo[2.2.2]oct-5- ene-2-carboxylate remained, several peaks were showed on LCMS and 16% of desired mass. The mixture was diluted with water (10 mL) and extracted with ethyl acetate (10 mL × 2). The combined organic layers were washed with brine (10 mL), dried over anhydrous sodium sulfate and filtrated. The filtrate was concentrated to afford a residue. The residue was purified by prep-TLC (Petroleum ether: Ethyl acetate= 3: 1) to afford tert-butyl 5-[4-fluoro-5- [7-fluoro-3-(methoxymethoxy)-8-(2-triisopropylsilylethynyl)-1-naphthyl]-3-methyl- pyrrolo[2,3-c]pyridin-1-yl]-2-azabicyclo[2.2.2]octane-2-carboxylate (27 mg, 35.20 μmol, 36.49% yield, 97% purity) as yellow oil.

[0208] MS (ES+) C43H55F2N3O4Si requires:743, found:744 [M+H]+. Step 4 tert-butyl 5-[5-[8-ethynyl-7-fluoro-3-(methoxymethoxy)-1-naphthyl]-4-fluoro-3-methyl- pyrrolo[2,3-c]pyridin-1-yl]-2-azabicyclo[2.2.2]octane-2-carboxylate

[0209] To a solution of tert- ro-3-(methoxymethoxy)-8-(2-triisopropylsilylethynyl)-1-naphthyl]-3-methyl-pyrrolo[2,3-c]pyridin-1-yl]-2- azabicyclo[2.2.2]octane-2-carboxylate (27 mg, 36.29 μmol, 1 eq) in DMF (1 mL) was added CsF (16.54 mg, 108.87 μmol, 4.02 μL, 3 eq). The mixture was stirred at 20 °C for 20 min. LCMS showed 83% of desired mass. The mixture was diluted with water (5 mL) and extracted with ethyl acetate (5 mL). The organic layer was washed with brine (5 mL), dried over anhydrous sodium sulfate and filtrated. The filtrate was concentrated to afford tert-butyl 5-[5-[8-ethynyl-7-fluoro-3-(methoxymethoxy)-1-naphthyl]-4-fluoro-3-methyl-pyrrolo[2,3- c]pyridin-1-yl]-2-azabicyclo[2.2.2]octane-2-carboxylate (21 mg, crude) as yellow oil.

[0210] MS (ES+) C34H35F2N3O4requires:587, found:588 [M+H]+. Step 5 4-[1-(2-azabicyclo[2.2.2]octan-5-yl)-4-fluoro-3-methyl-pyrrolo[2,3-c]pyridin-5-yl]-5- ethynyl-6-fluoro-naphthalen-2-ol

[0211] To a solution of tert-butyl 5-[5-[8-ethynyl-7-fluoro-3-(methoxymethoxy)-1- naphthyl]-4-fluoro-3-methyl-pyrrolo[2,3-c]pyridin-1-yl]-2-azabicyclo[2.2.2]octane-2- carboxylate (21.00 mg, 35.74 μmol, 1 eq) in dichloromethane (0.6 mL) was added TFA (460.50 mg, 4.04 mmol, 0.3 mL, 113.02 eq). The mixture was stirred at 20 °C for 20 min. LCMS showed the reaction was completed. Several peaks were shown on LCMS and 86% of desired mass was detected. The mixture was quenched with saturated NaHCO3 aqueoussolution (3 mL), then extracted with dichloromethane (3 mL × 2). The combined organic layers were concentrated to afford a residue which was purified by prep-HPLC (column: Phenomenex luna C18150*25mm* 10um;mobile phase: [water(FA)-ACN];gradient:12%- 32% B over 10 min). The eluent was freeze-dried to afford 4-[1-(2-azabicyclo[2.2.2]octan-5- yl)-4-fluoro-3-methyl-pyrrolo[2,3-c]pyridin-5-yl]-5-ethynyl-6-fluoro-naphthalen-2-ol (2.6 mg, 5.05 μmol, 14.12% yield, 95% purity, FA) as a yellow solid.

[0212] MS (ES+) C27H23F2N3O requires:443, found:444 [M+H]+.

[0213] 1H NMR (400 MHz, CD3OD) δ = 8.58 (s, 1H), 8.45 (s, 1H), 7.83 (dd, J = 5.7, 9.1 Hz, 1H), 7.71 (s, 1H), 7.38 - 7.25 (m, 2H), 7.16 (dd, J = 2.4, 7.6 Hz, 1H), 5.20 - 5.15 (m, 1H), 3.79 - 3.73 (m, 1H), 3.62 - 3.56 (m, 1H), 3.44 - 3.39 (m, 1H), 3.07 - 3.01 (m, 0.5H), 2.96 - 2.91 (m, 0.5H), 2.86 - 2.71 (m, 1H), 2.60 - 2.51 (m, 1H), 2.48 (s, 3H), 2.38 - 2.30 (m, 1H), 2.23 - 2.04 (m, 2H), 1.81 - 1.62 (m, 2H). EXAMPLE 40 4-[1-[(1R,5S)-3-azabicyclo[3.13-methyl-pyrrolo[2,3-c]pyridin-5- yl]-5-ethynyl-6-fluoro-naphthalen-2-ol Step 1 tert-butyl (1R,5S)-6-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)-3- azabicyclo[3.1.0]hexane-3-carboxylate

[0214] TMEDA (9.89 g, 85.10 mmol, 12.84 mL, 8 eq) was added to a mixture of dichlorochromium (10.46 g, 85.10 mmol, 8 eq) in THF (40 mL). The mixture was stirred at 20 °C for 15 min. Tert-butyl 2,5-dihydropyrrole-1-carboxylate (1.8 g, 10.64 mmol, 1 eq) in THF (20 mL) was added to the mixture followed by a solution of 2-(dichloromethyl)-4,4,5,5- tetramethyl-1,3,2-dioxaborolane (4.50 g, 21.34 mmol, 2.01 eq) and LiI (5.70 g, 42.55 mmol, 1.63 mL, 4 eq) in THF (20 mL). The mixture was stirred at 20 °C for 16 h. TLC (Petroleum ether : Ethyl acetate=5:1) showed tert-butyl 2,5-dihydropyrrole-1-carboxylate remained and a new spot with higher polarity. The mixture was diluted with water (30 mL) and extracted with ethyl acetate (30 mL × 2), the combined organic layers were washed with brine (30 mL), dried over anhydrous sodium sulfate and filtered. The filtrate was concentrated to afford a residue. The residue was purified by flash silica gel chromatography (80 g SepaFlash® Silica Flash Column, Eluent of 0~30% Ethyl acetate / Petroleum ether gradient @ 80 mL / min) to afford tert-butyl (1R,5S)-6-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)-3- azabicyclo[3.1.0]hexane-3-carboxylate (1 g, 2.91 mmol, 27.36% yield, 90% purity) as a white solid.1H NMR (400 MHz, CDCl3) δ = 3.66 - 3.49 (m, 2H), 3.40 - 3.29 (m, 2H), 1.65 - 1.62 (m, 2H), 1.42 (s, 9H), 1.22 (s, 12H), -0.27 (t, J = 4.5 Hz, 1H). Step 2 [(1R,5S)-3-tert-butoxycarbonyl-3-azabicyclo[3.1.0]hexan-6-yl]boronic acid

[0215] To a solution of tert-butyl (,4,5,5-tetramethyl-1,3,2-dioxaborolan-2- yl)-3-azabicyclo[3.1.0]hexane-3-carboxylate (300 mg, 970.22 μmol, 1 eq) in H2O (5 mL) and acetone (5 mL) were added NaIO4 (415.04 mg, 1.94 mmol, 107.52 μL, 2 eq) and NH4OAc (149.57 mg, 1.94 mmol, 2 eq). The mixture was stirred at 20 °C for 48 h. TLC (Petroleum ether : Ethyl acetate=5:1,I2) showed no tert-butyl (1R,5S)-6-(4,4,5,5-tetramethyl-1,3,2- dioxaborolan-2-yl)-3-azabicyclo[3.1.0]hexane-3-carboxylate remained and a new spot with higher polarity. The mixture was diluted with water (10 mL) and extracted with ethyl acetate (10 mL × 2). The combined organic layers were washed with saturated Na2SO3aqueous solution (10 mL × 3), dried over anhydrous sodium sulfate and filtered. The filtrate wasconcentrated to afford [(1R,5S)-3-tert-butoxycarbonyl-3-azabicyclo[3.1.0]hexan-6-yl]boronic acid (214 mg, crude) as a white solid.1H NMR (400 MHz, CDCl3) δ = 4.94 (s, 2H), 3.62 - 3.58 (m, 1H), 3.52 - 3.48 (m, 1H), 3.39 - 3.35 (m, 2H), 1.69 - 1.66 (m, 2H), 1.44 (s, 9H), -0.45 (t, J = 4.4 Hz, 1H). Step 3 tert-butyl (1R,5S)-6-(5-chloro-4-fluoro-3-methyl-pyrrolo[2,3-c]pyridin-1-yl)-3- azabicyclo[3.1.0]hexane-3-carboxylate

[0216] To a solution of 5-chlo -1H-pyrrolo[2,3-c]pyridine (90 mg,487.55 μmol, 1 eq) and [(1R,5S)-3-tert-butoxycarbonyl-3-azabicyclo[3.1.0]hexan-6- yl]boronic acid (214 mg, 942.46 μmol, 1.93 eq) in dichloromethane (10 mL) were added Cu(OAc)2 (177.11 mg, 975.09 μmol, 2 eq), pyridine (77.13 mg, 975.09 μmol, 78.70 μL, 2 eq) and Et3N (98.67 mg, 975.09 μmol, 135.72 μL, 2 eq). The mixture was stirred at 20 °C for 16 h. LCMS showed 65% of 5-chloro-4-fluoro-3-methyl-1H-pyrrolo[2,3-c]pyridine remained, several peaks were showed on LCMS and 33% of desired mass. The mixture was diluted with water (5 mL) and extracted with dichloromethane (5 mL × 2). The combined organic layers were washed with brine (30 mL), dried over anhydrous sodium sulfate and filtered. The filtrate was concentrated to afford a residue. The residue was purified by prep-TLC (Petroleum ether : Ethyl acetate=3:1) to afford tert-butyl (1R,5S)-6-(5-chloro-4-fluoro-3- methyl-pyrrolo[2,3-c]pyridin-1-yl)-3-azabicyclo[3.1.0]hexane-3-carboxylate (54 mg, 141.71 μmol, 29.07% yield, 96% purity) as yellow oil. MS (ES+) C18H21ClFN3O2requires:365 and 367, found:366 and 368 [M+H]+. Step 4 tert-butyl (1R,5S)-6-[4-fluoro-5-[7-fluoro-3-(methoxymethoxy)-8-(2- triisopropylsilylethynyl)-1-naphthyl]-3-methyl-pyrrolo[2,3-c]pyridin-1-yl]-3- azabicyclo[3.1.0]hexane-3-carboxylate

[0217] To a sol luoro-3-methyl-pyrrolo[2,3- c]pyridin-1-yl)-3-aza cyc o . . e a e- -ca o y ae mg, 147.61 μmol, 1 eq) and 2- [2-fluoro-6-(methoxymethoxy)-8-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)-1- naphthyl]ethynyl-triisopropyl-silane (98.35 mg, 191.89 μmol, 1.3 eq) in dioxane (3 mL) were added CATACXIUM(R) A PD G3 (21.50 mg, 29.52 μmol, 0.2 eq) and K3PO4 (1.5 M, 295.22 μL, 3 eq). The mixture was stirred at 100 °C for 16 h under nitrogen. LCMS showed the reaction was completed, several peaks were showed on LCMS and 32% of desired mass. The mixture was diluted with water (5 mL) and extracted with dichloromethane (5 mL × 2). The combined organic layers were washed with brine (5 mL), dried over anhydrous sodium sulfate and filtered. The filtrate was concentrated to afford a residue. The residue was purified by prep-TLC (Petroleum ether : Ethyl acetate=3:1) to afford tert-butyl (1R,5S)-6-[4-fluoro-5- [7-fluoro-3-(methoxymethoxy)-8-(2-triisopropylsilylethynyl)-1-naphthyl]-3-methyl- pyrrolo[2,3-c]pyridin-1-yl]-3-azabicyclo[3.1.0]hexane-3-carboxylate (47 mg, 61.71 μmol, 41.81% yield, 94% purity) as yellow oil. MS (ES+) C41H51F2N3O4Si requires:715, found:716 [M+H]+. Step 5 tert-butyl (1R,5S)-6-[5-[8-ethynyl-7-fluoro-3-(methoxymethoxy)-1-naphthyl]-4-fluoro-3- methyl-pyrrolo[2,3-c]pyridin-1-yl]-3-azabicyclo[3.1.0]hexane-3-carboxylate

[0218] To a solution of tert-butyl (1R,5S)-6-[4-fluoro-5-[7-fluoro-3-(methoxymethoxy)- 8-(2-triisopropylsilylethynyl)-1-naphthyl]-3-methyl-pyrrolo[2,3-c]pyridin-1-yl]-3- azabicyclo[3.1.0]hexane-3-carboxylate (47 mg, 65.65 μmol, 1 eq) in DMF (2 mL) was added CsF (29.92 mg, 196.94 μmol, 3 eq). The mixture was stirred at 25 °C for 30 min. LCMS showed 91% of desired mass. The mixture was diluted with water (5 mL) and extracted with ethyl acetate (5 mL). The organic layer was washed with brine (5 mL), dried over anhydrous sodium sulfate and filtered. The filtrate was concentrated to afford tert-butyl (1R,5S)-6-[5-[8- ethynyl-7-fluoro-3-(methoxymethoxy)-1-naphthyl]-4-fluoro-3-methyl-pyrrolo[2,3-c]pyridin- 1-yl]-3-azabicyclo[3.1.0]hexane-3-carboxylate (37 mg, crude) as yellow oil. MS (ES+) C32H31F2N3O4requires:559, found:560 [M+H]+. Step 6 4-[1-[(1R,5S)-3-azabicyclo[3.1.0]hexan-6-yl]-4-fluoro-3-methyl-pyrrolo[2,3-c]pyridin-5- yl]-5-ethynyl-6-fluoro-naphthalen-2-ol

[0219] To a solution of tert-nyl-7-fluoro-3-(methoxymethoxy)- 1-naphthyl]-4-fluoro-3-methyl-pyrrolo[2,3-c]pyridin-1-yl]-3-azabicyclo[3.1.0]hexane-3- carboxylate (37 mg, 66.12 μmol, 1 eq) in dichloromethane (0.6 mL) was added TFA (460.50 mg, 4.04 mmol, 0.3 mL, 61.08 eq). The mixture was stirred at 25 °C for 30 min. LCMS showed 72% of desired mass. The mixture was quenched with saturated NaHCO3 aqueous solution (3 mL), then extracted with dichloromethane (3 mL × 2), the combined organic layers were concentrated to afford a residue. The residue was purified by prep-HPLC (column: Phenomenex luna C18150*25mm* 10um;mobile phase: [water(FA)- ACN];gradient:8%-28% B over 10 min). The eluent was freeze-dried to afford 4-[1-[(1R,5S)- 3-azabicyclo[3.1.0]hexan-6-yl]-4-fluoro-3-methyl-pyrrolo[2,3-c]pyridin-5-yl]-5-ethynyl-6- fluoro-naphthalen-2-ol (4.5 mg, 9.36 μmol, 14.16% yield, 96% purity, FA) as a yellow solid.

[0220] MS (ES+) C25H19F2N3O requires:415, found:416 [M+H]+.

[0221] 1H NMR (400 MHz, CD3OD) δ = 8.58 (d, J = 1.5 Hz, 1H), 8.45 (s, 0.8H), 7.83 (dd, J = 5.7, 9.1 Hz, 1H), 7.36 - 7.25 (m, 3H), 7.16 (d, J = 2.3 Hz, 1H), 3.71 (d, J = 11.9 Hz, 2H), 3.58 - 3.46 (m, 3H), 3.04 (s, 1H), 2.61 - 2.52 (m, 2H), 2.40 (s, 3H). EXAMPLE 41 5-[6-(8-ethynyl-7-fluoro-3-h -fluoro-1-methyl-pyrazolo[4,3-c]pyridin-3-yl]-2-azabicyclo[2.2.2]octan-6-one Step 1 tert-butyl 5-(6-chloro-7-fluoro-1-methyl-pyrazolo[4,3-c]pyridin-3-yl)-2- azabicyclo[2.2.2]oct-5-ene-2-carboxylate

[0222] To a solution of 6-chlor-methyl-pyrazolo[4,3-c]pyridine (0.33 g, 1.06 mmol, 1 eq), tert-butyl 5-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)-2- azabicyclo[2.2.2]oct-5-ene-2-carboxylate (390.69 mg, 1.17 mmol, 1.1 eq) and K3PO4 (1.5 M, 2.12 mL, 3.0 eq) in dioxane (21 mL) was added Ad2nBuP Pd G3 (cataCXium® A Pd G3) (100 mg, 137.31 μmol, 0.13 eq), the mixture was stirred at 60 °C for 12 h under N2. LCMS showed the starting material was consumed completely and a peak (57%) with the desired mass. The mixture was cooled to 25 °C and poured into a mixture of brine (30 mL) and water (30 mL). The aqueous phase was extracted with ethyl acetate (40 mL × 2). The combined organic phase was washed with brine (10 mL × 2), dried over anhydrous Na2SO4, filtered and concentrated under vacuum. The residue was purified by flash silica gel chromatography (40 g SepaFlash® Silica Flash Column, Eluent of 15~25% Ethyl acetate / Petroleum ethergradient @ 45 mL / min) to afford tert-butyl 5-(6-chloro-7-fluoro-1-methyl-pyrazolo[4,3- c]pyridin-3-yl)-2-azabicyclo[2.2.2]oct-5-ene-2-carboxylate (1.52 g, 3.87 mmol, 91.30% yield) as white solid. MS (ES+) C19H22ClFN4O2requires: 392, found: 393 [M+H]+1H NMR (400 MHz, CD3OD) δ ppm 8.88 (s, 1H), 7.26 (s, 1H), 4.22 (s, 3H), 3.75 (d, J = 13.6 Hz, 1H), 3.50 - 3.35 (m, 2H), 3.15 - 3.06 (m, 1H), 2.15 - 2.04 (m, 1H), 1.90 - 1.79 (m, 1H), 1.62 - 1.54 (m, 2H), 1.47 (d, J = 16.8 Hz, 9H) Step 2 tert-butyl 5-(6-chloro-7-fluoro-1-methyl-pyrazolo[4,3-c]pyridin-3-yl)-6-hydroxy-2- azabicyclo[2.2.2]octane-2-carboxylate

[0223] To a solution of tert-butoro-1-methyl-pyrazolo[4,3-c]pyridin- 3-yl)-2-azabicyclo[2.2.2]oct-5-ene-2-carboxylate (1.52 g, 3.87 mmol, 1 eq) in THF (18 mL) was added BH3.THF (1 M, 9.67 mL, 2.5 eq) at 0 °C under N2. Then the mixture was stirred at 25 °C for 2 h. Then the mixture was quenched by H2O (698.00 mg, 38.73 mmol, 698 μL, 10.01 eq) at 0 °C under N2. Then NaOH (6 M, 3.87 mL, 6 eq) and H2O2 (2.29 g, 20.18 mmol, 1.94 mL, 30% purity, 5.22 eq) were added to the mixture at 0 °C under N2. Then the mixture was stirred at 40 °C for 5 h. LCMS showed the starting material remained and a peak (33%) with the desired mass. The mixture was cooled to 25 °C and poured into a mixture of saturated NH4Cl (10 mL) and water (10 mL). The aqueous phase was extracted with ethyl acetate (30 mL × 2). The combined organic phase was washed with brine (10 mL × 2), dried over anhydrous Na2SO4, filtered and concentrated under vacuum. The residue was purified by flash silica gel chromatography (12 g SepaFlash® Silica Flash Column, Eluent of 8~35% Ethyl acetate / Petroleum ether gradient @ 45 mL / min) to afford tert-butyl 5-(6-chloro-7- fluoro-1-methyl-pyrazolo[4,3-c]pyridin-3-yl)-6-hydroxy-2-azabicyclo[2.2.2]octane-2- carboxylate (373 mg, 907.83 μmol, 23.46% yield) as yellow solid. MS (ES+) C19H24ClFN4O3requires: 410, found: 411 [M+H]+Step 3 tert-butyl 5-(6-chloro-7-fluoro-1-methyl-pyrazolo[4,3-c]pyridin-3-yl)-6-oxo-2- azabicyclo[2.2.2]octane-2-carboxylate

[0224] To a solution of (COCl) μmol, 15.98 μL, 1.5 eq) in DCM(0.75 mL) was added DMSO (28.52 mg, 365.08 μmol, 28.52 μL, 3 eq) at -78 °C, the mixture was stirred at -78 °C for 20 min, then a solution of tert-butyl 5-(6-chloro-7-fluoro-1-methyl- pyrazolo[4,3-c]pyridin-3-yl)-6-hydroxy-2-azabicyclo[2.2.2]octane-2-carboxylate (50.0 mg, 121.69 μmol, 1 eq) in DCM (0.25 mL) was added during 5 min at -78 °C. The resulting mixture was stirred at -78 °C for 20 min, then TEA (61.57 mg, 608.47 μmol, 84.69 μL, 5 eq) was added to the mixture. The mixture was stirred at -78 °C for 20 min, and warmed to 0 °C and then stirred for 30 min. LCMS showed the starting material was consumed completely and a peak (98%) with the desired mass. The mixture was cooled to 25 °C and poured into a mixture of saturated NH4Cl (10 mL) and water (10 mL). The aqueous phase was extracted with ethyl acetate (30 mL × 2). The combined organic phase was washed with brine (10 mL × 2), dried over anhydrous Na2SO4, filtered and concentrated under vacuum to afford tert- butyl 5-(6-chloro-7-fluoro-1-methyl-pyrazolo[4,3-c]pyridin-3-yl)-6-oxo-2- azabicyclo[2.2.2]octane-2-carboxylate (49.7 mg, 121.56 μmol, 99.89% yield) as yellow gel was used into the next step without further purification. MS (ES+) C19H22ClFN4O3requires: 408, found: 409 [M+H]+Step 4 tert-butyl 5-[7-fluoro-6-[7-fluoro-3-(methoxymethoxy)-8-(2-triisopropylsilylethynyl)-1- naphthyl]-1-methyl-pyrazolo[4,3-c]pyridin-3-yl]-6-oxo-2-azabicyclo[2.2.2]octane-2- carboxylate

[0225] To a mixture of tert- -1-methyl-pyrazolo[4,3-c]pyridin-3-yl)-6-oxo-2-azabicyclo[2.2.2]octane-2-carboxylate (39 mg, 95.39 μmol, 1 eq) and 2-[2- fluoro-6-(methoxymethoxy)-8-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)-1- naphthyl]ethynyl-triisopropyl-silane (88.00 mg, 171.70 μmol, 1.8 eq) in dioxane (1.9 mL) were added XPhos Pd G4 (8.21 mg, 9.54 μmol, 0.1 eq) and K3PO4 (1.5 M, 191.10 μL, 3.01 eq) under N2. The mixture was stirred at 100 °C for 12 h under N2. LCMS showed the starting material was consumed completely and a peak (24%) with the desired mass. The mixture was cooled to 25 °C and poured into a mixture of brine (3 mL) and water (10 mL). The aqueous phase was extracted with ethyl acetate (8 mL × 2). The combined organic phase was washed with brine (10 mL × 2), dried over anhydrous Na2SO4, filtered and concentrated under vacuum. The residue was purified by prep-TLC (SiO2, Petroleum ether / Ethyl acetate = 3:1) to afford tert-butyl 5-[7-fluoro-6-[7-fluoro-3-(methoxymethoxy)-8-(2- triisopropylsilylethynyl)-1-naphthyl]-1-methyl-pyrazolo[4,3-c]pyridin-3-yl]-6-oxo-2- azabicyclo[2.2.2]octane-2-carboxylate (22 mg, 20.29 μmol, 21.27% yield, 70% purity) as a yellow solid. MS (ES+) C42H52F2N4O5Si requires: 758, found: 759 [M+H]+Step 5 tert-butyl 5-[6-[8-ethynyl-7-fluoro-3-(methoxymethoxy)-1-naphthyl]-7-fluoro-1-methyl- pyrazolo[4,3-c]pyridin-3-yl]-6-oxo-2-azabicyclo[2.2.2]octane-2-carboxylate

[0226] To a solution of tert-butyl 5-[7-fluoro-6-[7-fluoro-3-(methoxymethoxy)-8-(2- triisopropylsilylethynyl)-1-naphthyl]-1-methyl-pyrazolo[4,3-c]pyridin-3-yl]-6-oxo-2- azabicyclo[2.2.2]octane-2-carboxylate (22 mg, 28.99 μmol, 1 eq) in DMF (0.5 mL) was added CsF (13.2 mg, 86.90 μmol, 3.21 μL, 3 eq), the mixture was stirred at 25 °C for 1 h. LCMS showed the starting material was consumed completely and a peak (58%) with the desired mass. The mixture was poured into a mixture of brine (2 mL) and water (1 mL). The aqueous phase was extracted with ethyl acetate (3 mL × 2). The combined organic phase was washed with brine (1 mL × 2), dried over anhydrous Na2SO4, filtered and concentrated under vacuum to afford tert-butyl 5-[6-[8-ethynyl-7-fluoro-3-(methoxymethoxy)-1-naphthyl]-7- fluoro-1-methyl-pyrazolo[4,3-c]pyridin-3-yl]-6-oxo-2-azabicyclo[2.2.2]octane-2-carboxylate (17 mg, 28.21 μmol, 97.32% yield) as yellow gel was used into the next step without further purification. MS (ES+) C33H32F2N4O5 requires: 602, found: 603 [M+H]+Step 6 5-[6-(8-ethynyl-7-fluoro-3-hydroxy-1-naphthyl)-7-fluoro-1-methyl-pyrazolo[4,3- c]pyridin-3-yl]-2-azabicyclo[2.2.2]octan-6-one

[0227] To a solution of tert-bluoro-3-(methoxymethoxy)-1- naphthyl]-7-fluoro-1-methyl-pyrazolo[4,3-c]pyridin-3-yl]-6-oxo-2-azabicyclo[2.2.2]octane- 2-carboxylate (17 mg, 28.21 μmol, 1 eq) in DCM (0.45 mL) was added TFA (230.25 mg, 2.02 mmol, 150 μL, 71.58 eq) the mixture was stirred at 25 °C for 30 min. LCMS showed the starting material was consumed completely and a peak (74%) with the desired mass. The mixture was concentrated under vacuum. The residue was purified by Prep-HPLC (column: Phenomenex Luna C18150*25 mm* 10um;mobile phase: [water (FA) -ACN];gradient:16%- 46% B over 10 min) and freeze-dried to afford 5-[6-(8-ethynyl-7-fluoro-3-hydroxy-1- naphthyl)-7-fluoro-1-methyl-pyrazolo[4,3-c]pyridin-3-yl]-2-azabicyclo[2.2.2]octan-6-one (2.4 mg, 5.17 μmol, 18.33% yield, 98.8% purity) as a yellow solid.

[0228] MS (ES+) C26H20F2N4O2requires: 458, found: 459 [M+H]+

[0229] 1H NMR (400 MHz, CD3OD) δ ppm 9.28 (d, J = 1.3 Hz, 1H), 7.91 - 7.83 (m, 1H), 7.39 - 7.29 (m, 2H), 7.23 (dd, J = 2.3, 8.5 Hz, 1H), 4.37 (s, 3H), 4.15 - 4.06 (m, 1H), 3.86 - 3.78 (m, 1H), 3.78 - 3.71 (m, 1H), 3.42 (d, J = 12.7 Hz, 2H), 3.26 (s, 0.5H), 3.12 (s, 0.5H), 2.30 - 2.21 (m, 1H), 2.20 - 2.07 (m, 3H). EXAMPLE 42 4-[3-(2-azabicyclo[2.2.2]oct-5-e hyl-pyrazolo[4,3-c]pyridin-6-yl]-5-ethynyl-6-fluoro-naphthalen-2-ol Step 1 tert-butyl 5-[7-fluoro-6-[7-fluoro-3-(methoxymethoxy)-8-(2-triisopropylsilylethynyl)-1- naphthyl]-1-methyl-pyrazolo[4,3-c]pyridin-3-yl]-2-azabicyclo[2.2.2]oct-5-ene-2- carboxylate

[0230] To a mixture of tert--1-methyl-pyrazolo[4,3-c]pyridin- 3-yl)-2-azabicyclo[2.2.2]oct-5-ene-2-carboxylate (100 mg, 254.55 μmol, 1 eq) and 2-[2- fluoro-6-(methoxymethoxy)-8-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)-1- naphthyl]ethynyl-triisopropyl-silane (234.8 mg, 458.12 μmol, 1.8 eq) in dioxane (5.1 mL) was added XPhos Pd G4(21.90 mg, 25.45 μmol, 0.1 eq) and K3PO4(1.5 M, 510 μL, 3.01 eq) under N2. The mixture was stirred at 100 °C for 12 h under N2. LCMS showed the startingmaterial was consumed completely and a peak (72%) with the desired mass. The mixture was cooled to 25 °C and poured into a mixture of brine (10 mL) and water (10 mL). The aqueous phase was extracted with ethyl acetate (30 mL × 2). The combined organic phase was washed with brine (10 mL × 2), dried over anhydrous Na2SO4, filtered and concentrated under vacuum. The residue was purified by flash silica gel chromatography (12 g SepaFlash® Silica Flash Column, Eluent of 5~35% Ethyl acetate / Petroleum ether gradient @ 45 mL / min) to afford tert-butyl 5-[7-fluoro-6-[7-fluoro-3-(methoxymethoxy)-8-(2- triisopropylsilylethynyl)-1-naphthyl]-1-methyl-pyrazolo[4,3-c]pyridin-3-yl]-2- azabicyclo[2.2.2]oct-5-ene-2-carboxylate (185 mg, 249.00 μmol, 97.82% yield) as yellow solid. MS (ES+) C42H52F2N4O4Si requires: 742, found 743 [M+H]+, Step 2 tert-butyl 5-[6-[8-ethynyl-7-fluoro-3-(methoxymethoxy)-1-naphthyl]-7-fluoro-1-methyl- pyrazolo[4,3-c]pyridin-3-yl]-2-azabicyclo[2.2.2]oct-5-ene-2-carboxylate

[0231] To a solution of tert-ro-3-(methoxymethoxy)-8-(2- triisopropylsilylethynyl)-1-naphthyl]-1-methyl-pyrazolo[4,3-c]pyridin-3-yl]-2- azabicyclo[2.2.2]oct-5-ene-2-carboxylate (60 mg, 80.76 μmol, 1 eq) in DMF (0.5 mL) was added CsF (36.80 mg, 242.27 μmol, 8.94 μL, 3 eq), the mixture was stirred at 25 °C for 1 h. LCMS showed the starting material was consumed completely and a peak (82%) with the desired mass. The mixture was poured into a mixture of saturated NH4Cl (10 mL) and water (10 mL). The aqueous phase was extracted with ethyl acetate (30 mL × 2). The combined organic phase was washed with brine (10 mL × 2), dried over anhydrous Na2SO4, filtered and concentrated under vacuum to afford tert-butyl 5-[6-[8-ethynyl-7-fluoro-3- (methoxymethoxy)-1-naphthyl]-7-fluoro-1-methyl-pyrazolo[4,3-c]pyridin-3-yl]-2- azabicyclo[2.2.2]oct-5-ene-2-carboxylate (47 mg, 80.12 μmol, 99.21% yield) as yellow gel was used into the next step without further purification. MS (ES+) C33H32F2N4O4requires: 586, found 587 [M+H]+Step 3 4-[3-(2-azabicyclo[2.2.2]oct-5-en-5-yl)-7-fluoro-1-methyl-pyrazolo[4,3-c]pyridin-6-yl]-5- ethynyl-6-fluoro-naphthalen-2-ol

[0232] To a solution of tert-b uoro-3-(methoxymethoxy)-1-naphthyl]-7-fluoro-1-methyl-pyrazolo[4,3-c]pyridin-3-yl]-2-azabicyclo[2.2.2]oct-5-ene-2- carboxylate (42 mg, 71.60 μmol, 1 eq) in DCM (1.26 mL) was added TFA (644.70 mg, 5.65 mmol, 420.00 μL, 78.97 eq), the mixture was stirred at 25 °C for 30 min. LCMS showed the starting material was consumed completely and a peak (85%) with the desired mass. The mixture was concentrated under vacuum. The residue was purified by Prep-HPLC (column: Phenomenex Luna C18150*25 mm* 10um; mobile phase: [water (FA) -ACN]; gradient:14%-44% B over 10 min) and freeze-dried to afford 4-[3-(2-azabicyclo[2.2.2]oct-5- en-5-yl)-7-fluoro-1-methyl-pyrazolo[4,3-c]pyridin-6-yl]-5-ethynyl-6-fluoro-naphthalen-2-ol (3.3 mg, 6.69 μmol, 9.34% yield, 99% purity, FA) as a yellow solid.

[0233] MS (ES+) C26H20F2N4O requires: 442, found: 443 [M+H]+

[0234] 1H NMR (400 MHz, DMSO-d6) δ ppm 9.08 (s, 1H), 8.54 (s, 1H), 7.91 - 7.84 (m, 1H), 7.38 - 7.30 (m, 2H), 7.27 - 7.21 (m, 2H), 4.50 - 4.43 (m, 1H), 4.28 (s, 3H), 3.98 (s, 1H), 3.37 (d, J = 11.2 Hz, 1H), 3.22 (s, 0.5H), 3.12 (s, 0.5H), 3.00 - 2.93 (m, 1H), 2.30 - 2.17 (m, 1H), 2.06 - 1.96 (m, 1H), 1.83 - 1.73 (m, 1H), 1.72 - 1.62 (m, 1H). EXAMPLES 43 and 444-[3-(2-azabicyclo[2.2.2]octan l-pyrazolo[4,3-c]pyridin-6-yl]-5-ethynyl-6-fluoro-naphthalen-2-ol (two isomers) Step 1 tert-butyl 5-[7-fluoro-6-[7-fluoro-3-(methoxymethoxy)-8-(2-triisopropylsilylethynyl)-1- naphthyl]-1-methyl-pyrazolo[4,3-c]pyridin-3-yl]-2-azabicyclo[2.2.2]octane-2- carboxylate

[0235] To a mixture of tert--1-methyl-pyrazolo[4, 3-c]pyridin- 3-yl) -2-azabicyclo[2.2.2]octane-2-carboxylate (100 mg, 253.25 μmol, 1 eq) and 2-[2-fluoro- 6-(methoxymethoxy)-8-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)-1-naphthyl]ethynyl- triisopropyl-silane (233.6 mg, 455.77 μmol, 1.8 eq) in dioxane (5.1 mL) were added XPhos Pd G4 (21.80 mg, 25.33 μmol, 0.1 eq) and K3PO4 (1.5 M, 510 μL, 3.02 eq) under N2. The mixture was stirred at 100 °C for 12 h under N2. LCMS showed the starting material was consumed completely and a overlapped peak with the desired mass. The mixture was cooled to 25 °C and poured into a mixture of brine (10 mL) and water (10 mL). The aqueous phase was extracted with ethyl acetate (30 mL × 2). The combined organic phase was washed with brine (10 mL × 2), dried over anhydrous Na2SO4, filtered and concentrated under vacuum. The residue was purified by flash silica gel chromatography (12 g SepaFlash® Silica Flash Column, Eluent of 5~35% Ethyl acetate / Petroleum ether gradient @ 45 mL / min) to afford tert-butyl 5-[7-fluoro-6-[7-fluoro-3-(methoxymethoxy)-8-(2-triisopropylsilylethynyl)-1-naphthyl]-1-methyl-pyrazolo[4,3-c]pyridin-3-yl]-2-azabicyclo[2.2.2]octane-2-carboxylate (166 mg, 222.82 μmol, 87.99% yield) as a yellow solid. MS (ES+) C42H54F2N4O4Si requires: 744, found 745 [M+H]+, Step 2 tert-butyl 5-[6-[8-ethynyl-7-fluoro-3-(methoxymethoxy)-1-naphthyl]-7-fluoro-1-methyl- pyrazolo[4,3-c]pyridin-3-yl]-2-azabicyclo[2.2.2]octane-2-carboxylate

[0236] To a solution of tert- ro-3-(methoxymethoxy)-8-(2-triisopropylsilylethynyl)-1-naphthyl]-1-methyl-pyrazolo[4,3-c]pyridin-3-yl]-2- azabicyclo[2.2.2]octane-2-carboxylate (100 mg, 134.23 μmol, 1 eq) in DMF (0.5 mL) was added CsF (61.2 mg, 402.90 μmol, 14.87 μL, 3 eq), the mixture was stirred at 25 °C for 1 h. LCMS showed the starting material was consumed completely and a peak (78%) with the desired mass. The mixture was poured into a mixture of brine (2 mL) and water (10 mL). The aqueous phase was extracted with ethyl acetate (8 mL × 2). The combined organic phase was washed with brine (10 mL × 2), dried over anhydrous Na2SO4, filtered and concentrated under vacuum to afford tert-butyl 5-[6-[8-ethynyl-7-fluoro-3-(methoxymethoxy)-1-naphthyl]- 7-fluoro-1-methyl-pyrazolo[4,3-c]pyridin-3-yl]-2-azabicyclo[2.2.2]octane-2-carboxylate (79 mg, 134.21 μmol, 99.98% yield) as yellow gel. MS (ES+) C33H34F2N4O4 requires: 588, found 589 [M+H]+Step 3 4-[3-(2-azabicyclo[2.2.2]octan-5-yl)-7-fluoro-1-methyl-pyrazolo[4,3-c]pyridin-6-yl]-5- ethynyl-6-fluoro-naphthalen-2-ol (two isomers)

[0237] To a solution of tert-b uoro-3-(methoxymethoxy) -1-naphthyl]-7-fluoro-1-methyl-pyrazolo[4, 3-c]pyridin-3-yl]-2-azabicyclo[2.2.2]octane-2- carboxylate (79 mg, 134.21 μmol, 1 eq) in DCM (1.8 mL) was added TFA (921.00 mg, 8.08 mmol, 600 μL, 60.19 eq) the mixture was stirred at 25 °C for 30 min. LCMS showed the starting material was consumed completely and two peaks (71+15%) with the desired mass. The mixture was concentrated under vacuum. The residue was purified by prep-HPLC (column: Phenomenex Luna C18150*25 mm* 10um; mobile phase: [water (FA) -ACN]; gradient:10%-40% B over 10 min) and freeze-dried to afford 4-[3-(2-azabicyclo[2.2.2]octan- 5-yl)-7-fluoro-1-methyl-pyrazolo[4,3-c]pyridin-6-yl]-5-ethynyl-6-fluoro-naphthalen-2-ol (10.9 mg, 21.93 μmol, 16.34% yield, 98.7% purity, FA) as a yellow solid and 4-[3-(2- azabicyclo[2.2.2]octan-5-yl)-7-fluoro-1-methyl-pyrazolo[4,3-c]pyridin-6-yl]-5-ethynyl-6- fluoro-naphthalen-2-ol (2.8 mg, 5.48 μmol, 4.08% yield, 96% purity, FA) as a yellow solid.

[0238] MS (ES+) C26H22F2N4O requires: 444, found: 445 [M+H]+

[0239] 1H NMR (400 MHz, CD3OD) δ ppm 8.85 (s, 1H), 8.55 (s, 1H), 7.86 (dd, J = 5.8, 9.1 Hz, 1H), 7.37 - 7.28 (m, 2H), 7.20 (dd, J = 2.5, 6.7 Hz, 1H), 4.24 (s, 3H), 3.93 - 3.81 (m, 1H), 3.67 - 3.62 (m, 1H), 3.61 - 3.45 (m, 1H), 3.17 (d, J = 1.0 Hz, 1H), 3.14 (s, 1H), 2.78 - 2.58 (m, 1H), 2.52 - 2.39 (m, 1H), 2.38 - 2.28 (m, 1H), 2.28 - 2.09 (m, 2H), 2.07 - 1.91 (m, 2H).

[0240] MS (ES+) C26H22F2N4O requires: 444, found: 445 [M+H]+

[0241] 1H NMR (400 MHz, CD3OD) δ ppm 8.85 (s, 1H), 8.55 (s, 1H), 7.86 (dd, J = 5.7, 9.1 Hz, 1H), 7.38 - 7.28 (m, 2H), 7.21 (dd, J = 2.7, 5.3 Hz, 1H), 4.23 (s, 3H), 3.92 - 3.83 (m, 1H), 3.66 - 3.60 (m, 1H), 3.59 - 3.53 (m, 1H), 3.45 - 3.39 (m, 1H), 3.16 (s, 0.5H), 3.05 (s, 0.5H), 2.82 - 2.69 (m, 1H), 2.55 - 2.37 (m, 2H), 2.05 - 1.94(m, 2H), 1.84 - 1.59 (m, 2H). EXAMPLE 453-[(1R,5S)-3-azabicyclo[3.1.0] -7-fluoro-3-hydroxy-1-naphthyl)-7-fluoro-1-methyl-imidazo[4,5-c]pyridin-2-one Step 1 ethyl 6-chloro-5-fluoro-4-(methylamino)pyridine-3-carboxylate

[0242] To a solution of ethyl 4pyridine-3-carboxylate (4.7 g, 19.74 mmol, 1 eq) and DIEA (12.76 g, 98.72 mmol, 17.20 mL, 5 eq) in dioxane (50 mL) was added methanamine hydrochloride (3.33 g, 49.36 mmol, 2.5 eq). The mixture was stirred at 40 °C for 16 h. TLC (Petroleum ether : Ethyl acetate=10:1) showed ethyl 4,6-dichloro-5-fluoro- pyridine-3-carboxylate remained and a new spot with higher polarity. The mixture was diluted with water (100 mL) and extracted with ethyl acetate (100 mL × 2). The combined organic layers were washed with brine (100 mL), dried over anhydrous sodium sulfate and filtered. The filtrate was concentrated to afford a residue which was purified by flash silica gel chromatography (40 g SepaFlash® Silica Flash Column, Eluent of 0~8% Ethyl acetate / Petroleum ether gradient @ 80 mL / min) to afford ethyl 6-chloro-5-fluoro-4- (methylamino)pyridine-3-carboxylate (790 mg, 3.40 mmol, 17.20% yield, 100% purity) as a white solid. MS (ES+) C9H10ClFN2O2requires:232 and 234, found:233 and 235 [M+H]+.1H NMR (400 MHz, CDCl3) δ = 8.42 (s, 1H), 8.14 (s, 1H), 4.27 (q, J = 7.2 Hz, 2H), 3.25 - 3.06 (m, 3H), 1.31 (t, J = 7.2 Hz, 3H). Step 2 6-chloro-5-fluoro-4-(methylamino)pyridine-3-carboxylic acid

[0243] To a solution of ethyl 6-c (methylamino)pyridine-3-carboxylate(790 mg, 3.40 mmol, 1 eq) in EtOH (8 mL) was added a solution of LiOH•H2O (427.50 mg, 10.19 mmol, 3 eq) in H2O (3.4 mL). The mixture was stirred at 25 °C for 3 h. LCMS showed the reaction was completed and 98% of desired mass. The mixture was adjusted pH to 6 with 1M HCl aqueous solution, then diluted with water (20 mL) and extracted with ethyl acetate (20 mL ×2). The combined organic layers were dried over anhydrous sodium sulfate and filtered. The filtrate was concentrated to afford 6-chloro-5-fluoro-4-(methylamino)pyridine-3- carboxylic acid (550 mg, 2.69 mmol, 79.17% yield, 100% purity) as a white solid. MS (ES+) C7H6ClFN2O2 requires:204 and 206, found:205 and 207 [M+H]+. Step 3 6-chloro-7-fluoro-1-methyl-3H-imidazo[4,5-c]pyridin-2-one

[0244] To a solution of 6-chloro-5-fluoro-4-(methylamino)pyridine-3-carboxylic acid (500 mg, 2.44 mmol, 1 eq) in toluene (10 mL) were added DIEA (347.44 mg, 2.69 mmol, 468.25 μL, 1.1 eq) and DPPA (739.84 mg, 2.69 mmol, 580.26 μL, 1.1 eq). The mixture was stirred at 25 °C for 30 min then stirred at 80 °C for 2 h. LCMS showed several peaks were showed on LCMS and 67% of desired mass. The mixture was concentrated to afford a residue which was triturated with ethyl acetate (5 mL). The suspension was filtered, the filter cake was dried to afford 6-chloro-7-fluoro-1-methyl-3H-imidazo[4,5-c]pyridin-2-one (160 mg, 714.34 μmol, 29.23% yield, 90% purity) as a white solid.1H NMR (400 MHz, DMSO-d6) δ = 11.60 (s, 1H), 7.88 (s, 1H), 3.43 (d, J = 1.1 Hz, 3H). Step 4 tert-butyl (1R,5S)-6-(6-chloro-7-fluoro-1-methyl-2-oxo-imidazo[4,5-c]pyridin-3-yl)-3- azabicyclo[3.1.0]hexane-3-carboxylate

[0245] To a solution of 6-chloroy -3H-imidazo[4,5-c]pyridin-2-one (140 mg, 694.50 μmol, 1 eq) and [(1R,5S)-3-tert-butoxycarbonyl-3-azabicyclo[3.1.0]hexan-6- yl]boronic acid (150 mg, 660.61 μmol, 9.51e-1 eq) in dichloromethane (6 mL) were added Cu(OAc)2(252.29 mg, 1.39 mmol, 2 eq), pyridine (109.87 mg, 1.39 mmol, 112.11 μL, 2 eq) and Et3N (140.55 mg, 1.39 mmol, 193.33 μL, 2 eq). The mixture was stirred at 25 °C for 16 h. LCMS showed 57% of 6-chloro-7-fluoro-1-methyl-3H-imidazo[4,5-c]pyridin-2-one remained and 37% of desired mass. The mixture was diluted with water (10 mL) and extracted with dichloromethane (10 mL × 2). The combined organic layers were washed with brine (10 mL), dried over anhydrous sodium sulfate and filtered. The filtrate was concentrated to afford a residue. The residue was purified by flash silica gel chromatography (12 g SepaFlash® Silica Flash Column, Eluent of 0~50% Ethyl acetate / Petroleum ether gradient @ 80 mL / min) to afford tert-butyl (1R,5S)-6-(6-chloro-7-fluoro-1-methyl-2-oxo- imidazo[4,5-c]pyridin-3-yl)-3-azabicyclo[3.1.0]hexane-3-carboxylate (60 mg, 128.52 μmol, 18.51% yield, 82% purity) as a white solid.

[0246] MS (ES+) C17H20ClFN4O3requires:382 and 384, found:383 and 385 [M+H]+. Step 5 tert-butyl (1R,5S)-6-[7-fluoro-6-[7-fluoro-3-(methoxymethoxy)-8-(2- triisopropylsilylethynyl)-1-naphthyl]-1-methyl-2-oxo-imidazo[4,5-c]pyridin-3-yl]-3- azabicyclo[3.1.0]hexane-3-carboxylate

[0247] To a solutio -1-methyl-2-oxo-imidazo[4,5-c]pyridin-3-yl)-3-azabicyclo[3.1.0]hexane-3-carboxylate (60 mg, 156.73 μmol, 1 eq) and 2-[2-fluoro-6-(methoxymethoxy)-8-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)-1- naphthyl]ethynyl-triisopropyl-silane (160.66 mg, 313.47 μmol, 2 eq) in dioxane (2 mL) were added CATACXIUM(R) A PD G3 (22.83 mg, 31.35 μmol, 0.2 eq) and K3PO4 (1.5 M in water, 313.47 μL, 3 eq). The mixture was stirred at 100 °C for 16 h under N2. LCMS showed 18% of tert-butyl (1R,5S)-6-(6-chloro-7-fluoro-1-methyl-2-oxo-imidazo[4,5-c]pyridin-3-yl)- 3-azabicyclo[3.1.0]hexane-3-carboxylate remained and 17% of desired mass. The mixture was diluted with water (5 mL) and extracted with ethyl acetate (5 mL × 2). The combined organic layers were washed with brine (5 mL), dried over anhydrous sodium sulfate and filtered. The filtrate was concentrated to afford a residue. The residue was purified by prep- TLC (Petroleum ether: Ethyl acetate= 3: 1) to afford tert-butyl (1R,5S)-6-[7-fluoro-6-[7- fluoro-3-(methoxymethoxy)-8-(2-triisopropylsilylethynyl)-1-naphthyl]-1-methyl-2-oxo- imidazo[4,5-c]pyridin-3-yl]-3-azabicyclo[3.1.0]hexane-3-carboxylate (78 mg, 73.43 μmol, 46.85% yield, 69% purity) as brown oil. MS (ES+) C40H50F2N4O5Si requires:732, found:733 [M+H]+. Step 6 tert-butyl (1R,5S)-6-[6-[8-ethynyl-7-fluoro-3-(methoxymethoxy)-1-naphthyl]-7-fluoro-1- methyl-2-oxo-imidazo[4,5-c]pyridin-3-yl]-3-azabicyclo[3.1.0]hexane-3-carboxylate

[0248] To a solution of tert-y , -6-[7-fluoro-3-(methoxymethoxy)- 8-(2-triisopropylsilylethynyl)-1-naphthyl]-1-methyl-2-oxo-imidazo[4,5-c]pyridin-3-yl]-3- azabicyclo[3.1.0]hexane-3-carboxylate (70 mg, 95.51 μmol, 1 eq) in DMF (1.5 mL) was added CsF (43.52 mg, 286.52 μmol, 3 eq). The mixture was stirred at 25 °C for 0.5 h. LCMS showed 79% of desired mass. The mixture was diluted with water (5 mL) and extracted with ethyl acetate (5 mL). The organic layer was washed with brine (5 mL), dried over anhydrous sodium sulfate and filtered. The filtrate was concentrated to afford tert-butyl (1R,5S)-6-[6-[8- ethynyl-7-fluoro-3-(methoxymethoxy)-1-naphthyl]-7-fluoro-1-methyl-2-oxo-imidazo[4,5- c]pyridin-3-yl]-3-azabicyclo[3.1.0]hexane-3-carboxylate (55 mg, crude) as yellow oil. MS (ES+) C31H30F2N4O5requires:576, found:577 [M+H]+. Step 7 3-[(1R,5S)-3-azabicyclo[3.1.0]hexan-6-yl]-6-(8-ethynyl-7-fluoro-3-hydroxy-1-naphthyl)- 7-fluoro-1-methyl-imidazo[4,5-c]pyridin-2-one

[0249] To a solution of tert-butyl (1R,5S)-6-[6-[8-ethynyl-7-fluoro-3-(methoxymethoxy)- 1-naphthyl]-7-fluoro-1-methyl-2-oxo-imidazo[4,5-c]pyridin-3-yl]-3-azabicyclo[3.1.0]hexane- 3-carboxylate (55 mg, 95.39 μmol, 1 eq) in dichloromethane (0.6 mL) was added TFA(460.50 mg, 4.04 mmol, 0.3 mL, 42.34 eq). The mixture was stirred at 25 °C for 20 min. LCMS showed several peaks were showed on LCMS and 78% of desired mass. The mixture was quenched with saturated NaHCO3 aqueous solution (5 mL), then extracted with dichloromethane (3 mL × 2), the combined organic layers were concentrated to afford a residue. The residue was purified by prep-HPLC (column: Phenomenex luna C18 150*25mm* 10um;mobile phase: [water(FA)-ACN];gradient:12%-32% B over 10 min). The eluent was freeze-dried to afford 3-[(1R,5S)-3-azabicyclo[3.1.0]hexan-6-yl]-6-(8-ethynyl-7- fluoro-3-hydroxy-1-naphthyl)-7-fluoro-1-methyl-imidazo[4,5-c]pyridin-2-one (2.7 mg, 5.30 μmol, 5.56% yield, 94% purity, FA) as a yellow solid.

[0250] MS (ES+) C24H18F2N4O2requires:432, found:433 [M+H]+.

[0251] 1H NMR (400 MHz, CD3OD) δ = 8.50 (s, 0.6H), 8.26 (s, 1H), 7.85 (dd, J = 5.8, 9.1 Hz, 1H), 7.38 - 7.27 (m, 2H), 7.16 (d, J = 2.4 Hz, 1H), 3.63 (d, J = 11.7 Hz, 2H), 3.57 (d, J = 1.1 Hz, 3H), 3.50 (s, 1H), 3.42 (dd, J = 3.7, 12.0 Hz, 2H), 2.97 (s, 1H), 2.53 - 2.41 (m, 2H). EXAMPLE 46 4-(3-((1R,5S,6r)-3-azl)-7-fluoro-1-((1S,2S)-2- methylcyclopropyl)-1H-pyrazolo[4,3-c]pyridin-6-yl)-5-ethynyl-6-fluoronaphthalen-2-ol Step 1 4,4,5,5-tetramethyl-2-[(E)-prop-1-enyl]-1,3,2-dioxaborolane

[0252] To a solution of 2,2,6,6-tedine (5.77 g, 40.86 mmol, 6.94 mL, 1.2 eq) in THF (40 mL) was added dropwise n-BuLi (2.5 M, 18.39 mL, 1.35 eq) at - 78 °C under N2atmosphere. After addition, the mixture was stirred at 0 °C for 0.5 h, a solution of 4,4,5,5-tetramethyl-2-[(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)methyl]-1,3,2-dioxaborolane (10.95 g, 40.86 mmol, 1.2 eq) in THF (80 mL) was added dropwise at 0 °C under N2atmosphere. The resulting mixture was stirred at 0 °C for 0.5 h. The reaction was cooled to - 78 °C, acetaldehyde (5 M, 6.81 mL, 1 eq) in THF (40 mL) was added at - 78 °C, The resulting mixture was stirred at -78 °C for 4 h under N2 atmosphere. TLC (Petroleum ether : Ethyl acetate= 10:1) indicated two new spot formed. The reaction mixture was quenched by NH4Cl (200 mL) at 0 °C, and extracted with THF (200 mL x 3). The combined organic layers were washed with bine (100 mL x 3), dried over Na2SO4, filtered and concentrated under reduced pressure to give a residue which was purified by flash silica gel chromatography (120 g SepaFlash® Silica Flash Column, Eluent of 0~5%Ethylacetate / Petroleum ether gradient @ 100 mL / min) to afford 4,4,5,5-tetramethyl-2-[(E)-prop-1-enyl]-1,3,2- dioxaborolane (3.1 g, 18.45 mmol, 54.18% yield) as colorless oil.1H NMR (400 MHz, CDCl3) δ = 6.74 - 6.59 (m, 1H), 5.52 - 5.42 (m, 1H), 1.88 - 1.22 (m, 3H), 1.27 (s, 12H) Step 2 4,4,5,5-tetramethyl-2-(2-methylcyclopropyl)-1,3,2-dioxaborolane

[0253] ZnEt2(2 M, 26.78 mL, 3 eropwise to DCM (130 mL) at 0 °C under N2 atmosphere. When the white fume disappeared after the completion of dropwise, to the mixture was slowly added a solution of TFA (6.11 g, 53.56 mmol, 3.98 mL, 3 eq) in DCM (23 mL) at 0 °C under N2 atmosphere.30 min later, to the mixture was slowly added a solution of CH2I2 (14.34 g, 53.56 mmol, 4.32 mL, 3 eq) in DCM (23 mL) at 0 °C under N2 atmosphere.30 min later, to the mixture was slowly added a solution of 4,4,5,5-tetramethyl- 2-[(E)-prop-1-enyl]-1,3,2-dioxaborolane (3 g, 17.85 mmol, 1 eq) in DCM (23 mL) at 0 °C under N2atmosphere. The mixture was stirred at 25 °C for 30 min. TLC (Petroleum ether: Ethyl acetate= 10: 1) indicated 4,4,5,5-tetramethyl-2-[(E)-prop-1-enyl]-1,3,2-dioxaborolane was consumed and one new spot formed. The reaction mixture was diluted with NH4Cl solution (300 mL) and extracted with EtOAc (200 mL x 3). The combined organic layers were washed with bine (200 mL x 3), dried over Na2SO4, filtered and concentrated under reduced pressure to give a residue which was purified by flash silica gel chromatography (40 g SepaFlash® Silica Flash Column, Eluent of 0~5%Ethylacetate / Petroleum ether gradient @60 mL / min) to afford 4,4,5,5-tetramethyl-2-(2-methylcyclopropyl)-1,3,2-dioxaborolane (2.5 g, 13.73 mmol, 76.91% yield) as colorless oil.1H NMR (400 MHz, CDCl3) δ = 1.22 (s, 13H), 1.10 - 1.04 (m, 3H), 0.72 - 0.62 (m, 1H), 0.40 - 0.31 (m, 1H), -0.40 - -0.51 (m, 1H) Step 3 (2-methylcyclopropyl)boronic acid

[0254] To a solution of 4,4,5,5-tetr 2-methylcyclopropyl)-1,3,2-dioxaborolane(1 g, 5.49 mmol, 1 eq) in H2O (20 mL) and ACETONE (20 mL) were added NaIO4(2.35 g, 10.98 mmol, 608.70 μL, 2 eq) and NH4OAc (846.75 mg, 10.98 mmol, 2 eq). The mixture was stirred at 25 °C for 16 h. TLC (Petroleum ether : Ethyl acetate= 10: 1) indicated 4,4,5,5- tetramethyl-2-(2-methylcyclopropyl)-1,3,2-dioxaborolane was consumed and one new spot formed. The mixture was quenched with Na2SO3 (100 mL), then extracted with EtOAc (100 mL x 3). The organic phase was washed with Na2SO3(50 mL x 3), brine (50 mL), then dried over anhydrous Na2SO4, filtered and concentrated to afford (2-methylcyclopropyl)boronic acid (400 mg, 4.00 mmol, 72.88% yield) as a white solid.1H NMR (400 MHz, CDCl3) δ = 1.12 - 1.05 (m, 4H), 0.78 - 0.68 (m, 1H), 0.43 - 0.37 (m, 1H), -0.35 - -0.48 (m, 1H) Step 4 tert-butyl 6-[6-chloro-7-fluoro-1-(2-methylcyclopropyl)pyrazolo[4,3-c]pyridin-3-yl]-3- azabicyclo[3.1.0]hexane-3-carboxylate

[0255] To a solution of tert-butyoro-1H-pyrazolo[4,3-c]pyridin-3-yl)- 3-azabicyclo[3.1.0]hexane-3-carboxylate (200 mg, 566.91 μmol, 1 eq) and (2-methylcyclopropyl)boronic acid (113.30 mg, 1.13 mmol, 2 eq) in DCM (10 mL) were added Cu(OAc)2(205.94 mg, 1.13 mmol, 2 eq), PYRIDINE (89.68 mg, 1.13 mmol, 91.52 μL, 2 eq) and Et3N (114.73 mg, 1.13 mmol, 157.81 μL, 2 eq). The mixture was stirred at 25 °C for 16 h. LCMS showed a peak (36%) with desired mass. The reaction mixture was filtered and the filtrate was concentrated under reduced pressure to give a residue which was purified by flash silica gel chromatography (10 g SepaFlash® Silica Flash Column, Eluent of 0~50% Ethyl acetate / Petroleum ether gradient @ 20 mL / min) to afford tert-butyl 6-[6-chloro-7-fluoro-1-(2- methylcyclopropyl)pyrazolo[4,3-c]pyridin-3-yl]-3-azabicyclo[3.1.0]hexane-3-carboxylate (150 mg, 368.66 μmol, 65.03% yield) as a yellow solid. MS (ES+) C20H24ClFN4O2requires: 406, found: 407 [M+H]+. Step 5 tert-butyl (1R,5S,6r)-6-(7-fluoro-6-(7-fluoro-3-(methoxymethoxy)-8- ((triisopropylsilyl)ethynyl)naphthalen-1-yl)-1-((1S,2S)-2-methylcyclopropyl)-1H- pyrazolo[4,3-c]pyridin-3-yl)-3-azabicyclo[3.1.0]hexane-3-carboxylate

[0256] A mixture of tert-but7-fluoro-1-((1S,2S)-2- methylcyclopropyl)-1H-pyrazolo[4,3-c]pyridin-3-yl)-3-azabicyclo[3.1.0]hexane-3- carboxylate (100 mg, 245.77 μmol, 1 eq), 2-[2-fluoro-6-(methoxymethoxy)-8-(4,4,5,5- tetramethyl-1,3,2-dioxaborolan-2-yl)-1-naphthyl]ethynyl-triisopropyl-silane (188.95 mg, 368.66 μmol, 1.5 eq), K3PO4 (1.5 M, 491.54 μL, 3 eq), and CataCXium A Pd G3 (35.80 mg, 49.15 μmol, 0.2 eq) in THF (2 mL) was degassed and purged with N2for 3 times, and then the mixture was stirred at 60 °C for 16 h under N2 atmosphere. LCMS showed a peak (75%) with desired mass. The reaction mixture was diluted with water (10 mL) and extracted with ethyl acetate (10 mL x 3). The combined organic layers were washed with bine (10 mL x 3), dried over Na2SO4, filtered and concentrated under reduced pressure to give a residue which was purified by flash silica gel chromatography (4 g SepaFlash® Silica Flash Column, Eluentof 0~30% Ethyl acetate / Petroleum ether gradient @ 20 mL / min) to afford tert-butyl (1R,5S,6r)-6-(7-fluoro-6-(7-fluoro-3-(methoxymethoxy)-8- ((triisopropylsilyl)ethynyl)naphthalen-1-yl)-1-((1S,2S)-2-methylcyclopropyl)-1H- pyrazolo[4,3-c]pyridin-3-yl)-3-azabicyclo[3.1.0]hexane-3-carboxylate (180 mg, 237.78 μmol, 96.75% yield) as a brown solid. MS (ES+) C43H54F2N4O4Si requires: 756, found: 757 [M+H]+. Step 6 tert-butyl (1R,5S,6r)-6-(6-(8-ethynyl-7-fluoro-3-(methoxymethoxy)naphthalen-1-yl)-7- fluoro-1-((1S,2S)-2-methylcyclopropyl)-1H-pyrazolo[4,3-c]pyridin-3-yl)-3- azabicyclo[3.1.0]hexane-3-carboxylate

[0257] To a solution of tert-ro-6-(7-fluoro-3- (methoxymethoxy)-8-((triisopropylsilyl)ethynyl)naphthalen-1-yl)-1-((1S,2S)-2- methylcyclopropyl)-1H-pyrazolo[4,3-c]pyridin-3-yl)-3-azabicyclo[3.1.0]hexane-3- carboxylate (100 mg, 132.10 μmol, 1 eq) in DMF (2 mL) was added CsF (60.20 mg, 396.30 μmol, 3 eq). The mixture was stirred at 25 °C for 1 h. LCMS showed a peak (99%) with desired mass. The reaction mixture was diluted with H2O (10 mL) and extracted with ethyl acetate (10 mL x 3). The combined organic layers were washed with bine (10mL x 3), dried over Na2SO4, filtered and concentrated under reduced pressure to afford tert-butyl (1R,5S,6r)- 6-(6-(8-ethynyl-7-fluoro-3-(methoxymethoxy)naphthalen-1-yl)-7-fluoro-1-((1S,2S)-2- methylcyclopropyl)-1H-pyrazolo[4,3-c]pyridin-3-yl)-3-azabicyclo[3.1.0]hexane-3- carboxylate (80 mg, 131.86 μmol, 99.81% yield, 99% purity) as a yellow solid. MS (ES+) C34H34F2N4O4requires: 600, found: 601 [M+H]+. Step 74-(3-((1R,5S,6r)-3-azabicyclo[3.1.0]hexan-6-yl)-7-fluoro-1-((1S,2S)-2- methylcyclopropyl)-1H-pyrazolo[4,3-c]pyridin-6-yl)-5-ethynyl-6-fluoronaphthalen-2-ol

[0258] To a solution of tert- thynyl-7-fluoro-3-(methoxymethoxy)naphthalen-1-yl)-7-fluoro-1-((1S,2S)-2-methylcyclopropyl)-1H- pyrazolo[4,3-c]pyridin-3-yl)-3-azabicyclo[3.1.0]hexane-3-carboxylate (70 mg, 116.54 μmol, 1 eq) in DCM (1 mL) was added TFA (460.50 mg, 4.04 mmol, 0.3 mL, 34.65 eq). The mixture was stirred at 25 °C for 0.5 h. LCMS showed a peak (57%) with desired mass. The reaction mixture was concentrated under reduced pressure to give a residue which was purified by prep-HPLC (column: Phenomenex luna C18150*25 mm* 10um; mobile phase: [water (FA) -ACN]; gradient: 14%-44% B over 10 min). The eluent was lyophilized under reduced pressure to afford 4-(3-((1R,5S,6r)-3-azabicyclo[3.1.0]hexan-6-yl)-7-fluoro-1- ((1S,2S)-2-methylcyclopropyl)-1H-pyrazolo[4,3-c]pyridin-6-yl)-5-ethynyl-6- fluoronaphthalen-2-ol (12.9 mg, 24.90 μmol, 21.37% yield, 97% purity, FA) as a white solid.

[0259] MS (ES+) C27H22F2N4O requires: 456, found: 457 [M+H]+.

[0260] 1H NMR (400 MHz, CD3OD) δ = 8.82 (s, 1H), 8.60 - 8.47 (m, 0.5H), 7.92 - 7.82 (m, 1H), 7.38 - 7.29 (m, 2H), 7.25 - 7.28 (m, 1H), 3.63 - 3.55 (m, 2H), 3.52 - 3.45 (m, 3H), 3.24 - 7.17 (m, 1H), 2.53 - 2.38 (m, 3H), 1.63 - 1.37 (m, 2H), 1.27 - 1.25 (m, 3H), 1.01 - 0.90 (m, 1H). EXAMPLES 47 and 48methyl rac-(2R,6S)-6-[6-(8-ethynyl-7-fluoro-3-hydroxy-1-naphthyl)-7-fluoro-1-methyl- pyrazolo[4,3-c]pyridin-3-yl]-3-azabicyclo[3.1.0]hexane-2-carboxylate Step 1 O3-tert-butyl O2-methyl rac-(6S)-6-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)-3- azabicyclo[3.1.0]hexane-2,3-dicarboxylate

[0261] TMEDA (818.14 mg, 7. , 8 eq) was added to a mixture ofdichlorochromium (865.29 mg, 7.04 mmol, 8 eq) in THF (3.6 mL). The mixture was stirred at 20 °C for 15 min. O1-tert-butyl O2-methyl 2,5-dihydropyrrole-1,2-dicarboxylate (200 mg, 880.06 μmol, 1 eq) in THF (1.8 mL) was added to the mixture followed by a solution of 2- (dichloromethyl)-4,4,5,5-tetramethyl-1,3,2-dioxaborolane (371.20 mg, 1.76 mmol, 2 eq) and Lithium iodide (471.17 mg, 3.52 mmol, 135.01 μL, 4 eq) in THF (1.8 mL). The mixture was stirred at 20 °C for 12 h. LCMS showed no mass with starting material and no desired mass. TLC (Petroleum ether: Ethyl acetate, I2) indicated ~30% of O1-tert-butyl O2-methyl 2,5- dihydropyrrole-1,2-dicarboxylate was remained and one major new spot with larger polarity. The mixture was filtered and the filtrate was poured into a mixture of brine (5 mL) and water (20 mL). The aqueous phase was extracted with ethyl acetate (30 mL × 2). The combined organic phase was washed with brine (10 mL × 2), dried over anhydrous Na2SO4, filtered and concentrated under vacuum. The residue was purified by flash silica gel chromatography (12 g SepaFlash® Silica Flash Column, Eluent of 0~8% Ethyl acetate / Petroleum ether gradient @ 45 mL / min) to afford O3-tert-butyl O2-methyl rac-(6S)-6-(4,4,5,5-tetramethyl-1,3,2- dioxaborolan-2-yl)-3-azabicyclo[3.1.0]hexane-2,3-dicarboxylate (220 mg, 599.06 μmol, 68.07% yield) as yellow oil.1H NMR (400 MHz, DMSO-d6) 4.36 - 4.26 (m, 1H), 3.79 - 3.71 (m, 3H), 3.59 - 3.46 (m, 2H), 1.86 - 1.65 (m, 2H), 1.46 - 1.35 (m, 9H), 1.23 - 1.19 (m, 12H), 0.27 - 0.16 (m, 1H), -0.17 - - 0.20 (m, 1H). Step 2O3-tert-butyl O2-methyl rac-(6S)-6-(6-chloro-7-fluoro-1-methyl-pyrazolo[4,3-c]pyridin- 3-yl)-3-azabicyclo[3.1.0]hexane-2,3-dicarboxylate

[0262] To a solution of 6-c hyl-pyrazolo[4,3-c]pyridine (270mg, 866.82 μmol, 1 eq), O3-tert-butyl O2-methyl rac-(6S)-6-(4,4,5,5-tetramethyl-1,3, 2- dioxaborolan-2-yl)-3-azabicyclo[3.1.0]hexane-2,3-dicarboxylate (413 mg, 1.12 mmol, 1.3 eq) and K3PO4 (1.5 M, 1.77 mL, 3.05 eq) in dioxane (18 mL) was added Ad2nBuP Pd G3 (cataCXium® A Pd G3) (82.35 mg, 113.08 μmol, 0.13 eq), the mixture was stirred at 60 °C for 12 h under N2. LCMS showed the starting material was consumed completely and a peak (65%) with the desired mass. The mixture was cooled to 25 °C and poured into a mixture of brine (10 mL) and water (10 mL). The aqueous phase was extracted with ethyl acetate (30 mL × 2). The combined organic phase was washed with brine (10 mL × 2), dried over anhydrous Na2SO4, filtered and concentrated under vacuum. The residue was purified by flash silica gel chromatography (12 g SepaFlash® Silica Flash Column, Eluent of 13~25% Ethyl acetate / Petroleum ether gradient @ 45 mL / min) to afford O3-tert-butyl O2-methyl rac- (6S)-6-(6-chloro-7-fluoro-1-methyl-pyrazolo[4,3-c]pyridin-3-yl)-3-azabicyclo[3.1.0]hexane- 2,3-dicarboxylate (180 mg, 423.68 μmol, 48.88% yield) as a yellow solid. MS (ES+) C21H28OSi requires: 324, found: 280 [M-C3H9+H]+Step 3 O3-tert-butyl O2-methyl rac-(2R,6S)-6-(6-chloro-7-fluoro-1-methyl-pyrazolo[4,3- c]pyridin-3-yl)-3-azabicyclo[3.1.0]hexane-2,3-dicarboxylate and O3-tert-butyl O2- methyl rac-(2S, 6S) -6-(6-chloro-7-fluoro-1-methyl-pyrazolo[4,3-c]pyridin-3-yl)-3- azabicyclo[3.1.0]hexane-2,3-dicarboxylate

[0263] O3 pyrazolo[4,3-c]pyridin-3-yl)-3-azabicyclo[3.1.0]hexane-2,3-dicarboxylate (180 mg, 423.68 μmol) was purified by Prep-SFC (column: DAICEL CHIRALPAK AD (250 mm*30 mm, 10um); mobile phase: [CO2-MeOH (0.1%NH3H2O)]; B%:60%, isocratic elution mode) and freeze- dried to afford O3-tert-butyl O2-methyl rac-(2R,6S)-6-(6-chloro-7-fluoro-1-methyl- pyrazolo[4,3-c]pyridin-3-yl)-3-azabicyclo[3.1.0]hexane-2,3-dicarboxylate (72 mg, 169.47 μmol, 40.00% yield) as a yellow solid and O3-tert-butyl O2-methyl rac-(2S, 6S) -6-(6-chloro- 7-fluoro-1-methyl-pyrazolo[4,3-c]pyridin-3-yl)-3-azabicyclo[3.1.0]hexane-2,3-dicarboxylate (80 mg, 188.30 μmol, 44.44% yield) as a yellow solid.

[0264] MS (ES+) C19H22ClFN4O4 requires: 424, found: 425 [M+H]+

[0265] 1H NMR (400 MHz, CD3OD) δ ppm 8.75 (s, 1H), 4.12 (s, 3H), 3.85 - 3.77 (m, 4H), 3.73 - 3.66 (m, 1H), 2.41 - 2.24 (m, 3H), 2.01 (s, 1H), 1.50 - 1.41 (m, 9H), 1.31 - 1.27 (m, 1H)

[0266] MS (ES+) C19H22ClFN4O4requires: 424, found: 425 [M+H]+

[0267] 1H NMR (400 MHz, CD3OD) δ ppm 8.75 (s, 1H), 4.12 (s, 3H), 3.86 - 3.77 (m, 4H), 3.73 - 3.66 (m, 1H), 2.41 - 2.23 (m, 3H), 1.51 - 1.41 (m, 9H), 1.39 - 1.35 (m, 1H) Step 4 O3-tert-butyl O2-methyl rac-(2R,6S)-6-[7-fluoro-6-[7-fluoro-3-(methoxymethoxy)-8-(2- triisopropylsilylethynyl)-1-naphthyl]-1-methyl-pyrazolo[4,3-c]pyridin-3-yl]-3- azabicyclo[3.1.0]hexane-2,3-dicarboxylate

[0268] To a solution of S)-6-(6-chloro-7-fluoro-1-methyl-pyrazolo[4,3-c]pyridin-3-yl)-3-azabicyclo[3.1.0]hexane-2,3-dicarboxylate (72 mg, 169.47 μmol, 1 eq) 2-[2-fluoro-6-(methoxymethoxy)-8-(4,4,5,5-tetramethyl-1,3,2- dioxaborolan-2-yl)-1-naphthyl]ethynyl-triisopropyl-silane (222.36 mg, 433.84 μmol, 2.56 eq) and K3PO4 (1.5 M, 340 μL, 3.01 eq) in dioxane (3.4 mL) was added XPhos Pd G4 (16.0 mg, 18.59 μmol, 0.11 eq), the mixture was stirred at 100 °C for 5 h under N2. LCMS showed the starting material was consumed completely and a peak (37%) with the desired mass. The mixture was cooled to 25 °C and poured into a mixture of saturated NH4Cl (10 mL) and water (10 mL). The aqueous phase was extracted with ethyl acetate (30 mL × 2). The combined organic phase was washed with brine (10 mL × 2), dried over anhydrous Na2SO4, filtered and concentrated under vacuum. The residue was purified by prep-TLC (SiO2, Petroleum ether / Ethyl acetate= 5: 1) to afford O3-tert-butyl O2-methyl rac-(2R,6S)-6-[7- fluoro-6-[7-fluoro-3-(methoxymethoxy)-8-(2-triisopropylsilylethynyl)-1-naphthyl]-1-methyl- pyrazolo[4,3-c]pyridin-3-yl]-3-azabicyclo[3.1.0]hexane-2,3-dicarboxylate (95 mg, 122.59 μmol, 72.33% yield) as yellow solid. MS (ES+) C42H52F2N4O6Si requires: 774, found: 775 [M+H]+Step 5 O3-tert-butyl O2-methyl rac-(2R,6S)-6-[6-[8-ethynyl-7-fluoro-3-(methoxymethoxy)-1- naphthyl]-7-fluoro-1-methyl-pyrazolo[4,3-c]pyridin-3-yl]-3-azabicyclo[3.1.0]hexane-2,3- dicarboxylate

[0269] To a solution of S)-6-[7-fluoro-6-[7-fluoro-3-(methoxymethoxy)-8-(2-triisopropylsilylethynyl)-1-naphthyl]-1-methyl-pyrazolo[4,3- c]pyridin-3-yl]-3-azabicyclo[3.1.0]hexane-2,3-dicarboxylate (95.00 mg, 122.59 μmol, 1 eq) in DMF (1 mL) was added CsF (55.9 mg, 368.01 μmol, 13.58 μL, 3 eq), the mixture was stirred at 25 °C for 1 h. LCMS showed the starting material was consumed completely and a peak (94%) with the desired mass. The mixture was poured into a mixture of brine (2 mL) and water (10 mL). The aqueous phase was extracted with ethyl acetate (3 mL × 2). The combined organic phase was washed with brine (3 mL × 2), dried over anhydrous Na2SO4, filtered and concentrated under vacuum to afford O3-tert-butyl O2-methyl rac-(2R,6S)-6-[6- [8-ethynyl-7-fluoro-3-(methoxymethoxy)-1-naphthyl]-7-fluoro-1-methyl-pyrazolo[4,3- c]pyridin-3-yl]-3-azabicyclo[3.1.0]hexane-2,3-dicarboxylate (75 mg, 121.24 μmol, 98.90% yield) as yellow gel was used into the next step without further purification. MS (ES+) C33H32F2N4O6requires:618, found: 619 [M+H]+Step 6 methyl rac-(2R,6S)-6-[6-(8-ethynyl-7-fluoro-3-hydroxy-1-naphthyl)-7-fluoro-1-methyl- pyrazolo[4,3-c]pyridin-3-yl]-3-azabicyclo[3.1.0]hexane-2-carboxylate H N (R) Me

[0270] To a solution of O3-tert-butyl O2-methyl rac-(2R,6S)-6-[6-[8-ethynyl-7-fluoro-3- (methoxymethoxy)-1-naphthyl]-7-fluoro-1-methyl-pyrazolo[4,3-c]pyridin-3-yl]-3- azabicyclo[3.1.0]hexane-2,3-dicarboxylate (75 mg, 121.24 μmol, 1 eq) in DCM (0.3 mL) was added TFA (153.50 mg, 1.35 mmol, 100 μL, 11.10 eq), the mixture was stirred at 25 °C for 30 min. LCMS showed the starting material was consumed completely and a peak (24%) with the desired mass. The mixture was concentrated under vacuum. The residue was purified by Prep-HPLC (column: Phenomenex Luna C18150*25 mm* 10um;mobile phase: [water(FA)-ACN];gradient:14%-44% B over 10 min) and freeze-dried to afford methyl rac- (2R,6S)-6-[6-(8-ethynyl-7-fluoro-3-hydroxy-1-naphthyl)-7-fluoro-1-methyl-pyrazolo[4,3- c]pyridin-3-yl]-3-azabicyclo[3.1.0]hexane-2-carboxylate (7.4 mg, 13.79 μmol, 11.38% yield, 97% purity, FA) as a yellow solid.

[0271] MS (ES+) C26H20F2N4O3 requires: 474, found: 475 [M+H]+

[0272] 1H NMR (400 MHz, CD3OD) δ ppm 8.84 (d, J = 1.5 Hz, 1H), 8.35 (s, 0.2H), 7.85 (dd, J = 5.8, 9.1 Hz, 1H), 7.37 - 7.28 (m, 2H), 7.21 (d, J = 2.5 Hz, 1H), 4.15 (s, 3H), 4.08 (s, 1H), 3.79 (d, J = 0.9 Hz, 3H), 3.30 - 3.24 (m, 2H), 3.20 (d, J = 5.9 Hz, 1H), 2.48 - 2.38 (m, 2H), 2.31 - 2.22 (m, 1H). EXAMPLE 49 H N H F F 4-[3-(3-azabicyclo[3.1.0]hexalopropyl)-7-fluoro-pyrazolo[4,3- c]pyridin-6-yl]-5-ethynyl-6-fluoro-naphthalen-2-ol Step 1 vinyl 4-methylbenzenesulfonate

[0273] A solution of n-BuLi (2.5 M,. L, 1.24 eq) in THF (35.60 g, 493.72 mmol, 40 mL, 18.83 eq) was stirred at 35 °C for 4 h under N2. Then the mixture was added TosCl (5g, 26.23 mmol, 1 eq) in THF (13 mL) at -70 °C and stirred at -70 °C for 1 h and 20 °C for 1 h. LCMS showed the desired mass. The mixture was quenched with NH4Cl (40 mL), extracted with EtOAc (30 mL * 3). The organic phase was collected and washed with brine (100 mL), dried over anhydrous Na2SO4, filtered and concentrated to give a crude product. The crude product was purified by flash column chromatography (40 g SepaFlash Silica Flash Column, Eluent of 4~20% Ethyl acetate / Petroleum ether gradient @45 mL / min) to afford vinyl 4-methylbenzenesulfonate (2.8 g, 13.84 mmol, 52.78% yield, 98% purity) as a colorless oil.1H NMR (400 MHz, CDCl3) δ ppm 7.80 (d, J = 8.3 Hz, 2H), 7.37 (d, J = 8.1 Hz, 2H), 6.65 - 6.57 (m, 1H), 4.93 - 4.86 (m, 1H), 4.72 - 4.66 (m, 1H), 2.46 (s, 3H). Step 2 (2,2-difluorocyclopropyl) 4-methylbenzenesulfonate

[0274] To a mixture of vinyl 4-meulfonate (2.3 g, 11.60 mmol, 1 eq) and NaF (48.72 mg, 1.16 mmol, 48.72 μL, 0.1 eq) in xylene (1.25 mL) was added trimethylsilyl 2,2-difluoro-2-fluorosulfonyl-acetate (17.42 g, 69.61 mmol, 13.72 mL, 6 eq) dropwise at 120 °C over 2 h. The resulting mixture was then stirred for 2 h at 120 °C. TLC (petroleum ether: EtOAc=10:1) showed most of vinyl 4-methylbenzenesulfonate was consumed and a new spot formed. The mixture was concentrated to remove the solvent and purified by flash column chromatography (12 g SepaFlash Silica Flash Column, Eluent of 0~6% Ethyl acetate / Petroleum ether gradient @45 mL / min) to afford (2,2-difluorocyclopropyl) 4- methylbenzenesulfonate (1.5 g, 6.04 mmol, 52.08% yield) as a light yellow oil.1H NMR (400 MHz, CDCl3) δ ppm 7.84 (d, J = 8.3 Hz, 2H), 7.39 (d, J = 8.1 Hz, 2H), 4.30 - 4.21 (m, 1H), 2.48 (s, 3H), 1.80 - 1.58 (m, 2H). Step 3 tert-butyl 6-[6-chloro-1-(2,2-difluorocyclopropyl)-7-fluoro-pyrazolo[4,3-c]pyridin-3-yl]- 3-azabicyclo[3.1.0]hexane-3-carboxylate

[0275] To a solution of NaH (1 ol, 60% purity, 5 eq) in 3 mL ofanhydrous DMF was added tert-butyl 6-(6-chloro-7-fluoro-1H-pyrazolo[4,3-c]pyridin-3-yl)- 3-azabicyclo[3.1.0]hexane-3-carboxylate (250 mg, 708.64 μmol, 1 eq) under N2atmosphere, and the mixture was stirred at 20 °C for 1 h. Then the solution of (2,2-difluorocyclopropyl) 4- methylbenzenesulfonate (351.83 mg, 1.42 mmol, 2 eq) in 3 mL of DMF was added dropwise. The mixture was stirred at 60 °C for 2 h. LCMS showed 14% of tert-butyl 6-(6-chloro-7- fluoro-1H-pyrazolo[4,3-c]pyridin-3-yl)-3-azabicyclo[3.1.0]hexane-3-carboxylate remained and 15% of desired mass. The mixture was quenched with NH4Cl (25 mL), extracted with EtOAc (25 mL * 3). The organic phase was washed with brine (30 mL), then dried over anhydrous Na2SO4, filtered and concentrated under vacuum to give a crude product as a yellow solid. The crude product was purified by flash column chromatography (12 g SepaFlash Silica Flash Column, eluent of 0~5% Ethyl acetate / Petroleum ether gradient @45 mL / min) and prep-HPLC (column: Phenomenex luna C18150*25mm* 10um; mobile phase: [water(FA)-ACN]; gradient: 55%-85% B over 10 min), the eluent was dried by freeze-drying to afford tert-butyl 6-[6-chloro-1-(2,2-difluorocyclopropyl)-7-fluoro-pyrazolo[4,3-c]pyridin- 3-yl]-3-azabicyclo[3.1.0]hexane-3-carboxylate (38 mg, 85.95 μmol, 12.13% yield, 97% purity) as a white solid. MS (ES+) C19H20N4F3ClO2requires: 428, found: 429 [M+H]+Step 4 tert-butyl 6-[1-(2,2-difluorocyclopropyl)-7-fluoro-6-[7-fluoro-3-(methoxymethoxy)-8-(2- triisopropylsilylethynyl)-1-naphthyl]pyrazolo[4,3-c]pyridin-3-yl]-3- azabicyclo[3.1.0]hexane-3-carboxylate

[0276] To a solution of tert- fluorocyclopropyl)-7-fluoro-pyrazolo[4,3-c]pyridin-3-yl]-3-azabicyclo[3.1.0]hexane-3-carboxylate (38 mg, 88.61 μmol, 1 eq) and 2-[2-fluoro-6-(methoxymethoxy)-8-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)-1- naphthyl]ethynyl-triisopropyl-silane (90.83 mg, 177.22 μmol, 2 eq) in THF (1 mL) were added K3PO4 (1.5 M, 295.37 μL, 5 eq) and CATACXIUM(R) A PD G3 (6.45 mg, 8.86 μmol, 0.1 eq). The mixture was degassed and placed under N2for 3 times, then it was stirred at 60 °C for 16 hrs. LCMS showed a peak (49%) with desired mass. The mixture was diluted with H2O (5 mL), then extracted with EtOAc (5 mL * 3). The organic phase was collected and washed with brine (15 mL), dried over anhydrous Na2SO4, filtered and concentrated to give a crude product. The crude product was purified by prep-TLC (petroleum ether:EtOAc=2:1) to afford tert-butyl 6-[1-(2,2-difluorocyclopropyl)-7-fluoro-6-[7-fluoro-3-(methoxymethoxy)-8- (2-triisopropylsilylethynyl)-1-naphthyl]pyrazolo[4,3-c]pyridin-3-yl]-3- azabicyclo[3.1.0]hexane-3-carboxylate (30 mg, 37.36 μmol, 42.16% yield, 97% purity) as a yellow solid. MS (ES+) C42H50N4F4O4Si requires: 778, found: 779 [M+H]+Step 5 tert-butyl 6-[1-(2,2-difluorocyclopropyl)-6-[8-ethynyl-7-fluoro-3-(methoxymethoxy)-1- naphthyl]-7-fluoro-pyrazolo[4,3-c]pyridin-3-yl]-3-azabicyclo[3.1.0]hexane-3-carboxylate

[0277] To a solution of tert-butyl 6-[1-(2,2-difluorocyclopropyl)-7-fluoro-6-[7-fluoro-3- (methoxymethoxy)-8-(2-triisopropylsilylethynyl)-1-naphthyl]pyrazolo[4,3-c]pyridin-3-yl]-3- azabicyclo[3.1.0]hexane-3-carboxylate (30 mg, 38.51 μmol, 1 eq) in DMF (3 mL) was added CsF (29.25 mg, 192.57 μmol, 7.11 μL, 5 eq) and the mixture was stirred at 20 °C for 0.5 hr. LCMS showed a peak (98%) with desired mass. The mixture was diluted with H2O (5 mL), then extracted with EtOAc (5 mL * 3). The organic phase was washed with brine (15 mL * 3), dried over anhydrous Na2SO4, filtered and concentrated under vacuum to afford tert-butyl 6-[1-(2,2-difluorocyclopropyl)-6-[8-ethynyl-7-fluoro-3-(methoxymethoxy)-1-naphthyl]-7- fluoro-pyrazolo[4,3-c]pyridin-3-yl]-3-azabicyclo[3.1.0]hexane-3-carboxylate (25 mg, crude) as a yellow solid. MS (ES+) C33H30N4F4O4 requires: 622, found: 623 [M+H]+Step 6 4-[3-(3-azabicyclo[3.1.0]hexan-6-yl)-1-(2,2-difluorocyclopropyl)-7-fluoro-pyrazolo[4,3- c]pyridin-6-yl]-5-ethynyl-6-fluoro-naphthalen-2-ol H N H F F

[0278] To a solution of tert-clopropyl)-6-[8-ethynyl-7-fluoro-3- (methoxymethoxy)-1-naphthyl]-7-fluoro-pyrazolo[4,3-c]pyridin-3-yl]-3- azabicyclo[3.1.0]hexane-3-carboxylate (25 mg, 40.15 μmol, 1 eq) in DCM (0.6 mL) was added TFA (460.50 mg, 4.04 mmol, 0.3 mL) and the mixture was stirred at 20 °C for 0.5 hr. LCMS showed a major peak (92%) with desired mass. The mixture was quenched with NaHCO3(5 mL) at 0 °C, then extracted with EtOAc (10 mL * 3). The organic phase was collected and washed with brine (30 mL), dried over anhydrous Na2SO4, filtered and concentrated to give a crude product. The crude product was diluted with DMF (1 mL) and purified by prep-HPLC (column: Phenomenex luna C18150*25mm* 10um; mobile phase: [water(FA)-ACN]; gradient: 10%-40% B over 10 min). The eluent was dried by freeze- drying to afford 4-[3-(3-azabicyclo[3.1.0]hexan-6-yl)-1-(2,2-difluorocyclopropyl)-7-fluoro-pyrazolo[4,3-c]pyridin-6-yl]-5-ethynyl-6-fluoro-naphthalen-2-ol (16.3 mg, 31.08 μmol, 77.40% yield, 100% purity, FA) as a light yellow solid.

[0279] MS (ES+) C26H18N4OF4 requires: 478, found: 479 [M+H]+

[0280] 1H NMR (400 MHz, CD3OD) δ ppm 8.91 - 8.84 (m, 1H), 8.52 (s, 0.5H), 7.91 - 7.83 (m, 1H), 7.39 - 7.29 (m, 2H), 7.24 - 7.20 (m, 1H), 4.52 - 4.44 (m, 1H), 3.63 - 3.55 (m, 2H), 3.48 (d, J = 11.6 Hz, 2H), 3.20 (s, 0.5H), 3.05 (s, 0.5H), 2.54 - 2.44 (m, 3H), 2.43 - 2.27 (m, 2H). EXAMPLE 50 3-[3-(3-azabicyclo[3.1.0]hexa8-ethynyl-7-fluoro-3-hydroxy-1- naphthyl)-7-fluoro-pyrazolo[4,3-c]pyridin-4-yl]propanenitrile Step 1 tert-butyl 6-[6-chloro-4-(2-cyanoethyl)-1-cyclopropyl-7-fluoro-pyrazolo[4,3-c]pyridin-3- yl]-3-azabicyclo[3.1.0]hexane-3-carboxylate

[0281] To a solution of tert-butoro-1-cyclopropyl-7-fluoro- pyrazolo[4,3-c]pyridin-3-yl)-3-azabicyclo[3.1.0]hexane-3-carboxylate (100 mg, 211.98 μmol, 1 eq) and 3-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)propanenitrile (42.21 mg, 233.17 μmol, 1.1 eq) in THF (4 mL) were added cataCXium® A Pd G3 (15.44 mg, 21.20 μmol, 0.1 eq) and K3PO4(1.5 M, 423.95 μL, 3 eq). The mixture was stirred at 60 °C for 16 h under N2. LCMS showed several peaks were showed on LCMS and 37% of desired mass was detected.The mixture was diluted with water (5 mL) and extracted with ethyl acetate (5 mL × 2). The combined organic layers were washed with brine (5 mL), dried over anhydrous sodium sulfate and filtrated. The filtrate was concentrated to afford a residue. The residue was purified by prep-TLC (Petroleum ether : Ethyl acetate=3:1) to afford tert-butyl 6-[6-chloro-4- (2-cyanoethyl)-1-cyclopropyl-7-fluoro-pyrazolo[4,3-c]pyridin-3-yl]-3- azabicyclo[3.1.0]hexane-3-carboxylate (50 mg, 107.64 μmol, 50.78% yield, 96% purity) as yellow oil. MS (ES+) C22H25ClFN5O2requires:445, found:446 [M+H]+. Step 2 tert-butyl 6-[4-(2-cyanoethyl)-1-cyclopropyl-7-fluoro-6-[7-fluoro-3-(methoxymethoxy)- 8-(2-triisopropylsilylethynyl)-1-naphthyl]pyrazolo[4,3-c]pyridin-3-yl]-3- azabicyclo[3.1.0]hexane-3-carboxylate

[0282] To a solution of tert-noethyl)-1-cyclopropyl-7-fluoro- pyrazolo[4,3-c]pyridin-3-yl]-3-azabicyclo[3.1.0]hexane-3-carboxylate (50 mg, 112.13 μmol, 1 eq) and 2-[2-fluoro-6-(methoxymethoxy)-8-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)- 1-naphthyl]ethynyl-triisopropyl-silane (114.94 mg, 224.26 μmol, 2 eq) in dioxane (2 mL) were added cataCXium® A Pd G3 (16.33 mg, 22.43 μmol, 0.2 eq) and K3PO4 (1.5 M, 224.26 μL, 3 eq). The mixture was stirred at 60 °C for 16 h under N2. LCMS showed several peaks were showed on LCMS and 70% of desired mass was detected. The mixture was diluted with water (5 mL) and extracted with ethyl acetate (5 mL × 2). The combined organic layers were washed with brine (5 mL), dried over anhydrous sodium sulfate and filtrated. The filtrate was concentrated to afford a residue. The residue was purified by prep-TLC (Petroleum ether : Ethyl acetate=3:1) to afford tert-butyl 6-[4-(2-cyanoethyl)-1-cyclopropyl-7-fluoro-6-[7- fluoro-3-(methoxymethoxy)-8-(2-triisopropylsilylethynyl)-1-naphthyl]pyrazolo[4,3- c]pyridin-3-yl]-3-azabicyclo[3.1.0]hexane-3-carboxylate (27 mg, 33.24 μmol, 29.64% yield, 98% purity) as yellow oil. MS (ES+) C45H55F2N5O4Si requires:795, found:796[M+H]+.Step 3 tert-butyl 6-[4-(2-cyanoethyl)-1-cyclopropyl-6-[8-ethynyl-7-fluoro-3-(methoxymethoxy)- 1-naphthyl]-7-fluoro-pyrazolo[4,3-c]pyridin-3-yl]-3-azabicyclo[3.1.0]hexane-3- carboxylate

[0283] To a solution of tert-buty 6-[ -( -cyanoet y )-1-cyclopropyl-7-fluoro-6-[7- fluoro-3-(methoxymethoxy)-8-(2-triisopropylsilylethynyl)-1-naphthyl]pyrazolo[4,3- c]pyridin-3-yl]-3-azabicyclo[3.1.0]hexane-3-carboxylate (27 mg, 33.92 μmol, 1 eq) in DMF (2 mL) was added CsF (30 mg, 0.19 mmol, 5.82 eq). The mixture was stirred at 25 °C for 30 min. LCMS showed a main peak with desired mass. The mixture was diluted with water (5 mL) and extracted with ethyl acetate (5 mL). The organic layer was washed with brine (5 mL), dried over anhydrous sodium sulfate and filtrated. The filtrate was concentrated to afford tert-butyl 6-[4-(2-cyanoethyl)-1-cyclopropyl-6-[8-ethynyl-7-fluoro-3- (methoxymethoxy)-1-naphthyl]-7-fluoro-pyrazolo[4,3-c]pyridin-3-yl]-3- azabicyclo[3.1.0]hexane-3-carboxylate (22 mg, crude) as yellow oil. MS (ES+) C36H35F2N5O4requires:639, found:640[M+H]+. Step 4 3-[3-(3-azabicyclo[3.1.0]hexan-6-yl)-1-cyclopropyl-6-(8-ethynyl-7-fluoro-3-hydroxy-1- naphthyl)-7-fluoro-pyrazolo[4,3-c]pyridin-4-yl]propanenitrile

[0284] To a solution of tert-butyl 6-[4-(2-cyanoethyl)-1-cyclopropyl-6-[8-ethynyl-7- fluoro-3-(methoxymethoxy)-1-naphthyl]-7-fluoro-pyrazolo[4,3-c]pyridin-3-yl]-3- azabicyclo[3.1.0]hexane-3-carboxylate (22 mg, 34.39 μmol, 1 eq) in DCM (0.6 mL) was added TFA (460.50 mg, 4.04 mmol, 0.3 mL, 117.43 eq). The mixture was stirred at 25 °C for 0.5 h LCMS showed 92% of desired mass was detected. The mixture was quenched with saturated NaHCO3aqueous solution (3 mL) and extracted with dichloromethane (3 mL × 2), the combined organic layers were concentrated to afford a residue. The residue was purified by prep-HPLC (column: Phenomenex luna C18150*25mm* 10um; mobile phase: [water(FA)-ACN]; gradient: 16%-36% B over 10 min). The eluent was freeze-dried to afford 3-[3-(3-azabicyclo[3.1.0]hexan-6-yl)-1-cyclopropyl-6-(8-ethynyl-7-fluoro-3-hydroxy-1- naphthyl)-7-fluoro-pyrazolo[4,3-c]pyridin-4-yl]propanenitrile (4.1 mg, 7.50 μmol, 21.79% yield) as a white solid.

[0285] MS (ES+) C29H23F2N5O requires:495, found:496[M+H]+.

[0286] 1H NMR (400 MHz, CD3OD) δ = 8.51 (s, 1H), 7.87 (dd, J = 5.7, 9.0 Hz, 1H), 7.37 - 7.29 (m, 2H), 7.23 (d, J = 2.6 Hz, 1H), 3.89 - 3.80 (m, 1H), 3.68 - 3.59 (m, 3H), 3.56 - 3.48 (m, 3H), 3.14 (s, 1H), 3.08 - 2.90 (m, 2H), 2.54 - 2.45 (m, 3H), 1.28 - 1.18 (m, 2H), 1.17 - 1.08 (m, 2H). EXAMPLE 51 4-[3-(3-azabicyclo[3.1.0]hex-fluoro-4-methyl-pyrazolo[4,3- c]pyridin-6-yl]-5-ethynyl-6-fluoro-naphthalen-2-ol

[0287] Prepared similarly to Example 50 using 2,4,6-trimethyl-1,3,5,2,4,6- trioxatriborinane in place of 3-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)propanenitrile on step 1.

[0288] MS (ES+) C27H22F2N4O requires:456, found: 457

[0289] 1H NMR (400 MHz, CD3OD) δ = 8.55 - 8.48 (m, 0.3H), 7.95 - 7.83 (m, 1H), 7.41 - 7.31 (m, 2H), 7.28 - 7.19 (m, 1H), 3.91 - 3.79 (m, 1H), 3.68 - 3.62 (m, 2H), 3.59 - 3.52 (m, 2H), 3.18 (s, 1H), 2.95 - 2.87 (m, 3H), 2.59 - 2.40 (m, 3H), 1.34 - 1.22 (m, 2H), 1.17 - 1.10 (m, 2H). EXAMPLE 52 4-[3-(3-azabicyclo[3.1.0]he opropyl-7-fluoro-pyrazolo[4,3-c]pyridin-6-yl]-5-ethynyl-6-fluoro-naphthalen-2-ol

[0290] Prepared similarly to Example 50 using 2-benzyl-4,4,5,5-tetramethyl-1,3,2- dioxaborolane in place of 3-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)propanenitrile on step 1.

[0291] MS (ES+) C33H26F2N4O requires:532, found: 533

[0292] 1H NMR (400 MHz, CD3OD) δ = 8.63 - 8.48 (m, 0.6H), 7.92 - 7.82 (m, 1H), 7.41 - 7.15 (m, 8H), 4.73 - 4.62 (m, 2H), 3.94 - 3.79 (m, 1H), 3.28 - 3.03 (m, 5H), 2.40 - 2.14 (m, 3H), 1.40 - 1.06 (m, 4H). EXAMPLE 534-(3-((1R,5S,6r)-3-azabicyclo[3.1.0]hexan-6-yl)-1-cyclopropyl-7-fluoro-4-(prop-1-en-2- yl)-1H-pyrazolo[4,3-c]pyridin-6-yl)-5-ethynyl-6-fluoronaphthalen-2-ol

[0293] Prepared similarly to Example 50 using 4,4,5,5-tetramethyl-2-(prop-1-en-2-yl)- 1,3,2-dioxaborolane in place of 3-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)propanenitrile on step 1.

[0294] MS (ES+) C29H24F2N4O requires: 482, found: 483 [M+H]+.

[0295] 1H NMR (600 MHz, CDCl3) δ 7.91 (dd, J = 9.1, 5.7 Hz, 1H), 7.45 – 7.41 (m, 1H), 7.40 – 7.35 (m, 1H), 7.33 (d, J = 5.7 Hz, 1H), 3.94 (dt, J = 7.3, 3.7 Hz, 1H), 3.75 – 3.64 (m, 4H), 3.39 –3.23 (m, 2H), 2.69 – 2.58 (m, 2H), 2.53 (d, J = 4.2 Hz, 1H), 1.46 (td, J = 7.8, 2.2 Hz, 3H), 1.35 – 1.20 (m, 2H), 1.21 – 1.13 (m, 2H). EXAMPLE 54 4-[3-(3-azabicyclo[3.1.0]hexaclopropyl-7-fluoro-pyrazolo[4,3- c]pyridin-6-yl]-5-ethynyl-6-fluoro-naphthalen-2-ol Step 1 tert-butyl 6-(6-chloro-4-cyclobutyl-1-cyclopropyl-7-fluoro-pyrazolo[4,3-c]pyridin-3-yl)- 3-azabicyclo[3.1.0]hexane-3-carboxylate Boc N

[0296] A mixture of ter cyclopropyl-7-fluoro-pyrazolo[4,3-c]pyridin-3-yl)-3-azabicyclo[3.1.0]hexane-3-carboxylate (200 mg, 423.95 μmol, 1 eq), bromocyclobutane (57.23 mg, 423.95 μmol, 39.91 μL, 1 eq), Ir[dF(CF3)ppy]2(dtbpy)(PF6) (4.76 mg, 4.24 μmol, 0.01 eq), TTMSS (105.42 mg, 423.95 μmol, 130.79 μL, 1 eq),NiCl2∙dtbpy (843.66 μg, 2.12 μmol, 0.005 eq) and Na2CO3(89.87 mg, 847.91 μmol, 2 eq) in DME (10 mL) was degassed and purged with N2, and then the mixture was stirred at 25 °C for 16 h irradiated with a 455 nm blue LED. TLC (Petroleum ether: Ethyl acetate = 5:1) showed tert-butyl 6-(4-bromo-6-chloro-1-cyclopropyl-7-fluoro-pyrazolo[4,3-c]pyridin-3-yl)- 3-azabicyclo[3.1.0]hexane-3-carboxylate consumed completely and several new spots formed. The mixture was filtered and the filtrate was concentrated under reduced pressure. The residue was purified by flash silica gel chromatography (20 g SepaFlash® Silica Flash Column, Eluent of 0~20% Ethyl acetate / Petroleum ether gradient @ 100 mL / min) to afford tert-butyl 6-(6-chloro-4-cyclobutyl-1-cyclopropyl-7-fluoro-pyrazolo[4,3-c]pyridin-3-yl)-3- azabicyclo[3.1.0]hexane-3-carboxylate (120 mg, 268.49 μmol, 63.33% yield) as colorless oil.

[0297] MS (ES+) C23H28N4FClO2 requires: 446 found 447 [M+H]+Step 2 tert-butyl 6-[4-cyclobutyl-1-cyclopropyl-7-fluoro-6-[7-fluoro-3-(methoxymethoxy)-8-(2- triisopropylsilylethynyl)-1-naphthyl]pyrazolo[4,3-c]pyridin-3-yl]-3- azabicyclo[3.1.0]hexane-3-carboxylate

[0298] To a solution of tert-utyl-1-cyclopropyl-7-fluoro- pyrazolo[4,3-c]pyridin-3-yl)-3-azabicyclo[3.1.0]hexane-3-carboxylate (80 mg, 178.99 μmol, 1 eq) in dioxane (2.5 mL) were added 2-[2-fluoro-6-(methoxymethoxy)-8-(4,4,5,5- tetramethyl-1,3,2-dioxaborolan-2-yl)-1-naphthyl]ethynyl-triisopropyl-silane (183.48 mg, 357.99 μmol, 2 eq), cataCXium® A Pd G3(13.04 mg, 17.90 μmol, 0.1 eq) and K3PO4(1.5 M in H2O, 357.99 μL, 3 eq) under N2, the mixture was stirred at 100 °C for 3 h under N2. LCMS showed tert-butyl 6-(6-chloro-7-fluoro-4-isopropyl-1-methyl-pyrazolo[4,3-c]pyridin-3-yl)-3- azabicyclo[3.1.0]hexane-3-carboxylate consumed completely and a peak (46%) with desired mass. The reaction was diluted with water (10 mL), extracted with ethyl acetate (10 mL x 3), the organic layer was washed with brine (10 mL x 3), dried over Na2SO4, filtered and the filtrate was concentrated under reduced pressure. The mixture was purified by prep-TLC(Petroleum ether: Ethyl acetate=5:1) to afford tert-butyl 6-[4-cyclobutyl-1-cyclopropyl-7- fluoro-6-[7-fluoro-3-(methoxymethoxy)-8-(2-triisopropylsilylethynyl)-1- naphthyl]pyrazolo[4,3-c]pyridin-3-yl]-3-azabicyclo[3.1.0]hexane-3-carboxylate (46 mg, 57.71 μmol, 32.24% yield) as colorless oil.

[0299] MS (ES+) C46H58N4F2O4Si requires: 797 found 798 [M+H]+Step 3 tert-butyl 6-[4-cyclobutyl-1-cyclopropyl-6-[8-ethynyl-7-fluoro-3-(methoxymethoxy)-1- naphthyl]-7-fluoro-pyrazolo[4,3-c]pyridin-3-yl]-3-azabicyclo[3.1.0]hexane-3-carboxylate

[0300] To a solution of tert-butyl 6-[4-cyclobutyl-1-cyclopropyl-7-fluoro-6-[7-fluoro-3- (methoxymethoxy)-8-(2-triisopropylsilylethynyl)-1-naphthyl]pyrazolo[4,3-c]pyridin-3-yl]-3- azabicyclo[3.1.0]hexane-3-carboxylate (56 mg, 70.26 μmol, 1 eq) in DMF (0.5 mL) was added CsF (32.02 mg, 210.78 μmol, 3 eq), the mixture was stirred at 25 °C for 0.5 hr. LCMS showed a peak (87%) with desired mass. The reaction was diluted with water (10 mL), extracted with ethyl acetate (10 mL x 3), the organic layer was washed with brine (10 mL x 3), dried over Na2SO4, filtered and the filtrate was concentrated under reduced pressure to afford tert-butyl 6-[4-cyclobutyl-1-cyclopropyl-6-[8-ethynyl-7-fluoro-3-(methoxymethoxy)- 1-naphthyl]-7-fluoro-pyrazolo[4,3-c]pyridin-3-yl]-3-azabicyclo[3.1.0]hexane-3-carboxylate (45 mg, crude) as colorless oil.

[0301] MS (ES+) C37H38N4F2O4requires: 640 found 641 [M+H]+Step 4 4-[3-(3-azabicyclo[3.1.0]hexan-6-yl)-4-cyclobutyl-1-cyclopropyl-7-fluoro-pyrazolo[4,3- c]pyridin-6-yl]-5-ethynyl-6-fluoro-naphthalen-2-ol

[0302] To a solution of tert- clopropyl-6-[8-ethynyl-7-fluoro-3-(methoxymethoxy)-1-naphthyl]-7-fluoro-pyrazolo[4,3-c]pyridin-3-yl]-3- azabicyclo[3.1.0]hexane-3-carboxylate (40 mg, 62.43 μmol, 1 eq) in DCM (0.4 mL) was added TFA (284.74 mg, 2.50 mmol, 185.50 μL, 40 eq), the mixture was stirred at 25 °C for 20 min. LCMS showed tert-butyl 6-[4-cyclobutyl-1-cyclopropyl-6-[8-ethynyl-7-fluoro-3- (methoxymethoxy)-1-naphthyl]-7-fluoro-pyrazolo[4,3-c]pyridin-3-yl]-3- azabicyclo[3.1.0]hexane-3-carboxylate was consumed completely and a peak (45%) with desired mass. The mixture was concentrated under reduced pressure. The residue was purified by prep-HPLC (column: Welch Xtimate C18150*25mm*5um; mobile phase: [water(FA)-ACN]; gradient: 16%-46% B over 10 min), the eluent was lyophilized under reduced pressure to afford 4-[3-(3-azabicyclo[3.1.0]hexan-6-yl)-4-cyclobutyl-1-cyclopropyl- 7-fluoro-pyrazolo[4,3-c]pyridin-6-yl]-5-ethynyl-6-fluoro-naphthalen-2-ol (8.9 mg, 16.24 μmol, 26.01% yield) as a white solid.

[0303] MS (ES+) C30H26F2N4O requires: 496, found 497 [M+H]+

[0304] 1H NMR (400 MHz, CD3OD) δ = 7.85 (dd, J = 5.8, 9.1 Hz, 1H), 7.36 - 7.27 (m, 2H), 7.23 (d, J = 2.4 Hz, 1H), 4.39 (quin, J = 8.2 Hz, 1H), 3.85 - 3.75 (m, 1H), 3.64 - 3.56 (m, 2H), 3.55 - 3.46 (m, 2H), 3.09 (s, 1H), 2.71 - 2.60 (m, 1H), 2.60 - 2.50 (m, 1H), 2.48 - 2.40 (m, 4H), 2.39 - 2.29 (m, 1H), 2.17 - 2.04 (m, 1H), 2.03 - 1.89 (m, 1H), 1.25 - 1.16 (m, 2H), 1.13 - 1.05 (m, 2H). EXAMPLE 554-[3-(3-azabicycl lopropyl-7-fluoro-4-(trifluoromethyl)pyrazolo[4,3-c]pyridin-6-yl]-5-ethynyl-6-fluoro-naphthalen-2-ol Step 1 3-(3-azabicyclo[3.1.0]hexan-6-yl)-6-chloro-1-cyclopropyl-7-fluoro-4- (trifluoromethyl)pyrazolo[4,3-c]pyridin

[0305] To a solution of tert-butloro-1-cyclopropyl-7-fluoro- pyrazolo[4,3-c]pyridin-3-yl)-3-azabicyclo[3.1.0]hexane-3-carboxylate (393 mg, 833.07 μmol, 1 eq) in DMF (8 mL) were added methyl 2,2-difluoro-2-fluorosulfonyl-acetate (480.25 mg, 2.50 mmol, 318.04 μL, 3 eq) and CuI (476.32 mg, 2.50 mmol, 3 eq) under N2 at 25 °C, then the mixture was stirred at 100 °C for 16 h under N2. LCMS showed the starting material was consumed completely and a peak (65%) with the desired mass. The mixture was cooled to 25 °C, filtered and added NaHCO3(3 mL) and water (10 mL). The aqueous phase was extracted with ethyl acetate (30 mL × 2). The combined organic phase was washed with brine (10 mL × 2), dried over anhydrous Na2SO4, filtered and concentrated under vacuum to afford 3-(3- azabicyclo[3.1.0]hexan-6-yl)-6-chloro-1-cyclopropyl-7-fluoro-4- (trifluoromethyl)pyrazolo[4,3-c]pyridine (300 mg, crude) as yellow oil was used into the next step without further purification.

[0306] MS (ES+) C15H13ClF4N4 requires: 360, found 361 [M+H]+Step 2tert-butyl 6-[6-chloro-1-cyclopropyl-7-fluoro-4-(trifluoromethyl)pyrazolo[4,3-c]pyridin- 3-yl]-3-azabicyclo[3.1.0]hexane-3-carboxylate

[0307] To a mixture of 3-(3-az n-6-yl)-6-chloro-1-cyclopropyl-7-fluoro-4-(trifluoromethyl)pyrazolo[4,3-c]pyridine (300 mg, 831.63 μmol, 1 eq) in DCM (6 mL) were added DMAP (20.32 mg, 166.33 μmol, 0.2 eq), TEA (252.46 mg, 2.49 mmol, 347.26 μL, 3 eq) and Boc2O (363.00 mg, 1.66 mmol, 382.11 μL, 2 eq), the mixture was stirred at 25 °C for 2 h. LCMS showed the starting material was consumed completely and a peak (49%) with the desired mass. The mixture was filtered and washed with EtOAc (10 mL), the filtrate was concentrated under vacuum. The residue was purified by flash silica gel chromatography (40 g SepaFlash® Silica Flash Column, Eluent of 0~18% Ethyl acetate / Petroleum ether gradient @ 45 mL / min) to afford tert-butyl 6-[6-chloro-1-cyclopropyl-7- fluoro-4-(trifluoromethyl)pyrazolo[4,3-c]pyridin-3-yl]-3-azabicyclo[3.1.0]hexane-3- carboxylate (140 mg, 303.79 μmol, 36.53% yield) as a yellow solid.

[0308] MS (ES+) C20H21ClF4N4O2 requires: 460, found 461 [M+H]+Step 3 tert-butyl 6-[1-cyclopropyl-7-fluoro-6-[7-fluoro-3-(methoxymethoxy)-8-(2- triisopropylsilylethynyl)-1-naphthyl]-4-(trifluoromethyl)pyrazolo[4,3-c]pyridin-3-yl]-3- azabicyclo[3.1.0]hexane-3-carboxylate

[0309] To a solution of tert-butyl 6-[6-chloro-1-cyclopropyl-7-fluoro-4- (trifluoromethyl)pyrazolo[4,3-c]pyridin-3-yl]-3-azabicyclo[3.1.0]hexane-3-carboxylate (40 mg, 86.80 μmol, 1 eq), 2-[2-fluoro-6-(methoxymethoxy)-8-(4,4,5,5-tetramethyl-1,3,2- dioxaborolan-2-yl)-1-naphthyl]ethynyl-triisopropyl-silane (60.06 mg, 117.17 μmol, 1.35 eq) and K3PO4 (1.5 M, 173.60 μL, 3 eq) in dioxane (1.7 mL) was added CATACXIUM (R) A PD G3(6.32 mg, 8.68 μmol, 0.1 eq), the mixture was stirred at 60 °C for 16 h under N2. LCMS showed the starting material was consumed completely and a peak (29%) with the desired mass. The mixture was cooled to 25 °C and poured into a mixture of saturated NH4Cl (10 mL) and water (10 mL). The aqueous phase was extracted with ethyl acetate (30 mL × 2). The combined organic phase was washed with brine (10 mL × 2), dried over anhydrous Na2SO4, filtered and concentrated under vacuum. The residue was purified by flash silica gel chromatography (12 g SepaFlash® Silica Flash Column, Eluent of 0~25% Ethyl acetate / Petroleum ether gradient @ 45 mL / min) to afford tert-butyl 6-[1-cyclopropyl-7-fluoro-6-[7- fluoro-3-(methoxymethoxy)-8-(2-triisopropylsilylethynyl)-1-naphthyl]-4- (trifluoromethyl)pyrazolo[4,3-c]pyridin-3-yl]-3-azabicyclo[3.1.0]hexane-3-carboxylate (42 mg, 51.79 μmol, 59.67% yield) as a yellow solid.

[0310] MS (ES+) C43H51F5N4O4Si requires: 810, found 811 [M+H]+Step 4 tert-butyl 6-[1-cyclopropyl-6-[8-ethynyl-7-fluoro-3-(methoxymethoxy)-1-naphthyl]-7- fluoro-4-(trifluoromethyl)pyrazolo[4,3-c]pyridin-3-yl]-3-azabicyclo[3.1.0]hexane-3- carboxylate

[0311] To a solution of tert-uoro-6-[7-fluoro-3- (methoxymethoxy)-8-(2-triisopropylsilylethynyl)-1-naphthyl]-4- (trifluoromethyl)pyrazolo[4,3-c]pyridin-3-yl]-3-azabicyclo[3.1.0]hexane-3-carboxylate (42 mg, 51.79 μmol, 1 eq) in DMF (0.5 mL) was added CsF (23.63 mg, 155.53 μmol, 5.74 μL,3.0 eq), the mixture was stirred at 25 °C for 1 h. LCMS showed the starting material was consumed completely and a peak (97%) with the desired mass. The mixture was poured into a mixture of brine (3 mL) and water (2 mL). The aqueous phase was extracted with ethyl acetate (3 mL × 2). The combined organic phase was washed with brine (1 mL × 2), dried over anhydrous Na2SO4, filtered and concentrated under vacuum to afford tert-butyl 6-[1- cyclopropyl-6-[8-ethynyl-7-fluoro-3-(methoxymethoxy)-1-naphthyl]-7-fluoro-4- (trifluoromethyl)pyrazolo[4,3-c]pyridin-3-yl]-3-azabicyclo[3.1.0]hexane-3-carboxylate (33 mg, 50.41 μmol, 97.34% yield) as yellow gel was used into the next step without further purification.

[0312] MS (ES+) C34H31F5N4O4requires: 654, found 655 [M+H]+. Step 5 4-[3-(3-azabicyclo[3.1.0]hexan-6-yl)-1-cyclopropyl-7-fluoro-4- (trifluoromethyl)pyrazolo[4,3-c]pyridin-6-yl]-5-ethynyl-6-fluoro-naphthalen-2-ol

[0313] To a solution of tert-8-ethynyl-7-fluoro-3- (methoxymethoxy)-1-naphthyl]-7-fluoro-4-(trifluoromethyl)pyrazolo[4,3-c]pyridin-3-yl]-3- azabicyclo[3.1.0]hexane-3-carboxylate (33 mg, 50.41 μmol, 1 eq) in DCM (0.45 mL) was added TFA (230.25 mg, 2.02 mmol, 150 μL, 40.06 eq), the mixture was stirred at 25 °C for 30 min. LCMS showed the starting material was consumed completely and a peak (82%) with the desired mass. The mixture was concentrated under vacuum (<30 °C). The residue was purified by Prep-HPLC (column: Welch Xtimate C18150*25 mm*5um;mobile phase: [water (FA) -ACN];gradient:12%-42% B over 10 min) and freeze-dried to afford 4-[3-(3- azabicyclo[3.1.0]hexan-6-yl)-1-cyclopropyl-7-fluoro-4-(trifluoromethyl)pyrazolo[4,3- c]pyridin-6-yl]-5-ethynyl-6-fluoro-naphthalen-2-ol (6.5 mg, 11.68 μmol, 23.17% yield, FA) as a yellow solid.

[0314] MS (ES+) C27H19F5N4O requires: 510, found: 511 [M+H]+.

[0315] 1H NMR (400 MHz, CD3OD) δ ppm 8.54 (s, 0.5H), 7.88 (dd, J = 5.7, 9.2 Hz, 1H), 7.37 (d, J = 2.6 Hz, 1H), 7.33 (t, J = 9.0 Hz, 1H), 7.25 (d, J = 2.4 Hz, 1H), 3.96 - 3.87 (m, 1H), 3.51 - 3.46 (m, 2H), 3.44 - 3.38 (m, 2H), 3.19 (s, 1H), 2.48 - 2.42 (m, 1H), 2.42 - 2.33 (m, 2H), 1.34 - 1.22 (m, 2H), 1.21 - 1.13 (m, 2H). EXAMPLE 56 4-[3-(3-azabicyclo[3.1.0]hex -fluoro-4-(1-hydroxy-1-methyl-ethyl)pyrazolo[4,3-c]pyridin-6-yl]-5-ethynyl-6-fluoro-naphthalen-2-ol Step 1 tert-butyl 6-[6-chloro-1-cyclopropyl-7-fluoro-4-(1-hydroxy-1-methyl-ethyl)pyrazolo[4,3- c]pyridin-3-yl]-3-azabicyclo[3.1.0]hexane-3-carboxylate

[0316] To a solution of tert-butoro-1-cyclopropyl-7-fluoro- pyrazolo[4,3-c]pyridin-3-yl)-3-azabicyclo[3.1.0]hexane-3-carboxylate (150 mg, 344.91 μmol, 1 eq) in THF (3 mL) was added MeMgBr (3 M, 574.86 μL, 5 eq) under N2at 0 °C. The mixture was stirred at 25 °C for 2 hr. LCMS showed a main peak with desired mass. The reaction was quenched with saturated aqueous solution of NH4Cl (10 mL), extracted with ethyl acetate (10 mL x 3), the organic layer was washed with brine (10 mL x 3), dried over Na2SO4, filtered and the filtrate was concentrated under reduced pressure. The residue was purified by prep-TLC (Petroleum ether: Ethyl acetate=3:1) to afford tert-butyl 6-[6-chloro-1-cyclopropyl-7-fluoro-4-(1-hydroxy-1-methyl-ethyl)pyrazolo[4,3-c]pyridin-3-yl]-3- azabicyclo[3.1.0]hexane-3-carboxylate (90 mg, 199.59 μmol, 57.87% yield) as a white solid.

[0317] MS (ES+) C22H28N4ClFO3 requires: 450 found 451 [M+H]+Step 2 tert-butyl 6-[1-cyclopropyl-7-fluoro-6-[7-fluoro-3-(methoxymethoxy)-8-(2- triisopropylsilylethynyl)-1-naphthyl]-4-(1-hydroxy-1-methyl-ethyl)pyrazolo[4,3- c]pyridin-3-yl]-3-azabicyclo[3.1.0]hexane-3-carboxylate

[0318] To a solution of tert- ropyl-7-fluoro-4-(1-hydroxy-1-methyl-ethyl)pyrazolo[4,3-c]pyridin-3-yl]-3-azabicyclo[3.1.0]hexane-3-carboxylate (40 mg, 88.70 μmol, 1 eq) in THF (1.5 mL) were added 2-[2-fluoro-6-(methoxymethoxy)-8-(4,4,5,5- tetramethyl-1,3,2-dioxaborolan-2-yl)-1-naphthyl]ethynyl-triisopropyl-silane (90.93 mg, 177.41 μmol, 2 eq) , cataCXium® A Pd G3(6.46 mg, 8.87 μmol, 0.1 eq) and K3PO4(1.5 M in H2O, 177.41 μL, 3 eq) under N2, the mixture was stirred at 60 °C for 16 h. LCMS showed 12% of tert-butyl 6-[6-chloro-1-cyclopropyl-7-fluoro-4-(1-hydroxy-1-methyl- ethyl)pyrazolo[4,3-c]pyridin-3-yl]-3-azabicyclo[3.1.0]hexane-3-carboxylate remained and a peak (30%) with desired mass. The reaction mixture was diluted with water (10 mL), extracted with ethyl acetate (10 mL x 3), the organic layers were washed with brine (10 mL x 3), dried over Na2SO4, filtered and the filtrate was concentrated under reduced pressure. The mixture was purified by prep-TLC (Petroleum ether: Ethyl acetate=3:1) to afford tert-butyl 6- [1-cyclopropyl-7-fluoro-6-[7-fluoro-3-(methoxymethoxy)-8-(2-triisopropylsilylethynyl)-1- naphthyl]-4-(1-hydroxy-1-methyl-ethyl)pyrazolo[4,3-c]pyridin-3-yl]-3- azabicyclo[3.1.0]hexane-3-carboxylate (10 mg, 12.48 μmol, 14.07% yield) as brown oil.

[0319] MS (ES+) C45H58N4F2O5Si requires: 800 found 801 [M+H]+Step 3tert-butyl 6-[1-cyclopropyl-6-[8-ethynyl-7-fluoro-3-(methoxymethoxy)-1-naphthyl]-7- fluoro-4-(1-hydroxy-1-methyl-ethyl)pyrazolo[4,3-c]pyridin-3-yl]-3- azabicyclo[3.1.0]hexane-3-carboxylate

[0320] To a solution of tert- luoro-6-[7-fluoro-3-(methoxymethoxy)-8-(2-triisopropylsilylethynyl)-1-naphthyl]-4-(1-hydroxy-1-methyl- ethyl)pyrazolo[4,3-c]pyridin-3-yl]-3-azabicyclo[3.1.0]hexane-3-carboxylate (10 mg, 12.48 μmol, 1 eq) in DMF (0.2 mL) was added CsF (5.69 mg, 37.45 μmol, 3 eq), the mixture was stirred at 25 °C for 20 min. LCMS showed a peak (92%) with desired mass. The reaction was diluted with water (10 mL), extracted with ethyl acetate (10 mL x 3), the organic layers were washed with brine (10 mL x 3), dried over Na2SO4, filtered and the filtrate was concentrated under reduced pressure to afford tert-butyl 6-[1-cyclopropyl-6-[8-ethynyl-7-fluoro-3- (methoxymethoxy)-1-naphthyl]-7-fluoro-4-(1-hydroxy-1-methyl-ethyl)pyrazolo[4,3- c]pyridin-3-yl]-3-azabicyclo[3.1.0]hexane-3-carboxylate (10 mg, crude) as colorless oil.

[0321] MS (ES+) C36H38N4F2O5 requires: 644 found 645 [M+H]+Step 4 4-[3-(3-azabicyclo[3.1.0]hexan-6-yl)-1-cyclopropyl-7-fluoro-4-(1-hydroxy-1-methyl- ethyl)pyrazolo[4,3-c]pyridin-6-yl]-5-ethynyl-6-fluoro-naphthalen-2-ol

[0322] To a solution of tert-y y p py [8-ethynyl-7-fluoro-3- (methoxymethoxy)-1-naphthyl]-7-fluoro-4-(1-hydroxy-1-methyl-ethyl)pyrazolo[4,3-c]pyridin-3-yl]-3-azabicyclo[3.1.0]hexane-3-carboxylate (10 mg, 15.51 μmol, 1 eq) in DCM (0.2 mL) was added TFA (159.17 mg, 1.40 mmol, 103.70 μL, 90 eq). The mixture was stirred at 25 °C for 20 min.

[0323] LCMS showed a peak (87%) with desired mass. The mixture was concentrated under reduced pressure. The residue was purified by prep-HPLC (column: Welch Xtimate C18150*25mm*5um; mobile phase: [water(FA)-ACN]; gradient:15%-45% B over 10 min), the eluent was lyophilized under reduced pressure to afford 4-[3-(3-azabicyclo[3.1.0]hexan- 6-yl)-1-cyclopropyl-7-fluoro-4-(1-hydroxy-1-methyl-ethyl)pyrazolo[4,3-c]pyridin-6-yl]-5- ethynyl-6-fluoro-naphthalen-2-ol (4.5 mg, 8.07 μmol, 52.02% yield, 98% purity) as a white solid.

[0324] MS (ES+) C29H26F2N4O2 requires: 500, found 501 [M+H]+.

[0325] 1H NMR (400 MHz, CD3OD) δ = 8.64 - 8.46 (m, 1H), 7.84 (dd, J = 5.7, 9.1 Hz, 1H), 7.34 - 7.27 (m, 2H), 7.20 (d, J = 2.4 Hz, 1H), 3.92 - 3.77 (m, 1H), 3.50 - 3.43 (m, 2H), 3.41 - 3.35 (m, 2H), 3.13 - 3.06 (m, 2H), 2.42 - 2.32 (m, 2H), 1.74 (s, 3H), 1.72 (s, 3H), 1.25 - 1.16 (m, 2H), 1.14 - 1.05 (m, 2H). EXAMPLE 57 (1S,5S,6S)-3-(6-(8-ethynyl-7-alen-1-yl)-7-fluoro-1-methyl-1H- pyrazolo[4,3-c]pyridin-3-yl)-3,8-diazabicyclo[3.2.1]octan-6-ol

[0326] MS (ES+) C25H21F2N5O2 requires: 461, found: 462 [M+H]+.

[0327] 1H NMR (600 MHz, MeOD) δ 9.00 (s, 1H), 7.89 (dd, J = 9.2, 5.6 Hz, 1H), 7.39 (s, 1H), 7.35 (t, J = 9.0 Hz, 1H), 7.27 (d, J = 2.6 Hz, 1H), 4.69 – 4.62 (m, 1H), 4.50 – 4.42 (m, 1H), 4.21 (d, J = 7.4 Hz, 1H), 4.13 (d, J = 11.9 Hz, 1H), 4.09 (d, J = 2.1 Hz, 3H), 4.03 (d, J = 4.8 Hz, 1H), 3.61 (d, J = 13.2 Hz, 1H), 3.55 (dd, J = 19.3, 11.8 Hz, 1H), 2.71 – 2.66 (m, 1H), 2.04 – 1.99 (m, 1H).EXAMPLE 58 3-((1R,5S,6s)-3-aza -(8-ethynyl-7-fluoro-3-hydroxynaphthalen-1-yl)-7-fluoro-1-methyl-1H-pyrrolo[3,2-c]pyridine-2-carbonitrile

[0328] MS (ES+) C26H18F2N4O requires: 440.1, found: 441.2 [M+H]+.

[0329] 1H NMR (600 MHz, MeOD) δ 8.82 (s, 1H), 7.86 (dd, J = 9.1, 5.7 Hz, 1H), 7.35 (d, J = 2.6 Hz, 1H), 7.32 (t, J = 8.9 Hz, 1H), 7.20 (d, J = 2.6 Hz, 1H), 4.08 (d, J = 1.1 Hz, 3H), 3.76 (dd, J = 11.9, 2.5 Hz, 2H), 3.68 (d, J = 11.8 Hz, 2H), 3.18 (s, 1H), 2.63 (t, J = 3.7 Hz, 2H), 2.35 (t, J = 4.0 Hz, 1H). EXAMPLE 59 4-(3-((1R,5S,6r)-3-azabicuoro-1-(prop-2-yn-1-yl)-1H- pyrazolo[4,3-c]pyridin-6-yl)-5-ethynyl-6-fluoronaphthalen-2-ol

[0330] 1H NMR (600 MHz, MeOD) δ 8.91 (d, J = 1.3 Hz, 1H), 7.87 (dd, J = 9.2, 5.7 Hz, 1H), 7.37 (d, J = 2.6 Hz, 1H), 7.33 (t, J = 8.9 Hz, 1H), 7.23 (d, J = 2.6 Hz, 1H), 5.28 (dd, J = 4.5, 2.5 Hz, 2H), 3.72 (dd, J = 11.7, 2.1 Hz, 2H), 3.66 (dt, J = 11.9, 3.4 Hz, 2H), 3.14 (s, 1H), 2.89 (t, J = 2.5 Hz, 1H), 2.61 (dtd, J = 14.9, 7.3, 3.8 Hz, 2H), 2.52 (t, J = 3.8 Hz, 1H).

[0331] MS (ES+) C26H18F2N4O requires: 440.1, found: 441.2 [M+H]+. EXAMPLE 604-(3-((1R,4R)-2,5-diazabicyclluoro-1-methyl-1H-pyrazolo[4,3- c]pyridin-6-yl)-5-ethynyl-6-fluoronaphthalen-2-ol

[0332] MS (ES+) C25H21F2N5O requires: 445, found: 446 [M+H]+.

[0333] 1H NMR (600 MHz, MeOD) δ 9.02 (s, 1H), 7.91 (dd, J = 9.2, 5.6 Hz, 1H), 7.43 (d, J = 2.6 Hz, 1H), 7.38 (t, J = 8.9 Hz, 1H), 7.31 (t, J = 2.2 Hz, 1H), 4.53 (s, 1H), 4.21 – 4.14 (m, 1H), 4.11 (s, 3H), 4.08 – 4.00 (m, 1H), 3.93 (s, 1H), 3.81 – 3.67 (m, 1H), 3.53 (d, J = 12.5 Hz, 1H), 3.46 (d, J = 46.2 Hz, 1H), 2.40 – 2.30 (m, 1H), 2.30 – 2.18 (m, 1H), 2.18 – 2.04 (m, 2H). EXAMPLE 61 4-(3-((1R,5S,6r)-3-azabicyclo[lopropyl-7-fluoro-4-methoxy-1H- pyrazolo[4,3-c]pyridin-6-yl)-5-ethynyl-6-fluoronaphthalen-2-ol Step 1 3-((1R,5S,6r)-3-(tert-butoxycarbonyl)-3-azabicyclo[3.1.0]hexan-6-yl)-6-chloro-1- cyclopropyl-7-fluoro-1H-pyrazolo[4,3-c]pyridine 5-oxide

[0334] To a cooled 0 °C solutio ,5S,6r)-6-(6-chloro-1-cyclopropyl-7-fluoro-1H-pyrazolo[4,3-c]pyridin-3-yl)-3-azabicyclo[3.1.0]hexane-3-carboxylate (10 g, 25.5 mmol) in DCM (127 mL) was added urea--hydrogen peroxide (1 / 1) (7.18 g, 76 mmol) and 2,2,2-trifluoroacetic anhydride (10.84 mL, 76 mmol). The resulting mixture was stirred at 25 °C for 2 h. Reaction was done. H2O was added and the layers were separated. The aqueous phase was extracted with CH2Cl2 (3 x), the combined organic layers were washed with sat NaHCO3x2, dried over MgSO4, filtered, and concentrated under reduced pressure to give 3- ((1R,5S,6r)-3-(tert-butoxycarbonyl)-3-azabicyclo[3.1.0]hexan-6-yl)-6-chloro-1-cyclopropyl- 7-fluoro-1H-pyrazolo[4,3-c]pyridine 5-oxide (8.5 g, 20.79 mmol, 82 % yield) as a white solid. MS (ES+) C19H22ClFN4O3 requires: 408, found: 409 [M+H]+. Step 2 tert-butyl (1R,5S,6r)-6-(6-chloro-1-cyclopropyl-7-fluoro-4-hydroxy-1H-pyrazolo[4,3- c]pyridin-3-yl)-3-azabicyclo[3.1.0]hexane-3-carboxylate

[0335] To a solution of 3-((1R,5xycarbonyl)-3-azabicyclo[3.1.0]hexan- 6-yl)-6-chloro-1-cyclopropyl-7-fluoro-1H-pyrazolo[4,3-c]pyridine 5-oxide (8.5 g, 20.74 mmol) in DCM (100 mL) was added TFAA (8.79 mL, 62.2 mmol) and the resulting mixture was stirred at 0 °C for 2 h. The reaction was warmed to rt for 1h then quenched by pouring into Sat. Sodium bicarbonate solution (100 mL). The biphasic mixture was stirred rapidly for 20 min after which time a bright red solution was formed. The aqueous layer was separated and extracted with DCM (2x 30 mL). The combined aqueous layer was washed with brine (100 mL), dried over MgSO4and concentrated to give tert-butyl (1R,5S,6r)-6-(6-chloro-1-cyclopropyl-7-fluoro-4-hydroxy-1H-pyrazolo[4,3-c]pyridin-3-yl)-3-azabicyclo[3.1.0]hexane- 3-carboxylate (3.2 g, 7.83 mmol, 37.7 % yield) as a red solid. The residue was purified via silica gel chromatography (0 - 100 % EtOAc in hexanes) to give tert-butyl (1R,5S,6r)-6-(6- chloro-1-cyclopropyl-7-fluoro-4-hydroxy-1H-pyrazolo[4,3-c]pyridin-3-yl)-3- azabicyclo[3.1.0]hexane-3-carboxylate (3.2 g, 7.83 mmol, 37.7 % yield) as a red solid. MS (ES+) C19H22ClFN4O3requires: 408, found: 409 [M+H]+. Step 3 tert-butyl (1R,5S,6r)-6-(6-chloro-1-cyclopropyl-7-fluoro-4-methoxy-1H-pyrazolo[4,3- c]pyridin-3-yl)-3-azabicyclo[3.1.0]hexane-3-carboxylate

[0336] To a solution of tert-butychloro-1-cyclopropyl-7-fluoro-4- hydroxy-1H-pyrazolo[4,3-c]pyridin-3-yl)-3-azabicyclo[3.1.0]hexane-3-carboxylate (984 mg, 2.407 mmol) in DMF (12 mL) was added K2CO3 (499 mg, 3.61 mmol) and methyl iodide (0.226 mL, 3.61 mmol) and the resulting mixture was stirred at rt for 3 h. The volatiles were removed under reduced pressure. The residue was purified via silica gel chromatography (0 - 100 % EtOAc in hexanes) to give tert-butyl (1R,5S,6r)-6-(6-chloro-1-cyclopropyl-7-fluoro-4- methoxy-1H-pyrazolo[4,3-c]pyridin-3-yl)-3-azabicyclo[3.1.0]hexane-3-carboxylate (84 mg, 0.199 mmol, 8.25 % yield) and tert-butyl (1R,5S,6r)-6-(6-chloro-1-cyclopropyl-7-fluoro-5- methyl-4-oxo-4,5-dihydro-1H-pyrazolo[4,3-c]pyridin-3-yl)-3-azabicyclo[3.1.0]hexane-3- carboxylate (386 mg, 0.913 mmol, 37.9 % yield) as a colorless oil. MS (ES+) C20H24ClFN4O3 requires: 422, found: 423 [M+H]+. Step 4 tert-butyl (1R,5S,6r)-6-(1-cyclopropyl-7-fluoro-6-(7-fluoro-3-(methoxymethoxy)-8- ((triisopropylsilyl)ethynyl)naphthalen-1-yl)-4-methoxy-1H-pyrazolo[4,3-c]pyridin-3-yl)- 3-azabicyclo[3.1.0]hexane-3-carboxylate

[0337] A suspension of tert-b oro-1-cyclopropyl-7-fluoro-4-methoxy-1H-pyrazolo[4,3-c]pyridin-3-yl)-3-azabicyclo[3.1.0]hexane-3-carboxylate (86 mg, 0.203 mmol), tripotassium phosphate (130 mg, 0.610 mmol), and CataCXium Pd G3 (14.81 mg, 0.020 mmol) and ((2-fluoro-6-(methoxymethoxy)-8-(4,4,5,5-tetramethyl-1,3,2- dioxaborolan-2-yl)naphthalen-1-yl)ethynyl)triisopropylsilane (125 mg, 0.244 mmol) in 1,4- Dioxane (1525 µl)-Water (508 µl) was degassed with N2 for 2 minutes. The reaction mixture was heated to 80 °C and stirred for 2 h. The reaction mixture was allowed to cool to room temperature. The reaction mixture was diluted with EtOAc (25.0 mL) and washed with sat NaCl (10.0 mL). The layers were separated and the organic layer was washed with sat NaCl (10.0 mL), dried over Na2SO4, filtered, and concentrated under reduced pressure. The residue was purified via silica gel chromatography (5 - 75 % EtOAc in hexanes) to give tert- butyl (1R,5S,6r)-6-(1-cyclopropyl-7-fluoro-6-(7-fluoro-3-(methoxymethoxy)-8- ((triisopropylsilyl)ethynyl)naphthalen-1-yl)-4-methoxy-1H-pyrazolo[4,3-c]pyridin-3-yl)-3- azabicyclo[3.1.0]hexane-3-carboxylate (42 mg, 0.054 mmol, 26.7 % yield) as a pale yellow oil. MS (ES+) C43H54F2N4O5Si requires: 772 , found: 773 [M+H]+. Step 5 4-(3-((1R,5S,6r)-3-azabicyclo[3.1.0]hexan-6-yl)-1-cyclopropyl-7-fluoro-4-methoxy-1H- pyrazolo[4,3-c]pyridin-6-yl)-5-ethynyl-6-fluoronaphthalen-2-ol

[0338] To a solution of tert-butyl (1R,5S,6r)-6-(1-cyclopropyl-7-fluoro-6-(7-fluoro-3- (methoxymethoxy)-8-((triisopropylsilyl)ethynyl)naphthalen-1-yl)-4-methoxy-1H- pyrazolo[4,3-c]pyridin-3-yl)-3-azabicyclo[3.1.0]hexane-3-carboxylate (42 mg, 0.054 mmol) in DCM (0.4 mL) was added and the resulting mixture was stirred at rt for 1 h. The volatiles were removed under reduced pressure. The residue was taken up in DMF (0.4 mL) and treated with CsF (165 mg, 1.087 mmol) at 60 °C for 1 h. The residue was purified by mass- triggered preparative HPLC (Mobile phase: A = 0.1% TFA / H2O, B = 0.1% TFA / MeCN; Gradient: B = 10 - 60%; 12 min; Column: XBridge C18, 5 μm, 19 mm x 150 mm) to give 4- (3-((1R,5S,6r)-3-azabicyclo[3.1.0]hexan-6-yl)-1-cyclopropyl-7-fluoro-4-methoxy-1H- pyrazolo[4,3-c]pyridin-6-yl)-5-ethynyl-6-fluoronaphthalen-2-ol 2,2,2-trifluoroacetate (9.0 mg, 0.015 mmol, 28.2 % yield) as a white solid. MS (ES+) C27H22F2N4O2 requires: 472, found: 473 [M+H]+.1H NMR (600 MHz, MeOD) δ 7.83 (dd, J = 9.1, 5.7 Hz, 1H), 7.39 – 7.26 (m, 2H), 7.21 (d, J = 2.5 Hz, 1H), 4.02 (s, 3H), 3.79 (dt, J = 7.2, 3.6 Hz, 1H), 3.69 – 3.56 (m, 4Hz), 3.20 (s, 1H), 2.63 (d, J = 3.8 Hz, 1H), 2.46 (dt, J = 7.5, 3.7 Hz, 2H), 1.19 (d, J = 5.1 Hz, 2H), 1.09 (p, J = 4.3, 3.7 Hz, 2H). EXAMPLE 62 4-(3-((1R,5S,6r)-3-azabicyclo[3.opropyl-7-fluoro-4-isopropoxy-1H- pyrazolo[4,3-c]pyridin-6-yl)-5-ethynyl-6-fluoronaphthalen-2-ol

[0339] Prepared similarly to Example 61 using isopropyl iodide in place of methyl iodide on step 3.

[0340] 1H NMR (600 MHz, MeOD) δ 7.83 (dd, J = 9.1, 5.7 Hz, 1H), 7.35 – 7.25 (m, 2H), 7.18 (d, J = 2.6 Hz, 1H), 5.42 (p, J = 6.1 Hz, 1H), 3.78 (tt, J = 7.2, 3.7 Hz, 1H), 3.63 (q, J = 2.7, 2.2 Hz, 4H), 3.19 (d, J = 1.6 Hz, 1H), 2.58 – 2.38 (m, 2H), 1.41 (dd, J = 10.4, 6.2 Hz, 6H), 1.19 (dd, J = 6.4, 3.5 Hz, 2H), 1.12 – 1.05 (m, 2H).

[0341] MS (ES+) C29H26F2N4O2 requires: 500, found: 501 [M+H]+.EXAMPLE 63 4-(3-((1R,5S,6r)-3-azabicyclo clopropyl-4-ethoxy-7-fluoro-1H-pyrazolo[4,3-c]pyridin-6-yl)-5-ethynyl-6-fluoronaphthalen-2-ol

[0342] Prepared similarly to Example 61 using ethyl iodide in place of methyl iodide on step 3.

[0343] 1H NMR (600 MHz, MeOD) δ 7.83 (dd, J = 9.1, 5.7 Hz, 1H), 7.34 – 7.25 (m, 2H), 7.19 (d, J = 2.6 Hz, 1H), 4.48 (ddq, J = 37.5, 10.8, 7.1 Hz, 2H), 3.78 (tt, J = 7.2, 3.6 Hz, 1H), 3.63 (t, J = 2.1 Hz, 4H), 3.20 (d, J = 1.0 Hz, 1H), 2.65 (s, 1H), 2.55 (t, J = 3.8 Hz, 1H), 2.48 (dtd, J = 8.0, 6.5, 5.9, 4.1 Hz, 2H), 1.43 (t, J = 7.0 Hz, 3H), 1.20 (dd, J = 6.2, 3.6 Hz, 2H), 1.09 (ddq, J = 7.2, 3.2, 1.8 Hz, 2H).

[0344] MS (ES+) C28H24F2N4O2 requires: 486, found: 487 [M+H]+. EXAMPLE 64 4-(3-((1R,5S,6r)-3-azabicyclo[3clobutoxy-1-cyclopropyl-7-fluoro- 1H-pyrazolo[4,3-c]pyridin-6-yl)-5-ethynyl-6-fluoronaphthalen-2-ol

[0345] Prepared similarly to Example 61 using cyclobutyl bromide in place of methyl iodide on step 3.

[0346] 1H NMR (600 MHz, MeOD) δ 7.83 (dd, J = 9.1, 5.7 Hz, 1H), 7.34 – 7.25 (m, 2H), 7.17 (d, J = 2.6 Hz, 1H), 5.30 (p, J = 7.2 Hz, 1H), 3.78 (tt, J = 7.2, 3.7 Hz, 1H), 3.64 (s, 2H),3.60 (q, J = 7.1 Hz, 1H), 3.18 (s, J = 1.5 Hz, 1H), 2.56 – 2.35 (m, 5H), 2.30 – 2.19 (m, 2H), 1.82 (q, J = 10.5 Hz, 1H), 1.70 – 1.60 (m, 1H), 1.23 – 1.15 (m, 3H), 1.13 – 1.04 (m, 2H).

[0347] MS (ES+) C30H26F2N4O2 requires: 512, found: 513 [M+H]+EXAMPLE 65 4-(3-((1R,5S,6r)-3-azabicyclo[3. lopentyloxy)-1-cyclopropyl-7-fluoro-1H-pyrazolo[4,3-c]pyridin-6-yl)-5-ethynyl-6-fluoronaphthalen-2-ol

[0348] Prepared similarly to Example 61 using cyclopentyl bromide in place of methyl iodide on step 3.

[0349] 1H NMR (600 MHz, MeOD) δ 7.83 (dd, J = 9.1, 5.7 Hz, 1H), 7.34 – 7.26 (m, 2H), 7.19 (d, J = 2.6 Hz, 1H), 5.52 (tt, J = 6.4, 3.6 Hz, 1H), 3.78 (tt, J = 7.2, 3.6 Hz, 1H), 3.68 – 3.56 (m, 4H), 3.19 (t, J = 1.5 Hz, 1H), 2.65 (s, 1H), 2.53 – 2.46 (m, 2H), 2.43 (t, J = 3.8 Hz, 1H), 2.07 – 1.89 (m, 2H), 1.81 (tt, J = 11.7, 5.3 Hz, 2H), 1.66 (qt, J = 11.0, 5.5 Hz, 2H), 1.22 – 1.15 (m, 3H), 1.09 (ddq, J = 7.4, 3.3, 1.7 Hz, 2H).

[0350] MS (ES+) C31H28F2N4O2 requires: 526, found: 527 [M+H]+. EXAMPLE 66 4-(3-((1R,5S,6r)-3-azabicyc. . opropyl-4-(difluoromethoxy)-7- fluoro-1H-pyrazolo[4,3-c]pyridin-6-yl)-5-ethynyl-6-fluoronaphthalen-2-ol

[0351] The title compound was prepared by adding Acetonitrile (1223 µl), diethyl (bromodifluoromethyl)phosphonate (87 µl, 0.489 mmol, 2 eq.) and tert-butyl (1R,5S,6r)-6-(6- chloro-1-cyclopropyl-7-fluoro-4-hydroxy-1H-pyrazolo[4,3-c]pyridin-3-yl)-3- azabicyclo[3.1.0]hexane-3-carboxylate (100 mg, 0.245 mmol, 1 eq.) to a cooled 0 °C solution of potassium hydroxide (274 mg, 4.89 mmol, 20 eq.) in Water (1223 µl). The resulting mixture was stirred at 0 °C for 1 h, and cooled to rt for 1 h.

[0352] MS (ES+) C27H20F4N4O2 requires: 508, found: 509 [M+H]+.

[0353] 1H NMR (600 MHz, MeOD) δ 7.75 (dd, J = 9.1, 5.7 Hz, 1H), 7.57 (t, J = 72.3 Hz, 1H), 7.24 – 7.20 (m, 2H), 7.12 (d, J = 2.6 Hz, 1H), 3.75 (tt, J = 7.2, 3.6 Hz, 1H), 3.54 (d, J = 3.6 Hz, 4H), 2.45 (t, J = 3.8 Hz, 1H), 2.41 (qd, J = 4.9, 4.5, 2.9 Hz, 2H), 1.16 – 1.06 (m, 2H), 1.05 – 0.99 (m, 2H). EXAMPLE 67 4-(3-((1R,5S,6r)-3-azabiyclopropyl-7-fluoro-4-(2,2,2- trifluoroethoxy)-1H-pyrazolo[4,3-c]pyridin-6-yl)-5-ethynyl-6-fluoronaphthalen-2-ol

[0354] Prepared similarly to Example 61 using 1,1,1-trifluoro-2-iodoethane in place of methyl iodide on step 3.

[0355] MS (ES+) C28H21F5N4O2requires: 540, found: 541 [M+H]+.

[0356] 1H NMR (600 MHz, CD3OD) δ 7.75 (dd, J = 9.1, 5.7 Hz, 1H), 7.23 – 7.20 (m, 2H), 7.12 (d, J = 2.5 Hz, 1H), 4.96 – 4.90 (m, 1H), 4.86 – 4.82 (m, 1H), 3.73 (tt, J = 7.2, 3.6 Hz, 1H), 3.56 – 3.47 (m, 4H), 2.40 (dddd, J = 12.1, 7.2, 3.5, 0.9 Hz, 2H), 2.34 (t, J = 3.9 Hz, 1H), 1.16 – 1.10 (m, 2H), 1.04 – 0.99 (m, 2H). EXAMPLE 684-(3-((1R,5S,6r)-3-a l)-1-cyclopropyl-4-(3,3-difluorocyclobutoxy)-7-fluoro-1H-pyrazolo[4,3-c]pyridin-6-yl)-5-ethynyl-6- fluoronaphthalen-2-ol

[0357] Prepared similarly to Example 61 using 3-bromo-1,1-difluorocyclobutane in place of methyl iodide on step 3.

[0358] MS (ES+) C30H24F4N4O2requires: 548, found: 549 [M+H]+.

[0359] 1H NMR (600 MHz, CD3OD) δ 7.74 (dd, J = 9.2, 5.7 Hz, 1H), 7.24 – 7.19 (m, 2H), 7.09 (d, J = 2.5 Hz, 1H), 5.14 (dd, J = 7.7, 5.0 Hz, 1H), 3.71 (tt, J = 7.2, 3.6 Hz, 1H), 3.56 – 3.52 (m, 4H), 3.52 – 3.48 (m, 1H), 3.01 (dt, J = 14.0, 6.7 Hz, 1H), 2.91 (dd, J = 13.2, 7.0 Hz, 1H), 2.83 – 2.70 (m, 2H), 2.44 – 2.41 (m, 1H), 2.40 (q, J = 1.9 Hz, 2H), 1.12 – 1.08 (m, 2H), 1.01 (dddd, J = 8.7, 7.1, 2.6, 1.3 Hz, 2H). EXAMPLE 69 4-(4-(azetidin-3-yloxy)-3-((1.0]hexan-6-yl)-1-cyclopropyl-7- fluoro-1H-pyrazolo[4,3-c]pyridin-6-yl)-5-ethynyl-6-fluoronaphthalen-2-ol

[0360] Prepared similarly to Example 61 using tert-butyl 3-iodoazetidine-1-carboxylate in place of methyl iodide on step 3.

[0361] MS (ES+) C29H25F2N5O2requires: 513, found: 514 [M+H]+.

[0362] 1H NMR (600 MHz, MeOD) δ 7.96 (ddd, J = 16.4, 9.2, 5.6 Hz, 1H), 7.50 (dd, J = 14.0, 2.6 Hz, 1H), 7.43 (td, J = 8.9, 7.1 Hz, 1H), 7.39 – 7.36 (m, 1H), 4.33 (dd, J = 6.6, 3.5 Hz, 1H), 3.99 (d, J = 12.6 Hz, 1H), 3.95 – 3.87 (m, 2H), 3.79 (ddd, J = 12.3, 8.9, 3.7 Hz, 2H), 3.75 – 3.68 (m, 2H), 3.62 (ddd, J = 11.4, 7.0, 4.1 Hz, 2H), 2.72 (dt, J = 20.1, 3.6 Hz, 1H),2.60 (ddt, J = 14.8, 7.5, 3.9 Hz, 1H), 2.54 (ddt, J = 11.1, 7.6, 3.8 Hz, 1H), 1.35 – 1.27 (m, 2H), 1.26 – 1.19 (m, 1H), 1.13 (ddp, J = 9.2, 6.6, 2.4 Hz, 2H). EXAMPLE 70 4-(3-((1R,5S,6r)-3-azabicyclo propoxy-1-cyclopropyl-7-fluoro-1H-pyrazolo[4,3-c]pyridin-6-yl)-5-ethynyl-6-fluoronaphthalen-2-ol

[0363] The title compound was prepared by charging a microwave vial with tert-butyl (1R,5S,6r)-6-(6-chloro-1-cyclopropyl-7-fluoro-4-hydroxy-1H-pyrazolo[4,3-c]pyridin-3-yl)-3- azabicyclo[3.1.0]hexane-3-carboxylate (150 mg, 0.367 mmol, 1 eq.), bromocyclopropane (88 µl, 1.101 mmol, 3 eq.), cesium carbonate (239 mg, 0.734 mmol, 2 eq.). DMF (3669 µL) was added and the solution degassed with N2. The vial was sealed and the reaction mixture was heated to 180 °C in the microwave reactor for 2 h.

[0364] MS (ES+) C29H24F2N4O2 requires: 498, found: 499 [M+H]+.

[0365] 1H NMR (600 MHz, CD3OD) δ 7.84 (dd, J = 9.1, 5.7 Hz, 1H), 7.32 – 7.28 (m, 2H), 7.22 (d, J = 2.6 Hz, 1H), 4.37 (tt, J = 6.2, 3.0 Hz, 1H), 3.79 (tt, J = 7.2, 3.6 Hz, 1H), 3.61 (d, J = 1.8 Hz, 4H), 3.57 (s, 1H), 3.21 (d, J = 1.0 Hz, 1H), 2.45 (s, 1H), 1.21 – 1.17 (m, 2H), 1.09 (dtd, J = 7.4, 3.1, 1.5 Hz, 2H), 0.88 – 0.84 (m, 2H), 0.80 – 0.74 (m, 2H). EXAMPLE 71 4-(3-((1R,5S,6r)-3-azabicyc. . clopropyl-7-fluoro-4-(oxetan-3- yloxy)-1H-pyrazolo[4,3-c]pyridin-6-yl)-5-ethynyl-6-fluoronaphthalen-2-ol

[0366] Prepared similarly to Example 61 using 3-iodooxetane in place of methyl iodide on step 3.

[0367] MS (ES+) C29H24F2N4O3 requires: 514, found: 533 [M+H3O]+.

[0368] 1H NMR (600 MHz, MeOD) δ 7.90 (ddd, J = 9.3, 5.7, 4.0 Hz, 1H), 7.43 – 7.37 (m, 2H), 7.38 – 7.34 (m, 1H), 4.16 (dd, J = 13.9, 5.5 Hz, 1H), 3.91 (dq, J = 7.7, 5.0 Hz, 1H), 3.77 (ddt, J = 9.0, 7.2, 3.6 Hz, 1H), 3.67 – 3.62 (m, 2H), 3.58 (dd, J = 11.6, 3.0 Hz, 2H), 3.56 (d, J = 0.9 Hz, 1H), 3.35 – 3.33 (m, 1H), 3.22 (dd, J = 14.0, 7.9 Hz, 1H), 2.74 (t, J = 3.8 Hz, 1H), 2.48 – 2.42 (m, 2H), 1.22 (dt, J = 10.5, 3.5 Hz, 1H), 1.17 – 1.13 (m, 1H), 1.06 (dtq, J = 7.6, 5.1, 2.5 Hz, 2H). EXAMPLE 72 4-(3-((1R,5S,6r)-3-azabicyclyclopropyl-4-ethyl-7-fluoro-1H- pyrazolo[4,3-c]pyridin-6-yl)-5-ethynyl-6-fluoronaphthalen-2-ol Step 1 tert-butyl (1R,5S,6r)-6-(6-chloro-1-cyclopropyl-7-fluoro-4- (((trifluoromethyl)sulfonyl)oxy)-1H-pyrazolo[4,3-c]pyridin-3-yl)-3- azabicyclo[3.1.0]hexane-3-carboxylate

[0369] To a solution of tert-buty, , chloro-1-cyclopropyl-7-fluoro-4- hydroxy-1H-pyrazolo[4,3-c]pyridin-3-yl)-3-azabicyclo[3.1.0]hexane-3-carboxylate (1.06 g, 2.59 mmol) in DCM (40 mL) was added Hunig's base (1.358 mL, 7.78 mmol) and triflic anhydride (0.876 mL, 5.19 mmol) and the resulting mixture was stirred at -78 °C for 4 h. satNaHCO3(5 mL) was added at -78 °C and the reaction was warmed to rt. The layers were separated. The aqueous phase was extracted with CH2Cl2(2 x 5.00 mL), the combined organic layers were dried over MgSO4, filtered, and concentrated under reduced pressure. The residue was purified via silica gel chromatography (0 - 60 % EtOAc in hexanes) to give tert-butyl (1R,5S,6r)-6-(6-chloro-1-cyclopropyl-7-fluoro-4-(((trifluoromethyl)sulfonyl)oxy)- 1H-pyrazolo[4,3-c]pyridin-3-yl)-3-azabicyclo[3.1.0]hexane-3-carboxylate (1.31 g, 2.422 mmol, 93 % yield) as a colorless oil. MS (ES+) C20H21ClF4N4O5S requires: 540, found: 485 [M-tBu]+. Step 2 tert-butyl (1R,5S,6r)-6-(6-chloro-1-cyclopropyl-4-ethyl-7-fluoro-1H-pyrazolo[4,3- c]pyridin-3-yl)-3-azabicyclo[3.1.0]hexane-3-carboxylate

[0370] A solution of tert-butyl (loro-1-cyclopropyl-7-fluoro-4- (((trifluoromethyl)sulfonyl)oxy)-1H-pyrazolo[4,3-c]pyridin-3-yl)-3-azabicyclo[3.1.0]hexane- 3-carboxylate (527 mg, 0.974 mmol) in THF (0.5 mL) was degassed by bubbling with N2 for 2 min. A solution of diethylzinc (0.974 mL, 1.072 mmol) was added at rt. A degassed solution of Pd2(dba)3 (44.6 mg, 0.049 mmol) and tri(furan-2-yl)phosphane (22.62 mg, 0.097 mmol) in THF (0.5 mL) was then added. After 5h, the reaction was quenched with sat. NH4Cl. The reaction mixture was diluted with EtOAc (5.00 mL) and washed with sat NH4Cl (5.00 mL). The layers were separated and the organic layer was washed with sat NaCl (5.00 mL), dried over MgSO4, filtered, and concentrated under reduced pressure. The residue was purified via silica gel chromatography (0 - 55 % EtOAc in hexanes) to give tert-butyl (1R,5S,6r)-6-(6-chloro-1-cyclopropyl-4-ethyl-7-fluoro-1H-pyrazolo[4,3-c]pyridin-3-yl)-3- azabicyclo[3.1.0]hexane-3-carboxylate (300 mg, 0.713 mmol, 73.2 % yield) as a colorless oil. MS (ES+) C21H26ClFN4O2 requires: 420, found: 421 [M+H]+. Step 3tert-butyl (1R,5S,6r)-6-(1-cyclopropyl-4-ethyl-7-fluoro-6-(7-fluoro-3-(methoxymethoxy)- 8-((triisopropylsilyl)ethynyl)naphthalen-1-yl)-1H-pyrazolo[4,3-c]pyridin-3-yl)-3- azabicyclo[3.1.0]hexane-3-carboxylate

[0371] A suspension of tert-b oro-1-cyclopropyl-4-ethyl-7-fluoro-1H-pyrazolo[4,3-c]pyridin-3-yl)-3-azabicyclo[3.1.0]hexane-3-carboxylate (90 mg, 0.214 mmol), tripotassium phosphate (136 mg, 0.641 mmol), and Reactant 3 (15.57 mg, 0.021 mmol) and ((2-fluoro-6-(methoxymethoxy)-8-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2- yl)naphthalen-1-yl)ethynyl)triisopropylsilane (132 mg, 0.257 mmol) in 1,4-Dioxane (1604 µl)-Water (535 µl) was degassed with N2 for 2 minutes. The reaction mixture was heated to 80 °C and stirred for 2 h. The reaction mixture was allowed to cool to room temperature. The reaction mixture was diluted with EtOAc (25.0 mL) and washed with sat NaCl (10.0 mL). The layers were separated and the organic layer was washed with sat NaCl (10.0 mL), dried over Na2SO4, filtered, and concentrated under reduced pressure. The residue was purified via silica gel chromatography (5 - 75 % EtOAc in hexanes) to give tert-butyl (1R,5S,6r)-6-(1- cyclopropyl-4-ethyl-7-fluoro-6-(7-fluoro-3-(methoxymethoxy)-8- ((triisopropylsilyl)ethynyl)naphthalen-1-yl)-1H-pyrazolo[4,3-c]pyridin-3-yl)-3- azabicyclo[3.1.0]hexane-3-carboxylate (123 mg, 0.160 mmol, 74.6 % yield) as a pale yellow oil. MS (ES+) C21H26ClFN4O2 requires: 770, found: 771 [M+H]+. Step 44-(3-((1R,5S,6r)-3-azabicyclo[3.1.0]hexan-6-yl)-1-cyclopropyl-4-ethyl-7-fluoro-1H- pyrazolo[4,3-c]pyridin-6-yl)-5-ethynyl-6-fluoronaphthalen-2-ol

[0372] To a solution of tert-butyl (1R,5S,6r)-6-(1-cyclopropyl-4-ethyl-7-fluoro-6-(7- fluoro-3-(methoxymethoxy)-8-((triisopropylsilyl)ethynyl)naphthalen-1-yl)-1H-pyrazolo[4,3- c]pyridin-3-yl)-3-azabicyclo[3.1.0]hexane-3-carboxylate (40 mg, 0.052 mmol) in DCM (0.5 mL) was and the resulting mixture was stirred at rt for 1 h. the volatiles were removed under reduced pressure. The residue was taken up in DMF (0.4 mL) and treated with CsF (158 mg, 1.038 mmol) at 60 °C for 1h.The residue was purified by mass-triggered preparative HPLC (Mobile phase: A = 0.1% TFA / H2O, B = 0.1% TFA / MeCN; Gradient: B = 10 - 90%; 12 min; Column: XBridge C18, 5 μm, 19 mm x 150 mm) to give 4-(3-((1R,5S,6r)-3- azabicyclo[3.1.0]hexan-6-yl)-1-cyclopropyl-4-ethyl-7-fluoro-1H-pyrazolo[4,3-c]pyridin-6- yl)-5-ethynyl-6-fluoronaphthalen-2-ol 2,2,2-trifluoroacetate (7.5 mg, 0.013 mmol, 24.73 % yield) as a white solid.

[0373] MS (ES+) C28H24F2N4O requires: 470, found: 471 [M+H]+.

[0374] 1H NMR (600 MHz, MeOD) δ 7.92 (dd, J = 9.2, 5.6 Hz, 1H), 7.44 (d, J = 2.6 Hz, 1H), 7.38 (t, J = 8.9 Hz, 1H), 7.34 (d, J = 2.5 Hz, 1H), 3.95 (tt, J = 7.2, 3.6 Hz, 1H), 3.76 – 3.63 (m, 4H), 3.46 – 3.36 (m, 2H), 2.69 – 2.59 (m, 3H), 2.55 (t, J = 3.7 Hz, 1H), 1.47 (t, J = 7.6 Hz, 3H), 1.36 – 1.23 (m, 2H), 1.20 – 1.14 (m, 2H). EXAMPLE 73 4-(3-((1R,5S,6r)-3-azabicyclo[clopropyl-7-fluoro-4-isobutyl-1H- pyrazolo[4,3-c]pyridin-6-yl)-5-ethynyl-6-fluoronaphthalen-2-ol

[0375] Prepared similarly to Example 72 using isobutyl zinc bromide on step 2.

[0376] 1H NMR (600 MHz, CDCl3) δ 7.93 (dd, J = 9.2, 5.6 Hz, 1H), 7.45 (d, J = 2.6 Hz, 1H), 7.39 (, . , , . , J = 2.5 Hz, 1H), 3.96 (dt, J = 7.4, 3.6 Hz, 1H), 3.69 (s, 4H), 3.41 (s, 1H), 3.22 (d, J = 7.5 Hz, 2H), 2.66 (d, J = 0.9 Hz, 2H), 2.55 (t, J = 3.7 Hz, 1H),2.24 (dq, J = 13.6, 6.9 Hz, 1H), 1.33 (d, J = 10.8 Hz, 1H), 1.29 – 1.23 (m, 1H), 1.21 – 1.15 (m, 2H), 1.08 (dd, J = 16.1, 6.6 Hz, 6H).

[0377] MS (ES+) C30H28F2N4O requires: 498, found: 499 [M+H]+. EXAMPLE 74 4-(3-((1R,5S,6r)-3-azabicyclo propyl-7-fluoro-4-isopropyl-1H-pyrazolo[4,3-c]pyridin-6-yl)-5-ethynyl-6-fluoronaphthalen-2-ol

[0378] Prepared similarly to Example 72 using isopropyl zinc bromide on step 2.

[0379] 1H NMR (600 MHz, MeOD) δ 7.89 (dd, J = 9.1, 5.6 Hz, 1H), 7.38 – 7.31 (m, 2H), 7.28 (d, J = 2.5 Hz, 1H), 4.04 – 3.94 (m, 2H), 3.90 (tt, J = 7.6, 3.8 Hz, 1H), 3.74 – 3.63 (m, 3H), 3.42 (dt, J = 3.3, 1.6 Hz, 1H), 2.65 (s, 1H), 2.54 (s, 2H), 1.47 (dd, J = 6.9, 3.1 Hz, 6H), 1.37 – 1.20 (m, 2H), 1.20 – 1.07 (m, 3H).

[0380] MS (ES+) C29H26F2N4O requires: 484, found: 485 [M+H]+. EXAMPLE 75 4-(3-((1R,5S,6r)-3-aza1-cyclopropyl-7-fluoro-4- (isopropyl(methyl)amino)-1H-pyrazolo[4,3-c]pyridin-6-yl)-5-ethynyl-6- fluoronaphthalen-2-ol Step 1 tert-butyl (1R,5S,6r)-6-(6-chloro-1-cyclopropyl-7-fluoro-4-(isopropylamino)-1H- pyrazolo[4,3-c]pyridin-3-yl)-3-azabicyclo[3.1.0]hexane-3-carboxylate

[0381] A suspension of propan- 0.111 mmol, 1.2 eq.), N-ethyl-N-isopropylpropan-2-amine (47.2 µl, 0.277 mmol, 3 eq.) in 1,4-Dioxane (462 µl) was degassed with N2 for 3 minutes. tert-butyl (1R,5S,6r)-6-(6-chloro-1-cyclopropyl-7-fluoro-4- (((trifluoromethyl)sulfonyl)oxy)-1H-pyrazolo[4,3-c]pyridin-3-yl)-3-azabicyclo[3.1.0]hexane- 3-carboxylate (50 mg, 0.092 mmol) was added to the reaction. The reaction mixture was heated to 80 °C and stirred for 16 h. Sat NH4Cl (2.00 mL) was added to dilute the solution. The aqueous phase was extracted with EtOAc (2 x 2.00 mL), the combined organic layers were washed with sat NH4Cl, dried over MgSO4, filtered, and concentrated under reduced pressure.

[0382] The residue was purified via silica gel chromatography (0 - 100 % EtOAc in hexanes) to give tert-butyl (1R,5S,6r)-6-(6-chloro-1-cyclopropyl-7-fluoro-4- (isopropylamino)-1H-pyrazolo[4,3-c]pyridin-3-yl)-3-azabicyclo[3.1.0]hexane-3-carboxylate (27 mg, 0.060 mmol, 64.9 % yield) as a yellow oil.

[0383] MS (ES+) C22H29ClFN5O2 requires: 449, found: 450 [M+H]+.

[0384] 1H NMR (600 MHz, CDCl3) δ 5.01 (d, J = 7.5 Hz, 1H), 4.33 (dp, J = 7.5, 6.4 Hz, 1H), 3.84 (d, J = 11.1 Hz, 1H), 3.76 (d, J = 11.1 Hz, 1H), 3.64 (tt, J = 7.2, 3.7 Hz, 1H), 3.53 (d, J = 9.3 Hz, 2H), 2.13 –2.09 (m, 2H), 1.80 (t, J = 3.5 Hz, 1H), 1.47 (s, 9H), 1.30 (s, 3H), 1.29 (s, 3H), 1.19 (qdd, J = 4.8, 3.4, 1.1 Hz, 2H), 1.11 – 1.07 (m, 2H). Step 2 tert-butyl (1R,5S,6r)-6-(6-chloro-1-cyclopropyl-7-fluoro-4-(isopropyl(methyl)amino)- 1H-pyrazolo[4,3-c]pyridin-3-yl)-3-azabicyclo[3.1.0]hexane-3-carboxylate

[0385] To a cooled 0 °C solution of tert-butyl (1R,5S,6r)-6-(6-chloro-1-cyclopropyl-7- fluoro-4-(isopropylamino)-1H-pyrazolo[4,3-c]pyridin-3-yl)-3-azabicyclo[3.1.0]hexane-3- carboxylate (15 mg, 0.033 mmol) in DMF (667 µl) was added sodium hydride (2.400 mg, 0.100 mmol, 3 eq.) and iodomethane (2.490 µl, 0.040 mmol, 1.2 eq.). The resulting mixture was stirred at rt for 1h. Sat NH4Cl (2.00 mL) was added and the layers were separated. The aqueous phase was extracted with EtOAc (3 x 2.00 mL), the combined organic layers were dried over MgSO4, filtered, and concentrated under reduced pressure.

[0386] The residue was purified via silica gel chromatography (0 - 70 % EtOAc in hexanes) to give tert-butyl (1R,5S,6r)-6-(6-chloro-1-cyclopropyl-7-fluoro-4- (isopropyl(methyl)amino)-1H-pyrazolo[4,3-c]pyridin-3-yl)-3-azabicyclo[3.1.0]hexane-3- carboxylate (7.3 mg, 0.016 mmol, 47.2 % yield) as a white oil.

[0387] MS (ES+) C23H31ClFN5O2 requires: 463, found: 464 [M+H]+.

[0388] 1H NMR (600 MHz, CD3OD) δ 4.19 (qd, J = 7.5, 7.0, 3.2 Hz, 1H), 3.83 (d, J = 11.2 Hz, 1H), 3.76 (d, J = 11.2 Hz, 1H), 3.69 (td, J = 7.2, 3.6 Hz, 1H), 3.46 (td, J = 10.8, 9.8, 5.5 Hz, 2H), 2.82 (t, J = 1.7 Hz, 3H), 2.18 (dq, J = 6.5, 3.1 Hz, 1H), 2.11 (dt, J = 11.3, 3.2 Hz, 2H), 1.47 – 1.43 (m, 9H), 1.18 (d, J = 6.5 Hz, 5H), 1.12 (d, J = 6.7 Hz, 3H), 1.08 (d, J = 7.4 Hz, 2H). Step 3 tert-butyl (1R,5S,6r)-6-(1-cyclopropyl-7-fluoro-6-(7-fluoro-3-(methoxymethoxy)-8- ((triisopropylsilyl)ethynyl)naphthalen-1-yl)-4-(isopropyl(methyl)amino)-1H- pyrazolo[4,3-c]pyridin-3-yl)-3-azabicyclo[3.1.0]hexane-3-carboxylate

[0389] A solution of tert-b, , -cyclopropyl-7-fluoro-4- (isopropyl(methyl)amino)-1H-pyrazolo[4,3-c]pyridin-3-yl)-3-azabicyclo[3.1.0]hexane-3- carboxylate (15 mg, 0.032 mmol), potassium phosphate (20.59 mg, 0.097 mmol, 3 eq.), in 1,4-dioxane (172 µl) and water (43.1 µl) was degassed with N2for 2 minutes. CataCXium Pd G3 (2.354 mg, 3.23 μmol, 0.1 eq.) and ((2-fluoro-6-(methoxymethoxy)-8-(4,4,5,5- tetramethyl-1,3,2-dioxaborolan-2-yl)naphthalen-1-yl)ethynyl)triisopropylsilane (19.88 mg,0.039 mmol, 1.2 eq.) were added and the mixture was degassed with N2for an additional 3 minutes. The reaction mixture was heated to 100 °C and stirred for 16 h. The reaction mixture was diluted with MeOH, filtered through celite, and the filtrate was concentrated under reduced pressure. The residue was purified via silica gel chromatography (0 - 60 % EtOAc in hexanes) to give tert-butyl (1R,5S,6r)-6-(1-cyclopropyl-7-fluoro-6-(7-fluoro-3- (methoxymethoxy)-8-((triisopropylsilyl)ethynyl)naphthalen-1-yl)-4- (isopropyl(methyl)amino)-1H-pyrazolo[4,3-c]pyridin-3-yl)-3-azabicyclo[3.1.0]hexane-3- carboxylate (9 mg, 0.011 mmol, 34.2 % yield) as a yellow oil.

[0390] MS (ES+) C46H61F2N5O4Si requires: 814, found: 815 [M+H]+. Step 4 4-(3-((1R,5S,6r)-3-azabicyclo[3.1.0]hexan-6-yl)-1-cyclopropyl-7-fluoro-4- (isopropyl(methyl)amino)-1H-pyrazolo[4,3-c]pyridin-6-yl)-5-ethynyl-6- fluoronaphthalen-2-ol

[0391] To a solution of tertopropyl-7-fluoro-6-(7-fluoro-3- (methoxymethoxy)-8-((triisopropylsilyl)ethynyl)naphthalen-1-yl)-4- (isopropyl(methyl)amino)-1H-pyrazolo[4,3-c]pyridin-3-yl)-3-azabicyclo[3.1.0]hexane-3- carboxylate (9 mg, 0.011 mmol) in DCM (55.3 µl) was added 4M hydrogen chloride in dioxane (4.03 mg, 0.111 mmol) and the resulting mixture was stirred at rt for 1 h. Sat NaHCO3 (1.00 mL) was added and the layers were separated. The aqueous phase was extracted with CH2Cl2(2 x 1.00 mL) and concentrated under reduced pressure. The crude intermediate was redissolved in DMSO (55.3 µl) and added cesium fluoride (1.679 mg, 0.011 mmol), stirred at rt for 1 h. The solvent was evaporated. The residue was purified by mass- triggered preparative HPLC (Mobile phase: A = 0.1% TFA / H2O, B = 0.1% TFA / MeCN; Gradient: B = 10 - 90%; 12 min; Column: XBridge C18, 5 μm, 19 mm x 150 mm) to give 4- (3-((1R,5S,6r)-3-azabicyclo[3.1.0]hexan-6-yl)-1-cyclopropyl-7-fluoro-4- (isopropyl(methyl)amino)-1H-pyrazolo[4,3-c]pyridin-6-yl)-5-ethynyl-6-fluoronaphthalen-2- ol bis(2,2,2-trifluoroacetate) (3.2 mg, 4.31 μmol, 39.0 % yield) as a white solid.

[0392] MS (ES+) C30H29F2N5O requires: 513, found: 514 [M+H]+.

[0393] 1H NMR (600 MHz, MeOD) δ 7.84 (dd, J = 9.1, 5.7 Hz, 1H), 7.33 – 7.27 (m, 2H), 7.22 (d, J = 2.6 Hz, 1H), 4.20 (p, J = 6.6 Hz, 1H), 3.81 (tt, J = 7.3, 3.6 Hz, 1H), 3.70 – 3.61 (m, 4H), 3.19 (d, J = 1.4 Hz, 1H), 3.20 – 3.17 (m, 1H), 2.94 (s, 3H), 2.61 (dt, J = 7.4, 3.8 Hz, 1H), 2.56 – 2.50 (m, 2H), 1.28 (d, J = 6.6 Hz, 3H), 1.22 (d, J = 6.6 Hz, 3H), 1.12 – 1.04 (m, 2H). EXAMPLE 76 4-(3-((1R,5S,6r)-3-azabicyclo ropyl-7-fluoro-4-(methylamino)-1H-pyrazolo[4,3-c]pyridin-6-yl)-5-ethynyl-6-fluoronaphthalen-2-ol

[0394] Prepared similarly to Example 75.

[0395] MS (ES+) C27H23F2N5O requires: 471, found: 472 [M+H]+.

[0396] 1H NMR (600 MHz, CD3OD) δ 7.95 – 7.88 (m, 1H), 7.43 (d, J = 2.7 Hz, 1H), 7.41 – 7.36 (m, 2H), 3.89 (s, 1H), 3.82 – 3.74 (m, 2H), 3.68 – 3.56 (m, 4H), 3.16 (s, 2H), 2.65 (s, 1H), 2.59 – 2.49 (m, 2H), 1.28 (d, J = 8.6 Hz, 1H), 1.24 – 1.15 (m, 1H), 1.15 – 1.09 (m, 2H). EXAMPLE 77 4-(3-((1R,5S,6r)-3-az. . 1-cyclopropyl-7-fluoro-4- (isopropylamino)-1H-pyrazolo[4,3-c]pyridin-6-yl)-5-ethynyl-6-fluoronaphthalen-2-ol

[0397] Prepared similarly to Example 75.

[0398] MS (ES+) C29H27F2N5O requires: 499, found: 500 [M+H]+.

[0399] 1H NMR (600 MHz, MeOD) δ 7.92 (dd, J = 9.2, 5.7 Hz, 1H), 7.44 (d, J = 2.6 Hz, 1H), 7.41 – 7.37 (m, 2H), 4.19 (p, J = 6.4 Hz, 1H), 3.90 (tt, J = 7.3, 3.7 Hz, 1H), 3.73 (dd, J = 11.9, 3.2 Hz, 2H), 3.65 (dt, J = 11.9, 4.0 Hz, 3H), 2.64 (d, J = 3.8 Hz, 1H), 2.59 (dt, J = 7.6, 3.9 Hz, 1H), 2.52 (dt, J = 7.6, 3.9 Hz, 1H), 1.39 (dd, J = 14.4, 6.3 Hz, 6H), 1.30 (d, J = 11.3 Hz, 1H), 1.24 – 1.20 (m, 1H), 1.15 – 1.12 (m, 2H). EXAMPLE 78 4-(3-((1R,5S,6r)-3-azabicyc lopropyl-4-(dimethylamino)-7-fluoro-1H-pyrazolo[4,3-c]pyridin-6-yl)-5-ethynyl-6-fluoronaphthalen-2-ol

[0400] Prepared similarly to Example 75.

[0401] MS (ES+) C28H25F2N5O requires: 485, found: 486 [M+H]+.

[0402] 1H NMR (600 MHz, MeOD) δ 7.87 (dd, J = 9.1, 5.7 Hz, 1H), 7.36 (d, J = 2.6 Hz, 1H), 7.33 (t, J = 8.9 Hz, 1H), 7.30 (d, J = 2.6 Hz, 1H), 3.87 (tt, J = 7.2, 3.6 Hz, 1H), 3.70 – 3.63 (m, 4H), 3.16 (s, 6H), 2.57 – 2.51 (m, 2H), 1.31 – 1.23 (m, 2H), 1.20 (d, J = 10.7 Hz, 1H), 1.11 (ddd, J = 7.2, 4.0, 2.1 Hz, 2H). EXAMPLE 79 4-(4-(azetidin-1-yl)-3-((1R,5S,. . xan-6-yl)-1-cyclopropyl-7-fluoro- 1H-pyrazolo[4,3-c]pyridin-6-yl)-5-ethynyl-6-fluoronaphthalen-2-ol

[0403] Prepared similarly to Example 75.

[0404] MS (ES+) C29H25F2N5O requires: 497, found: 498 [M+H]+.

[0405] 1H NMR (600 MHz, CD3OD) δ 7.92 (dd, J = 9.1, 5.6 Hz, 1H), 7.44 (d, J = 2.6 Hz, 1H), 7.41 – 7.37 (m, 2H), 4.68 (q, J = 8.3 Hz, 2H), 4.62 (q, J = 8.2 Hz, 2H), 3.93 (ddq, J = 11.1, 7.4, 3.6 Hz, 1H), 3.67 (d, J = 3.3 Hz, 2H), 3.66 – 3.62 (m, 2H), 2.59 (dd, J = 7.6, 4.6 Hz, 3H), 2.38 (t, J = 3.7 Hz, 1H), 1.33 – 1.27 (m, 2H), 1.22 (d, J = 10.7 Hz, 1H), 1.13 (ddd, J = 6.5, 4.1, 2.2 Hz, 2H). EXAMPLE 80 4-(3-((1R,5S,6r)-3-azabicyclo[ propyl-4-(diethylamino)-7-fluoro-1H-pyrazolo[4,3-c]pyridin-6-yl)-5-ethynyl-6-fluoronaphthalen-2-ol

[0406] Prepared similarly to Example 75.

[0407] MS (ES+) C30H29F2N5O requires: 513, found: 514 [M+H]+.

[0408] 1H NMR (600 MHz, MeOD) δ 7.87 (dd, J = 9.1, 5.7 Hz, 1H), 7.36 (d, J = 2.6 Hz, 1H), 7.33 (t, J = 8.9 Hz, 1H), 7.26 (d, J = 2.6 Hz, 1H), 3.85 (tt, J = 7.2, 3.5 Hz, 1H), 3.67 – 3.65 (m, 4H), 3.60 (dq, J = 13.5, 6.7 Hz, 4H), 2.57 (dd, J = 3.9, 2.7 Hz, 1H), 2.55 – 2.52 (m, 2H), 1.25 (d, J = 10.9 Hz, 1H), 1.21 (d, J = 4.1 Hz, 1H), 1.15 (t, J = 7.0 Hz, 6H), 1.12 – 1.09 (m, 2H). EXAMPLE 81 4-(3-((1R,5S,6r)-3-azabicyclo[. . propyl-4-(ethyl(methyl)amino)-7- fluoro-1H-pyrazolo[4,3-c]pyridin-6-yl)-5-ethynyl-6-fluoronaphthalen-2-ol

[0409] Prepared similarly to Example 75.

[0410] MS (ES+) C29H27F2N5O requires: 499, found: 500 [M+H]+.

[0411] 1H NMR (500 MHz, MeOD) δ 7.87 (dd, J = 9.2, 5.7 Hz, 1H), 7.36 (d, J = 2.6 Hz, 1H), 7.33 (t, J = 9.0 Hz, 1H), 7.28 (d, J = 2.5 Hz, 1H), 3.86 (tt, J = 7.1, 3.6 Hz, 1H), 3.66 – 3.64 (m, 5H), 3.58 (dq, J = 13.8, 7.0, 6.3 Hz, 1H), 3.13 (s, 3H), 2.61 (dd, J = 6.7, 4.1 Hz, 1H), 2.54 (dd, J = 7.3, 3.3 Hz, 1H), 2.51 (t, J = 3.8 Hz, 1H), 1.29 – 1.23 (m, 1H), 1.20 (t, J = 7.1 Hz, 4H), 1.10 (ddd, J = 7.3, 3.6, 2.0 Hz, 2H). EXAMPLE 82 4-(3-((1R,5S,6r)-3-azabicycl propyl-4-(cyclopropylamino)-7-fluoro-1H-pyrazolo[4,3-c]pyridin-6-yl)-5-ethynyl-6-fluoronaphthalen-2-ol

[0412] Prepared similarly to Example 75.

[0413] MS (ES+) C29H25F2N5O requires: 497, found: 498 [M+H]+.

[0414] 1H NMR (600 MHz, MeOD) δ 7.94 (dd, J = 9.2, 5.7 Hz, 1H), 7.47 (d, J = 2.6 Hz, 1H), 7.44 (d, J = 2.6 Hz, 1H), 7.41 (t, J = 8.9 Hz, 1H), 3.93 (tt, J = 7.4, 3.7 Hz, 1H), 3.74 (d, J = 3.8 Hz, 1H), 3.72 (d, J = 4.0 Hz, 1H), 3.63 (d, J = 3.2 Hz, 1H), 3.61 (d, J = 3.1 Hz, 1H), 2.79 (tt, J = 6.9, 3.7 Hz, 1H), 2.56 – 2.51 (m, 2H), 1.30 (dd, J = 8.8, 5.2 Hz, 2H), 1.22 (d, J = 10.3 Hz, 1H), 1.16 – 1.13 (m, 2H), 1.05 – 0.97 (m, 1H), 0.92 (dddd, J = 22.9, 14.4, 6.8, 3.7 Hz, 4H). EXAMPLE 83 4-(3-((1R,5S,6r)-3-azabicyclo. . propyl-7-fluoro-4-(phenylamino)- 1H-pyrazolo[4,3-c]pyridin-6-yl)-5-ethynyl-6-fluoronaphthalen-2-ol

[0415] Prepared similarly to Example 75.

[0416] MS (ES+) C32H25F2N5O requires: 533, found: 534 [M+H]+.

[0417] 1H NMR (600 MHz, CD3OD) δ 7.85 (dd, J = 9.1, 5.7 Hz, 1H), 7.43 (d, J = 7.9 Hz, 2H), 7.34 (d, J = 8.6 Hz, 2H), 7.32 – 7.27 (m, 3H), 7.07 (t, J = 7.4 Hz, 1H), 3.90 (s, 1H), 3.58 (d, J = 4.1 Hz, 1H), 3.57 – 3.53 (m, 2H), 3.51 (d, J = 5.0 Hz, 1H), 3.49 (d, J = 4.9 Hz, 1H), 2.54 (s, 1H), 2.52 (s, 2H), 1.34 – 1.26 (m, 2H), 1.24 (d, J = 10.7 Hz, 1H), 1.14 (dd, J = 6.2, 3.4 Hz, 2H). EXAMPLE 84 1-(3-((1R,5S,6r)-3-azabicycl propyl-6-(8-ethynyl-7-fluoro-3-hydroxynaphthalen-1-yl)-7-fluoro-1H-pyrazolo[4,3-c]pyridin-4-yl)ethan-1-one Step 1 tert-butyl (1R,5S,6r)-6-(6-chloro-1-cyclopropyl-4-(1-ethoxyvinyl)-7-fluoro-1H- pyrazolo[4,3-c]pyridin-3-yl)-3-azabicyclo[3.1.0]hexane-3-carboxylate H NBoc OEt

[0418] A solution of tert-butyl (1R,5S,6r)-6-(6-chloro-1-cyclopropyl-7-fluoro-4- (((trifluoromethyl)sulfonyl)oxy)-1H-pyrazolo[4,3-c]pyridin-3-yl)-3-azabicyclo[3.1.0]hexane- 3-carboxylate (100 mg, 0.185 mmol), lithium chloride (21.94 mg, 0.518 mmol), in THF (2.5 mL) was degassed by bubbling with N2for 2 min. Neat tributyl(1-ethoxyvinyl)stannane (68.1 µl, 0.203 mmol) and tetrakis (214 mg, 0.185 mmol) were added at rt. The reaction was heatedto 80 °C for 1h then cooled to rt. The volatiles were removed under reduced pressure. The residue was purified via silica gel chromatography (0 - 50 % EtOAc in hexanes) to give tert- butyl (1R,5S,6r)-6-(6-chloro-1-cyclopropyl-7-fluoro-4-isopropyl-1H-pyrazolo[4,3-c]pyridin- 3-yl)-3-azabicyclo[3.1.0]hexane-3-carboxylate (50 mg, 0.115 mmol, 62.2 % yield) as a colorless oil. MS (ES+) C22H28ClFN4O2 requires: 435, found: 436 [M+H]+. Step 2 tert-butyl (1R,5S,6r)-6-(1-cyclopropyl-4-(1-ethoxyvinyl)-7-fluoro-6-(7-fluoro-3- (methoxymethoxy)-8-((triisopropylsilyl)ethynyl)naphthalen-1-yl)-1H-pyrazolo[4,3- c]pyridin-3-yl)-3-azabicyclo[3.1.0]hexane-3-carboxylate

[0419] A suspension of tert-butyl (1R,5S,6r)-6-(6-chloro-1-cyclopropyl-4-(1- ethoxyvinyl)-7-fluoro-1H-pyrazolo[4,3-c]pyridin-3-yl)-3-azabicyclo[3.1.0]hexane-3- carboxylate (50 mg, 0.108 mmol), tripotassium phosphate (68.8 mg, 0.324 mmol), and Reactant 3 (7.87 mg, 10.80 μmol) and ((2-fluoro-6-(methoxymethoxy)-8-(4,4,5,5- tetramethyl-1,3,2-dioxaborolan-2-yl)naphthalen-1-yl)ethynyl)triisopropylsilane (66.4 mg, 0.130 mmol) in 1,4-Dioxane (750 µl)-Water (250 µl) was degassed with N2for 2 minutes. The reaction mixture was heated to 80 °C and stirred for 2 h. The reaction mixture was allowed to cool to room temperature. The reaction mixture was diluted with EtOAc (25.0 mL) and washed with sat NaCl (10.0 mL). The layers were separated and the organic layer was washed with sat NaCl (10.0 mL), dried over Na2SO4, filtered, and concentrated under reduced pressure to give a brown oil. The residue was purified via silica gel chromatography (0 - 60 % EtOAc in hexanes) to give tert-butyl (1R,5S,6r)-6-(1-cyclopropyl-4-(1- ethoxyvinyl)-7-fluoro-6-(7-fluoro-3-(methoxymethoxy)-8- ((triisopropylsilyl)ethynyl)naphthalen-1-yl)-1H-pyrazolo[4,3-c]pyridin-3-yl)-3- azabicyclo[3.1.0]hexane-3-carboxylate (36.2 mg, 0.045 mmol, 41.2 % yield) as an orange oil. tert-butyl (1R,5S,6r)-6-(1-cyclopropyl-4-(1-ethoxyvinyl)-7-fluoro-6-(7-fluoro-3-(methoxymethoxy)-8-((triisopropylsilyl)ethynyl)naphthalen-1-yl)-1H-pyrazolo[4,3-c]pyridin- 3-yl)-3-azabicyclo[3.1.0]hexane-3-carboxylate (36.2 mg, 0.045 mmol, 41.2 % yield) as a brown oil. This material was taken crude to the next step without further purification. MS (ES+) C46H58F2N4O5Si requires: 812, found: 813 [M+H]+Step 3 1-(3-((1R,5S,6r)-3-azabicyclo[3.1.0]hexan-6-yl)-1-cyclopropyl-6-(8-ethynyl-7-fluoro-3- hydroxynaphthalen-1-yl)-7-fluoro-1H-pyrazolo[4,3-c]pyridin-4-yl)ethan-1-one

[0420] To a solution of tert propyl-4-(1-ethoxyvinyl)-7-fluoro-6-(7-fluoro-3-(methoxymethoxy)-8-((triisopropylsilyl)ethynyl)naphthalen-1-yl)-1H- pyrazolo[4,3-c]pyridin-3-yl)-3-azabicyclo[3.1.0]hexane-3-carboxylate (11 mg, 0.014 mmol) in DCM (0.4 mL) was added HCl (125 µl, 0.500 mmol) and the resulting mixture was stirred at rt for 1 h. The volatiles were removed under reduced pressure. The residue was taken up in DMF (0.4 mL) and treated with CsF (41.1 mg, 0.271 mmol) at 60 °C for 1h. The residue was purified by mass-triggered preparative HPLC (Mobile phase: A = 0.1% TFA / H2O, B = 0.1% TFA / MeCN; Gradient: B = 10 - 90%; 20 min; Column: XBridge C18, 5 μm, 19 mm x 150 mm) to give 1-(3-((1R,5S,6r)-3-azabicyclo[3.1.0]hexan-6-yl)-1-cyclopropyl-6-(8-ethynyl-7- fluoro-3-hydroxynaphthalen-1-yl)-7-fluoro-1H-pyrazolo[4,3-c]pyridin-4-yl)ethan-1-one 2,2,2-trifluoroacetate (6 mg, 10.02 μmol, 74.1 % yield) as a white solid.

[0421] MS (ES+) C28H22F2N4O21. requires: 484, found: 485 [M+H]+. EXAMPLE 854-(3-(3,8-diazabicyclo[3.2.1 ropyl-7-fluoro-1H-pyrrolo[3,2- c]pyridin-6-ynaphthalen-2-ol Step 1 2-chloro-3-fluoro-5-((trimethylsilyl)ethynyl)pyridin-4-amine

[0422] A solution of 2-chloro-n-4-amine (2 g, 7.34 mmol), Pd(PPh3)4 (0.424 g, 0.367 mmol), and CuI (0.210 g, 1.101 mmol) in DMF (36.7 mL) was degassed with N2for 5 minutes. ethynyltrimethylsilane (1.149 mL, 8.07 mmol) and TEA (2.56 mL, 18.35 mmol) were added and the mixture was degassed with N2 for an additional 5 minutes. The reaction mixture was stirred at 25°C and stirred for 1h. The reaction mixture was diluted with EtOAc and washed with sat NH4Cl. The layers were separated and the organic layer was washed with sat NaCl , dried over MgSO4, filtered, and concentrated under reduced pressure. The residue was purified via silica gel chromatography (5 - 80 % EtOAc in hexanes) to give 2-chloro-3-fluoro-5-((trimethylsilyl)ethynyl)pyridin-4-amine (1.749 g, 7.20 mmol, 98 % yield) as a white solid.1H NMR (600 MHz, MeOD) δ 7.84 (s, 1H), 0.27 (d, J = 0.7 Hz, 9H). Step 2 6-chloro-7-fluoro-1H-pyrrolo[3,2-c]pyridine

[0423] To a solution of 2-chloro-3-fluoro-5-((trimethylsilyl)ethynyl)pyridin-4-amine (1.749 g, 7.20 mmol) in DMF (36.0 mL) was added KOtBu (2.425 g, 21.61 mmol) and the resulting mixture was stirred at 40°C overnight. The reaction mixture was diluted with EtOAc and washed with sat NH4Cl. The layers were separated and the organic layer was washed with H2O (3x), then dried over Na2SO4, filtered, and concentrated under reduced pressure to give 6-chloro-7-fluoro-1H-pyrrolo[3,2-c]pyridine (1.19g, 6.98 mmol, 97 % yield) as a brown solid. Used as is in next step.1H NMR (600 MHz, MeOD) δ 8.43 (s, 1H), 7.46 (d, J = 3.2 Hz, 1H), 6.72 (t, J = 3.3 Hz, 1H). Step 3 6-chloro-1-cyclopropyl-7-fluoro-1H-pyrrolo[3,2-c]pyridine

[0424] To a solution of 6-chloro-7rrolo[3,2-c]pyridine (670 mg, 3.93 mmol) in DCE (15 mL) was added sodium bicarbonate (660 mg, 7.86 mmol), 2,2'-bipyridine (614 mg, 3.93 mmol) and cyclopropylboronic acid (675 mg, 7.86 mmol) and the resulting mixture was stirred at 70°C for 16hrs with air filled ballon ( oxygen needed). The reaction mixture was filtered through celite and the filtrate was concentrated under reduced pressure. The residue was purified via silica gel chromatography (10 - 90 % EtOAc in hexanes) to give 6-chloro-1-cyclopropyl-7-fluoro-1H-pyrrolo[3,2-c]pyridine (230 mg, 1.092 mmol, 27.8 % yield) and as an off-white solid. MS (ES+) C10H8ClFN2 requires: 210, found: 211 [M+H]+.1H NMR (600 MHz, MeOD) δ 8.38 (d, J = 0.9 Hz, 1H), 7.41 (d, J = 3.3 Hz, 1H), 6.63 (dd, J = 3.3, 2.4 Hz, 1H), 3.71 – 3.66 (m, 1H), 1.19 – 1.13 (m, 2H), 1.13 – 1.08 (m, 2H). Step 4 3-bromo-6-chloro-1-cyclopropyl-7-fluoro-1H-pyrrolo[3,2-c]pyridine

[0425] To a solution of 6-chloro-1-cyclopropyl-7-fluoro-1H-pyrrolo[3,2-c]pyridine (200 mg, 0.950 mmol) in DMF (2 mL) was added NBS (203 mg, 1.139 mmol) and the resulting mixture was stirred at 20°C for 1.5hr. The reaction mixture was diluted with EtOAc and washed with 10% Na2SO3(3x). The layers were separated and the organic layer was washed with sat NaCl, dried over MgSO4, filtered, and concentrated under reduced pressure. The off white solid was used as is in next step. MS (ES+) C10H7BrClFN2requires: 289, found: 290 [M+H]+.1H NMR (600 MHz, MeOD) δ 8.30 (s, 1H), 7.56 (s, 1H), 3.73 – 3.66 (m, 1H), 1.19 – 1.10 (m, 4H). Step 5 Tert-butyl 3-(6-chloro-1-cyclopropyl-7-fluoro-1H-pyrrolo[3,2-c]pyridin-3-yl)-3,8- diazabicyclo[3.2.1]octane-8-carboxylate

[0426] A solution of 3-bromoy p pyl-7-fluoro-1H-pyrrolo[3,2-c]pyridine (100 mg, 0.345 mmol), tert-butyl 3,8-diazabicyclo[3.2.1]octane-8-carboxylate (183 mg, 0.863 mmol), in Toluene (2 mL) was degassed with N2for 5 minutes. NaOtBu (100 mg, 1.036 mmol) and CPhos / JackiePhos Hybrid (39.4 mg, 0.035 mmol) were added and the mixture was degassed with N2for an additional 5 minutes. The reaction mixture was than placed in a pre-heated block at 90°C and stirred for 4hrs. sat NH4Cl was added and the layers were separated. The aqueous phase was extracted with EtOAc (3x), the combined organic layers were washed with sat NaCl, dried over MgSO4, filtered, and concentrated under reduced pressure. The residue was purified via silica gel chromatography (0 - 80 % EtOAc in hexanes) to give tert-butyl 3-(6-chloro-1-cyclopropyl-7-fluoro-1H-pyrrolo[3,2-c]pyridin-3- yl)-3,8-diazabicyclo[3.2.1]octane-8-carboxylate (53 mg, 0.126 mmol, 36.5 % yield) as a pale yellow oil. MS (ES+) C21H26ClFN4O2 requires: 420, found: 421 [M+H]+.1H NMR (600 MHz, MeOD) δ 8.41 (s, 1H), 6.89 (s, 1H), 4.30 (s, 2H), 3.61 – 3.54 (m, 1H), 3.28 (s, 1H), 2.86 (s,1H), 2.09 (d, J = 6.2 Hz, 2H), 1.98 (s, 2H), 1.48 (s, 9H), 1.29 – 1.28 (m, 2H), 1.14 – 1.04 (m, 4H). Step 6 Tert-butyl 3-(1-cyclopropyl-7-fluoro-6-(7-fluoro-3-(methoxymethoxy)-8- ((triisopropylsilyl)ethynyl)naphthalen-1-yl)-1H-pyrrolo[3,2-c]pyridin-3-yl)-3,8- diazabicyclo[3.2.1]octane-8-carboxylate

[0427] A solution of tert-butyropyl-7-fluoro-1H-pyrrolo[3,2- c]pyridin-3-yl)-3,8-diazabicyclo[3.2.1]octane-8-carboxylate (53 mg, 0.126 mmol), Cs2CO3(82 mg, 0.252 mmol) in 1,4-Dioxane (472 µl)-Water (157 µl) was degassed with N2 for 5 minutes. then CataCXium Pd G3 (13.76 mg, 0.019 mmol) and ((2-fluoro-6- (methoxymethoxy)-8-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)naphthalen-1- yl)ethynyl)triisopropylsilane (97 mg, 0.189 mmol) was added and the mixture was degassed with N2 for an additional 2 minutes. The reaction mixture was heated to 80°C for 4hrs. sat NH4Cl was added and the layers were separated. The aqueous phase was extracted with EtOAc (3x), the combined organic layers were washed with sat NaCl, dried over Na2SO4, filtered, and concentrated under reduced pressure. The residue was purified via silica gel chromatography (10 - 90 % EtOAc in hexanes) to give tert-butyl 3-(1-cyclopropyl-7-fluoro- 6-(7-fluoro-3-(methoxymethoxy)-8-((triisopropylsilyl)ethynyl)naphthalen-1-yl)-1H- pyrrolo[3,2-c]pyridin-3-yl)-3,8-diazabicyclo[3.2.1]octane-8-carboxylate (70 mg, 0.091 mmol, 72.1 % yield) as a brown liquid. MS (ES+) C44H56F2N4O4Si requires: 771, found: 772 [M+H]+. Step 74-(3-(3,8-diazabicyclo[3.2.1]octan-3-yl)-1-cyclopropyl-7-fluoro-1H-pyrrolo[3,2- c]pyridin-6-yl)-5-ethynyl-6-fluoronaphthalen-2-ol

[0428] To a solution of tert-b-fluoro-6-(7-fluoro-3- (methoxymethoxy)-8-((triisopropylsilyl)ethynyl)naphthalen-1-yl)-1H-pyrrolo[3,2-c]pyridin- 3-yl)-3,8-diazabicyclo[3.2.1]octane-8-carboxylate (70 mg, 0.091 mmol) in DCM (0.25 mL) was added 4M HCl in Dioxane (0.227 mL, 0.908 mmol) at 0°C and the resulting mixture was stirred at 20°C for 2hr. The volatiles were removed under reduced pressure. This material was then redissolved in DMF (0.250 mL) and CsF (69.0 mg, 0.454 mmol) was added to reaction and solution was heated to 60°C for 2hrs. The residue was filtered and purified by mass-triggered preparative HPLC (Mobile phase: A = 0.1% TFA / H2O, B = 0.1% TFA / MeCN; Gradient: B = 10 - 50%; 20 min; Column: XBridge C18, 5 μm, 19 mm x 150 mm) to give 4-(3-(3,8-diazabicyclo[3.2.1]octan-3-yl)-1-cyclopropyl-7-fluoro-1H-pyrrolo[3,2- c]pyridin-6-yl)-5-ethynyl-6-fluoronaphthalen-2-ol (21 mg, 0.036 mmol, 39.6 % yield) as a pale yellow solid.

[0429] MS (ES+) C28H24F2N4O requires: 470, found: 471 [M+H]+.

[0430] 1H NMR (600 MHz, MeOD) δ 9.03 (s, 1H), 7.94 (dd, J = 9.2, 5.6 Hz, 1H), 7.48 (d, J = 2.6 Hz, 1H), 7.42 – 7.38 (m, 2H), 7.37 (d, J = 2.6 Hz, 1H), 4.21 (s, 2H), 3.82 – 3.75 (m, 1H), 3.66 – 3.55 (m, 2H), 3.38 (s, 1H), 3.29 – 3.20 (m, 2H), 2.48 – 2.35 (m, 2H), 2.24 – 2.17 (m, 2H), 1.25 – 1.17 (m, 2H), 1.16 – 1.09 (m, 2H). EXAMPLE 864-(3-((1S,4S)-2,5-diazabicyclo[2 lopropyl-7-fluoro-1H-pyrrolo[3,2- c]pyridin-6-ynaphthalen-2-ol

[0431] Made similarly to Example 85. MS (ES+) C28H24F2N4O requires: 470, found: 471 [M+H]+.1H NMR (600 MHz, MeOD) δ 8.89 (s, 1H), 7.92 (dd, J = 9.1, 5.6 Hz, 1H), 7.44 (d, J = 2.5 Hz, 1H), 7.38 (t, J = 9.0 Hz, 1H), 7.33 (d, J = 2.6 Hz, 1H), 7.29 (d, J = 5.1 Hz, 1H), 3.92 – 3.83 (m, 2H), 3.81 (s, 1H), 3.80 – 3.68 (m, 2H), 3.46 – 3.39 (m, 1H), 3.34 (q, J = 1.6 Hz, 2H), 2.43 – 2.06 (m, 1H), 2.04 – 1.92 (m, 3H), 1.24 – 1.10 (m, 4H). EXAMPLE 87 4-(3-((1R,5S,6r)-3-azabcyclopropyl-7-fluoro-4-(1- hydroxyethyl)-1H-pyrazolo[4,3-c]pyridin-6-yl)-5-ethynyl-6-fluoronaphthalen-2-ol Step 1 tert-butyl (1R,5S,6r)-6-(4-acetyl-6-chloro-1-cyclopropyl-7-fluoro-1H-pyrazolo[4,3- c]pyridin-3-yl)-3-azabicyclo[3.1.0]hexane-3-carboxylate

[0432] To a solution of tert-butyl (1R,5S,6r)-6-(6-chloro-1-cyclopropyl-4-(1- ethoxyvinyl)-7-fluoro-1H-pyrazolo[4,3-c]pyridin-3-yl)-3-azabicyclo[3.1.0]hexane-3- carboxylate (116 mg, 0.251 mmol) in Dioxane (2.5 mL) was added HCl (0.752 mL, 0.752 mmol) and the resulting mixture was stirred at rt for 4 h. Retention time on LCMS is identical between the SM and Product. An NMR aliquot showed completion after 4h. The volatiles were removed under reduced pressure to give tert-butyl (1R,5S,6r)-6-(4-acetyl-6-chloro-1- cyclopropyl-7-fluoro-1H-pyrazolo[4,3-c]pyridin-3-yl)-3-azabicyclo[3.1.0]hexane-3- carboxylate (109 mg, 0.251 mmol, 100 % yield)MS (ES+) C21H24ClFN4O3 requires: 434, found: 457 [M+Na]+. Step 2 tert-butyl (1R,5S,6r)-6-(4-acetyl-1-cyclopropyl-7-fluoro-6-(7-fluoro-3- (methoxymethoxy)-8-((triisopropylsilyl)ethynyl)naphthalen-1-yl)-1H-pyrazolo[4,3- c]pyridin-3-yl)-3-azabicyclo[3.1.0]hexane-3-carboxylate

[0433] A suspension of tey , , y -6-chloro-1-cyclopropyl-7- fluoro-1H-pyrazolo[4,3-c]pyridin-3-yl)-3-azabicyclo[3.1.0]hexane-3-carboxylate (54 mg, 0.124 mmol), tripotassium phosphate (79 mg, 0.373 mmol), and Reactant 3 (9.04 mg, 0.012 mmol) and ((2-fluoro-6-(methoxymethoxy)-8-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2- yl)naphthalen-1-yl)ethynyl)triisopropylsilane (76 mg, 0.149 mmol) in 1,4-Dioxane (931 µl)- Water (310 µl) was degassed with N2 for 2 minutes. The reaction mixture was heated to 80 °C and stirred for 2 h. The reaction mixture was allowed to cool to room temperature. The reaction mixture was diluted with EtOAc (25.0 mL) and washed with sat NaCl (10.0 mL). The layers were separated and the organic layer was washed with sat NaCl (10.0 mL), dried over Na2SO4, filtered, and concentrated under reduced pressure. The residue was purified via silica gel chromatography (5 - 75 % EtOAc in hexanes) to give tert-butyl (1R,5S,6r)-6-(4- acetyl-1-cyclopropyl-7-fluoro-6-(7-fluoro-3-(methoxymethoxy)-8- ((triisopropylsilyl)ethynyl)naphthalen-1-yl)-1H-pyrazolo[4,3-c]pyridin-3-yl)-3-azabicyclo[3.1.0]hexane-3-carboxylate (54.4 mg, 0.069 mmol, 55.8 % yield) as a pale yellow oil. MS (ES+) C44H54F2N4O5Si requires: 784, found: 785 [M+H]+. Step 3 tert-butyl (1R,5S,6r)-6-(1-cyclopropyl-7-fluoro-6-(7-fluoro-3-(methoxymethoxy)-8- ((triisopropylsilyl)ethynyl)naphthalen-1-yl)-4-(1-hydroxyethyl)-1H-pyrazolo[4,3- c]pyridin-3-yl)-3-azabicyclo[3.1.0]hexane-3-carboxylate

[0434] To a solution of tetyl-1-cyclopropyl-7-fluoro-6-(7- fluoro-3-(methoxymethoxy)-8-((triisopropylsilyl)ethynyl)naphthalen-1-yl)-1H-pyrazolo[4,3- c]pyridin-3-yl)-3-azabicyclo[3.1.0]hexane-3-carboxylate (22.2 mg, 0.028 mmol) in Ethanol (1 mL) was added sodium borohydride (1.070 mg, 0.028 mmol) and the resulting mixture was stirred at 0 °C for 1 h. The volatiles were removed under reduced pressure. The residue was purified via silica gel chromatography (0 - 50 % EtOAc in hexanes) to give tert-butyl (1R,5S,6r)-6-(1-cyclopropyl-7-fluoro-6-(7-fluoro-3-(methoxymethoxy)-8- ((triisopropylsilyl)ethynyl)naphthalen-1-yl)-4-(1-hydroxyethyl)-1H-pyrazolo[4,3-c]pyridin-3- yl)-3-azabicyclo[3.1.0]hexane-3-carboxylate (22 mg, 0.028 mmol, 99 % yield) as a colorless oil. MS (ES+) C44H56F2N4O5Si requires: 787, found: 788 [M+H]+. Step 4 4-(3-((1R,5S,6r)-3-azabicyclo[3.1.0]hexan-6-yl)-1-cyclopropyl-7-fluoro-4-(1- hydroxyethyl)-1H-pyrazolo[4,3-c]pyridin-6-yl)-5-ethynyl-6-fluoronaphthalen-2-ol

[0435] To a solution of tertpropyl-7-fluoro-6-(7-fluoro-3- (methoxymethoxy)-8-((triisopropylsilyl)ethynyl)naphthalen-1-yl)-4-(1-hydroxyethyl)-1H- pyrazolo[4,3-c]pyridin-3-yl)-3-azabicyclo[3.1.0]hexane-3-carboxylate (22 mg, 0.028 mmol) in DCM (0.3 mL) was added HCl (0.070 mL, 0.280 mmol) and the resulting mixture was stirred at rt for 1 h. The volatiles were removed under reduced pressure. The residue was taken up in DMF (0.4 mL) and treated with CsF (85 mg, 0.559 mmol) at 60 °C for 1h. The residue was purified by mass-triggered preparative HPLC (Mobile phase: A = 0.1% TFA / H2O, B = 0.1% TFA / MeCN; Gradient: B = 10 - 50%; 20 min; Column: XBridge C18, 5 μm, 19 mm x 150 mm) to give 4-(3-((1R,5S,6r)-3-azabicyclo[3.1.0]hexan-6-yl)-1- cyclopropyl-7-fluoro-4-(1-hydroxyethyl)-1H-pyrazolo[4,3-c]pyridin-6-yl)-5-ethynyl-6- fluoronaphthalen-2-ol 2,2,2-trifluoroacetate (4 mg, 6.66 μmol, 23.83 % yield) as a white solid.

[0436] MS (ES+) C28H24F2N4O2 requires: 486, found: 487 [M+H]+

[0437] 1H NMR (600 MHz, MeOD) δ 7.90 (ddd, J = 9.2, 6.8, 5.6 Hz, 1H), 7.41 (dd, J = 7.7, 2.6 Hz, 1H), 7.36 (td, J = 8.9, 7.5 Hz, 1H), 7.31 (dd, J = 5.9, 2.6 Hz, 1H), 5.62 (q, J = 6.6 Hz, 0.5H), 5.44 (q, J = 6.7 Hz, 0.5H), 3.94 (ddt, J = 7.2, 5.9, 3.5 Hz, 1H), 3.76 – 3.60 (m, 4H), 3.39 – 3.34 (m, 0.5H), 3.29 (d, J = 0.9 Hz, 0.5H), 2.87 (t, J = 3.8 Hz, 0.5H), 2.68 (t, J = 3.7 Hz, 0.5H), 2.63 – 2.54 (m, 2H), 1.69 (dd, J = 6.7, 3.2 Hz, 3H), 1.30 (d, J = 10.9 Hz, 1H), 1.24 (dd, J = 8.5, 4.3 Hz, 1H), 1.20 – 1.10 (m, 2H). EXAMPLE 884-(3-((1R,5S,6r)-3-azabicyclo[3.1.0]hexan-6-yl)-1-cyclopropyl-4-ethyl-7-fluoro-1H- pyrazolo[4,3-c]pyridin-6-yl)-5-ethynyl-6-fluoronaphthalen-2-amine Step 1 tert-butyl (1R,5S,6r)-6-(1-cyclopropyl-4-ethyl-7-fluoro-6-(7-fluoro-3-hydroxy-8- ((triisopropylsilyl)ethynyl)naphthalen-1-yl)-1H-pyrazolo[4,3-c]pyridin-3-yl)-3- azabicyclo[3.1.0]hexane-3-carboxylate

[0438] To a solution of tert propyl-4-ethyl-7-fluoro-6-(7-fluoro-3-(methoxymethoxy)-8-((triisopropylsilyl)ethynyl)naphthalen-1-yl)-1H-pyrazolo[4,3- c]pyridin-3-yl)-3-azabicyclo[3.1.0]hexane-3-carboxylate (123 mg, 0.160 mmol) in DCM (2659 µl) was added 4M hydrogen chloride in dioxane (36.0 µl, 1.037 mmol, 6.5 eq.) and the resulting mixture was stirred at rt for 20 min. Sat NaHCO3(1.00 mL) was added and the layers were separated. The aqueous phase was extracted with CH2Cl2 (2 x 1.00 mL), and concentrated under reduced pressure to yield a yellow foam-solid. The crude product was carried forward without further purification.

[0439] MS (ES+) C42H52F2N4O3Si requires: 726, found: 727 [M+H]+. Step 2 tert-butyl (1R,5S,6r)-6-(1-cyclopropyl-4-ethyl-7-fluoro-6-(7-fluoro-3- (((trifluoromethyl)sulfonyl)oxy)-8-((triisopropylsilyl)ethynyl)naphthalen-1-yl)-1H- pyrazolo[4,3-c]pyridin-3-yl)-3-azabicyclo[3.1.0]hexane-3-carboxylate

[0440] To a cooled 0 °C solution of tert-butyl (1R,5S,6r)-6-(1-cyclopropyl-4-ethyl-7- fluoro-6-(7-fluoro-3-hydroxy-8-((triisopropylsilyl)ethynyl)naphthalen-1-yl)-1H-pyrazolo[4,3- c]pyridin-3-yl)-3-azabicyclo[3.1.0]hexane-3-carboxylate (117.7 mg, 0.162 mmol) in DCM (2698 µl) was added N-ethyl-N-isopropylpropan-2-amine (338 µl, 1.943 mmol, 12 eq.), followed by trifluoromethanesulfonic anhydride (95 µl, 0.567 mmol, 3.5 eq.). The resulting mixture was stirred at rt for 1 h. The volatiles were removed under reduced pressure. The residue was purified via silica gel chromatography (0 - 60 % EtOAc in hexanes) to give tert- butyl (1R,5S,6r)-6-(1-cyclopropyl-4-ethyl-7-fluoro-6-(7-fluoro-3- (((trifluoromethyl)sulfonyl)oxy)-8-((triisopropylsilyl)ethynyl)naphthalen-1-yl)-1H- pyrazolo[4,3-c]pyridin-3-yl)-3-azabicyclo[3.1.0]hexane-3-carboxylate (98.4 mg, 0.115 mmol, 70.8 % yield) as a yellow oil.

[0441] MS (ES+) C43H51F5N4O5SSi requires: 859, found: 859 [M]+. Step 3 tert-butyl (1R,5S,6r)-6-(6-(3-((tert-butoxycarbonyl)amino)-7-fluoro-8- ((triisopropylsilyl)ethynyl)naphthalen-1-yl)-1-cyclopropyl-4-ethyl-7-fluoro-1H- pyrazolo[4,3-c]pyridin-3-yl)-3-azabicyclo[3.1.0]hexane-3-carboxylate

[0442] A solution of tert-bopyl-4-ethyl-7-fluoro-6-(7-fluoro- 3-(((trifluoromethyl)sulfonyl)oxy)-8-((triisopropylsilyl)ethynyl)naphthalen-1-yl)-1H- pyrazolo[4,3-c]pyridin-3-yl)-3-azabicyclo[3.1.0]hexane-3-carboxylate (98.4 mg, 0.115 mmol), cesium carbonate (112 mg, 0.344 mmol, 3 eq.) in Dioxane (1636 µl) was degassed with N2 for 3 minutes. Pd2(dba)3 (52.4 mg, 0.057 mmol, 0.5 eq.), tert-butyl carbamate (67.1 mg, 0.573 mmol, 5 eq.) and dicyclohexyl(2',6'-diisopropoxy-[1,1'-biphenyl]-2-yl)phosphane (RuPhos) (26.7 mg, 0.057 mmol, 0.5 eq.) were added and the mixture was degassed with N2 for an additional 3 minutes. The reaction mixture was heated to 100 °C and stirred for 16 h. The reaction mixture was diluted with MeOH, filtered through celite, and the filtrate was concentrated under reduced pressure. The residue was purified via silica gel chromatography (0 - 60 % EtOAc in hexanes) to give tert-butyl (1R,5S,6r)-6-(6-(3-((tert-butoxycarbonyl)amino)-7-fluoro-8-((triisopropylsilyl)ethynyl)naphthalen-1-yl)-1- cyclopropyl-4-ethyl-7-fluoro-1H-pyrazolo[4,3-c]pyridin-3-yl)-3-azabicyclo[3.1.0]hexane-3- carboxylate (104.1 mg, 0.126 mmol, 110 % yield) as a yellow oil.

[0443] MS (ES+) C47H61F2N5O4Si requires: 826, found: 827 [M+H]+. Step 4 4-(3-((1R,5S,6r)-3-azabicyclo[3.1.0]hexan-6-yl)-1-cyclopropyl-4-ethyl-7-fluoro-1H- pyrazolo[4,3-c]pyridin-6-yl)-5-ethynyl-6-fluoronaphthalen-2-amine

[0444] To a solution of tert tert-butoxycarbonyl)amino)-7-fluoro-8-((triisopropylsilyl)ethynyl)naphthalen-1-yl)-1-cyclopropyl-4-ethyl-7-fluoro-1H- pyrazolo[4,3-c]pyridin-3-yl)-3-azabicyclo[3.1.0]hexane-3-carboxylate (104.1 mg, 0.126 mmol) in DMF (1800 µl) was added cesium fluoride (191 mg, 1.260 mmol, 10 eq.) and the resulting mixture was stirred at rt for 1 h. H2O (1.00 mL) was added to dilute the solution. The aqueous phase was extracted with EtOAc (3 x 1.00 mL), the combined organic layers were washed with sat NaHCO3, dried over MgSO4, filtered, and concentrated under reduced pressure. The crude was carried forward to next step without further purification.

[0445] Tert-butyl (1R,5S,6r)-6-(6-(3-((tert-butoxycarbonyl)amino)-8-ethynyl-7- fluoronaphthalen-1-yl)-1-cyclopropyl-4-ethyl-7-fluoro-1H-pyrazolo[4,3-c]pyridin-3-yl)-3- azabicyclo[3.1.0]hexane-3-carboxylate (100 mg, 0.149 mmol) was redissolved in DCM (2133 µl) was added 4M hydrogen chloride in dioxane (51.8 µl, 1.493 mmol, 10 eq.) and the resulting mixture was stirred at rt for 1 h. The residue was purified by mass-triggered preparative HPLC (Mobile phase: A = 0.1% TFA / H2O, B = 0.1% TFA / MeCN; Gradient: B = 10 - 60%; 12 min; Column: XBridge C18, 5 μm, 19 mm x 150 mm) to give 4-(3-((1R,5S,6r)- 3-azabicyclo[3.1.0]hexan-6-yl)-1-cyclopropyl-4-ethyl-7-fluoro-1H-pyrazolo[4,3-c]pyridin-6- yl)-5-ethynyl-6-fluoronaphthalen-2-amine as a white solid.

[0446] MS (ES+) C28H25F2N5 requires: 469, found: 470 [M+H]+.

[0447] 1H NMR (600 MHz, MeOD) δ 7.86 (dd, J = 9.2, 5.6 Hz, 1H), 7.38 (d, J = 2.4 Hz, 1H), 7.34 (dd, J = 17.1, 8.2 Hz, 2H), 3.99 (tq, J = 7.0, 3.5 Hz, 1H), 3.73 (dd, J = 12.0, 6.1 Hz,2H), 3.68 (t, J = 2.8 Hz, 1H), 3.67 – 3.63 (m, 1H), 3.45 (q, J = 7.7 Hz, 2H), 2.64 (d, J = 3.5 Hz, 1H), 2.59 (s, 1H), 1.49 (t, J = 7.6 Hz, 3H), 1.34 (d, J = 11.0 Hz, 1H), 1.27 (dd, J = 9.7, 5.0 Hz, 2H), 1.20 (tt, J = 5.6, 2.5 Hz, 2H). EXAMPLE 89 4-(3-((1S,4S)-2,5-diazabicyclo[ clopropyl-7-fluoro-4-(prop-1-en-2-yl)-1H-pyrazolo[4,3-c]pyridin-6-yl)-5-ethynyl-6-fluoronaphthalen-2-ol Step 1 3-bromo-6-chloro-7-fluoro-1H-pyrazolo[4,3-c]pyridine

[0448] To a solution of 6-chloro-7pyrazolo[4,3-c]pyridine (500 mg, 2.91 mmol) in DMF (1 mL) was added NBS (778 mg, 4.37 mmol) and the resulting mixture was stirred at 20°C for 16hrs. The reaction mixture was diluted with EtOAc and washed with 10% Na2SO3. The layers were separated and the organic layer was washed with sat NaCl, dried over MgSO4, filtered, and concentrated under reduced pressure to give 3-bromo-6-chloro-7- fluoro-1H-pyrazolo[4,3-c]pyridine (600 mg, 2.4 mmol, 82 % yield). The off white solid was used as is in next step. MS (ES+) C6H2BrClFN3 requires: 250.5, found: 252.0 [M+H]+. Step 2 3-bromo-6-chloro-1-cyclopropyl-7-fluoro-1H-pyrazolo[4,3-c]pyridine

[0449] To a solution of 3-bromo-6-chloro-7-fluoro-1H-pyrazolo[4,3-c]pyridine (600 mg, 2.396 mmol) in DCE (12 mL) was added sodium bicarbonate (402 mg, 4.79 mmol), 2,2'- bipyridine (374 mg, 2.396 mmol) and cyclopropylboronic acid (412 mg, 4.79 mmol) and copper (II) acetate (435 mg, 2.396 mmol), the resulting mixture was stirred at 70 °C overnight with air filled ballon ( oxygen needed). The reaction mixture was filtered through celite and the filtrate was concentrated under reduced pressure. EtOAc and H2O was added to the filtrate and the layers were separated. The organic phase was washed with H2O 3x, dried over MgSO4, filtered, and concentrated under reduced pressure. The residue was purified via silica gel chromatography (10 - 80 % EtOAc in hexanes) to give 3-bromo-6-chloro-1- cyclopropyl-7-fluoro-1H-pyrazolo[4,3-c]pyridine (255 mg, 0.878 mmol, 36.6 % yield) as a off white solid. MS (ES+) C9H6BrClFN3 requires: 290, found: 291 [M+H]+.1H NMR (600 MHz, MeOD) δ 8.52 (s, 1H), 3.91 (tt, J = 7.2, 3.6 Hz, 1H), 1.35 – 1.29 (m, 2H), 1.23 – 1.16 (m, 2H). Step 3 Tert-butyl (1S,4S)-5-(6-chloro-1-cyclopropyl-7-fluoro-1H-pyrazolo[4,3-c]pyridin-3-yl)- 2,5-diazabicyclo[2.2.2]octane-2-carboxylate

[0450] A solution of 3-bromo-6-chloro-1-cyclopropyl-7-fluoro-1H-pyrazolo[4,3- c]pyridine (100 mg, 0.344 mmol), tert-butyl (1S,4S)-2,5-diazabicyclo[2.2.2]octane-2- carboxylate (146 mg, 0.688 mmol), and Cs2CO3 (336 mg, 1.033 mmol) in THF (1.5 mL) wasdegassed with N2for 5 minutes. BINAP (32.2 mg, 0.052 mmol) and Pd2(dba)3(15.76 mg, 0.017 mmol) were added and the mixture was degassed with N2for an additional 2 minutes. The reaction mixture was heated to 80°C and stirred for 16hrs. Sat NH4Cl was added and the layers were separated. The aqueous phase was extracted with EtOAc (3x), the combined organic layers were washed with sat NaCl, dried over Na2SO4, filtered, and concentrated under reduced pressure. The residue was purified via silica gel chromatography (10 - 80 % EtOAc in hexanes) to give tert-butyl (1S,4S)-5-(6-chloro-1-cyclopropyl-7-fluoro-1H- pyrazolo[4,3-c]pyridin-3-yl)-2,5-diazabicyclo[2.2.2]octane-2-carboxylate (95 mg, 0.225 mmol, 65.4 % yield) as an orange oil. MS (ES+) C20H25ClFN5O2 requires: 421, found: 422 [M+H]+.1H NMR (600 MHz, MeOD) δ 8.57 (s, 1H), 4.40 – 4.32 (m, 1H), 4.30 (s, 1H), 3.90 (dt, J = 9.8, 2.8 Hz, 1H), 3.82 (ddd, J = 16.2, 9.8, 2.0 Hz, 1H), 3.77 – 3.63 (m, 2H), 3.56 – 3.46 (m, 1H), 2.22 – 2.11 (m, 1H), 2.06 – 1.99 (m, 1H), 1.95 – 1.84 (m, 2H), 1.47 (d, J = 7.1 Hz, 9H), 1.23 – 1.15 (m, 2H), 1.12 – 1.06 (m, 2H). Step 4 Tert-butyl (1S,4S)-5-(4-bromo-6-chloro-1-cyclopropyl-7-fluoro-1H-pyrazolo[4,3- c]pyridin-3-yl)-2,5-diazabicyclo[2.2.2]octane-2-carboxylate

[0451] To a cooled 0°C solution of tert-butyl (1S,4S)-5-(6-chloro-1-cyclopropyl-7- fluoro-1H-pyrazolo[4,3-c]pyridin-3-yl)-2,5-diazabicyclo[2.2.2]octane-2-carboxylate (170 mg, 0.403 mmol) in THF (790 µl) under N2 was added lithium magnesium 2,2,6,6- tetramethylpiperidin-1-ide dichloride in 1M THF (2418 µl, 2.418 mmol). The resulting mixture was stirred at 0°C for 15mins.Then added a solution of 1,2-dibromo-1,1,2,2- tetrachloroethane (525 mg, 1.612 mmol) in THF (1580 µl) at 0°C. The resulting mixture was stirred at 0°C for 1hr under N2. Sat Na2S2O3 was added and the layers were separated. The aqueous phase was extracted with EtOAc (3x), the combined organic layers were washedwith sat NaCl, dried over Na2SO4, filtered, and concentrated under reduced pressure. The residue was purified via silica gel chromatography (10 - 100 % EtOAc in hexanes) to give tert-butyl (1S,4S)-5-(4-bromo-6-chloro-1-cyclopropyl-7-fluoro-1H-pyrazolo[4,3-c]pyridin-3- yl)-2,5-diazabicyclo[2.2.2]octane-2-carboxylate (130 mg, 0.260 mmol, 64.4 % yield) as a pale yellow amorphous material. MS (ES+) C20H24BrClFN5O2 requires: 501, found: 502 [M+H]+.1H NMR (500 MHz, MeOD) δ 4.58 (s, 1H), 4.19 (s, 1H), 3.96 – 3.85 (m, 2H), 3.85 – 3.71 (m, 2H), 3.48 – 3.35 (m, 1H), 2.32 (d, J = 7.2 Hz, 1H), 2.03 – 1.89 (m, 2H), 1.76 (t, J = 10.2 Hz, 1H), 1.48 (d, J = 4.4 Hz, 9H), 1.25 – 1.21 (m, 2H), 1.16 – 1.07 (m, 2H). Step 5 Tert-butyl (1S,4S)-5-(6-chloro-1-cyclopropyl-7-fluoro-4-(prop-1-en-2-yl)-1H- pyrazolo[4,3-c]pyridin-3-yl)-2,5-diazabicyclo[2.2.2]octane-2-carboxylate

[0452] A solution of tert-butyl (1S,4S)-5-(4-bromo-6-chloro-1-cyclopropyl-7-fluoro-1H- pyrazolo[4,3-c]pyridin-3-yl)-2,5-diazabicyclo[2.2.2]octane-2-carboxylate (13 mg, 0.026 mmol), K3PO4(16.53 mg, 0.078 mmol), in Dioxane (97 µl) / Water (32.4 µl) was degassed with N2for 5 minutes.4,4,5,5-tetramethyl-2-(prop-1-en-2-yl)-1,3,2-dioxaborolane (5.23 mg, 0.031 mmol) and PdCl2(dppf)-CH2Cl2adduct (2.120 mg, 2.60 μmol) were added and the mixture was degassed with N2for an additional 2minutes. The reaction mixture was heated to 85°C for 2hrs. Sat NH4Cl was added and the layers were separated. The aqueous phase was extracted with EtOAc (3x), the combined organic layers were washed with sat NaCl, dried over Na2SO4, filtered, and concentrated under reduced pressure. The residue was purified via silica gel chromatography (0 - 80 % EtOAc in hexanes) to give tert-butyl (1S,4S)-5-(6- chloro-1-cyclopropyl-7-fluoro-4-(prop-1-en-2-yl)-1H-pyrazolo[4,3-c]pyridin-3-yl)-2,5- diazabicyclo[2.2.2]octane-2-carboxylate (8 mg, 0.017 mmol, 66.7 % yield) as a yellow oil. MS (ES+) C23H29ClFN5O2requires: 461, found: 462 [M+H]+.Step 6 Tert-butyl (1S,4S)-5-(1-cyclopropyl-7-fluoro-6-(7-fluoro-3-(methoxymethoxy)-8- ((triisopropylsilyl)ethynyl)naphthalen-1-yl)-4-(prop-1-en-2-yl)-1H-pyrazolo[4,3- c]pyridin-3-yl)-2,5-diazabicyclo[2.2.2]octane-2-carboxylate O O

[0453] A solution of tert-butyl (1S,4S)-5-(6-chloro-1-cyclopropyl-7-fluoro-4-(prop-1-en- 2-yl)-1H-pyrazolo[4,3-c]pyridin-3-yl)-2,5-diazabicyclo[2.2.2]octane-2-carboxylate (10 mg, 0.022 mmol), Cs2CO3(14.11 mg, 0.043 mmol) in 1,4-Dioxane (81 µl)-Water (27.1 µl) was degassed with N2 for 5 minutes. Then CataCXium Pd G3 (2.365 mg, 3.25 μmol) and ((2- fluoro-6-(methoxymethoxy)-8-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)naphthalen-1- yl)ethynyl)triisopropylsilane (16.64 mg, 0.032 mmol) was added and the mixture was degassed with N2for an additional 2 minutes. The reaction mixture was heated to 80°C for 16hrs. Sat NH4Cl was added and the layers were separated. The aqueous phase was extracted with EtOAc (3x), the combined organic layers were washed with sat NaCl, dried over Na2SO4, filtered, and concentrated under reduced pressure. The residue was purified via silica gel chromatography (10 - 90 % EtOAc in hexanes) to give tert-butyl (1S,4S)-5-(1- cyclopropyl-7-fluoro-6-(7-fluoro-3-(methoxymethoxy)-8- ((triisopropylsilyl)ethynyl)naphthalen-1-yl)-4-(prop-1-en-2-yl)-1H-pyrazolo[4,3-c]pyridin-3- yl)-2,5-diazabicyclo[2.2.2]octane-2-carboxylate (10 mg, 0.012 mmol, 56.9 % yield) as a brown amorphous material. MS (ES+) C46H59F2N5O4Si requires: 812, found: 813 [M+H]+. Step 7 4-(3-((1S,4S)-2,5-diazabicyclo[2.2.2]octan-2-yl)-1-cyclopropyl-7-fluoro-4-(prop-1-en-2- yl)-1H-pyrazolo[4,3-c]pyridin-6-yl)-5-ethynyl-6-fluoronaphthalen-2-ol

[0454] To a solution of tert-butyl (1S,4S)-5-(1-cyclopropyl-7-fluoro-6-(7-fluoro-3- (methoxymethoxy)-8-((triisopropylsilyl)ethynyl)naphthalen-1-yl)-4-(prop-1-en-2-yl)-1H- pyrazolo[4,3-c]pyridin-3-yl)-2,5-diazabicyclo[2.2.2]octane-2-carboxylate (10 mg, 0.012 mmol) in DCM (0.1 mL) was added 4M HCl in Dioxane (0.031 mL, 0.123 mmol) at 0 °C and the resulting mixture was stirred at 25°C for 1hr. The volatiles were removed under reduced pressure. This material was then redissolved in DMSO (0.100 mL) and CsF (9.35 mg, 0.062 mmol) was added to reaction and solution was heated to 80°C for 4hrs. The residue was filtered and purified by mass-triggered preparative HPLC (Mobile phase: A = 0.1% TFA / H2O, B = 0.1% TFA / MeCN; Gradient: B = 20 - 60%; 12 min; Column: XBridge C18, 5 μm, 19 mm x 150 mm) to give 4-(3-((1S,4S)-2,5-diazabicyclo[2.2.2]octan-2-yl)-1- cyclopropyl-7-fluoro-4-(prop-1-en-2-yl)-1H-pyrazolo[4,3-c]pyridin-6-yl)-5-ethynyl-6- fluoronaphthalen-2-ol (0.6 mg, 0.959 μmol, 7.79 % yield) as a pale yellow solid.

[0455] MS (ES+) C30H27F2N5O requires: 511, found: 512 [M+H]+.

[0456] 1H NMR (600 MHz, MeOD) δ 7.87 (dd, J = 9.1, 5.7 Hz, 1H), 7.37 (d, J = 2.6 Hz, 1H), 7.33 (t, J = 8.9 Hz, 1H), 7.26 (dd, J = 7.8, 2.6 Hz, 1H), 5.58 (s, 1H), 5.39 (s, 1H), 3.93 – 3.81 (m, 4H), 3.79 – 3.72 (m, 2H), 3.42 – 3.34 (m, 2H), 2.35 (s, 1H), 2.29 (d, J = 3.0 Hz, 3H), 2.17 – 2.05 (m, 2H), 1.90 (s, 1H), 1.36 – 1.20 (m, 2H), 1.13 (d, J = 7.1 Hz, 2H). EXAMPLE 904-(3-((1S,4S)-2,5-diazabicyclo[2.2.2]octan-2-yl)-1-cyclopropyl-4-ethyl-7-fluoro-1H- pyrazolo[4,3-c]pyridin-6-yl)-5-ethynyl-6-fluoronaphthalen-2-ol Step 1 Tert-butyl (1S,4S)-5-(6-chloro-1-cyclopropyl-4-ethyl-7-fluoro-1H-pyrazolo[4,3- c]pyridin-3-yl)-2,5-diazabicyclo[2.2.2]octane-2-carboxylate

[0457] A solution of tert-butyl (1S,4S)-5-(4-bromo-6-chloro-1-cyclopropyl-7-fluoro-1H- pyrazolo[4,3-c]pyridin-3-yl)-2,5-diazabicyclo[2.2.2]octane-2-carboxylate (50 mg, 0.100 mmol) in THF (0.5 mL) was degassed by bubbling with N2for 5min. Then Pd2(dba)3 (4.57 mg, 4.99 μmol) and tri(furan-2-yl)phosphane (2.318 mg, 9.98 μmol) was added. Followed by diethylzinc in toluene (90 mg, 0.110 mmol) and the resulting mixture was stirred at 25°C for 2hrs. The reaction mixture was diluted with EtOAc and washed with sat NH4Cl. The layers were separated and the organic layer was washed with sat NaCl (5.00 mL), dried over MgSO4, filtered, and concentrated under reduced pressure. The residue was purified via silica gel chromatography (0 - 80 % EtOAc in hexanes) to give tert-butyl (1S,4S)-5-(6-chloro-1- cyclopropyl-4-ethyl-7-fluoro-1H-pyrazolo[4,3-c]pyridin-3-yl)-2,5-diazabicyclo[2.2.2]octane- 2-carboxylate (15 mg, 0.033 mmol, 33.4 % yield) as a pale yellow solid. MS (ES+) C22H29ClFN5O2 requires: 449, found: 450 [M+H]+.1H NMR (600 MHz, MeOD) δ 4.58 (s, 1H), 4.19 (s, 1H), 3.93 – 3.73 (m, 3H), 3.67 – 3.55 (m, 2H), 3.47 – 3.35 (m, 1H), 3.07 (q, J = 7.2 Hz, 2H), 2.38 – 2.22 (m, 1H), 2.11 – 1.90 (m, 1H), 1.84 – 1.74 (m, 1H), 1.49 (d, J = 2.5 Hz, 9H), 1.32 (t, J = 7.5 Hz, 3H), 1.21 (s, 2H), 1.13 – 1.07 (m, 2H). Step 2 Tert-butyl (1S,4S)-5-(1-cyclopropyl-4-ethyl-7-fluoro-6-(7-fluoro-3-(methoxymethoxy)-8- ((triisopropylsilyl)ethynyl)naphthalen-1-yl)-1H-pyrazolo[4,3-c]pyridin-3-yl)-2,5- diazabicyclo[2.2.2]octane-2-carboxylateO O

[0458] A solution of tert-butyl (1S,4S)-5-(6-chloro-1-cyclopropyl-4-ethyl-7-fluoro-1H- pyrazolo[4,3-c]pyridin-3-yl)-2,5-diazabicyclo[2.2.2]octane-2-carboxylate (15 mg, 0.033 mmol), Cs2CO3(21.72 mg, 0.067 mmol) in 1,4-Dioxane (125 µl)-Water (41.7 µl) was degassed with N2 for 5 minutes. Then CataCXium Pd G3 (3.64 mg, 5.00 μmol) and ((2- fluoro-6-(methoxymethoxy)-8-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)naphthalen-1- yl)ethynyl)triisopropylsilane (34.2 mg, 0.067 mmol) was added and the mixture was degassed with N2for an additional 2 minutes. The reaction mixture was heated to 80°C overnight. sat NH4Cl was added and the layers were separated. The aqueous phase was extracted with EtOAc (3x), the combined organic layers were washed with sat NaCl, dried over Na2SO4, filtered, and concentrated under reduced pressure. The residue was purified via silica gel chromatography (10 - 90 % EtOAc in hexanes) to give tert-butyl (1S,4S)-5-(1-cyclopropyl-4- ethyl-7-fluoro-6-(7-fluoro-3-(methoxymethoxy)-8-((triisopropylsilyl)ethynyl)naphthalen-1- yl)-1H-pyrazolo[4,3-c]pyridin-3-yl)-2,5-diazabicyclo[2.2.2]octane-2-carboxylate (15 mg, 0.019 mmol, 56.2 % yield) as a yellow liquid. MS (ES+) C45H59F2N5O4Si requires: 800, found: 801 [M+H]+. Step 3 4-(3-((1S,4S)-2,5-diazabicyclo[2.2.2]octan-2-yl)-1-cyclopropyl-4-ethyl-7-fluoro-1H- pyrazolo[4,3-c]pyridin-6-yl)-5-ethynyl-6-fluoronaphthalen-2-ol

[0459] To a solution of tert-b propyl-4-ethyl-7-fluoro-6-(7-fluoro-3-(methoxymethoxy)-8-((triisopropylsilyl)ethynyl)naphthalen-1-yl)-1H-pyrazolo[4,3- c]pyridin-3-yl)-2,5-diazabicyclo[2.2.2]octane-2-carboxylate (15 mg, 0.019 mmol) in DCM (0.1 mL) was added 4M HCl in Dioxane (0.047 mL, 0.187 mmol) at 0°C and the resulting mixture was stirred at 25°C for 1hr. The volatiles were removed under reduced pressure. This material was then redissolved in DMSO (0.100 mL) and CsF (14.24 mg, 0.094 mmol) was added to reaction and solution was heated to 60°C for 2hrs. The residue was filtered and purified by mass-triggered preparative HPLC (Mobile phase: A = 0.1% TFA / H2O, B = 0.1% TFA / MeCN; Gradient: B = 20 - 60%; 12 min; Column: XBridge C18, 5 μm, 19 mm x 150 mm) to give 4-(3-((1S,4S)-2,5-diazabicyclo[2.2.2]octan-2-yl)-1-cyclopropyl-4-ethyl-7- fluoro-1H-pyrazolo[4,3-c]pyridin-6-yl)-5-ethynyl-6-fluoronaphthalen-2-ol (5.6 mg, 9.13 μmol, 48.7 % yield) as an off-white solid. MS (ES+) C29H27F2N5O requires: 499, found: 500 [M+H]+.1H NMR (600 MHz, MeOD) δ 7.94 (dd, J = 9.2, 5.6 Hz, 1H), 7.47 (d, J = 2.6 Hz, 1H), 7.41 (t, J = 8.9 Hz, 1H), 7.37 (dd, J = 5.8, 2.5 Hz, 1H), 4.17 – 4.02 (m, 1H), 4.02 – 3.94 (m, 1H), 3.94 – 3.77 (m, 4H), 3.57 (d, J = 26.0 Hz, 1H), 3.52 – 3.41 (m, 1H), 3.38 – 3.32 (m, 1H), 3.26 – 3.18 (m, 1H), 2.58 – 2.41 (m, 1H), 2.25 – 2.13 (m, 2H), 2.07 – 1.94 (m, 1H), 1.46 (t, J = 7.6 Hz, 3H), 1.37 (d, J = 11.2 Hz, 1H), 1.32 – 1.27 (m, 1H), 1.23 – 1.17 (m, 2H). EXAMPLE 914-(3-((1S,4S)-2,5-diazabicyclo[ clopropyl-7-fluoro-4-methoxy-1H-pyrazolo[4,3-c]pyridin-6-yl)-5-ethynyl-6-fluoronaphthalen-2-ol Step 1 tert-butyl (1S,4S)-5-(6-chloro-1-cyclopropyl-7-fluoro-4-methoxy-1H-pyrazolo[4,3- c]pyridin-3-yl)-2,5-diazabicyclo[2.2.2]octane-2-carboxylate

[0460] To a solution of tert-butyl (1S,4S)-5-(4-bromo-6-chloro-1-cyclopropyl-7-fluoro- 1H-pyrazolo[4,3-c]pyridin-3-yl)-2,5-diazabicyclo[2.2.2]octane-2-carboxylate (20 mg, 0.040 mmol) in Dioxane (100 µl) was added NaOMe (2.59 mg, 0.048 mmol) and the resulting mixture was stirred at 80°C overnight. sat NH4Cl was added and the layers were separated. The aqueous phase was extracted with EtOAc (3x), the combined organic layers were washed with sat NaCl, dried over MgSO4, filtered, and concentrated under reduced pressure. The residue was purified via silica gel chromatography (10 - 80 % EtOAc in hexanes) to give tert- butyl (1S,4S)-5-(6-chloro-1-cyclopropyl-7-fluoro-4-methoxy-1H-pyrazolo[4,3-c]pyridin-3- yl)-2,5-diazabicyclo[2.2.2]octane-2-carboxylate (14 mg, 0.031 mmol, 78 % yield) as an off- white solid. MS (ES+) C21H27ClFN5O3 requires: 451, found: 452 [M+H]+. Step 2Tert-butyl (1S,4S)-5-(1-cyclopropyl-7-fluoro-6-(7-fluoro-3-(methoxymethoxy)-8- ((triisopropylsilyl)ethynyl)naphthalen-1-yl)-4-methoxy-1H-pyrazolo[4,3-c]pyridin-3-yl)- 2,5-diazabicyclo[2.2.2]octane-2-carboxylate

[0461] A solution of tert-butyl (1S,4S)-5-(6-chloro-1-cyclopropyl-7-fluoro-4-methoxy- 1H-pyrazolo[4,3-c]pyridin-3-yl)-2,5-diazabicyclo[2.2.2]octane-2-carboxylate (14 mg, 0.031 mmol), Cs2CO3 (20.19 mg, 0.062 mmol) in 1,4-Dioxane (116 µl)-Water (38.7 µl) was degassed with N2for 5 minutes. Then CataCXium Pd G3 (3.38 mg, 4.65 μmol) and ((2- fluoro-6-(methoxymethoxy)-8-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)naphthalen-1- yl)ethynyl)triisopropylsilane (31.8 mg, 0.062 mmol) was added and the mixture was degassed with N2 for an additional 2 minutes. The reaction mixture was heated to 80°C overnight. sat NH4Cl was added and the layers were separated. The aqueous phase was extracted with EtOAc (3x), the combined organic layers were washed with sat NaCl, dried over Na2SO4, filtered, and concentrated under reduced pressure. The residue was purified via silica gel chromatography (10 - 90 % EtOAc in hexanes) to give tert-butyl (1S,4S)-5-(1-cyclopropyl-7- fluoro-6-(7-fluoro-3-(methoxymethoxy)-8-((triisopropylsilyl)ethynyl)naphthalen-1-yl)-4- methoxy-1H-pyrazolo[4,3-c]pyridin-3-yl)-2,5-diazabicyclo[2.2.2]octane-2-carboxylate (5 mg, 6.23 μmol, 20.12 % yield) as a brown oil. MS (ES+) C44H57F2N5O5Si requires: 802, found: 802 [M]+. Step 3 4-(3-((1S,4S)-2,5-diazabicyclo[2.2.2]octan-2-yl)-1-cyclopropyl-7-fluoro-4-methoxy-1H- pyrazolo[4,3-c]pyridin-6-yl)-5-ethynyl-6-fluoronaphthalen-2-ol

[0462] To a solution of tert-butyl (1S,4S)-5-(1-cyclopropyl-7-fluoro-6-(7-fluoro-3- (methoxymethoxy)-8-((triisopropylsilyl)ethynyl)naphthalen-1-yl)-4-methoxy-1H- pyrazolo[4,3-c]pyridin-3-yl)-2,5-diazabicyclo[2.2.2]octane-2-carboxylate (5 mg, 6.23 μmol) in DCM (0.1 mL) was added 4M HCl in Dioxane (0.016 mL, 0.062 mmol) at 0°C and the resulting mixture was stirred at 25°C for 1hr. The volatiles were removed under reduced pressure. DMSO (0.100 mL) and CsF (4.73 mg, 0.031 mmol) was added and solution was heated to 60°C for 2hrs. The residue was filtered and purified by mass-triggered preparative HPLC (Mobile phase: A = 0.1% TFA / H2O, B = 0.1% TFA / MeCN; Gradient: B = 20 - 60%; 12 min; Column: XBridge C18, 5 μm, 19 mm x 150 mm) to give 4-(3-((1S,4S)-2,5- diazabicyclo[2.2.2]octan-2-yl)-1-cyclopropyl-7-fluoro-4-methoxy-1H-pyrazolo[4,3- c]pyridin-6-yl)-5-ethynyl-6-fluoronaphthalen-2-ol (0.9 mg, 1.462 μmol, 23.45 % yield) as an off-white solid.MS (ES+) C28H25F2N5O2 requires: 501, found: 502 [M+H]+.1H NMR (600 MHz, MeOD) δ 7.83 (dd, J = 9.1, 5.6 Hz, 1H), 7.33 – 7.27 (m, 2H), 7.20 (d, J = 2.6 Hz, 1H), 4.35 (d, J = 9.8 Hz, 1H), 3.98 (s, 3H), 3.90 – 3.76 (m, 2H), 3.76 – 3.67 (m, 2H), 3.45 – 3.42 (m, 1H), 3.34 (s, 1H), 2.12 (s, 2H), 1.96 (d, J = 32.6 Hz, 2H), 1.29 (s, 2H), 1.20 (s, 1H), 1.05 (d, J = 6.3 Hz, 1H). EXAMPLE 92 4-(3-((1R,4R)-2,5-diazabicyclyclopropyl-4-(dimethylamino)-7- fluoro-1H-pyrazolo[4,3-c]pyridin-6-yl)-5-ethynyl-6-fluoronaphthalen-2-ol

[0463] Made similarly to Example 91. MS (ES+) C29H28F2N6O requires: 514, found: 515 [M+H]+.1H NMR (600 MHz, MeOD) δ 7.88 (dd, J = 9.1, 5.7 Hz, 1H), 7.38 – 7.26 (m, 3H), 4.18 (d, J = 15.4 Hz, 1H), 3.93 (dd, J = 12.2, 2.2 Hz, 1H), 3.89 – 3.75 (m, 3H), 3.68 (dt, J = 12.2, 2.7 Hz, 1H), 3.52 – 3.41 (m, 1H), 3.36 – 3.32 (m, 1H), 3.12 (d, J = 6.0 Hz, 6H), 2.42 – 2.25 (m, 1H), 2.22 – 2.08 (m, 2H), 2.00 – 1.92 (m, 1H), 1.35 – 1.19 (m, 2H), 1.15 – 1.06 (m, 2H).

[0464] The following Example was synthesized with procedures that were similar to the examples disclosed herein and can generally be made by methods disclosed herein from the appropriate starting materials. Table 3. Example Compounds. Example Structure IUPAC Name 93 4 3 2 i h l i 7 fl 1 h l-EXAMPLE 94 4-[3-[(1S,5R)-3-azabicyclo[3.1.0]hexan-6-yl]-9-oxa-1,2,6- triazatricyclo[6.3.1.04,12]dodeca-2,4,6,8(12)-tetraen-7-yl]-5-ethynyl-6-fluoro- naphthalen-2-ol Step 1 6-chloro-7-fluoro-3-iodo-1-tetrahydropyran-2-yl-pyrazolo[4,3-c]pyridine

[0465] To a mixture of 6-chloro- 1H-pyrazolo[4, 3-c]pyridine (1 g, 3.36 mmol, 1 eq) in DCM (9 mL) was added PTSA (28.95 mg, 168.09 μmol, 0.05 eq) at 25 °C. Then DHP (848.36 mg, 10.09 mmol, 922.13 μL, 3 eq) was added to the resulting mixture and stirred at 25 °C for 5 h. LCMS showed a peak (78%) with the desired mass. The mixture was concentrated under vacuum. The residue was purified by flash silica gel chromatography (12 g SepaFlash® Silica Flash Column, Eluent of 2~8% Ethyl acetate / Petroleum ether gradient @ 45 mL / min) to afford 6-chloro-7-fluoro-3-iodo-1-tetrahydropyran-2-yl-pyrazolo[4,3- c]pyridine (1.27 g, 3.33 mmol, 99.00% yield) as yellow solid. MS (ES+) C11H10ClFIN3O requires: 381, found 382 [M+H]+, Step 2 tert-butyl-[2-(6-chloro-3-iodo-1-tetrahydropyran-2-yl-pyrazolo[4,3-c]pyridin-7- yl)oxyethoxy]-dimethyl-silane

[0466] To a solution of 2-[tert-bl]oxyethanol (586.9 mg, 3.33 mmol, 1 eq) in DMF (12 mL) was added NaH (199.7 mg, 4.99 mmol, 55.47 μL, 60% purity, 1.5 eq) at 0 °C under N2, the reaction mixture was stirred at 0 °C under N2 for 0.5 h. Then a solution of 6-chloro-7-fluoro-3-iodo-1-tetrahydropyran-2-yl-pyrazolo[4,3-c]pyridine (1.27 g, 3.33 mmol, 1 eq) in DMF (2 mL) was added to the reaction mixture, and then warmed to 25 °C and stirred at 25 °C under N2 for 2 h. LCMS showed 46% of the starting material remained and a peak (44%) with the desired mass. The mixture was poured into a mixture of saturated NH4Cl (10 mL) and water (10 mL). The aqueous phase was extracted with ethyl acetate (30 mL × 2). The combined organic phase was washed with brine (10 mL × 2), dried over anhydrous Na2SO4, filtered and concentrated under vacuum. The residue was purified by flash silica gel chromatography (12 g SepaFlash® Silica Flash Column, Eluent of 0~55% Ethyl acetate / Petroleum ether gradient @ 45 mL / min) to afford tert-butyl-[2-(6-chloro-3-iodo-1-tetrahydropyran-2-yl-pyrazolo[4,3-c]pyridin-7-yl)oxyethoxy]-dimethyl-silane (700 mg, 1.30 mmol, 39.10% yield) as white solid. MS (ES+) C19H29ClIN3O3Si requires: 537, found 538 [M+H]+, Step 3 2-[(6-chloro-3-iodo-1H-pyrazolo[4,3-c]pyridin-7-yl)oxy]ethanol

[0467] To a solution of tert-butyl iodo-1-tetrahydropyran-2-yl-pyrazolo[4,3-c]pyridin-7-yl)oxyethoxy]-dimethyl-silane (700 mg, 1.30 mmol, 1 eq) in DCM (1.75 mL) was added HCl / dioxane (2 M, 3.50 mL, 5.38 eq), the reaction mixture was stirred at 25 °C for 1 h. LCMS showed the starting material was consumed completely and a peak (65%) with the desired mass. The mixture was concentrated under vacuum. The residue was dissolved in CH3CN (10 mL) and stirred for 10 min, then filtered. The cake was dissolved in ethyl acetate (30 mL) and saturated NaHCO3 (15 mL). The aqueous phase was extracted with ethyl acetate (30 mL × 2). The combined organic phase was washed with brine (10 mL × 2), dried over anhydrous Na2SO4, filtered and concentrated under vacuum to afford 2-[(6-chloro- 3-iodo-1H-pyrazolo[4,3-c]pyridin-7-yl)oxy]ethanol (310 mg, 913.06 μmol, 70.16% yield) as white solid was used into the next step without further purification. MS (ES+) C8H7ClIN3O2requires: 339, found 340 [M+H]+.1H NMR (400 MHz, DMSO-d6) δ 8.36 (s, 1H), 4.30 - 4.23 (m, 2H), 3.76 (t, J = 5.0 Hz, 2H). Step 4 7-chloro-3-iodo-9-oxa-1,2,6-triazatricyclo[6.3.1.04,12]dodeca-2,4,6,8(12)-tetraene

[0468] To a solution of 2-[(6-chlopyrazolo[4,3-c]pyridin-7-yl)oxy]ethanol (310 mg, 913.06 μmol, 1 eq) in DCM (30 mL) were added DIPEA (704.90 mg, 5.45 mmol, 950 μL, 5.97 eq), CBr4(604.50 mg, 1.82 mmol, 2 eq) and PPh3(310.00 mg, 1.18 mmol, 1.29 eq), the reaction mixture was stirred at 25 °C for 12 h. LCMS showed the 20% startingmaterial remained and a peak (25%) with the desired mass. The mixture was concentrated under vacuum. The residue was purified by flash silica gel chromatography (12 g SepaFlash® Silica Flash Column, Eluent of 0~55% Ethyl acetate / Petroleum ether gradient @ 45 mL / min) to afford 7-chloro-3-iodo-9-oxa-1,2,6-triazatricyclo[6.3.1.04,12]dodeca- 2,4,6,8(12)-tetraene (180 mg, 559.87 μmol, 61.32% yield) as yellow solid. MS (ES+) C8H5ClIN3O requires: 321, found 322 [M+H]+. Step 5 tert-butyl (1S,5R)-6-(7-chloro-9-oxa-1,2,6-triazatricyclo[6.3.1.04,12]dodeca-2,4,6,8(12)- tetraen-3-yl)-3-azabicyclo[3.1.0]hexane-3-carboxylate

[0469] To a solution of 7-chlor6-triazatricyclo[6.3.1.04, 12]dodeca- 2,4,6,8(12)-tetraene (110 mg, 342.14 μmol, 1 eq), tert-butyl (1R,5S) -6-(4,4,5,5-tetramethyl- 1,3,2-dioxaborolan-2-yl)-3-azabicyclo[3.1.0]hexane-3-carboxylate (211.59 mg, 684.29 μmol, 2 eq) and K3PO4 (1.5 M, 700 μL, 3.07 eq) in dioxane (7 mL) was added Ad2nBuP Pd G3 (cataCXium® A Pd G3) (32.51 mg, 44.64 μmol, 0.13 eq), the mixture was stirred at 60 °C for 12 h under N2. LCMS showed 27% of the starting material remained and a peak (40%) with the desired mass. The mixture was cooled to 25 °C and poured into a mixture of saturated NH4Cl (2 mL) and water (3 mL). The aqueous phase was extracted with ethyl acetate (6 mL × 2). The combined organic phase was washed with brine (5 mL × 2), dried over anhydrous Na2SO4, filtered and concentrated under vacuum. The residue was purified by flash silica gel chromatography (12 g SepaFlash® Silica Flash Column, Eluent of 20~65% Ethyl acetate / Petroleum ether gradient @ 45 mL / min) to afford tert-butyl (1S,5R)-6-(7-chloro-9- oxa-1,2,6-triazatricyclo[6.3.1.04,12]dodeca-2,4,6,8(12)-tetraen-3-yl)-3- azabicyclo[3.1.0]hexane-3-carboxylate (128 mg, 339.67 μmol, 99.28% yield) as yellow solid. MS (ES+) C18H21ClN4O3 requires: 376, found: 377 [M+H]+Step 6tert-butyl (1S,5R)-6-[7-[7-fluoro-3-(methoxymethoxy)-8-(2-triisopropylsilylethynyl)-1- naphthyl]-9-oxa-1,2,6-triazatricyclo[6.3.1.04,12]dodeca-2,4,6,8(12)-tetraen-3-yl]-3- azabicyclo[3.1.0]hexane-3-carboxylate

[0470] To a solution of tert- -9-oxa-1,2,6-triazatricyclo[6.3.1.04,12]dodeca-2,4,6,8(12)-tetraen-3-yl)-3-azabicyclo[3.1.0]hexane-3- carboxylate (108 mg, 286.60 μmol, 1 eq), 2-[2-fluoro-6-(methoxymethoxy) -8-(4,4,5,5- tetramethyl-1,3,2-dioxaborolan-2-yl)-1-naphthyl]ethynyl-triisopropyl-silane (293.78 mg, 573.19 μmol, 2 eq) and K3PO4 (1.5 M, 576.00 μL, 3.01 eq) in dioxane (6 mL) was added XPhos Pd G4 (24.66 mg, 28.66 μmol, 0.1 eq), the mixture was stirred at 100 °C for 12 h under N2. LCMS showed the starting material was consumed completely and a peak (27%) with the desired mass. The mixture was cooled to 25 °C and poured into a mixture of saturated NH4Cl (10 mL) and water (10 mL). The aqueous phase was extracted with ethyl acetate (30 mL × 2). The combined organic phase was washed with brine (10 mL × 2), dried over anhydrous Na2SO4, filtered and concentrated under vacuum. The residue was purified by flash silica gel chromatography (12 g SepaFlash® Silica Flash Column, Eluent of 38~65% Ethyl acetate / Petroleum ether gradient @ 45 mL / min) to afford tert-butyl (1S,5R)-6-[7-[7- fluoro-3-(methoxymethoxy)-8-(2-triisopropylsilylethynyl)-1-naphthyl]-9-oxa-1,2,6- triazatricyclo[6.3.1.04,12]dodeca-2,4,6,8(12)-tetraen-3-yl]-3-azabicyclo[3.1.0]hexane-3- carboxylate (115 mg, 158.20 μmol, 55.20% yield) as yellow solid. MS (ES+) C41H51FN4O5Si requires: 726, found: 727 [M+H]+Step 7 tert-butyl (1S,5R)-6-[7-[8-ethynyl-7-fluoro-3-(methoxymethoxy)-1-naphthyl]-9-oxa- 1,2,6-triazatricyclo[6.3.1.04,12]dodeca-2,4,6,8(12)-tetraen-3-yl]-3- azabicyclo[3.1.0]hexane-3-carboxylate

[0471] To a solution of tert- ro-3-(methoxymethoxy)-8-(2-triisopropylsilylethynyl)-1-naphthyl]-9-oxa-1,2,6-triazatricyclo[6.3.1.04,12]dodeca- 2,4,6,8(12)-tetraen-3-yl]-3-azabicyclo[3.1.0]hexane-3-carboxylate (40 mg, 55.02 μmol, 1 eq) in DMF (0.5 mL) was added CsF (27.66 mg, 182.06 μmol, 6.72 μL, 3.31 eq), the mixture was stirred at 25 °C for 0.5 h. LCMS showed the starting material was consumed completely and a peak (97%) with the desired mass. The mixture was cooled to 25 °C and poured into a mixture of saturated NH4Cl (10 mL) and water (10 mL). The aqueous phase was extracted with ethyl acetate (30 mL × 2). The combined organic phase was washed with brine (10 mL × 2), dried over anhydrous Na2SO4, filtered and concentrated under vacuum to afford tert- butyl (1S,5R)-6-[7-[8-ethynyl-7-fluoro-3-(methoxymethoxy)-1-naphthyl]-9-oxa-1,2,6- triazatricyclo[6.3.1.04,12]dodeca-2,4,6,8(12)-tetraen-3-yl]-3-azabicyclo[3.1.0]hexane-3- carboxylate (31.40 mg, 55.03 μmol, 100.00% yield) as yellow solid was used into the next step without further purification. MS (ES+) C32H31FN4O5 requires: 570, found: 571 [M+H]+Step 8 4-[3-[(1S,5R)-3-azabicyclo[3.1.0]hexan-6-yl]-9-oxa-1,2,6- triazatricyclo[6.3.1.04,12]dodeca-2,4,6,8(12)-tetraen-7-yl]-5-ethynyl-6-fluoro- naphthalen-2-ol

[0472] To a solution of tert-by , ynyl-7-fluoro-3-(methoxymethoxy)- 1-naphthyl]-9-oxa-1,2,6-triazatricyclo[6.3.1.04,12]dodeca-2,4,6,8(12)-tetraen-3-yl]-3-azabicyclo[3.1.0]hexane-3-carboxylate (31.4 mg, 55.03 μmol, 1 eq) in DCM (0.740 mL) was added TFA (376.46 mg, 3.30 mmol, 245.25 μL, 60 eq), the mixture was stirred at 25 °C for 30 min. LCMS showed the starting material was consumed completely and a peak (65%) with the desired mass. The mixture was concentrated under vacuum. The residue was purified by Prep-HPLC (column: Phenomenex Luna C18150*25mm*10um; mobile phase: [water (FA) -ACN]; gradient: 0%-30% B over 10 min) and freeze-dried to afford 4-[3-[(1S,5R)-3- azabicyclo[3.1.0]hexan-6-yl]-9-oxa-1,2,6-triazatricyclo[6.3.1.04,12]dodeca-2,4,6,8(12)- tetraen-7-yl]-5-ethynyl-6-fluoro-naphthalen-2-ol (6.5 mg, 13.76 μmol, 25.00% yield, 100% purity, FA) as yellow solid.

[0473] MS (ES+) C25H19FN4O2requires: 426, found: 427 [M+H]+

[0474] 1H NMR (400 MHz, CD3OD) δ ppm 8.61 (s, 1.1H), 7.83 (dd, J = 5.8, 9.2 Hz, 1H), 7.33 - 7.25 (m, 2H), 7.17 (d, J = 2.6 Hz, 1H), 4.60 - 4.56 (m, 2H), 4.48 - 4.40 (m, 2H), 3.57 - 3.51 (m, 2H), 3.46 - 3.39 (m, 2H), 3.09 (s, 1H), 2.49 - 2.42 (m, 3H). EXAMPLE 95 5-ethynyl-6-fluoro-4-[(4, , - - u - -methyl-10-oxa-2,12,16,17,19- pentazapentacyclo[9.6.1.14,7.02,8.015,18]nonadeca-1(17),11(18),12,14-tetraen-13- yl]naphthalen-2-ol Step 1 2,6-dichloro-5-fluoro-pyridine-3-carbonyl chloride

[0475] To a solution of 2,6-dichloro-5-fluoro-pyridine-3-carboxylic acid (1.5 g, 7.14 mmol, 1 eq) and DMF (52.21 mg, 714.32 μmol, 54.96 μL, 0.1 eq) in DCM (10 mL) was added oxalyl chloride (2.72 g, 21.43 mmol, 1.88 mL, 3 eq) at 0 °C, then the mixture was stirred at 20 °C for 1 h. TLC (Petroleum ether : Ethyl acetate= 1:1) (added MeOH) indicated 2,6-dichloro-5-fluoro-pyridine-3-carboxylic acid was consumed completely one new spot formed. The mixture was diluted with toluene (2 mL) and concentrated under reduced pressure to afford 2,6-dichloro-5-fluoro-pyridine-3-carbonyl chloride (1.5 g, 6.57 mmol, 91.93% yield) as yellow oil. Step 2 tert-butyl (1S,2S,5R)-3-(2,6-dichloro-5-fluoro-pyridine-3-carbonyl)-2-(hydroxymethyl)- 3,8-diazabicyclo[3.2.1]octane-8-carboxylate

[0476] To the mixture of tert-bydroxymethyl)-3,8- diazabicyclo[3.2.1]octane-8-carboxylate (2.39 g, 9.85 mmol, 1.5 eq) and TEA (1.99 g, 19.70 mmol, 2.74 mL, 3 eq) in DCM (5 mL) was added 2,6-dichloro-5-fluoro-pyridine-3-carbonyl chloride (1.5 g, 6.57 mmol, 1 eq) in DCM (2 mL) at -10 °C, then the mixture was stirred at 20 °C for 1 h. LCMS showed a peak (64%) with the desired mass[M-18]. The mixture was diluted with water (50 mL), then extracted with DCM (30 mL x 3), the combined organic phase was dried with anhydrous Na2SO4, filtered and concentrated in vacuum. The residue was purified by flash silica gel chromatography (20 g SepaFlash® Silica Flash Column, Eluent of 0~60% Ethyl acetate / Petroleum ether gradient @ 50 mL / min) to afford tert- butyl (1S,2S,5R)-3-(2,6-dichloro-5-fluoro-pyridine-3-carbonyl)-2-(hydroxymethyl)-3,8- diazabicyclo[3.2.1]octane-8-carboxylate (2 g, 4.42 mmol, 67.33% yield, 96% purity) as a yellow solid. MS (ES+) C18H22N3O4FCl2requires: 433, found: 416 [M-18].1H NMR (400 MHz, CDCl3) δ = 7.62 - 7.46 (m, 1H), 5.06 - 4.83 (m, 1H), 4.55 - 4.20 (m, 4H), 3.69 - 3.54 (m, 1H), 3.15 - 3.05 (m, 1H), 2.05 - 1.88 (m, 4H), 1.50 (s, 9H). Step 3tert-butyl (1S,2S,14R)-7-chloro-8-fluoro-11-oxo-4-oxa-6,12,17- triazatetracyclo[12.2.1.02,12.05,10]heptadeca-5(10),6,8-triene-17-carboxylate

[0477] To a solution of tert-butyl (1S,2S,5R)-3-(2,6-dichloro-5-fluoro-pyridine-3- carbonyl)-2-(hydroxymethyl)-3,8-diazabicyclo[3.2.1]octane-8-carboxylate (2 g, 4.61 mmol, 1 eq) in THF (20 mL) was added NaH (920.96 mg, 23.03 mmol, 60% purity, 5 eq) at 0 °C under N2, then the mixture was stirred at 20 °C for 1 h and 60°C for 5 h. LCMS showed a peak (91%) with the desired mass. The reaction mixture was quenched by Sat.aq.NH4Cl (50 mL) at 0 °C, extracted with ethyl acetate (30 mL x 3). The combined organic layers were washed with brine (30 mL x 2), dried over, filtered and concentrated under reduced pressure to give a residue. The residue was purified by flash silica gel chromatography (20 g SepaFlash® Silica Flash Column, Eluent of 0~80% Ethyl acetate / Petroleum ether gradient @ 100 mL / min) to afford tert-butyl (1S,2S,14R)-7-chloro-8-fluoro-11-oxo-4-oxa- 6,12,17-triazatetracyclo[12.2.1.02,12.05,10]heptadeca-5(10),6,8-triene-17-carboxylate (1 g, 2.51 mmol, 54.58% yield, 100% purity) as a yellow solid. MS (ES+) C18H21N3O4FCl requires: 397, found: 398. Step 4 tert-butyl (1S,2S,14R)-7,9-dichloro-8-fluoro-11-oxo-4-oxa-6,12,17- triazatetracyclo[12.2.1.02,12.05,10]heptadeca-5(10),6,8-triene-17-carboxylate

[0478] To a solution of tert-bu, , loro-8-fluoro-11-oxo-4-oxa-6,12,17- triazatetracyclo[12.2.1.02,12.05,10]heptadeca-5(10),6,8-triene-17-carboxylate (800 mg, 2.01mmol, 1 eq) in THF (10 mL) was added LDA (2 M, 5.03 mL, 5 eq) at -70 °C under N2, the mixture was stirred at -70 °C for 0.5 h, then 1,1,1,2,2,2-hexachloroethane (2.38 g, 10.05 mmol, 1.14 mL, 5 eq) in THF (5 mL) was added to the mixture and stirred at -70 °C for 0.5 h. LCMS showed a peak (73%) with the desired mass [M-56]. The mixture was quenched with sat.aq.NH4Cl (10 mL), extracted with ethyl acetate (10 mL x 3), the combined organic phase was dried with anhydrous Na2SO4, filtered and concentrated in vacuum. The residue was purified by flash silica gel chromatography (12 g SepaFlash® Silica Flash Column, Eluent of 0~80% Ethyl acetate / Petroleum ether gradient @ 40 mL / min) to afford tert- butyl (1S,2S,14R)-7,9-dichloro-8-fluoro-11-oxo-4-oxa-6,12,17- triazatetracyclo[12.2.1.02,12.05,10]heptadeca-5(10),6,8-triene-17-carboxylate (400 mg, 906.83 μmol, 45.10% yield, 98% purity) as a yellow solid. MS (ES+) C18H20N3O4FCl2 requires: 431, found: 376 [M-56]. Step 5 tert-butyl (4R,7S,8S)-13-chloro-14-fluoro-10-oxa-2,12,16,17,19- pentazapentacyclo[9.6.1.14,7.02,8.015,18]nonadeca-1(17),11(18),12,14-tetraene-19- carboxylate

[0479] To a solution of tert-bu-dichloro-8-fluoro-11-oxo-4-oxa- 6,12,17-triazatetracyclo[12.2.1.02,12.05,10]heptadeca-5(10),6,8-triene-17-carboxylate (180 mg, 416.40 μmol, 1 eq) in DMSO (5 mL) was added hydrazine hydrate (336.04 mg, 6.71 mmol, 325.62 μL, 16.12 eq) at 20 °C under N2, then the mixture was stirred at 80 °C for 2 h. LCMS showed a peak (65%) with the desired mass. The reaction mixture was diluted with water (5 mL), then extracted with ethyl acetate (5 mL x 3), washed with brine (5 mL x 3), the combined organic phase was dried with anhydrous Na2SO4, filtered and concentrated in vacuum. The residue was purified by flash silica gel chromatography (4 g SepaFlash® Silica Flash Column, Eluent of 0~80% Ethyl acetate / Petroleum ether gradient @ 40 mL / min) to afford tert-butyl (4R,7S,8S)-13-chloro-14-fluoro-10-oxa-2,12,16,17,19- pentazapentacyclo[9.6.1.14,7.02,8.015,18]nonadeca-1(17),11(18),12,14-tetraene-19-carboxylate (150 mg, 366.00 μmol, 87.89% yield, 100% purity) as a yellow solid. MS (ES+) C18H21N5FO3Cl requires:409, found: 410. Step 6 tert-butyl (4R,7S,8S)-13-chloro-14-fluoro-16-methyl-10-oxa-2,12,16,17,19- pentazapentacyclo[9.6.1.14,7.02,8.015,18]nonadeca-1(17),11(18),12,14-tetraene-19- carboxylate

[0480] To a solution of tert-bu loro-14-fluoro-10-oxa-2,12,16,17,19-pentazapentacyclo[9.6.1.14,7.02,8.015,18]nonadeca-1(17),11(18),12,14-tetraene-19-carboxylate (150 mg, 366.00 μmol, 1 eq) in DMF (1 mL) was added NaH (21.96 mg, 548.99 μmol, 60% purity, 1.5 eq) at 0 °C under N2, then the mixture was stirred at 0 °C for 2 mins, to the mixture was added MeI (62.34 mg, 439.19 μmol, 27.34 μL, 1.2 eq) at 0°C under N2, stirred at 0 °C for 2 h. LCMS showed a peak (90%) with the desired mass. The mixture was added Sat.aq.NH4Cl (5 mL), then extracted with ethyl acetate (5 mL x 3), washed with brine (5 mL x 3), the combined organic phase was dried with anhydrous Na2SO4, filtered and concentrated in vacuum. The residue was purified by flash silica gel chromatography (4 g SepaFlash® Silica Flash Column, Eluent of 0~80% Ethyl acetate / Petroleum ether gradient @ 40 mL / min) to afford tert-butyl (4R,7S,8S)-13-chloro-14-fluoro-16-methyl-10- oxa-2,12,16,17,19-pentazapentacyclo[9.6.1.14,7.02,8.015,18]nonadeca-1(17),11(18),12,14- tetraene-19-carboxylate (100 mg, 226.49 μmol, 61.88% yield, 96% purity) as a yellow solid. MS (ES+) C19H23N5FO3Cl requires: 423, found: 424. Step 7 tert-butyl (4R,7S,8S)-14-fluoro-13-[7-fluoro-3-(methoxymethoxy)-8-(2- triisopropylsilylethynyl)-1-naphthyl]-16-methyl-10-oxa-2,12,16,17,19- pentazapentacyclo[9.6.1.14,7.02,8.015,18]nonadeca-1(17),11(18),12,14-tetraene-19- carboxylate

[0481] To a solution of tert- ro-14-fluoro-16-methyl-10-oxa-2,12,16,17,19-pentazapentacyclo[9.6.1.14,7.02,8.015,18]nonadeca-1(17),11(18),12,14-tetraene- 19-carboxylate (100 mg, 235.92 μmol, 1 eq) and 2-[2-fluoro-6-(methoxymethoxy)-8-(4,4,5,5- tetramethyl-1,3,2-dioxaborolan-2-yl)-1-naphthyl]ethynyl-triisopropyl-silane (157.19 mg, 306.70 μmol, 1.3 eq) in THF (4 mL) were added K3PO4 (1.5 M, 471.84 μL, 3 eq) and CATACXIUM(R) A PD G3(34.36 mg, 47.18 μmol, 0.2 eq) at 20 °C under N2, then the mixture was stirred at 60 °C for 16 h. LCMS showed a peak (56%) with the desired mass. The reaction mixture was diluted with water (10 mL), then extracted with ethyl acetate (5 mL x 3), the combined organic phase was dried with anhydrous Na2SO4, filtered and concentrated in vacuum. The residue was purified by flash silica gel chromatography (12 g SepaFlash® Silica Flash Column, Eluent of 0~80% Ethyl acetate / Petroleum ether gradient @ 100mL / min) to afford tert-butyl (4R,7S,8S)-14-fluoro-13-[7-fluoro-3- (methoxymethoxy)-8-(2-triisopropylsilylethynyl)-1-naphthyl]-16-methyl-10-oxa- 2,12,16,17,19-pentazapentacyclo[9.6.1.14,7.02,8.015,18]nonadeca-1(17),11(18),12,14-tetraene- 19-carboxylate (120 mg, 96.13 μmol, 40.74% yield, 62% purity) as a yellow solid. MS (ES+) C42H53N5F2O5Si requires: 773, found: 774. Step 8 tert-butyl (4R,7S,8S)-13-[8-ethynyl-7-fluoro-3-(methoxymethoxy)-1-naphthyl]-14- fluoro-16-methyl-10-oxa-2,12,16,17,19- pentazapentacyclo[9.6.1.14,7.02,8.015,18]nonadeca-1(17),11(18),12,14-tetraene-19- carboxylate

[0482] To a solution of tert- -13-[7-fluoro-3-(methoxymethoxy)-8-(2-triisopropylsilylethynyl)-1-naphthyl]-16-methyl-10-oxa- 2,12,16,17,19-pentazapentacyclo[9.6.1.14,7.02,8.015,18]nonadeca-1(17),11(18),12,14-tetraene- 19-carboxylate (60 mg, 77.52 μmol, 1 eq) in DMF (1 mL) was added CsF (117.76 mg, 775.21 μmol, 10 eq) at 20 °C , then the mixture was stirred at 20 °C for 1 h. LCMS showed a peak (89%) with the desired mass. The reaction mixture was diluted with ice-water(2 mL), then extracted with ethyl acetate (2 mL x 3), washed with brine (2 mL x 3), the combined organic phase was dried with anhydrous Na2SO4, filtered and concentrated in vacuum to afford tert-butyl (4R,7S,8S)-13-[8-ethynyl-7-fluoro-3-(methoxymethoxy)-1-naphthyl]-14- fluoro-16-methyl-10-oxa-2,12,16,17,19-pentazapentacyclo[9.6.1.14,7.02,8.015,18]nonadeca- 1(17),11(18),12,14-tetraene-19-carboxylate (40 mg, 64.76 μmol, 83.54% yield) as a yellow solid. MS (ES+) C33H33N5F2O5requires: 617, found: 618. Step 9 5-ethynyl-6-fluoro-4-[(4R,7S,8S)-14-fluoro-16-methyl-10-oxa-2,12,16,17,19- pentazapentacyclo[9.6.1.14,7.02,8.015,18]nonadeca-1(17),11(18),12,14-tetraen-13- yl]naphthalen-2-ol

[0483] To a solution of tert-, , hynyl-7-fluoro-3- (methoxymethoxy)-1-naphthyl]-14-fluoro-16-methyl-10-oxa-2,12,16,17,19- pentazapentacyclo[9.6.1.14,7.02,8.015,18]nonadeca-1(17),11(18),12,14-tetraene-19-carboxylate (40 mg, 64.76 μmol, 1 eq) in DCM (0.5 mL) was added HCl / dioxane (2 M, 800.00 μL) at 20°C, then the mixture was stirred at 20 °C for 0.5 h. LCMS showed a peak (92%) with the desired mass. The reaction mixture was concentrated under reduced pressure to give a residue. The residue was purified by prep-HPLC (column: Phenomenex luna C18 150*25mm* 10um;mobile phase: [water(FA)-ACN];gradient:16%-36% B over 10 min) and lyophilized to afford 5-ethynyl-6-fluoro-4-[(4R,7S,8S)-14-fluoro-16-methyl-10-oxa- 2,12,16,17,19-pentazapentacyclo[9.6.1.14,7.02,8.015,18]nonadeca-1(17),11(18),12,14-tetraen- 13-yl]naphthalen-2-ol (15.3 mg, 29.45 μmol, 45.48% yield, 100% purity, FA) as a yellow solid.

[0484] MS (ES+) C26H21F2N5O2 requires: 473, found: 474

[0485] 1H NMR (400 MHz, CD3OD) δ = 8.59 - 8.42 (m, 0.6H), 7.83 (dd, J = 5.8, 9.1 Hz, 1H), 7.39 - 7.26 (m, 2H), 7.25 - 7.14 (m, 1H), 4.64 - 4.53 (m, 1H), 4.47 - 4.29 (m, 1H), 4.02 (s, 3H), 4.01 - 3.87 (m, 3H), 3.73 - 3.68 (m, 1H), 3.50 (s, 0.5H), 3.28 (s, 0.5H), 3.24 - 3.16 (m, 1H), 2.21 - 1.88 (m, 4H).

[0486] The following Examples were synthesized with procedures that were similar to the examples disclosed herein and can generally be made by methods disclosed herein from the appropriate starting materials. Table 4. Example Compounds. Example Structure IUPAC Name - 2-EXAMPLE 98 4-[1-(3-azabicyclo[3.1.0]hexl-imidazo[1,5-a]pyrazin-6-yl]-5- ethynyl-6-fluoro-naphthalen-2-ol Step 1 5-bromo-2-chloro-3-fluoro-pyrazine

[0487] To a solution of 6-bromo-3in-2-amine (9 g, 43.18 mmol, 1 eq) in pyridine hydrofluoride (180 mL) was added NaNO2 (3.57 g, 51.81 mmol, 1.2 eq) at 0 °C. The mixture was stirred at 25 °C for 1 h. TLC (Petroleum ether : Ethyl acetate = 20 :1) indicated reactant was consumed completely and one new spot formed. The reaction mixture was diluted with water (50 mL) and extracted with ethyl acetate (50 mL x 3). The combined organic layers were washed with bine (50 mL x 3), dried over Na2SO4, filtered and concentrated under reduced pressure to give a residue. The residue was purified by flash silica gel chromatography (40 g SepaFlash® Silica Flash Column, Eluent of 0~10% Ethyl acetate / Petroleum ether gradient @ 20 mL / min) to afford 5-bromo-2-chloro-3-fluoro- pyrazine (9 g, 42.57 mmol, 98.59% yield) as a colorless oil.1HNMR (400 MHz, CDCl3) δ = 8.43 (d, J = 2.6 Hz, 1H). Step 2 tert-butyl N-[(5-chloro-6-fluoro-pyrazin-2-yl)methyl]carbamate

[0488] A mixture of 5-br...

Claims

CLAIMS What is claimed is:

1. A compound of Formula IC: C), or a salt or tautomer thereof, wJ is chosen from N and CR11; X is chosen from CR4and NR4; Y is chosen from CR7, N, and NR7; Z is chosen from CR5, N, and NR5; R1is chosen from OH and NH2; R2is chosen from H and halo; R3is chosen from H, alkyl, alkenyl, alkoxy, cycloalkoxy, cycloalkyl, heterocycloalkyl, amino, alkylamino, dialkylamino, hydroxyalkyl, -C(O)CH3, haloalkyl, cyanoalkyl, benzyl, haloalkoxy, heterocycloalkoxy, halocycloalkoxy, cycloalkylamino, arylamino, and halo; R4is chosen from H, alkyl, amino, alkylamino, cycloalkyl, heterocycloalkyl, aryl, and heteroaryl, wherein alkyl, amino, alkylamino, cycloalkyl, heterocycloalkyl, aryl, and heteroaryl may be optionally substituted by one or more R8; R5is chosen from H, alkyl, alkynyl, amino, alkoxy, cycloalkyl, heterocycloalkyl, haloalkyl, aryl, heteroaryl, halo, cyano, alkyl sulfonyl, or hydroxyl, wherein alkyl, alkynyl, amino, alkoxy, cycloalkyl, heterocycloalkyl, haloalkyl, aryl, heteroaryl, and alkyl sulfonyl may be optionally substituted by one or more R9; and R6is chosen from H, alkyl, alkoxy, and halo; OR R5and R6combine to form a heterocycloalkyl; R7is chosen from H, alkyl, alkynyl, cycloalkyl, heterocycloalkyl, haloalkyl, aryl, - CH2OH, cyano, oxo, and heteroaryl, wherein alkyl, alkynyl, cycloalkyl, heterocycloalkyl, haloalkyl, aryl, and heteroaryl may be optionally substituted by one or more R12; each R8is independently chosen from alkyl, cycloalkyl, heterocycloalkyl, alkoxy, amino, alkylamino, dialkylamino, cyano, halo, hydroxy, oxo, and -C(O)OCH3, wherein alkyl, cycloalkyl, and alkoxy may be optionally substituted by one or more R10;each R9is independently chosen from alkyl, cycloalkyl, heterocycloalkyl, alkoxy, cyano, halo, amino, alkylamino, dialkylamino, and hydroxy; each R10is independently chosen from amino, halo, cyano, and hydroxy; R11is chosen from H, alkyl, halo, haloalkyl, cycloalkyl, and cyano; and each R12is independently chosen from alkyl, cycloalkyl, heterocycloalkyl, alkoxy, amino, cyano, halo, and hydroxy.

2. The compound of claim 1, or a salt or tautomer thereof, wherein R3is chosen from H, alkyl, alkenyl, cycloalkyl, alkylamino dialkylamino, alkoxy, cycloalkoxy, hydroxyalkyl, -C(O)CH3, cyanoalkyl, haloalkyl, benzyl, haloalkoxy, heterocycloalkoxy, cycloalkylamino, heterocycloalkyl, halocycloalkoxy, and arylamino.

3. The compound of claim 2, or a salt or tautomer thereof, wherein R3is chosen from H, cyclobutyl, isopropenyl, methyl, ethyl, dimethylamino, isopropoxy, cyclobutoxy, isobutoxy, cyclopentoxy, methoxy, 2-hydroxypropanyl, -C(O)CH3, 1-hydroxyethyl, methylamino, propylnitrile, trifluoromethyl, benzyl, difluoromethoxy, azetidinyloxy, cyclopropylamino, isopropyl(methyl)amino, isopropylamino, azetidinyl, isobutyl, 3,3- difluorocyclobutoxy, ethyl(methyl)amino, diethylamino, cyclopropoxy, phenylamino, oxetanyloxy, and trifluoroethoxy.

4. The compound of claim 1, or a salt or tautomer thereof, wherein J is chosen from N and CR11; X is CR4; Y is chosen from CR7, N, and NR7; Z is chosen from N, and NR5; R1is OH; R2is H; R3is H; R4is chosen from amino and heterocycloalkyl, either of which may be optionally substituted by one or more R8; R5is chosen from H, alkyl, alkynyl, and cycloalkyl, wherein alkyl, alkynyl, and cycloalkyl may be optionally substituted by one or more R9; R6is chosen from H and halo; R7is chosen from H, alkyl, alkynyl, -CH2OH, and cyano, wherein alkyl and alkynyl may be optionally substituted by one or more R12;each R8is independently chosen from cycloalkyl and heterocycloalkyl, either of which may be optionally substituted by one or more R10; each R9is independently heterocycloalkyl; each R10is independently amino; R11is chosen from H, halo, haloalkyl, cycloalkyl, and cyano; and each R12is independently chosen from alkyl, cycloalkyl, heterocycloalkyl, alkoxy, amino, cyano, halo, and hydroxy.

5. The compound of claim 1, or a salt or tautomer thereof, wherein X is CR4.

6. The compound of claim 5, or a salt or tautomer thereof, wherein R4is chosen from amino and heterocycloalkyl, wherein either may be optionally substituted by one or two R8.

7. The compound of claim 6, or a salt or tautomer thereof, wherein R4is heterocycloalkyl.

8. The compound of claim 7, or a salt or tautomer thereof, wherein R4is chosen from 3,8-diazabicyclo[3.2.1]octanyl, 8-azabicyclo[3.2.1]oct-2-enyl, piperazinyl, 2,5- diazabicyclo[2.2.2]octanyl, 2,5-diazabicyclo[2.2.1]heptanyl, 3,8- diazabicyclo[3.2.1]octanyl, and 3-azabicyclo[3.1.0]hexanyl.

9. The compound of claim 8, or a salt or tautomer thereof, wherein R4is chosen from , , . 10., , optionally substituted by one R8.

11. The compound of claim 10, or a salt or tautomer thereof, wherein R8is heterocycloalkyl.

12. The compound of claim 11, or a salt or tautomer thereof, wherein R4is . 13 of claim 10, or a salt or tautomer thereof, wherein R8is cycloalkyloptionally substituted with one or two R10.

14. The compound of claim 13, or a salt or tautomer thereof, wherein R8is cyclobutyl substituted by one R10.

15. The compound of claim 14, or a salt or tautomer thereof, wherein R10is dimethylamino.

16. The compound of claim 15, or a salt or tautomer thereof, wherein R4.

17. The compound of any one of the preceding claims, or a salt or tautowherein R3is H.

18. The compound of any one of the preceding claims, or a salt or tautomer thereof, wherein R6is fluoro.

19. The compound of any one of claims 1–17, or a salt thereof, wherein R6is H.

20. The compound of claim 1, or a salt or tautomer thereof, having a structural formula of Formula II: I).

21. The compound of claim 1,of, having a structural formula of Formula III:I).

22. The compound of claim 1 f, having a structural formula ofFormula IV: V), wherein n is chosen f23. The compound of any one of the preceding claims, or a salt or tautomer thereof, wherein J is CR11.

24. The compound of claim 23, or a salt or tautomer thereof, wherein R11is chosen from H and fluoro.

25. The compound of any one of claims 1–19, or a salt or tautomer thereof, wherein J is N.

26. The compound of any one of the preceding claims, or a salt or tautomer thereof, wherein Y is CR7.

27. The compound of claim 26, or a salt or tautomer thereof, wherein R7is H.

28. The compound of claim 26, or a salt or tautomer thereof, wherein R7is alkyl.

29. The compound of claim 28, or a salt or tautomer thereof, wherein R7is methyl.

30. The compound of claim 26, or a salt or tautomer thereof, wherein R7is -CH2OH.

31. The compound of claim 26, or a salt or tautomer thereof, wherein R7is oxo.

32. The compound of any one of claims 1–25, or a salt or tautomer thereof, wherein Y is N.

33. The compound of any one of the preceding claims, or a salt or tautomer thereof, wherein Z is NR5.

34. The compound of any one of the preceding claims, or a salt or tautomer thereof, wherein R5is chosen from H, alkyl and cycloalkyl, wherein alkyl and cycloalkyl may be optionally substituted by one or two R9.

35. The compound of claim 34, or a salt or tautomer thereof, wherein R5is chosen from H, methyl, ethyl, n-propyl, isopropyl, cyclopropyl, and cyclobutyl.

36. The compound of claim 35, or a salt or tautomer thereof, wherein R5is alkyl substituted by one R9.

37. The compound of claim 36, or a salt or tautomer thereof, wherein R9is heterocycloalkyl.

38. The compound of claim 37, or a salt or tautomer thereof, wherein R9is tetrahydrofuranyl.

39. The compound of claim 36, or a salt or tautomer thereof, wherein R9is dimethylamino.

40. The compound of claim 36, or a salt or tautomer thereof, wherein R9is cyano.

41. The compound of claim 35, or a salt or tautomer thereof, wherein R5is cyclopropyl substituted by one or two R9.

42. The compound of claim 41, or a salt or tautomer thereof, wherein R9is fluoro.

43. The compound of claim 41, or a salt or tautomer thereof, wherein R9is methyl.

44. The compound of any one of the preceding claims, or a salt or tautomer thereof, wherein R1is NH2.

45. The compound of any one of claims 1–43, or a salt or tautomer thereof, wherein R1is OH.

46. The compound of any one of the preceding claims, or a salt or tautomer thereof, wherein R2is chosen from H, chloro, and fluoro.

47. The compound of claim 46, or a salt or tautomer thereof, wherein R2is H.

48. The compound of claim 1, or a salt or tautomer thereof, having a structural formula of:F , ,221,, , ,, ,, ,,,, r a49. A pharmaceutical formulation comprising a compound as recited in any one of claims 1–48, or a salt or tautomer thereof, together with a pharmaceutically acceptable carrier.

50. The pharmaceutical formulation as recited in claim 49, formulated for oral administration.

51. The pharmaceutical formulation as recited in claim 49 or 50, additionally comprising another therapeutic agent.

52. A method of inhibition of NRAS G12D, comprising contacting NRAS G12D with a compound as recited in any one of claims 1–48, or a salt or tautomer thereof, or a pharmaceutical composition as recited in any one of claims 49–51.

53. A method of treatment of an NRAS G12D-mediated disease, comprising the administration of a therapeutically effective amount of a compound as recited in anyone of claims 1–48, or a salt or tautomer thereof, or a pharmaceutical composition as recited in any one of claims 49–51, to a patient in need thereof.

54. The method as recited in claim 53, wherein the NRAS G12D-mediated disease is cancer.

55. The method as recited in claim 54, wherein the cancer is chosen from Melanoma, Malignant Solid Tumors, Colorectal Carcinoma, Non-Small Cell Lung Carcinoma, Acute Myeloid Leukemia, Myelodysplastic Syndromes, Chronic Myelomonocytic Leukemia, Colorectal Adenocarcinoma, Multiple Myeloma, Non-Hodgkin Lymphoma, Pancreatic Carcinoma, Cutaneous Melanoma, Ovarian Carcinoma, Pancreatic Ductal Adenocarcinoma, Acute Lymphoblastic Leukemia, Thyroid Gland Carcinoma, Glioma, Neurofibromatosis, Poorly Differentiated Thyroid Gland Carcinoma, Myelodysplastic Syndrome With Excess Blasts, Juvenile Myelomonocytic Leukemia, Histiocytic And Dendritic Cell Neoplasm, Head And Neck Squamous Cell Carcinoma, Small Cell Lung Carcinoma, Low Grade Glioma, Squamous Cell Lung Carcinoma, Breast Carcinoma, Chronic Myelomonocytic Leukemia, Thyroid Gland Undifferentiated (Anaplastic) Carcinoma, Embryonal Rhabdomyosarcoma, Thyroid Gland Follicular Carcinoma, T-Cell Acute Lymphoblastic Leukemia, Mucosal Melanoma, Low Grade Ovarian Serous Adenocarcinoma, Thyroid Gland Papillary Carcinoma, Refractory Anemia With Excess Blasts, Myeloid Neoplasm, Myelodysplastic / Myeloproliferative Neoplasm, Rectal Carcinoma, Colon Carcinoma, Malignant Peripheral Nerve Sheath Tumor, Cholangiocarcinoma, Endometrial Carcinoma, Mantle Cell Lymphoma, Secondary Myelodysplastic Syndrome, Therapy-Related Myelodysplastic Syndrome, Lymphoma, Neuronal And Mixed Neuronal-Glial Tumors, Ganglioglioma, Soft Tissue Sarcoma, Bladder Carcinoma, Esophageal Carcinoma, Sarcoma, Thymic Carcinoma, Lung Adenocarcinoma, Lung Carcinoma, Uveal Melanoma, Head And Neck Carcinoma, Diffuse Glioma, Squamous Cell Carcinoma, Chronic Myeloid Leukemia, Adenocarcinoma of the Gastroesophageal Junction, Glioblastoma, Neuroblastoma, Astrocytic Tumor, Hepatocellular Carcinoma, Pancreatic Adenocarcinoma, Diffuse Large B-Cell Lymphoma, Anaplastic Astrocytoma, Gastric Adenocarcinoma, Gastric Carcinoma, Prostate Carcinoma, Renal Cell Carcinoma, B- Cell Acute Lymphoblastic Leukemia, Double-Hit Lymphoma, Dysembryoplastic Neuroepithelial Tumor, Gangliocytoma, Low-Grade Neuroepithelial Tumor,Peripheral T-Cell Lymphoma, Pilocytic Astrocytoma, Pilomyxoid Astrocytoma, Rhabdoid Tumor, and Schwannoma.

Images